{"predictions":[{"id":"20260501T150351-8db50e7f::tofacitinib::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"tofacitinib","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:52.647Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::gentian_violet_cation::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:52.268Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::entrectinib::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:53.024Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::palbociclib::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:55.686Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::mycophenolate::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:55.305Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::ketoconazole::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:54.545Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::vandetanib::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:54.163Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:53.786Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::ruxolitinib::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"ruxolitinib","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:54.924Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T150351-8db50e7f::tretinoin::parkinson's_disease","analysisId":"20260501T150351-8db50e7f","recordedAt":"2026-05-01T15:03:51.392Z","drug":"tretinoin","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-05-01T15:03:53.406Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260501T143833-37bbaa6e::temozolomide::glioblastoma","analysisId":"20260501T143833-37bbaa6e","recordedAt":"2026-05-01T14:38:33.081Z","drug":"TEMOZOLOMIDE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02715609","NCT04238819","NCT02490930","NCT01587144","NCT06782984"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2012-04-30","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:14.552Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T143833-37bbaa6e::lomustine::glioblastoma","analysisId":"20260501T143833-37bbaa6e","recordedAt":"2026-05-01T14:38:33.081Z","drug":"LOMUSTINE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00052455","NCT01934361","NCT06325683","NCT06336291","NCT00005796"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:13.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T143833-37bbaa6e::sunitinib::glioblastoma","analysisId":"20260501T143833-37bbaa6e","recordedAt":"2026-05-01T14:38:33.081Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00606008","NCT00611728","NCT00923117","NCT02928575","NCT00864864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-01","trialPhase":"Phase 2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:15.700Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T143833-37bbaa6e::gefitinib::glioblastoma","analysisId":"20260501T143833-37bbaa6e","recordedAt":"2026-05-01T14:38:33.081Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT01310855","NCT00042991","NCT00014170","NCT00250887"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1/PHASE2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:15.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T143833-37bbaa6e::neratinib::glioblastoma","analysisId":"20260501T143833-37bbaa6e","recordedAt":"2026-05-01T14:38:33.081Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:14.929Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T143833-37bbaa6e::bevacizumab::glioblastoma","analysisId":"20260501T143833-37bbaa6e","recordedAt":"2026-05-01T14:38:33.081Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02336165","NCT03623347","NCT00433381","NCT01413438","NCT05201326"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-12","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:14.163Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260501T142110-37bbaa6e::lomustine::glioblastoma","analysisId":"20260501T142110-37bbaa6e","recordedAt":"2026-05-01T14:21:10.887Z","drug":"LOMUSTINE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00052455","NCT01934361","NCT06325683","NCT06336291","NCT00005796"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:30.820Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T142110-37bbaa6e::sunitinib::glioblastoma","analysisId":"20260501T142110-37bbaa6e","recordedAt":"2026-05-01T14:21:10.887Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00606008","NCT00611728","NCT00923117","NCT02928575","NCT00864864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-01","trialPhase":"Phase 2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:30.046Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T142110-37bbaa6e::neratinib::glioblastoma","analysisId":"20260501T142110-37bbaa6e","recordedAt":"2026-05-01T14:21:10.887Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:31.204Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T142110-37bbaa6e::gefitinib::glioblastoma","analysisId":"20260501T142110-37bbaa6e","recordedAt":"2026-05-01T14:21:10.887Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT01310855","NCT00042991","NCT00014170","NCT00250887"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1/PHASE2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:31.983Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260501T142110-37bbaa6e::bevacizumab::glioblastoma","analysisId":"20260501T142110-37bbaa6e","recordedAt":"2026-05-01T14:21:10.887Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02336165","NCT03623347","NCT00433381","NCT01413438","NCT05201326"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-12","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:31.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260501T142110-37bbaa6e::temozolomide::glioblastoma","analysisId":"20260501T142110-37bbaa6e","recordedAt":"2026-05-01T14:21:10.887Z","drug":"TEMOZOLOMIDE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02715609","NCT04238819","NCT02490930","NCT01587144","NCT06782984"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2012-04-30","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:30.436Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::afatinib::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01523587","NCT05834348","NCT01415011","NCT01156545","NCT03053297"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-07-05","trialPhase":"Phase 2","repurposingScore":64,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:20.390Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::erlotinib::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"ERLOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01610336","NCT01068587","NCT01204307","NCT01514877","NCT00294736"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-22","trialPhase":"Phase 1","repurposingScore":60,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:20.781Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::repotrectinib::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"REPOTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04772235","NCT06552234","NCT06315010","NCT03093116","NCT06140836"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2017-03-28","trialPhase":"Phase 1/PHASE2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:19.999Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02201992","NCT05834348","NCT02679170","NCT02094573","NCT06569420"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-24","trialPhase":"Phase 2","repurposingScore":68,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:18.426Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:18.021Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":71,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:21.490Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT03807778","NCT04129502","NCT04051827","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-01-17","trialPhase":"Phase 1","repurposingScore":71,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:21.135Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05361564","NCT05834348","NCT02094573","NCT04591431","NCT06620835"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-24","trialPhase":"Phase 2","repurposingScore":64,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:19.604Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT03807778","NCT04129502","NCT04051827","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-01-17","trialPhase":"Phase 1","repurposingScore":71,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:19.212Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T194417-31a6d1c1::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260430T194417-31a6d1c1","recordedAt":"2026-04-30T19:44:17.046Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02039336","NCT05834348","NCT04504071","NCT04339829","NCT04609319"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-17","trialPhase":"Phase 1/PHASE2","repurposingScore":60,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:18.816Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T140650-37bbaa6e::gefitinib::glioblastoma","analysisId":"20260430T140650-37bbaa6e","recordedAt":"2026-04-30T14:06:50.846Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01310855","NCT00016991","NCT00042991","NCT00250887","NCT00025675"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:51.601Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T140650-37bbaa6e::temozolomide::glioblastoma","analysisId":"20260430T140650-37bbaa6e","recordedAt":"2026-04-30T14:06:50.846Z","drug":"TEMOZOLOMIDE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00089427","NCT00807027","NCT04119674","NCT00014105","NCT04280848"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2004-02-04","trialPhase":"Phase 1/PHASE2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:52.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T140650-37bbaa6e::sunitinib::glioblastoma","analysisId":"20260430T140650-37bbaa6e","recordedAt":"2026-04-30T14:06:50.846Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03275558","NCT03025893","NCT00611728","NCT02928575","NCT00864864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-11","trialPhase":"Phase 1","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:51.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T140650-37bbaa6e::neratinib::glioblastoma","analysisId":"20260430T140650-37bbaa6e","recordedAt":"2026-04-30T14:06:50.846Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:53.542Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T140650-37bbaa6e::bevacizumab::glioblastoma","analysisId":"20260430T140650-37bbaa6e","recordedAt":"2026-04-30T14:06:50.846Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00817284","NCT01349660","NCT01814813","NCT01967810","NCT01392209"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-01-06","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:53.163Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T140650-37bbaa6e::lomustine::glioblastoma","analysisId":"20260430T140650-37bbaa6e","recordedAt":"2026-04-30T14:06:50.846Z","drug":"LOMUSTINE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00948389","NCT03025893","NCT00504660","NCT02076152","NCT02843230"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-20","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:52.775Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T133322-a72ffab5::riluzole::amyotrophic_lateral_sclerosis","analysisId":"20260430T133322-a72ffab5","recordedAt":"2026-04-30T13:33:22.619Z","drug":"RILUZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01879241","NCT03272802","NCT00231140","NCT02238626","NCT05508074"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-10-04","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:23.832Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260430T133322-a72ffab5::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260430T133322-a72ffab5","recordedAt":"2026-04-30T13:33:22.619Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070119","NCT02623699","NCT05725759"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-12-08","trialPhase":"Phase 3","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:24.228Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::gilteritinib::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070093","NCT06734585","NCT05564390","NCT02927262","NCT04293562"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":60,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:10.440Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::pacritinib::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"PACRITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04282187","NCT02532010","NCT01620216","NCT02323607"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2012-06-15","trialPhase":"Phase 2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:12.372Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::sorafenib::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"SORAFENIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05596981","NCT01254890","NCT01253070","NCT02779283","NCT03622541"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-12-03","trialPhase":"Phase 2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:13.182Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"PROCEDURE","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::gilteritinib_fumarate::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"GILTERITINIB FUMARATE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070093","NCT06734585","NCT05564390","NCT02927262","NCT04293562"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":51,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:11.191Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::azacitidine::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"high","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05426798","NCT02085408","NCT01835587"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-04-19","trialPhase":"Phase 1/PHASE2","repurposingScore":58,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:12.776Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::quizartinib::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"QUIZARTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03793478","NCT03135054","NCT04107727","NCT02039726","NCT03552029"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-20","trialPhase":"Phase 3","repurposingScore":58,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:10.836Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::midostaurin::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01846624","NCT00233454","NCT02624570","NCT00866281","NCT00093600"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-08","trialPhase":"Phase 1","repurposingScore":60,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:14.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::ponatinib::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"PONATINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"high","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02779283","NCT01424982","NCT03147612","NCT03934372","NCT01207440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-23","trialPhase":"Phase 2","repurposingScore":83,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:13.618Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::idarubicin::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"IDARUBICIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02652871","NCT01587430","NCT00909168","NCT01296178"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-05-27","trialPhase":"Phase 2/PHASE3","repurposingScore":70,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:11.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260427T114446-f0ae7dad::decitabine::acute_myeloid_leukemia","analysisId":"20260427T114446-f0ae7dad","recordedAt":"2026-04-27T11:44:46.737Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"high","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05426798","NCT02085408","NCT03358719","NCT06113289","NCT06802523"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-12","trialPhase":"Phase 3","repurposingScore":62,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:11.591Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T194252-9b8e00d9::cobimetinib::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"COBIMETINIB","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","CDKN2A","MAP2K1","NF1","NRAS","PTEN"],"confidence":"high","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":84,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:06.580Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::tovorafenib::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"TOVORAFENIB","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","NRAS"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":29,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:08.484Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::regorafenib::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"REGORAFENIB","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","MAP2K1","NRAS","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:10.017Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::dasatinib_anhydrous::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"DASATINIB ANHYDROUS","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","MAP2K1","NF1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:09.631Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::trametinib::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"Trametinib","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","NRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":67,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:06.966Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::binimetinib::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"BINIMETINIB","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","MAP2K1","NF1","NRAS","PTEN"],"confidence":"high","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":84,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:08.863Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::sorafenib::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"SORAFENIB","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","MAP2K1","NF1","NRAS","PTEN","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:09.244Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::selumetinib::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"SELUMETINIB","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","MAP2K1","MITF","NF1","NRAS","PTEN","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:07.706Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::cobimetinib_fumarate::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"COBIMETINIB FUMARATE","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["MAP2K1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":70,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:07.321Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T194252-9b8e00d9::trametinib_dimethyl_sulfoxide::braf-mutant_cutaneous_melanoma;_mapk_pathway_inhibitor_resistance_and_immune_checkpoint_therapy","analysisId":"20260426T194252-9b8e00d9","recordedAt":"2026-04-26T19:42:52.981Z","drug":"TRAMETINIB DIMETHYL SULFOXIDE","disease":"BRAF-mutant cutaneous melanoma; MAPK pathway inhibitor resistance and immune checkpoint therapy","genes":["BRAF","CDKN2A","MAP2K1","MITF","NF1","NRAS","PTEN","RAC1","RB1","TP53"],"targets":["BRAF","CDKN2A","MAP2K1","NF1","NRAS","PTEN","RB1","TP53"],"confidence":"high","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":84,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:08.091Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193738-37bbaa6e::lomustine::glioblastoma","analysisId":"20260426T193738-37bbaa6e","recordedAt":"2026-04-26T19:37:38.973Z","drug":"LOMUSTINE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05410301","NCT06419946","NCT05017610","NCT02926222","NCT00006024"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:04.209Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T193738-37bbaa6e::sunitinib::glioblastoma","analysisId":"20260426T193738-37bbaa6e","recordedAt":"2026-04-26T19:37:38.973Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:05.802Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T193738-37bbaa6e::bevacizumab::glioblastoma","analysisId":"20260426T193738-37bbaa6e","recordedAt":"2026-04-26T19:37:38.973Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01413438","NCT00345163","NCT01433991","NCT03532295","NCT02386826"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-27","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:04.634Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T193738-37bbaa6e::neratinib::glioblastoma","analysisId":"20260426T193738-37bbaa6e","recordedAt":"2026-04-26T19:37:38.973Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:05.413Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T193738-37bbaa6e::gefitinib::glioblastoma","analysisId":"20260426T193738-37bbaa6e","recordedAt":"2026-04-26T19:37:38.973Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:06.199Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T193738-37bbaa6e::temozolomide::glioblastoma","analysisId":"20260426T193738-37bbaa6e","recordedAt":"2026-04-26T19:37:38.973Z","drug":"TEMOZOLOMIDE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00884416","NCT01119599","NCT04450160","NCT01089868","NCT01957956"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-04-20","trialPhase":"Phase 1","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:05.031Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T193424-8db50e7f::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:01.889Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::palbociclib::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:01.111Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::ketoconazole::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:00.720Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::mycophenolate::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:01.505Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::entrectinib::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:00.333Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::ruxolitinib::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"ruxolitinib","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:03.806Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::vandetanib::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:03.422Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::tretinoin::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"tretinoin","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:03.041Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::tofacitinib::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"tofacitinib","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:02.653Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T193424-8db50e7f::gentian_violet_cation::parkinson's_disease","analysisId":"20260426T193424-8db50e7f","recordedAt":"2026-04-26T19:34:24.084Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-27T11:52:02.271Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T183701-37bbaa6e::temozolomide::glioblastoma","analysisId":"20260426T183701-37bbaa6e","recordedAt":"2026-04-26T18:37:01.375Z","drug":"TEMOZOLOMIDE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00884416","NCT01119599","NCT04450160","NCT01089868","NCT01957956"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-04-20","trialPhase":"Phase 1","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:03.961Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T183701-37bbaa6e::lomustine::glioblastoma","analysisId":"20260426T183701-37bbaa6e","recordedAt":"2026-04-26T18:37:01.375Z","drug":"LOMUSTINE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05410301","NCT06419946","NCT05017610","NCT02926222","NCT00006024"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:03.196Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T183701-37bbaa6e::sunitinib::glioblastoma","analysisId":"20260426T183701-37bbaa6e","recordedAt":"2026-04-26T18:37:01.375Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:02.806Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T183701-37bbaa6e::neratinib::glioblastoma","analysisId":"20260426T183701-37bbaa6e","recordedAt":"2026-04-26T18:37:01.375Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:02.420Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T183701-37bbaa6e::bevacizumab::glioblastoma","analysisId":"20260426T183701-37bbaa6e","recordedAt":"2026-04-26T18:37:01.375Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01413438","NCT00345163","NCT01433991","NCT03532295","NCT02386826"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-27","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:04.349Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T183701-37bbaa6e::gefitinib::glioblastoma","analysisId":"20260426T183701-37bbaa6e","recordedAt":"2026-04-26T18:37:01.375Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:03.576Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T145919-0f8d1289::infliximab::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":[],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":21,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:21.245Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260426T145919-0f8d1289::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:20.071Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T145919-0f8d1289::adalimumab::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":[],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":21,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:20.465Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260426T145919-0f8d1289::celecoxib::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:23.547Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T145919-0f8d1289::mifamurtide::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T14:59:23.156Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T145919-0f8d1289::cyclosporine::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:22.780Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T145919-0f8d1289::chembl_chembl585502::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"CHEMBL:CHEMBL585502","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T14:59:22.385Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T145919-0f8d1289::inarigivir_soproxil::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"INARIGIVIR SOPROXIL","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T14:59:22.008Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T145919-0f8d1289::chembl_chembl1351908::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T14:59:21.626Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T145919-0f8d1289::azathioprine::inflammatory_bowel_disease","analysisId":"20260426T145919-0f8d1289","recordedAt":"2026-04-26T14:59:19.297Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:20.847Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::erlotinib::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:19.269Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::neratinib::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"NERATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT01111825","NCT06008275","NCT03812393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":57,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:21.205Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::paclitaxel::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:18.876Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::vandetanib::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"VANDETANIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T14:41:20.421Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":"TNBC","interventionType":null,"primaryPurpose":null},{"id":"20260426T144116-c4ff5e37::atezolizumab::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":[],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02322814","NCT03197935","NCT05742269","NCT04770272","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":21,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:18.477Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::lapatinib::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02158507","NCT01272141","NCT01426880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-01-07","trialPhase":"Phase 2","repurposingScore":57,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:21.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::carboplatin::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:20.810Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::afatinib::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:41:20.040Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::gefitinib::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"GEFITINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01732276"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2012-11-22","trialPhase":"Phase 2","repurposingScore":25,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:41:19.654Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T144116-c4ff5e37::pembrolizumab::triple-negative_breast_cancer","analysisId":"20260426T144116-c4ff5e37","recordedAt":"2026-04-26T14:41:16.908Z","drug":"PEMBROLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":[],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04585750","NCT04849364","NCT06353997","NCT05627960","NCT06134375"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-10-14","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:41:18.069Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":"TNBC","interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T135322-b7edb6bd::genistein::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"GENISTEIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:23.902Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::sorbitol::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"SORBITOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:26.195Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::interleukin_11::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"INTERLEUKIN-11","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:26.573Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:26.956Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::lithium::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"LITHIUM","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:23.521Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:25.816Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::procarbazine_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"PROCARBAZINE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:25.431Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::melatonin::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"MELATONIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:25.048Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:24.663Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T135322-b7edb6bd::pioglitazone_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260426T135322-b7edb6bd","recordedAt":"2026-04-26T13:53:22.651Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T13:53:24.278Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::mycophenolate::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:38.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::tofacitinib::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"tofacitinib","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:40.260Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::entrectinib::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:39.120Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::ketoconazole::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:38.364Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::tretinoin::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"tretinoin","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:41.541Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::ruxolitinib::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"ruxolitinib","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:39.881Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::gentian_violet_cation::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:42.292Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::palbociclib::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:41.916Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::vandetanib::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:41.166Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T124236-8db50e7f::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260426T124236-8db50e7f","recordedAt":"2026-04-26T12:42:36.775Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-26T12:42:39.502Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260426T120539-4308e5df::alirocumab::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03507374","NCT03273972","NCT03559309","NCT06080256"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-06","trialPhase":"NA","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:55.939Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260426T120539-4308e5df::rivaroxaban::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"RIVAROXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04925219","NCT03718429","NCT05009862","NCT04824729","NCT04853719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-10-24","trialPhase":"Phase 4","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:54.002Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T120539-4308e5df::alprostadil::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"ALPROSTADIL","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04312555","NCT01758874","NCT04197323"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-01","trialPhase":"Phase 2","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:54.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"PROCEDURE","primaryPurpose":"TREATMENT"},{"id":"20260426T120539-4308e5df::pravastatin_sodium::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00127218","NCT00000461","NCT00054938","NCT01872845","NCT00147797"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-28","trialPhase":"Phase 2","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:55.555Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T120539-4308e5df::inclisiran::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04929249","NCT06249165","NCT05362903","NCT04873934","NCT06126367"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2021-05-05","trialPhase":"Phase 3","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:55.168Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T120539-4308e5df::dexamethasone::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"DEXAMETHASONE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01983449","NCT02807779","NCT03942601","NCT01507558"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-01-11","trialPhase":"NA","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:54.778Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"PROCEDURE","primaryPurpose":"TREATMENT"},{"id":"20260426T120539-4308e5df::lomitapide_mesylate::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"LOMITAPIDE MESYLATE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06832371","NCT02399852"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-03-26","trialPhase":"N/A","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:13:57.472Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260426T120539-4308e5df::lovastatin::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02548936","NCT00125593","NCT04638400","NCT01105975","NCT00127218"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-08-01","trialPhase":"Phase 4","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:57.095Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"PREVENTION"},{"id":"20260426T120539-4308e5df::cholestyramine_resin::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"CHOLESTYRAMINE RESIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01053065","NCT00000461","NCT06501443"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-28","trialPhase":"Phase 2","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:56.708Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260426T120539-4308e5df::mipomersen::atherosclerosis","analysisId":"20260426T120539-4308e5df","recordedAt":"2026-04-26T12:05:39.420Z","drug":"MIPOMERSEN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01598948"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-05-15","trialPhase":"Phase 3","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:56.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260425T194202-0f8d1289::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:07.670Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::infliximab::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":[],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":21,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:07.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::inarigivir_soproxil::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"INARIGIVIR SOPROXIL","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T19:42:04.175Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::mifamurtide::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T19:42:04.558Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::chembl_chembl585502::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"CHEMBL:CHEMBL585502","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T19:42:06.886Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::cyclosporine::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:06.511Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::adalimumab::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":[],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":21,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:05.733Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::chembl_chembl1351908::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T19:42:04.942Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::azathioprine::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:06.118Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T194202-0f8d1289::celecoxib::inflammatory_bowel_disease","analysisId":"20260425T194202-0f8d1289","recordedAt":"2026-04-25T19:42:02.958Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:05.332Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::cetuximab::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05395052"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-05-27","trialPhase":"Phase 1","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:24:15.178Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05207423","NCT05241873","NCT04535557","NCT04576208","NCT04129502"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-16","trialPhase":"Phase 3","repurposingScore":70,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:17.141Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05207423","NCT05241873","NCT04535557","NCT04576208","NCT04129502"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-16","trialPhase":"Phase 3","repurposingScore":70,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:17.892Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::amivantamab::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":70,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:24:18.284Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::repotrectinib::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"REPOTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06140836","NCT04772235","NCT06315010","NCT03093116","NCT06552234"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2017-03-28","trialPhase":"Phase 1/PHASE2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:24:17.536Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04504071","NCT06486142","NCT04768491","NCT04811001","NCT00553254"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-11-05","trialPhase":"Phase 2","repurposingScore":57,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:16.748Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::alectinib::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":55,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:16.355Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::crizotinib::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":66,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:15.966Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::afatinib::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":63,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:15.566Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T192413-7d07c28b::brigatinib::non-small_cell_lung_cancer","analysisId":"20260425T192413-7d07c28b","recordedAt":"2026-04-25T19:24:13.797Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":62,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:14.787Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T175909-db6625ae::donepezil::alzheimer's_disease","analysisId":"20260425T175909-db6625ae","recordedAt":"2026-04-25T17:59:09.801Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:11.804Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T175909-db6625ae::donanemab::alzheimer's_disease","analysisId":"20260425T175909-db6625ae","recordedAt":"2026-04-25T17:59:09.801Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:10.644Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T175909-db6625ae::lecanemab::alzheimer's_disease","analysisId":"20260425T175909-db6625ae","recordedAt":"2026-04-25T17:59:09.801Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:11.033Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T175909-db6625ae::galantamine::alzheimer's_disease","analysisId":"20260425T175909-db6625ae","recordedAt":"2026-04-25T17:59:09.801Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:11.419Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T175909-db6625ae::aducanumab::alzheimer's_disease","analysisId":"20260425T175909-db6625ae","recordedAt":"2026-04-25T17:59:09.801Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:12.582Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T175909-db6625ae::rivastigmine::alzheimer's_disease","analysisId":"20260425T175909-db6625ae","recordedAt":"2026-04-25T17:59:09.801Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:12.190Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::fruquintinib::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:15.923Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::cetuximab::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:12.922Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::capecitabine::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:13.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::encorafenib::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":58,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:13.676Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::fluorouracil::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:14.822Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::adagrasib::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":53,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:15.211Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::bevacizumab::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:15.567Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::regorafenib::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"high","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":85,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:16.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::tovorafenib::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:14.070Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T174112-82ff51c1::selumetinib::colorectal_cancer","analysisId":"20260425T174112-82ff51c1","recordedAt":"2026-04-25T17:41:12.116Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01333475","NCT01160926","NCT02450656","NCT02586987","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-06-02","trialPhase":"Phase 1","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:14.466Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::fluticasone::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:55.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::capsaicin::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"CAPSAICIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:54.603Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::tramadol::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"TRAMADOL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:53.847Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::lithium::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"LITHIUM","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","CREB1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00095355"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-03","trialPhase":"Phase 2","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:53.470Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::nicotine_polacrilex::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"NICOTINE POLACRILEX","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","CREB1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:54.981Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::zinc_sulfate_anhydrous::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"ZINC SULFATE ANHYDROUS","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:54.225Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::nortriptyline::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"NORTRIPTYLINE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:53.088Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::propranolol_hydrochloride::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"PROPRANOLOL HYDROCHLORIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:55.362Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::dactinomycin::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:56.508Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T173752-45ad1538::methylphenidate_hydrochloride::huntington's_disease","analysisId":"20260425T173752-45ad1538","recordedAt":"2026-04-25T17:37:52.442Z","drug":"METHYLPHENIDATE HYDROCHLORIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":43,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T17:37:56.123Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::adalimumab::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":[],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":21,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:22.599Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::chembl_chembl1351908::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T16:01:22.209Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::cyclosporine::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:21.831Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::infliximab::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":[],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":21,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:24.512Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::celecoxib::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:21.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::azathioprine::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:24.119Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::mifamurtide::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T16:01:24.890Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::chembl_chembl585502::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"CHEMBL:CHEMBL585502","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T16:01:23.353Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::inarigivir_soproxil::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"INARIGIVIR SOPROXIL","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":44,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T16:01:22.975Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T160120-0f8d1289::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260425T160120-0f8d1289","recordedAt":"2026-04-25T16:01:20.850Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:23.737Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::entrectinib::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:03.064Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::tofacitinib::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"tofacitinib","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:04.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::ruxolitinib::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"ruxolitinib","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:03.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::palbociclib::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:06.467Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::ketoconazole::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:06.088Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::gentian_violet_cation::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:05.710Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:05.335Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::mycophenolate::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:04.959Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::vandetanib::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:04.200Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260425T154302-8db50e7f::tretinoin::parkinson's_disease","analysisId":"20260425T154302-8db50e7f","recordedAt":"2026-04-25T15:43:02.358Z","drug":"tretinoin","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":50,"tier":null,"isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-25T15:43:03.444Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T155822-3b95d2bf::carboplatin::breast_cancer","analysisId":"20260414T155822-3b95d2bf","recordedAt":"2026-04-14T15:58:23.023Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01917578","NCT01238133","NCT04191135","NCT02476955","NCT01818063"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-08-06","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:35.480Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T155822-3b95d2bf::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260414T155822-3b95d2bf","recordedAt":"2026-04-14T15:58:23.023Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06531447","NCT00736333","NCT00286247","NCT01917578","NCT02838225"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2024-08-01","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:35.124Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143240-493b80a7::aducanumab::alzheimers_disease","analysisId":"20260414T143240-493b80a7","recordedAt":"2026-04-14T14:32:40.153Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04241068","NCT05469009","NCT02434718","NCT03639987","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-01-27","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:32.424Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143240-493b80a7::lecanemab::alzheimers_disease","analysisId":"20260414T143240-493b80a7","recordedAt":"2026-04-14T14:32:40.153Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02094729","NCT06384573","NCT06883019"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-24","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:34.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143240-493b80a7::rivastigmine::alzheimers_disease","analysisId":"20260414T143240-493b80a7","recordedAt":"2026-04-14T14:32:40.153Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01380288","NCT01696123","NCT00134953","NCT04731311"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-06-27","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:32.811Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143240-493b80a7::donanemab::alzheimers_disease","analysisId":"20260414T143240-493b80a7","recordedAt":"2026-04-14T14:32:40.153Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05508789","NCT06957418","NCT03367403","NCT06996730","NCT06566170"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-19","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:33.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143240-493b80a7::gantenerumab::alzheimers_disease","analysisId":"20260414T143240-493b80a7","recordedAt":"2026-04-14T14:32:40.153Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"low","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01224106","NCT01656525","NCT03443973","NCT04339413","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-19","trialPhase":"Phase 2","repurposingScore":22,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:32.037Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143240-493b80a7::galantamine::alzheimers_disease","analysisId":"20260414T143240-493b80a7","recordedAt":"2026-04-14T14:32:40.153Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00523666","NCT00338117","NCT01734395","NCT01921972"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-08-31","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:33.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143240-493b80a7::donepezil::alzheimers_disease","analysisId":"20260414T143240-493b80a7","recordedAt":"2026-04-14T14:32:40.153Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02006641","NCT01129596","NCT03954613","NCT04730635"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-12-10","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:33.591Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143240-493b80a7::solanezumab::alzheimers_disease","analysisId":"20260414T143240-493b80a7","recordedAt":"2026-04-14T14:32:40.153Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"low","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01148498","NCT00749216","NCT00905372","NCT02008357","NCT01760005"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-06-22","trialPhase":"Phase 2","repurposingScore":22,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:34.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143048-f6c499cb::palbociclib::pan-cancer","analysisId":"20260414T143048-f6c499cb","recordedAt":"2026-04-14T14:30:48.490Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06126276","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"FDA Approved","repurposingScore":37,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:30.473Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143048-f6c499cb::sirolimus::pan-cancer","analysisId":"20260414T143048-f6c499cb","recordedAt":"2026-04-14T14:30:48.490Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"FDA Approved","repurposingScore":37,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:28.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143048-f6c499cb::paclitaxel::pan-cancer","analysisId":"20260414T143048-f6c499cb","recordedAt":"2026-04-14T14:30:48.490Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT05585320","NCT01608009","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-06-22","trialPhase":"FDA Approved","repurposingScore":37,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:31.647Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143048-f6c499cb::panitumumab::pan-cancer","analysisId":"20260414T143048-f6c499cb","recordedAt":"2026-04-14T14:30:48.490Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"FDA Approved","repurposingScore":37,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:28.920Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143048-f6c499cb::temozolomide::pan-cancer","analysisId":"20260414T143048-f6c499cb","recordedAt":"2026-04-14T14:30:48.490Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"FDA Approved","repurposingScore":37,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:28.538Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143048-f6c499cb::gemcitabine::pan-cancer","analysisId":"20260414T143048-f6c499cb","recordedAt":"2026-04-14T14:30:48.490Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT04004234","NCT06607185","NCT06333314"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2026-01-13","trialPhase":"FDA Approved","repurposingScore":37,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:29.695Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143048-f6c499cb::cetuximab::pan-cancer","analysisId":"20260414T143048-f6c499cb","recordedAt":"2026-04-14T14:30:48.490Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT01816984","NCT06585488"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2024-09-23","trialPhase":"FDA Approved","repurposingScore":37,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:29.307Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T143048-f6c499cb::carboplatin::pan-cancer","analysisId":"20260414T143048-f6c499cb","recordedAt":"2026-04-14T14:30:48.490Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT06607185","NCT03989336","NCT06333314","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-06-22","trialPhase":"FDA Approved","repurposingScore":37,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:30.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04084717","NCT02194738","NCT04322890","NCT03052608","NCT02568267"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-09-10","trialPhase":"FDA Approved","repurposingScore":61,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:25.812Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT01102231","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2023-10-05","trialPhase":"FDA Approved","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:26.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT03492437","NCT02864992","NCT04739358","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-07","trialPhase":"FDA Approved","repurposingScore":70,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:26.993Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04322890","NCT05081674","NCT06709274","NCT05015010","NCT04302025"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-03-26","trialPhase":"FDA Approved","repurposingScore":57,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:26.595Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02716116","NCT04129502","NCT05207423","NCT05241873","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2016-03-23","trialPhase":"FDA Approved","repurposingScore":70,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:27.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04322890","NCT03052608","NCT06378892","NCT02584634","NCT06487078"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-03-26","trialPhase":"FDA Approved","repurposingScore":58,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:25.015Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04322890","NCT05361564","NCT05735327","NCT06522360","NCT01449461"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-03-26","trialPhase":"FDA Approved","repurposingScore":57,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:25.407Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04077463","NCT02609776","NCT05498428","NCT06116682"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-09-04","trialPhase":"FDA Approved","repurposingScore":70,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:24.226Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142903-184e78d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260414T142903-184e78d1","recordedAt":"2026-04-14T14:29:03.247Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01776684","NCT01649284","NCT03623750","NCT02145637"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-01-28","trialPhase":"FDA Approved","repurposingScore":57,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:24.615Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::bevacizumab::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03135652","NCT06293014","NCT00661154"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2017-05-01","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:20.283Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::encorafenib::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02278133","NCT05510895","NCT05004350","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2026-01-06","trialPhase":"FDA Approved","repurposingScore":55,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:20.673Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::regorafenib::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"high","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04446091","NCT02651415","NCT04745130","NCT03555149","NCT03946917"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-06-24","trialPhase":"FDA Approved","repurposingScore":79,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:23.437Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::capecitabine::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04751955","NCT00084643","NCT02280694","NCT00959946"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2021-02-12","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:22.617Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::tovorafenib::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2025-08-14","trialPhase":"FDA Approved","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:22.230Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::cetuximab::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03135652","NCT03944252","NCT04793958","NCT00439517"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2017-05-01","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:23.825Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::fluorouracil::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00280176","NCT04751955","NCT04793958","NCT02575508"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-01-20","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:21.068Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::adagrasib::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"medium","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04793958","NCT06412198","NCT06026410","NCT05578092"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-03-11","trialPhase":"FDA Approved","repurposingScore":50,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:21.843Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142731-f2abd71d::selumetinib::colorectal_cancer","analysisId":"20260414T142731-f2abd71d","recordedAt":"2026-04-14T14:27:31.284Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02188264","NCT00600496","NCT01134601","NCT01160926","NCT01116271"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-11","trialPhase":"FDA Approved","repurposingScore":35,"tier":null,"isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:23.048Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06531447","NCT00736333","NCT00286247","NCT01917578","NCT02838225"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2024-08-01","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:19.503Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::vinorelbine::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02658084","NCT00629148","NCT00006682","NCT02892123","NCT06690840"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-01-18","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:19.112Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::tamoxifen::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00884143","NCT00003678","NCT00756717","NCT00026286","NCT03184090"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-04-20","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:18.292Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::sacituzumab_govitecan::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06236269","NCT06100874","NCT06798506","NCT06793332"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-02-01","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-14T17:02:17.108Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::niraparib::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03154281","NCT03945721","NCT05261269","NCT05461690","NCT05232006"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-05-16","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:18.685Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::talazoparib::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04982848","NCT04849364","NCT04987931","NCT04892693","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2021-07-29","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:16.715Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::carboplatin::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01917578","NCT01238133","NCT04191135","NCT02476955","NCT01818063"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-08-06","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:16.319Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::rucaparib::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03840200","NCT02711137","NCT04171700","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-15","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:19.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::olaparib::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04024254","NCT04191135","NCT06135714","NCT01116648","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-07-18","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:17.510Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260414T142535-3b95d2bf::paclitaxel::breast_cancer","analysisId":"20260414T142535-3b95d2bf","recordedAt":"2026-04-14T14:25:35.709Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"low","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06531447","NCT03264547","NCT01917578","NCT04247126","NCT02838225"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2024-08-01","trialPhase":"FDA Approved","repurposingScore":34,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-14T17:02:17.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::pravastatin_sodium::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000461","NCT01634906","NCT00054938","NCT06501443","NCT06856772"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:36.660Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::alirocumab::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03559309","NCT01663402","NCT03067844","NCT05001984","NCT03355027"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:37.024Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::mipomersen::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"MIPOMERSEN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01598948"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-05-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:35.949Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::inclisiran::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05639218","NCT06813911","NCT06494501","NCT04765657","NCT03705234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2022-12-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:34.871Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::cholestyramine_resin::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"CHOLESTYRAMINE RESIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000461","NCT06501443","NCT01053065"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:36.304Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::alprostadil::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"ALPROSTADIL","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04312555","NCT01758874","NCT04197323"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:38.092Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::rivaroxaban::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"RIVAROXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05797376","NCT02544932","NCT04305028","NCT05009862","NCT04753372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-04-03","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:37.727Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::dexamethasone::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"DEXAMETHASONE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02807779","NCT03942601","NCT01507558","NCT01983449"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-06-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:37.377Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235938-40a02de6::lovastatin::atherosclerosis","analysisId":"20260404T235938-40a02de6","recordedAt":"2026-04-04T23:59:38.166Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000477","NCT00000553","NCT00651391","NCT00116870","NCT00125593"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:35.584Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::pacritinib::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"PACRITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01620216","NCT02323607","NCT02532010","NCT04282187"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2012-06-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:34.162Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::quizartinib::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"QUIZARTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03723681","NCT01390337","NCT04107727"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-10-28","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:32.729Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::decitabine::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03356080","NCT03217838","NCT04817241","NCT06232655"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2017-11-28","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:32.368Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::sorafenib::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"SORAFENIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02270788","NCT00875745","NCT01371981","NCT00908167","NCT01398501"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-10-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:34.518Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::midostaurin::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01174888","NCT00866281","NCT03280030","NCT01830361","NCT02078609"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:33.097Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::gilteritinib::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05312112","NCT02421939","NCT03922100","NCT06317649","NCT06713837"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2022-04-04","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:32.012Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::idarubicin::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"IDARUBICIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04897490","NCT01018069","NCT00878722","NCT00382954","NCT00840346"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2021-05-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:31.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::ponatinib::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"PONATINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04188405","NCT01424982","NCT02629692","NCT01667133","NCT02779283"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-12-04","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:31.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T235745-508b6ce9::azacitidine::acute_myeloid_leukemia","analysisId":"20260404T235745-508b6ce9","recordedAt":"2026-04-04T23:57:45.420Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05949762","NCT03356080","NCT03217838"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-07-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:33.453Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::quizartinib::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"QUIZARTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03723681","NCT01390337","NCT04107727"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-10-28","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:29.149Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::azacitidine::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05949762","NCT03356080","NCT03217838"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-07-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:29.868Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::ponatinib::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"PONATINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04188405","NCT01424982","NCT02629692","NCT01667133","NCT02779283"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-12-04","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:27.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::sorafenib::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"SORAFENIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02270788","NCT00875745","NCT01371981","NCT00908167","NCT01398501"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-10-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:30.939Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::pacritinib::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"PACRITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01620216","NCT02323607","NCT02532010","NCT04282187"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2012-06-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:30.586Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::decitabine::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03356080","NCT03217838","NCT04817241","NCT06232655"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2017-11-28","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:28.785Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::midostaurin::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01174888","NCT00866281","NCT03280030","NCT01830361","NCT02078609"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:29.506Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::gilteritinib::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05312112","NCT02421939","NCT03922100","NCT06317649","NCT06713837"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2022-04-04","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:28.424Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T221639-5a93aaf8::idarubicin::acute_myeloid_leukemia","analysisId":"20260404T221639-5a93aaf8","recordedAt":"2026-04-04T22:16:39.364Z","drug":"IDARUBICIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04897490","NCT01018069","NCT00878722","NCT00382954","NCT00840346"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2021-05-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:28.061Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::pravastatin_sodium::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000461","NCT01634906","NCT00054938","NCT06501443","NCT06856772"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:25.918Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::mipomersen::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"MIPOMERSEN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01598948"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-05-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:25.204Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::cholestyramine_resin::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"CHOLESTYRAMINE RESIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000461","NCT06501443","NCT01053065"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:25.560Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::lovastatin::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000477","NCT00000553","NCT00651391","NCT00116870","NCT00125593"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:24.852Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::inclisiran::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05639218","NCT06813911","NCT06494501","NCT04765657","NCT03705234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2022-12-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:24.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::alprostadil::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"ALPROSTADIL","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04312555","NCT01758874","NCT04197323"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:27.352Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::rivaroxaban::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"RIVAROXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05797376","NCT02544932","NCT04305028","NCT05009862","NCT04753372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-04-03","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:26.996Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::dexamethasone::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"DEXAMETHASONE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02807779","NCT03942601","NCT01507558","NCT01983449"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-06-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:26.635Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T220427-06bef20a::alirocumab::atherosclerosis","analysisId":"20260404T220427-06bef20a","recordedAt":"2026-04-04T22:04:27.763Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03559309","NCT01663402","NCT03067844","NCT05001984","NCT03355027"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:26.272Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T215330-eaa093e0::atezolizumab::triple-negative_breast_cancer","analysisId":"20260404T215330-eaa093e0","recordedAt":"2026-04-04T21:53:30.463Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT05266937","NCT04102618","NCT04954599","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:23.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T215330-eaa093e0::afatinib::triple-negative_breast_cancer","analysisId":"20260404T215330-eaa093e0","recordedAt":"2026-04-04T21:53:30.463Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:21.979Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T215330-eaa093e0::carboplatin::triple-negative_breast_cancer","analysisId":"20260404T215330-eaa093e0","recordedAt":"2026-04-04T21:53:30.463Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:21.245Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T215330-eaa093e0::erlotinib::triple-negative_breast_cancer","analysisId":"20260404T215330-eaa093e0","recordedAt":"2026-04-04T21:53:30.463Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:22.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T195201-966a7433::galantamine::alzheimer's_disease","analysisId":"20260404T195201-966a7433","recordedAt":"2026-04-04T19:52:01.896Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:16.020Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T195201-966a7433::aducanumab::alzheimer's_disease","analysisId":"20260404T195201-966a7433","recordedAt":"2026-04-04T19:52:01.896Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:14.595Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T195201-966a7433::donanemab::alzheimer's_disease","analysisId":"20260404T195201-966a7433","recordedAt":"2026-04-04T19:52:01.896Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:15.301Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T195201-966a7433::lecanemab::alzheimer's_disease","analysisId":"20260404T195201-966a7433","recordedAt":"2026-04-04T19:52:01.896Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:14.947Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T195201-966a7433::rivastigmine::alzheimer's_disease","analysisId":"20260404T195201-966a7433","recordedAt":"2026-04-04T19:52:01.896Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:16.379Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T195201-966a7433::donepezil::alzheimer's_disease","analysisId":"20260404T195201-966a7433","recordedAt":"2026-04-04T19:52:01.896Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:15.664Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T183906-003a1d2d::carboplatin::triple-negative_breast_cancer","analysisId":"20260404T183906-003a1d2d","recordedAt":"2026-04-04T18:39:06.381Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:11.735Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T183906-003a1d2d::atezolizumab::triple-negative_breast_cancer","analysisId":"20260404T183906-003a1d2d","recordedAt":"2026-04-04T18:39:06.381Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT05266937","NCT04102618","NCT04954599","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:14.224Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T183906-003a1d2d::erlotinib::triple-negative_breast_cancer","analysisId":"20260404T183906-003a1d2d","recordedAt":"2026-04-04T18:39:06.381Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:12.801Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260404T183906-003a1d2d::afatinib::triple-negative_breast_cancer","analysisId":"20260404T183906-003a1d2d","recordedAt":"2026-04-04T18:39:06.381Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:12.443Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::bevacizumab::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:04.929Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::adagrasib::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:04.565Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::regorafenib::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:03.846Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::sorafenib::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:06.707Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::selumetinib::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:06.349Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::tovorafenib::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:07.061Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::cetuximab::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:05.638Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::capecitabine::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:05.281Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T214925-c844c452::encorafenib::colorectal_cancer","analysisId":"20260402T214925-c844c452","recordedAt":"2026-04-02T21:49:25.841Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:04.208Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160240-6a7c9c65::lecanemab::alzheimers_disease","analysisId":"20260402T160240-6a7c9c65","recordedAt":"2026-04-02T16:02:40.980Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:02.059Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160240-6a7c9c65::galantamine::alzheimers_disease","analysisId":"20260402T160240-6a7c9c65","recordedAt":"2026-04-02T16:02:40.980Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:03.135Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160240-6a7c9c65::donanemab::alzheimers_disease","analysisId":"20260402T160240-6a7c9c65","recordedAt":"2026-04-02T16:02:40.980Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:02.417Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160240-6a7c9c65::aducanumab::alzheimers_disease","analysisId":"20260402T160240-6a7c9c65","recordedAt":"2026-04-02T16:02:40.980Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:01.702Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160240-6a7c9c65::rivastigmine::alzheimers_disease","analysisId":"20260402T160240-6a7c9c65","recordedAt":"2026-04-02T16:02:40.980Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:03.489Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160240-6a7c9c65::donepezil::alzheimers_disease","analysisId":"20260402T160240-6a7c9c65","recordedAt":"2026-04-02T16:02:40.980Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:02.780Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160143-c2761458::carboplatin::pan-cancer","analysisId":"20260402T160143-c2761458","recordedAt":"2026-04-02T16:01:43.334Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:00.992Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160143-c2761458::panitumumab::pan-cancer","analysisId":"20260402T160143-c2761458","recordedAt":"2026-04-02T16:01:43.334Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:48:00.280Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160143-c2761458::temozolomide::pan-cancer","analysisId":"20260402T160143-c2761458","recordedAt":"2026-04-02T16:01:43.334Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:59.558Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160143-c2761458::palbociclib::pan-cancer","analysisId":"20260402T160143-c2761458","recordedAt":"2026-04-02T16:01:43.334Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:01.347Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160143-c2761458::sirolimus::pan-cancer","analysisId":"20260402T160143-c2761458","recordedAt":"2026-04-02T16:01:43.334Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:48:00.636Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160143-c2761458::cetuximab::pan-cancer","analysisId":"20260402T160143-c2761458","recordedAt":"2026-04-02T16:01:43.334Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:58.844Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160143-c2761458::gemcitabine::pan-cancer","analysisId":"20260402T160143-c2761458","recordedAt":"2026-04-02T16:01:43.334Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:59.918Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160143-c2761458::paclitaxel::pan-cancer","analysisId":"20260402T160143-c2761458","recordedAt":"2026-04-02T16:01:43.334Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:58.125Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:56.699Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:55.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:55.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:54.908Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:57.772Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:54.546Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:57.413Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:57.055Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T160049-6adfafa0::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260402T160049-6adfafa0","recordedAt":"2026-04-02T16:00:49.939Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:56.342Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::regorafenib::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:50.989Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::cetuximab::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:52.765Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::capecitabine::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:52.412Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::tovorafenib::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:54.189Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::sorafenib::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:53.833Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::adagrasib::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:51.700Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::bevacizumab::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:52.052Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::selumetinib::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:53.477Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155953-c844c452::encorafenib::colorectal_cancer","analysisId":"20260402T155953-c844c452","recordedAt":"2026-04-02T15:59:53.073Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:51.346Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::sacituzumab_govitecan::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:49.555Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::rucaparib::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:49.198Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::olaparib::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:48.485Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::vinorelbine::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:50.628Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::tamoxifen::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:50.275Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::talazoparib::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:49.918Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::paclitaxel::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:48.839Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::niraparib::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:48.131Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:47.766Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155906-9fad091f::carboplatin::breast_cancer","analysisId":"20260402T155906-9fad091f","recordedAt":"2026-04-02T15:59:06.060Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:47.408Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155244-1f1ae2bb::donanemab::alzheimers_disease","analysisId":"20260402T155244-1f1ae2bb","recordedAt":"2026-04-02T15:52:44.789Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:45.986Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155244-1f1ae2bb::aducanumab::alzheimers_disease","analysisId":"20260402T155244-1f1ae2bb","recordedAt":"2026-04-02T15:52:44.789Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:45.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155244-1f1ae2bb::lecanemab::alzheimers_disease","analysisId":"20260402T155244-1f1ae2bb","recordedAt":"2026-04-02T15:52:44.789Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:45.631Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155244-1f1ae2bb::rivastigmine::alzheimers_disease","analysisId":"20260402T155244-1f1ae2bb","recordedAt":"2026-04-02T15:52:44.789Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:47.055Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155244-1f1ae2bb::galantamine::alzheimers_disease","analysisId":"20260402T155244-1f1ae2bb","recordedAt":"2026-04-02T15:52:44.789Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:46.702Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T155244-1f1ae2bb::donepezil::alzheimers_disease","analysisId":"20260402T155244-1f1ae2bb","recordedAt":"2026-04-02T15:52:44.789Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:46.348Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T152048-28a2f925::donepezil::alzheimers_disease","analysisId":"20260402T152048-28a2f925","recordedAt":"2026-04-02T15:20:48.184Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:43.835Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T152048-28a2f925::lecanemab::alzheimers_disease","analysisId":"20260402T152048-28a2f925","recordedAt":"2026-04-02T15:20:48.184Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:42.765Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T152048-28a2f925::aducanumab::alzheimers_disease","analysisId":"20260402T152048-28a2f925","recordedAt":"2026-04-02T15:20:48.184Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:42.413Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T152048-28a2f925::rivastigmine::alzheimers_disease","analysisId":"20260402T152048-28a2f925","recordedAt":"2026-04-02T15:20:48.184Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:44.547Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T152048-28a2f925::galantamine::alzheimers_disease","analysisId":"20260402T152048-28a2f925","recordedAt":"2026-04-02T15:20:48.184Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:44.190Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T152048-28a2f925::donanemab::alzheimers_disease","analysisId":"20260402T152048-28a2f925","recordedAt":"2026-04-02T15:20:48.184Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:43.481Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151811-65d64218::sirolimus::pan-cancer","analysisId":"20260402T151811-65d64218","recordedAt":"2026-04-02T15:18:11.853Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:41.337Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151811-65d64218::temozolomide::pan-cancer","analysisId":"20260402T151811-65d64218","recordedAt":"2026-04-02T15:18:11.853Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:40.276Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151811-65d64218::paclitaxel::pan-cancer","analysisId":"20260402T151811-65d64218","recordedAt":"2026-04-02T15:18:11.853Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:38.851Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151811-65d64218::palbociclib::pan-cancer","analysisId":"20260402T151811-65d64218","recordedAt":"2026-04-02T15:18:11.853Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:42.057Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151811-65d64218::carboplatin::pan-cancer","analysisId":"20260402T151811-65d64218","recordedAt":"2026-04-02T15:18:11.853Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:41.695Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151811-65d64218::panitumumab::pan-cancer","analysisId":"20260402T151811-65d64218","recordedAt":"2026-04-02T15:18:11.853Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:40.982Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151811-65d64218::gemcitabine::pan-cancer","analysisId":"20260402T151811-65d64218","recordedAt":"2026-04-02T15:18:11.853Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:40.631Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151811-65d64218::cetuximab::pan-cancer","analysisId":"20260402T151811-65d64218","recordedAt":"2026-04-02T15:18:11.853Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:39.566Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151533-62102268::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T151533-62102268","recordedAt":"2026-04-02T15:15:33.669Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:36.359Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151533-62102268::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T151533-62102268","recordedAt":"2026-04-02T15:15:33.669Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:35.286Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151533-62102268::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T151533-62102268","recordedAt":"2026-04-02T15:15:33.669Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:35.650Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151533-62102268::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T151533-62102268","recordedAt":"2026-04-02T15:15:33.669Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:38.134Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151533-62102268::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T151533-62102268","recordedAt":"2026-04-02T15:15:33.669Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:37.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151533-62102268::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T151533-62102268","recordedAt":"2026-04-02T15:15:33.669Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:36.710Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151533-62102268::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T151533-62102268","recordedAt":"2026-04-02T15:15:33.669Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:37.066Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151533-62102268::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T151533-62102268","recordedAt":"2026-04-02T15:15:33.669Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:36.006Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::regorafenib::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:31.715Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::atezolizumab::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:34.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::adagrasib::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:34.567Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::temsirolimus::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:33.142Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::sorafenib::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:32.788Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::selumetinib::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:32.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::encorafenib::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:34.204Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::dabrafenib::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:33.854Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T151230-181452b6::tovorafenib::colorectal_cancer","analysisId":"20260402T151230-181452b6","recordedAt":"2026-04-02T15:12:30.748Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:33.495Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:29.926Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:28.846Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::cisplatin::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:28.490Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::carboplatin::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:28.132Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::rucaparib::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:31.006Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::niraparib::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:30.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::olaparib::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:30.647Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::talazoparib::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:31.359Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::paclitaxel::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:29.570Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150916-b44315aa::gemcitabine::breast_cancer","analysisId":"20260402T150916-b44315aa","recordedAt":"2026-04-02T15:09:17.733Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:29.210Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:26.339Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:25.633Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:24.916Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:27.419Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:27.056Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:26.695Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:25.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:27.777Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T150846-77cf1de6::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T150846-77cf1de6","recordedAt":"2026-04-02T15:08:46.159Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:24.560Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::tovorafenib::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:22.408Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::encorafenib::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:23.488Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::dabrafenib::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:23.117Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::sorafenib::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:22.761Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::selumetinib::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:21.695Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::regorafenib::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:20.974Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::atezolizumab::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:24.201Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::adagrasib::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:23.846Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145940-0afbf512::temsirolimus::colorectal_cancer","analysisId":"20260402T145940-0afbf512","recordedAt":"2026-04-02T14:59:40.217Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:22.046Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::gemcitabine::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:18.485Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::cisplatin::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:17.757Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::carboplatin::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:17.399Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::olaparib::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:19.201Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::talazoparib::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:20.624Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::rucaparib::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:19.920Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::paclitaxel::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:19.565Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::niraparib::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:18.848Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:18.121Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T145153-9fad091f::sacituzumab_govitecan::breast_cancer","analysisId":"20260402T145153-9fad091f","recordedAt":"2026-04-02T14:51:53.930Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:20.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T143008-e8445e36::aducanumab::alzheimers_disease","analysisId":"20260402T143008-e8445e36","recordedAt":"2026-04-02T14:30:08.389Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:14.542Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T143008-e8445e36::lecanemab::alzheimers_disease","analysisId":"20260402T143008-e8445e36","recordedAt":"2026-04-02T14:30:08.389Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:14.895Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T143008-e8445e36::solanezumab::alzheimers_disease","analysisId":"20260402T143008-e8445e36","recordedAt":"2026-04-02T14:30:08.389Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:17.044Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T143008-e8445e36::donepezil::alzheimers_disease","analysisId":"20260402T143008-e8445e36","recordedAt":"2026-04-02T14:30:08.389Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:15.601Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T143008-e8445e36::galantamine::alzheimers_disease","analysisId":"20260402T143008-e8445e36","recordedAt":"2026-04-02T14:30:08.389Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:15.958Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T143008-e8445e36::gantenerumab::alzheimers_disease","analysisId":"20260402T143008-e8445e36","recordedAt":"2026-04-02T14:30:08.389Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:16.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T143008-e8445e36::donanemab::alzheimers_disease","analysisId":"20260402T143008-e8445e36","recordedAt":"2026-04-02T14:30:08.389Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:15.249Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T143008-e8445e36::rivastigmine::alzheimers_disease","analysisId":"20260402T143008-e8445e36","recordedAt":"2026-04-02T14:30:08.389Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:16.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135536-c2761458::palbociclib::pan-cancer","analysisId":"20260402T135536-c2761458","recordedAt":"2026-04-02T13:55:36.848Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:13.816Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135536-c2761458::carboplatin::pan-cancer","analysisId":"20260402T135536-c2761458","recordedAt":"2026-04-02T13:55:36.848Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:13.459Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135536-c2761458::panitumumab::pan-cancer","analysisId":"20260402T135536-c2761458","recordedAt":"2026-04-02T13:55:36.848Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:12.750Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135536-c2761458::temozolomide::pan-cancer","analysisId":"20260402T135536-c2761458","recordedAt":"2026-04-02T13:55:36.848Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:12.035Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135536-c2761458::sirolimus::pan-cancer","analysisId":"20260402T135536-c2761458","recordedAt":"2026-04-02T13:55:36.848Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:13.102Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135536-c2761458::cetuximab::pan-cancer","analysisId":"20260402T135536-c2761458","recordedAt":"2026-04-02T13:55:36.848Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:11.316Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135536-c2761458::gemcitabine::pan-cancer","analysisId":"20260402T135536-c2761458","recordedAt":"2026-04-02T13:55:36.848Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:12.394Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135536-c2761458::paclitaxel::pan-cancer","analysisId":"20260402T135536-c2761458","recordedAt":"2026-04-02T13:55:36.848Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:10.597Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135340-04055287::gemcitabine::pan-cancer","analysisId":"20260402T135340-04055287","recordedAt":"2026-04-02T13:53:40.927Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:08.811Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135340-04055287::paclitaxel::pan-cancer","analysisId":"20260402T135340-04055287","recordedAt":"2026-04-02T13:53:40.927Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:07.037Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135340-04055287::cetuximab::pan-cancer","analysisId":"20260402T135340-04055287","recordedAt":"2026-04-02T13:53:40.927Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:07.746Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135340-04055287::palbociclib::pan-cancer","analysisId":"20260402T135340-04055287","recordedAt":"2026-04-02T13:53:40.927Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:10.242Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135340-04055287::carboplatin::pan-cancer","analysisId":"20260402T135340-04055287","recordedAt":"2026-04-02T13:53:40.927Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:09.878Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135340-04055287::sirolimus::pan-cancer","analysisId":"20260402T135340-04055287","recordedAt":"2026-04-02T13:53:40.927Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:09.527Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135340-04055287::panitumumab::pan-cancer","analysisId":"20260402T135340-04055287","recordedAt":"2026-04-02T13:53:40.927Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:09.167Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T135340-04055287::temozolomide::pan-cancer","analysisId":"20260402T135340-04055287","recordedAt":"2026-04-02T13:53:40.927Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:08.458Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:04.534Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:04.892Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:03.810Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:06.681Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:06.328Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:05.971Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:05.605Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:05.252Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134950-7d3c2e3d::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T134950-7d3c2e3d","recordedAt":"2026-04-02T13:49:51.053Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:03.454Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::dabrafenib::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:02.017Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::encorafenib::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:02.372Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::temsirolimus::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:00.947Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::regorafenib::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:59.887Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::tovorafenib::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:01.305Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::atezolizumab::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:03.091Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::adagrasib::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:47:02.728Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::sorafenib::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:01.663Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T134413-8412cb7d::selumetinib::colorectal_cancer","analysisId":"20260402T134413-8412cb7d","recordedAt":"2026-04-02T13:44:13.454Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:47:00.590Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:57.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::carboplatin::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:56.323Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::olaparib::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:58.097Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::talazoparib::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:59.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::rucaparib::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:58.817Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::paclitaxel::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:58.452Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::niraparib::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:57.736Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::gemcitabine::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:57.380Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::cisplatin::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:56.673Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T133759-8448fb6c::sacituzumab_govitecan::breast_cancer","analysisId":"20260402T133759-8448fb6c","recordedAt":"2026-04-02T13:37:59.606Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:59.179Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T131717-e7777059::gantenerumab::alzheimers_disease","analysisId":"20260402T131717-e7777059","recordedAt":"2026-04-02T13:17:17.725Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:55.609Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T131717-e7777059::solanezumab::alzheimers_disease","analysisId":"20260402T131717-e7777059","recordedAt":"2026-04-02T13:17:17.725Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:55.964Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T131717-e7777059::rivastigmine::alzheimers_disease","analysisId":"20260402T131717-e7777059","recordedAt":"2026-04-02T13:17:17.725Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:55.253Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T131717-e7777059::galantamine::alzheimers_disease","analysisId":"20260402T131717-e7777059","recordedAt":"2026-04-02T13:17:17.725Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:54.895Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T131717-e7777059::donepezil::alzheimers_disease","analysisId":"20260402T131717-e7777059","recordedAt":"2026-04-02T13:17:17.725Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:54.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T131717-e7777059::donanemab::alzheimers_disease","analysisId":"20260402T131717-e7777059","recordedAt":"2026-04-02T13:17:17.725Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:54.171Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T131717-e7777059::aducanumab::alzheimers_disease","analysisId":"20260402T131717-e7777059","recordedAt":"2026-04-02T13:17:17.725Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:53.451Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T131717-e7777059::lecanemab::alzheimers_disease","analysisId":"20260402T131717-e7777059","recordedAt":"2026-04-02T13:17:17.725Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:53.810Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T075820-a8f122bc::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T075820-a8f122bc","recordedAt":"2026-04-02T07:58:20.716Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:50.225Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T075820-a8f122bc::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T075820-a8f122bc","recordedAt":"2026-04-02T07:58:20.716Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:52.375Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T075820-a8f122bc::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T075820-a8f122bc","recordedAt":"2026-04-02T07:58:20.716Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:52.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T075820-a8f122bc::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T075820-a8f122bc","recordedAt":"2026-04-02T07:58:20.716Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:49.510Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T075820-a8f122bc::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T075820-a8f122bc","recordedAt":"2026-04-02T07:58:20.716Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:51.660Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T075820-a8f122bc::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T075820-a8f122bc","recordedAt":"2026-04-02T07:58:20.716Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:51.302Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T075820-a8f122bc::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T075820-a8f122bc","recordedAt":"2026-04-02T07:58:20.716Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:50.938Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T075820-a8f122bc::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T075820-a8f122bc","recordedAt":"2026-04-02T07:58:20.716Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:52.733Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055852-9f2c64f1::gantenerumab::alzheimers_disease","analysisId":"20260402T055852-9f2c64f1","recordedAt":"2026-04-02T05:58:52.356Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:48.798Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055852-9f2c64f1::solanezumab::alzheimers_disease","analysisId":"20260402T055852-9f2c64f1","recordedAt":"2026-04-02T05:58:52.356Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:49.152Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055852-9f2c64f1::rivastigmine::alzheimers_disease","analysisId":"20260402T055852-9f2c64f1","recordedAt":"2026-04-02T05:58:52.356Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:48.442Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055852-9f2c64f1::galantamine::alzheimers_disease","analysisId":"20260402T055852-9f2c64f1","recordedAt":"2026-04-02T05:58:52.356Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:48.087Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055852-9f2c64f1::donepezil::alzheimers_disease","analysisId":"20260402T055852-9f2c64f1","recordedAt":"2026-04-02T05:58:52.356Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:47.722Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055852-9f2c64f1::donanemab::alzheimers_disease","analysisId":"20260402T055852-9f2c64f1","recordedAt":"2026-04-02T05:58:52.356Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:47.360Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055852-9f2c64f1::aducanumab::alzheimers_disease","analysisId":"20260402T055852-9f2c64f1","recordedAt":"2026-04-02T05:58:52.356Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:46.642Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055852-9f2c64f1::lecanemab::alzheimers_disease","analysisId":"20260402T055852-9f2c64f1","recordedAt":"2026-04-02T05:58:52.356Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:47.006Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055140-cf879016::paclitaxel::pan-cancer","analysisId":"20260402T055140-cf879016","recordedAt":"2026-04-02T05:51:40.242Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:42.715Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055140-cf879016::sirolimus::pan-cancer","analysisId":"20260402T055140-cf879016","recordedAt":"2026-04-02T05:51:40.242Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:45.221Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055140-cf879016::cetuximab::pan-cancer","analysisId":"20260402T055140-cf879016","recordedAt":"2026-04-02T05:51:40.242Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:43.433Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055140-cf879016::panitumumab::pan-cancer","analysisId":"20260402T055140-cf879016","recordedAt":"2026-04-02T05:51:40.242Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:44.860Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055140-cf879016::temozolomide::pan-cancer","analysisId":"20260402T055140-cf879016","recordedAt":"2026-04-02T05:51:40.242Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:44.147Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055140-cf879016::gemcitabine::pan-cancer","analysisId":"20260402T055140-cf879016","recordedAt":"2026-04-02T05:51:40.242Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:44.504Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055140-cf879016::palbociclib::pan-cancer","analysisId":"20260402T055140-cf879016","recordedAt":"2026-04-02T05:51:40.242Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:45.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T055140-cf879016::carboplatin::pan-cancer","analysisId":"20260402T055140-cf879016","recordedAt":"2026-04-02T05:51:40.242Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:45.574Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:41.641Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:40.922Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:39.485Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:40.563Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:40.203Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:41.998Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:41.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:39.128Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T054545-e9fd8e59::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T054545-e9fd8e59","recordedAt":"2026-04-02T05:45:45.841Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:42.355Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::tovorafenib::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:36.969Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::atezolizumab::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:38.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::encorafenib::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:38.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::dabrafenib::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:37.692Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::adagrasib::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:38.409Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::sorafenib::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:37.335Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::temsirolimus::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:36.612Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::selumetinib::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:36.253Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T051055-c844c452::regorafenib::colorectal_cancer","analysisId":"20260402T051055-c844c452","recordedAt":"2026-04-02T05:10:55.639Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:35.537Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::cisplatin::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:32.307Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::carboplatin::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:31.948Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::talazoparib::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:35.177Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::rucaparib::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:34.459Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::paclitaxel::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:34.103Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::olaparib::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:33.744Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::niraparib::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:33.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::gemcitabine::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:33.027Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:32.667Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T050727-9fad091f::sacituzumab_govitecan::breast_cancer","analysisId":"20260402T050727-9fad091f","recordedAt":"2026-04-02T05:07:27.254Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:34.819Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040923-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260402T040923-33db16bd","recordedAt":"2026-04-02T04:09:23.470Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:29.080Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040923-33db16bd::donepezil::alzheimers_disease","analysisId":"20260402T040923-33db16bd","recordedAt":"2026-04-02T04:09:23.470Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:30.155Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040923-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260402T040923-33db16bd","recordedAt":"2026-04-02T04:09:23.470Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:28.721Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040923-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260402T040923-33db16bd","recordedAt":"2026-04-02T04:09:23.470Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:31.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040923-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260402T040923-33db16bd","recordedAt":"2026-04-02T04:09:23.470Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:31.233Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040923-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260402T040923-33db16bd","recordedAt":"2026-04-02T04:09:23.470Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:30.876Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040923-33db16bd::galantamine::alzheimers_disease","analysisId":"20260402T040923-33db16bd","recordedAt":"2026-04-02T04:09:23.470Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:30.515Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040923-33db16bd::donanemab::alzheimers_disease","analysisId":"20260402T040923-33db16bd","recordedAt":"2026-04-02T04:09:23.470Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:29.799Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040657-99db93fe::panitumumab::pan-cancer","analysisId":"20260402T040657-99db93fe","recordedAt":"2026-04-02T04:06:57.101Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:27.291Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040657-99db93fe::cetuximab::pan-cancer","analysisId":"20260402T040657-99db93fe","recordedAt":"2026-04-02T04:06:57.101Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:25.867Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040657-99db93fe::gemcitabine::pan-cancer","analysisId":"20260402T040657-99db93fe","recordedAt":"2026-04-02T04:06:57.101Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:26.934Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040657-99db93fe::palbociclib::pan-cancer","analysisId":"20260402T040657-99db93fe","recordedAt":"2026-04-02T04:06:57.101Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:28.362Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040657-99db93fe::carboplatin::pan-cancer","analysisId":"20260402T040657-99db93fe","recordedAt":"2026-04-02T04:06:57.101Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:28.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040657-99db93fe::sirolimus::pan-cancer","analysisId":"20260402T040657-99db93fe","recordedAt":"2026-04-02T04:06:57.101Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:27.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040657-99db93fe::temozolomide::pan-cancer","analysisId":"20260402T040657-99db93fe","recordedAt":"2026-04-02T04:06:57.101Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:26.577Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040657-99db93fe::paclitaxel::pan-cancer","analysisId":"20260402T040657-99db93fe","recordedAt":"2026-04-02T04:06:57.101Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:25.146Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040419-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T040419-c6b7ce28","recordedAt":"2026-04-02T04:04:19.731Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:24.428Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040419-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T040419-c6b7ce28","recordedAt":"2026-04-02T04:04:19.731Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:23.354Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040419-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T040419-c6b7ce28","recordedAt":"2026-04-02T04:04:19.731Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:22.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040419-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T040419-c6b7ce28","recordedAt":"2026-04-02T04:04:19.731Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:21.559Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040419-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T040419-c6b7ce28","recordedAt":"2026-04-02T04:04:19.731Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:22.994Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040419-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T040419-c6b7ce28","recordedAt":"2026-04-02T04:04:19.731Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:21.917Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040419-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T040419-c6b7ce28","recordedAt":"2026-04-02T04:04:19.731Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:24.071Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040419-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T040419-c6b7ce28","recordedAt":"2026-04-02T04:04:19.731Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:22.634Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:20.485Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:20.128Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:21.200Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:20.840Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:19.414Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:19.055Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:18.700Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:17.986Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T040145-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260402T040145-b849edd6","recordedAt":"2026-04-02T04:01:46.015Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:19.772Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::olaparib::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:16.914Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::cisplatin::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:14.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::carboplatin::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:14.410Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::talazoparib::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:17.629Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:16.199Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::rucaparib::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:17.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::niraparib::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:16.556Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:15.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:15.484Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T035911-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260402T035911-c46e28d2","recordedAt":"2026-04-02T03:59:13.178Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:15.126Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T030039-33db16bd::donepezil::alzheimers_disease","analysisId":"20260402T030039-33db16bd","recordedAt":"2026-04-02T03:00:39.962Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:12.619Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T030039-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260402T030039-33db16bd","recordedAt":"2026-04-02T03:00:39.962Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:11.182Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T030039-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260402T030039-33db16bd","recordedAt":"2026-04-02T03:00:39.962Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:14.054Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T030039-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260402T030039-33db16bd","recordedAt":"2026-04-02T03:00:39.962Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:13.695Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T030039-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260402T030039-33db16bd","recordedAt":"2026-04-02T03:00:39.962Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:13.337Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T030039-33db16bd::galantamine::alzheimers_disease","analysisId":"20260402T030039-33db16bd","recordedAt":"2026-04-02T03:00:39.962Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:12.977Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T030039-33db16bd::donanemab::alzheimers_disease","analysisId":"20260402T030039-33db16bd","recordedAt":"2026-04-02T03:00:39.962Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:12.260Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T030039-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260402T030039-33db16bd","recordedAt":"2026-04-02T03:00:39.962Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:11.541Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025820-196d1672::paclitaxel::pan-cancer","analysisId":"20260402T025820-196d1672","recordedAt":"2026-04-02T02:58:20.158Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:07.602Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025820-196d1672::panitumumab::pan-cancer","analysisId":"20260402T025820-196d1672","recordedAt":"2026-04-02T02:58:20.158Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:09.752Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025820-196d1672::cetuximab::pan-cancer","analysisId":"20260402T025820-196d1672","recordedAt":"2026-04-02T02:58:20.158Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:08.323Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025820-196d1672::gemcitabine::pan-cancer","analysisId":"20260402T025820-196d1672","recordedAt":"2026-04-02T02:58:20.158Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:09.393Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025820-196d1672::palbociclib::pan-cancer","analysisId":"20260402T025820-196d1672","recordedAt":"2026-04-02T02:58:20.158Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:10.827Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025820-196d1672::carboplatin::pan-cancer","analysisId":"20260402T025820-196d1672","recordedAt":"2026-04-02T02:58:20.158Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:10.469Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025820-196d1672::sirolimus::pan-cancer","analysisId":"20260402T025820-196d1672","recordedAt":"2026-04-02T02:58:20.158Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:10.111Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025820-196d1672::temozolomide::pan-cancer","analysisId":"20260402T025820-196d1672","recordedAt":"2026-04-02T02:58:20.158Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:09.037Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025532-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T025532-c6b7ce28","recordedAt":"2026-04-02T02:55:32.359Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:05.454Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025532-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T025532-c6b7ce28","recordedAt":"2026-04-02T02:55:32.359Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:06.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025532-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T025532-c6b7ce28","recordedAt":"2026-04-02T02:55:32.359Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:04.735Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025532-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T025532-c6b7ce28","recordedAt":"2026-04-02T02:55:32.359Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:05.814Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025532-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T025532-c6b7ce28","recordedAt":"2026-04-02T02:55:32.359Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:04.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025532-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T025532-c6b7ce28","recordedAt":"2026-04-02T02:55:32.359Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:05.094Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025532-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T025532-c6b7ce28","recordedAt":"2026-04-02T02:55:32.359Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:04.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025532-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T025532-c6b7ce28","recordedAt":"2026-04-02T02:55:32.359Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:06.887Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:02.226Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:03.663Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:02.947Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:02.586Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:03.304Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:01.868Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:01.509Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:01.149Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025252-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260402T025252-b849edd6","recordedAt":"2026-04-02T02:52:52.173Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:46:00.434Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::cisplatin::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:57.209Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::carboplatin::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:56.849Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:58.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::talazoparib::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:46:00.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::rucaparib::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:59.717Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::niraparib::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:59.000Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::paclitaxel::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:58.281Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::gemcitabine::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:57.926Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:57.568Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T025029-b44315aa::olaparib::breast_cancer","analysisId":"20260402T025029-b44315aa","recordedAt":"2026-04-02T02:50:30.766Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:59.357Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020620-ff35af39::lecanemab::alzheimers_disease","analysisId":"20260402T020620-ff35af39","recordedAt":"2026-04-02T02:06:20.362Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:54.344Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020620-ff35af39::donepezil::alzheimers_disease","analysisId":"20260402T020620-ff35af39","recordedAt":"2026-04-02T02:06:20.362Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:55.061Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020620-ff35af39::aducanumab::alzheimers_disease","analysisId":"20260402T020620-ff35af39","recordedAt":"2026-04-02T02:06:20.362Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:53.986Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020620-ff35af39::solanezumab::alzheimers_disease","analysisId":"20260402T020620-ff35af39","recordedAt":"2026-04-02T02:06:20.362Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:56.490Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020620-ff35af39::gantenerumab::alzheimers_disease","analysisId":"20260402T020620-ff35af39","recordedAt":"2026-04-02T02:06:20.362Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:56.133Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020620-ff35af39::rivastigmine::alzheimers_disease","analysisId":"20260402T020620-ff35af39","recordedAt":"2026-04-02T02:06:20.362Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:55.778Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020620-ff35af39::galantamine::alzheimers_disease","analysisId":"20260402T020620-ff35af39","recordedAt":"2026-04-02T02:06:20.362Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:55.420Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020620-ff35af39::donanemab::alzheimers_disease","analysisId":"20260402T020620-ff35af39","recordedAt":"2026-04-02T02:06:20.362Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:54.703Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020204-cf879016::panitumumab::pan-cancer","analysisId":"20260402T020204-cf879016","recordedAt":"2026-04-02T02:02:04.624Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:52.195Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020204-cf879016::cetuximab::pan-cancer","analysisId":"20260402T020204-cf879016","recordedAt":"2026-04-02T02:02:04.624Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:50.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020204-cf879016::gemcitabine::pan-cancer","analysisId":"20260402T020204-cf879016","recordedAt":"2026-04-02T02:02:04.624Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:51.837Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020204-cf879016::palbociclib::pan-cancer","analysisId":"20260402T020204-cf879016","recordedAt":"2026-04-02T02:02:04.624Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:53.270Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020204-cf879016::carboplatin::pan-cancer","analysisId":"20260402T020204-cf879016","recordedAt":"2026-04-02T02:02:04.624Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:52.912Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020204-cf879016::sirolimus::pan-cancer","analysisId":"20260402T020204-cf879016","recordedAt":"2026-04-02T02:02:04.624Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:52.553Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020204-cf879016::temozolomide::pan-cancer","analysisId":"20260402T020204-cf879016","recordedAt":"2026-04-02T02:02:04.624Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:51.479Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T020204-cf879016::paclitaxel::pan-cancer","analysisId":"20260402T020204-cf879016","recordedAt":"2026-04-02T02:02:04.624Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:50.052Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015619-e131e2b6::cetuximab::non-small_cell_lung_cancer","analysisId":"20260402T015619-e131e2b6","recordedAt":"2026-04-02T01:56:19.826Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:49.687Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015619-e131e2b6::crizotinib::non-small_cell_lung_cancer","analysisId":"20260402T015619-e131e2b6","recordedAt":"2026-04-02T01:56:19.826Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:48.256Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015619-e131e2b6::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260402T015619-e131e2b6","recordedAt":"2026-04-02T01:56:19.826Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:47.180Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015619-e131e2b6::amivantamab::non-small_cell_lung_cancer","analysisId":"20260402T015619-e131e2b6","recordedAt":"2026-04-02T01:56:19.826Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:46.462Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015619-e131e2b6::ceritinib::non-small_cell_lung_cancer","analysisId":"20260402T015619-e131e2b6","recordedAt":"2026-04-02T01:56:19.826Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:49.332Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015619-e131e2b6::brigatinib::non-small_cell_lung_cancer","analysisId":"20260402T015619-e131e2b6","recordedAt":"2026-04-02T01:56:19.826Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:48.973Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015619-e131e2b6::alectinib::non-small_cell_lung_cancer","analysisId":"20260402T015619-e131e2b6","recordedAt":"2026-04-02T01:56:19.826Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:48.614Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015619-e131e2b6::tepotinib::non-small_cell_lung_cancer","analysisId":"20260402T015619-e131e2b6","recordedAt":"2026-04-02T01:56:19.826Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:47.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::atezolizumab::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:46.106Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::encorafenib::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:45.391Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::dabrafenib::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:45.033Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::adagrasib::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:45.749Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::sorafenib::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:44.680Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::temsirolimus::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:43.961Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::selumetinib::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:43.603Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::regorafenib::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:42.887Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T015150-c844c452::tovorafenib::colorectal_cancer","analysisId":"20260402T015150-c844c452","recordedAt":"2026-04-02T01:51:51.030Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:44.320Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::sacituzumab_govitecan::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:42.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::cisplatin::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:39.671Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::carboplatin::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:39.313Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::olaparib::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:41.100Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::talazoparib::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:42.528Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::rucaparib::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:41.814Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::paclitaxel::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:41.458Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::niraparib::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:40.744Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::gemcitabine::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:40.390Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T013122-a2a3fdd4::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260402T013122-a2a3fdd4","recordedAt":"2026-04-02T01:31:22.115Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:40.031Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000415-33db16bd::donepezil::alzheimers_disease","analysisId":"20260402T000415-33db16bd","recordedAt":"2026-04-02T00:04:15.320Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:37.524Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000415-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260402T000415-33db16bd","recordedAt":"2026-04-02T00:04:15.320Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:36.088Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000415-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260402T000415-33db16bd","recordedAt":"2026-04-02T00:04:15.320Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:38.953Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000415-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260402T000415-33db16bd","recordedAt":"2026-04-02T00:04:15.320Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:38.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000415-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260402T000415-33db16bd","recordedAt":"2026-04-02T00:04:15.320Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:38.237Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000415-33db16bd::galantamine::alzheimers_disease","analysisId":"20260402T000415-33db16bd","recordedAt":"2026-04-02T00:04:15.320Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:37.881Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000415-33db16bd::donanemab::alzheimers_disease","analysisId":"20260402T000415-33db16bd","recordedAt":"2026-04-02T00:04:15.320Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:37.167Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000415-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260402T000415-33db16bd","recordedAt":"2026-04-02T00:04:15.320Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:36.448Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000150-99db93fe::paclitaxel::pan-cancer","analysisId":"20260402T000150-99db93fe","recordedAt":"2026-04-02T00:01:50.625Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:32.503Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000150-99db93fe::panitumumab::pan-cancer","analysisId":"20260402T000150-99db93fe","recordedAt":"2026-04-02T00:01:50.625Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:34.658Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000150-99db93fe::cetuximab::pan-cancer","analysisId":"20260402T000150-99db93fe","recordedAt":"2026-04-02T00:01:50.625Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:33.222Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000150-99db93fe::gemcitabine::pan-cancer","analysisId":"20260402T000150-99db93fe","recordedAt":"2026-04-02T00:01:50.625Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:34.299Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000150-99db93fe::palbociclib::pan-cancer","analysisId":"20260402T000150-99db93fe","recordedAt":"2026-04-02T00:01:50.625Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:35.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000150-99db93fe::carboplatin::pan-cancer","analysisId":"20260402T000150-99db93fe","recordedAt":"2026-04-02T00:01:50.625Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:35.374Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000150-99db93fe::sirolimus::pan-cancer","analysisId":"20260402T000150-99db93fe","recordedAt":"2026-04-02T00:01:50.625Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:35.015Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260402T000150-99db93fe::temozolomide::pan-cancer","analysisId":"20260402T000150-99db93fe","recordedAt":"2026-04-02T00:01:50.625Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:33.940Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235916-62102268::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T235916-62102268","recordedAt":"2026-04-01T23:59:16.977Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:31.430Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235916-62102268::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T235916-62102268","recordedAt":"2026-04-01T23:59:16.977Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:30.713Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235916-62102268::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T235916-62102268","recordedAt":"2026-04-01T23:59:16.977Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:29.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235916-62102268::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T235916-62102268","recordedAt":"2026-04-01T23:59:16.977Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:29.998Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235916-62102268::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T235916-62102268","recordedAt":"2026-04-01T23:59:16.977Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:30.355Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235916-62102268::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T235916-62102268","recordedAt":"2026-04-01T23:59:16.977Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:29.640Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235916-62102268::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T235916-62102268","recordedAt":"2026-04-01T23:59:16.977Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:28.920Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235916-62102268::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T235916-62102268","recordedAt":"2026-04-01T23:59:16.977Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:31.787Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:27.129Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:28.563Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:27.847Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:27.489Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:28.203Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:26.773Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:26.416Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:26.058Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235703-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T235703-b849edd6","recordedAt":"2026-04-01T23:57:03.526Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:25.344Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:22.127Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:21.768Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:24.994Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:24.640Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:23.921Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:23.563Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:23.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:22.843Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:22.484Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T235453-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T235453-c46e28d2","recordedAt":"2026-04-01T23:54:54.699Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:24.280Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224405-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T224405-33db16bd","recordedAt":"2026-04-01T22:44:05.883Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:18.901Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224405-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T224405-33db16bd","recordedAt":"2026-04-01T22:44:05.883Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:19.978Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224405-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T224405-33db16bd","recordedAt":"2026-04-01T22:44:05.883Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:18.541Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224405-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T224405-33db16bd","recordedAt":"2026-04-01T22:44:05.883Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:21.410Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224405-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T224405-33db16bd","recordedAt":"2026-04-01T22:44:05.883Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:21.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224405-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T224405-33db16bd","recordedAt":"2026-04-01T22:44:05.883Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:20.692Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224405-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T224405-33db16bd","recordedAt":"2026-04-01T22:44:05.883Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:20.334Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224405-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T224405-33db16bd","recordedAt":"2026-04-01T22:44:05.883Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:19.620Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224148-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T224148-99db93fe","recordedAt":"2026-04-01T22:41:48.662Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:16.997Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224148-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T224148-99db93fe","recordedAt":"2026-04-01T22:41:48.662Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:15.561Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224148-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T224148-99db93fe","recordedAt":"2026-04-01T22:41:48.662Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:16.639Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224148-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T224148-99db93fe","recordedAt":"2026-04-01T22:41:48.662Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:18.177Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224148-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T224148-99db93fe","recordedAt":"2026-04-01T22:41:48.662Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:17.716Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224148-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T224148-99db93fe","recordedAt":"2026-04-01T22:41:48.662Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:17.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224148-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T224148-99db93fe","recordedAt":"2026-04-01T22:41:48.662Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:16.281Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T224148-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T224148-99db93fe","recordedAt":"2026-04-01T22:41:48.662Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:14.845Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223928-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T223928-c6b7ce28","recordedAt":"2026-04-01T22:39:28.779Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:14.125Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223928-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T223928-c6b7ce28","recordedAt":"2026-04-01T22:39:28.779Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:13.049Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223928-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T223928-c6b7ce28","recordedAt":"2026-04-01T22:39:28.779Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:11.974Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223928-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T223928-c6b7ce28","recordedAt":"2026-04-01T22:39:28.779Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:11.258Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223928-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T223928-c6b7ce28","recordedAt":"2026-04-01T22:39:28.779Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:12.690Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223928-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T223928-c6b7ce28","recordedAt":"2026-04-01T22:39:28.779Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:11.615Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223928-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T223928-c6b7ce28","recordedAt":"2026-04-01T22:39:28.779Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:13.765Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223928-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T223928-c6b7ce28","recordedAt":"2026-04-01T22:39:28.779Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:12.331Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:10.182Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:09.825Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:10.898Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:10.540Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:09.110Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:08.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:08.391Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:07.675Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223704-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T223704-b849edd6","recordedAt":"2026-04-01T22:37:04.448Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:09.468Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:06.599Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:04.449Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:04.091Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:07.316Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:05.883Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:06.957Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:06.242Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:05.525Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:05.164Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T223448-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T223448-c46e28d2","recordedAt":"2026-04-01T22:34:49.808Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:04.808Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211754-2b9aed26::donepezil::alzheimers_disease","analysisId":"20260401T211754-2b9aed26","recordedAt":"2026-04-01T21:17:54.881Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:02.297Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211754-2b9aed26::aducanumab::alzheimers_disease","analysisId":"20260401T211754-2b9aed26","recordedAt":"2026-04-01T21:17:54.881Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:00.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211754-2b9aed26::solanezumab::alzheimers_disease","analysisId":"20260401T211754-2b9aed26","recordedAt":"2026-04-01T21:17:54.881Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:03.731Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211754-2b9aed26::gantenerumab::alzheimers_disease","analysisId":"20260401T211754-2b9aed26","recordedAt":"2026-04-01T21:17:54.881Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:03.373Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211754-2b9aed26::rivastigmine::alzheimers_disease","analysisId":"20260401T211754-2b9aed26","recordedAt":"2026-04-01T21:17:54.881Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:03.015Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211754-2b9aed26::galantamine::alzheimers_disease","analysisId":"20260401T211754-2b9aed26","recordedAt":"2026-04-01T21:17:54.881Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:02.656Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211754-2b9aed26::donanemab::alzheimers_disease","analysisId":"20260401T211754-2b9aed26","recordedAt":"2026-04-01T21:17:54.881Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:01.938Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211754-2b9aed26::lecanemab::alzheimers_disease","analysisId":"20260401T211754-2b9aed26","recordedAt":"2026-04-01T21:17:54.881Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:45:01.222Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211533-65d64218::paclitaxel::pan-cancer","analysisId":"20260401T211533-65d64218","recordedAt":"2026-04-01T21:15:33.788Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:57.285Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211533-65d64218::panitumumab::pan-cancer","analysisId":"20260401T211533-65d64218","recordedAt":"2026-04-01T21:15:33.788Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:59.434Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211533-65d64218::cetuximab::pan-cancer","analysisId":"20260401T211533-65d64218","recordedAt":"2026-04-01T21:15:33.788Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:57.999Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211533-65d64218::gemcitabine::pan-cancer","analysisId":"20260401T211533-65d64218","recordedAt":"2026-04-01T21:15:33.788Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:59.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211533-65d64218::palbociclib::pan-cancer","analysisId":"20260401T211533-65d64218","recordedAt":"2026-04-01T21:15:33.788Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:00.506Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211533-65d64218::carboplatin::pan-cancer","analysisId":"20260401T211533-65d64218","recordedAt":"2026-04-01T21:15:33.788Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:45:00.148Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211533-65d64218::sirolimus::pan-cancer","analysisId":"20260401T211533-65d64218","recordedAt":"2026-04-01T21:15:33.788Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:59.789Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211533-65d64218::temozolomide::pan-cancer","analysisId":"20260401T211533-65d64218","recordedAt":"2026-04-01T21:15:33.788Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:58.716Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211305-62102268::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T211305-62102268","recordedAt":"2026-04-01T21:13:05.235Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:53.698Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211305-62102268::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T211305-62102268","recordedAt":"2026-04-01T21:13:05.235Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:55.132Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211305-62102268::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T211305-62102268","recordedAt":"2026-04-01T21:13:05.235Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:54.059Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211305-62102268::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T211305-62102268","recordedAt":"2026-04-01T21:13:05.235Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:54.417Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211305-62102268::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T211305-62102268","recordedAt":"2026-04-01T21:13:05.235Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:55.491Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211305-62102268::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T211305-62102268","recordedAt":"2026-04-01T21:13:05.235Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:54.774Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211305-62102268::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T211305-62102268","recordedAt":"2026-04-01T21:13:05.235Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:56.211Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211305-62102268::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T211305-62102268","recordedAt":"2026-04-01T21:13:05.235Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:56.568Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:51.907Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:52.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:52.265Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:53.342Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:52.981Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:51.549Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:51.193Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:50.836Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T211035-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T211035-b849edd6","recordedAt":"2026-04-01T21:10:35.062Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:50.123Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::cisplatin::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:46.902Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::carboplatin::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:46.536Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::talazoparib::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:49.764Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::rucaparib::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:49.407Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::niraparib::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:48.688Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:48.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::paclitaxel::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:47.971Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::gemcitabine::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:47.614Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:47.258Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T210813-b44315aa::olaparib::breast_cancer","analysisId":"20260401T210813-b44315aa","recordedAt":"2026-04-01T21:08:15.310Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:49.048Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192711-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T192711-33db16bd","recordedAt":"2026-04-01T19:27:11.437Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:43.668Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192711-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T192711-33db16bd","recordedAt":"2026-04-01T19:27:11.437Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:44.742Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192711-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T192711-33db16bd","recordedAt":"2026-04-01T19:27:11.437Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:43.311Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192711-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T192711-33db16bd","recordedAt":"2026-04-01T19:27:11.437Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:46.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192711-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T192711-33db16bd","recordedAt":"2026-04-01T19:27:11.437Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:45.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192711-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T192711-33db16bd","recordedAt":"2026-04-01T19:27:11.437Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:45.460Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192711-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T192711-33db16bd","recordedAt":"2026-04-01T19:27:11.437Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:45.101Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192711-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T192711-33db16bd","recordedAt":"2026-04-01T19:27:11.437Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:44.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192457-65d64218::panitumumab::pan-cancer","analysisId":"20260401T192457-65d64218","recordedAt":"2026-04-01T19:24:57.954Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:41.879Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192457-65d64218::cetuximab::pan-cancer","analysisId":"20260401T192457-65d64218","recordedAt":"2026-04-01T19:24:57.954Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:40.447Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192457-65d64218::gemcitabine::pan-cancer","analysisId":"20260401T192457-65d64218","recordedAt":"2026-04-01T19:24:57.954Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:41.522Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192457-65d64218::palbociclib::pan-cancer","analysisId":"20260401T192457-65d64218","recordedAt":"2026-04-01T19:24:57.954Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:42.953Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192457-65d64218::carboplatin::pan-cancer","analysisId":"20260401T192457-65d64218","recordedAt":"2026-04-01T19:24:57.954Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:42.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192457-65d64218::sirolimus::pan-cancer","analysisId":"20260401T192457-65d64218","recordedAt":"2026-04-01T19:24:57.954Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:42.239Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192457-65d64218::temozolomide::pan-cancer","analysisId":"20260401T192457-65d64218","recordedAt":"2026-04-01T19:24:57.954Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:41.162Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192457-65d64218::paclitaxel::pan-cancer","analysisId":"20260401T192457-65d64218","recordedAt":"2026-04-01T19:24:57.954Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:39.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192238-62102268::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T192238-62102268","recordedAt":"2026-04-01T19:22:38.528Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:39.014Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192238-62102268::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T192238-62102268","recordedAt":"2026-04-01T19:22:38.528Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:37.937Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192238-62102268::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T192238-62102268","recordedAt":"2026-04-01T19:22:38.528Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:36.860Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192238-62102268::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T192238-62102268","recordedAt":"2026-04-01T19:22:38.528Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:36.141Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192238-62102268::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T192238-62102268","recordedAt":"2026-04-01T19:22:38.528Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:37.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192238-62102268::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T192238-62102268","recordedAt":"2026-04-01T19:22:38.528Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:36.500Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192238-62102268::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T192238-62102268","recordedAt":"2026-04-01T19:22:38.528Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:38.655Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192238-62102268::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T192238-62102268","recordedAt":"2026-04-01T19:22:38.528Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:37.219Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:35.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:34.707Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:35.782Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:35.425Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:33.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:33.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:33.273Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:32.557Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T192004-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T192004-b849edd6","recordedAt":"2026-04-01T19:20:04.878Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:34.348Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::olaparib::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:31.483Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::cisplatin::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:29.333Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::carboplatin::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:28.978Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::talazoparib::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:32.200Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:30.768Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::rucaparib::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:31.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::niraparib::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:31.126Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::paclitaxel::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:30.411Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::gemcitabine::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:30.052Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T191737-e060b276::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T191737-e060b276","recordedAt":"2026-04-01T19:17:38.483Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:29.693Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175823-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T175823-33db16bd","recordedAt":"2026-04-01T17:58:23.712Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:27.194Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175823-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T175823-33db16bd","recordedAt":"2026-04-01T17:58:23.712Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:25.765Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175823-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T175823-33db16bd","recordedAt":"2026-04-01T17:58:23.712Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:28.626Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175823-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T175823-33db16bd","recordedAt":"2026-04-01T17:58:23.712Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:28.268Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175823-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T175823-33db16bd","recordedAt":"2026-04-01T17:58:23.712Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:27.910Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175823-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T175823-33db16bd","recordedAt":"2026-04-01T17:58:23.712Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:27.551Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175823-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T175823-33db16bd","recordedAt":"2026-04-01T17:58:23.712Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:26.836Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175823-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T175823-33db16bd","recordedAt":"2026-04-01T17:58:23.712Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:26.125Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175546-65d64218::paclitaxel::pan-cancer","analysisId":"20260401T175546-65d64218","recordedAt":"2026-04-01T17:55:46.103Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:22.184Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175546-65d64218::panitumumab::pan-cancer","analysisId":"20260401T175546-65d64218","recordedAt":"2026-04-01T17:55:46.103Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:24.333Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175546-65d64218::cetuximab::pan-cancer","analysisId":"20260401T175546-65d64218","recordedAt":"2026-04-01T17:55:46.103Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:22.899Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175546-65d64218::gemcitabine::pan-cancer","analysisId":"20260401T175546-65d64218","recordedAt":"2026-04-01T17:55:46.103Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:23.976Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175546-65d64218::palbociclib::pan-cancer","analysisId":"20260401T175546-65d64218","recordedAt":"2026-04-01T17:55:46.103Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:25.406Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175546-65d64218::carboplatin::pan-cancer","analysisId":"20260401T175546-65d64218","recordedAt":"2026-04-01T17:55:46.103Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:25.050Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175546-65d64218::sirolimus::pan-cancer","analysisId":"20260401T175546-65d64218","recordedAt":"2026-04-01T17:55:46.103Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:24.699Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175546-65d64218::temozolomide::pan-cancer","analysisId":"20260401T175546-65d64218","recordedAt":"2026-04-01T17:55:46.103Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:23.618Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175300-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T175300-c6b7ce28","recordedAt":"2026-04-01T17:53:00.894Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:21.110Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175300-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T175300-c6b7ce28","recordedAt":"2026-04-01T17:53:00.894Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:20.394Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175300-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T175300-c6b7ce28","recordedAt":"2026-04-01T17:53:00.894Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:19.676Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175300-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T175300-c6b7ce28","recordedAt":"2026-04-01T17:53:00.894Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:18.959Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175300-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T175300-c6b7ce28","recordedAt":"2026-04-01T17:53:00.894Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:20.034Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175300-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T175300-c6b7ce28","recordedAt":"2026-04-01T17:53:00.894Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:19.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175300-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T175300-c6b7ce28","recordedAt":"2026-04-01T17:53:00.894Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:18.605Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175300-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T175300-c6b7ce28","recordedAt":"2026-04-01T17:53:00.894Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:21.467Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:16.812Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:18.244Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:17.527Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:17.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:17.885Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:16.452Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:16.096Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:15.737Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T175006-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T175006-b849edd6","recordedAt":"2026-04-01T17:50:06.896Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:15.023Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::cisplatin::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:11.799Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::carboplatin::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:11.441Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::talazoparib::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:14.666Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::rucaparib::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:14.307Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::niraparib::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:13.591Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:13.231Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::paclitaxel::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:12.873Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::gemcitabine::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:12.513Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:12.155Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T174747-b44315aa::olaparib::breast_cancer","analysisId":"20260401T174747-b44315aa","recordedAt":"2026-04-01T17:47:48.658Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:13.948Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155556-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T155556-33db16bd","recordedAt":"2026-04-01T15:55:56.958Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:08.570Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155556-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T155556-33db16bd","recordedAt":"2026-04-01T15:55:56.958Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:09.647Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155556-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T155556-33db16bd","recordedAt":"2026-04-01T15:55:56.958Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:08.212Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155556-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T155556-33db16bd","recordedAt":"2026-04-01T15:55:56.958Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:11.084Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155556-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T155556-33db16bd","recordedAt":"2026-04-01T15:55:56.958Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:10.724Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155556-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T155556-33db16bd","recordedAt":"2026-04-01T15:55:56.958Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:10.366Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155556-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T155556-33db16bd","recordedAt":"2026-04-01T15:55:56.958Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:10.007Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155556-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T155556-33db16bd","recordedAt":"2026-04-01T15:55:56.958Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:09.288Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155334-65d64218::panitumumab::pan-cancer","analysisId":"20260401T155334-65d64218","recordedAt":"2026-04-01T15:53:34.467Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:06.778Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155334-65d64218::cetuximab::pan-cancer","analysisId":"20260401T155334-65d64218","recordedAt":"2026-04-01T15:53:34.467Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:05.346Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155334-65d64218::gemcitabine::pan-cancer","analysisId":"20260401T155334-65d64218","recordedAt":"2026-04-01T15:53:34.467Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:06.419Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155334-65d64218::palbociclib::pan-cancer","analysisId":"20260401T155334-65d64218","recordedAt":"2026-04-01T15:53:34.467Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:07.853Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155334-65d64218::carboplatin::pan-cancer","analysisId":"20260401T155334-65d64218","recordedAt":"2026-04-01T15:53:34.467Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:07.494Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155334-65d64218::sirolimus::pan-cancer","analysisId":"20260401T155334-65d64218","recordedAt":"2026-04-01T15:53:34.467Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:07.136Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155334-65d64218::temozolomide::pan-cancer","analysisId":"20260401T155334-65d64218","recordedAt":"2026-04-01T15:53:34.467Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:06.062Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155334-65d64218::paclitaxel::pan-cancer","analysisId":"20260401T155334-65d64218","recordedAt":"2026-04-01T15:53:34.467Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:04.628Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155055-62102268::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T155055-62102268","recordedAt":"2026-04-01T15:50:55.705Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:03.898Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155055-62102268::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T155055-62102268","recordedAt":"2026-04-01T15:50:55.705Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:02.826Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155055-62102268::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T155055-62102268","recordedAt":"2026-04-01T15:50:55.705Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:01.752Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155055-62102268::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T155055-62102268","recordedAt":"2026-04-01T15:50:55.705Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:01.034Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155055-62102268::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T155055-62102268","recordedAt":"2026-04-01T15:50:55.705Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:02.467Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155055-62102268::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T155055-62102268","recordedAt":"2026-04-01T15:50:55.705Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:01.393Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155055-62102268::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T155055-62102268","recordedAt":"2026-04-01T15:50:55.705Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:03.544Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T155055-62102268::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T155055-62102268","recordedAt":"2026-04-01T15:50:55.705Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:02.110Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:59.962Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:59.605Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:44:00.675Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:44:00.319Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:58.886Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:58.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:58.169Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:57.455Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154802-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T154802-b849edd6","recordedAt":"2026-04-01T15:48:02.126Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:59.246Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:56.382Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:54.234Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:53.880Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:57.099Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:55.667Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:56.739Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:56.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:55.308Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:54.951Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T154508-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T154508-c46e28d2","recordedAt":"2026-04-01T15:45:10.005Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:54.593Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T145112-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T145112-33db16bd","recordedAt":"2026-04-01T14:51:12.689Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:52.093Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T145112-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T145112-33db16bd","recordedAt":"2026-04-01T14:51:12.689Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:50.660Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T145112-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T145112-33db16bd","recordedAt":"2026-04-01T14:51:12.689Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:53.527Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T145112-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T145112-33db16bd","recordedAt":"2026-04-01T14:51:12.689Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:53.170Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T145112-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T145112-33db16bd","recordedAt":"2026-04-01T14:51:12.689Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:52.812Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T145112-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T145112-33db16bd","recordedAt":"2026-04-01T14:51:12.689Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:52.452Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T145112-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T145112-33db16bd","recordedAt":"2026-04-01T14:51:12.689Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:51.735Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T145112-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T145112-33db16bd","recordedAt":"2026-04-01T14:51:12.689Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:51.020Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144839-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T144839-99db93fe","recordedAt":"2026-04-01T14:48:39.491Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:47.083Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144839-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T144839-99db93fe","recordedAt":"2026-04-01T14:48:39.491Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:49.231Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144839-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T144839-99db93fe","recordedAt":"2026-04-01T14:48:39.491Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:47.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144839-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T144839-99db93fe","recordedAt":"2026-04-01T14:48:39.491Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:48.876Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144839-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T144839-99db93fe","recordedAt":"2026-04-01T14:48:39.491Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:50.302Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144839-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T144839-99db93fe","recordedAt":"2026-04-01T14:48:39.491Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:49.948Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144839-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T144839-99db93fe","recordedAt":"2026-04-01T14:48:39.491Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:49.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144839-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T144839-99db93fe","recordedAt":"2026-04-01T14:48:39.491Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:48.516Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144522-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T144522-c6b7ce28","recordedAt":"2026-04-01T14:45:22.700Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:45.290Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144522-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T144522-c6b7ce28","recordedAt":"2026-04-01T14:45:22.700Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:43.855Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144522-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T144522-c6b7ce28","recordedAt":"2026-04-01T14:45:22.700Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:45.649Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144522-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T144522-c6b7ce28","recordedAt":"2026-04-01T14:45:22.700Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:44.215Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144522-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T144522-c6b7ce28","recordedAt":"2026-04-01T14:45:22.700Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:43.497Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144522-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T144522-c6b7ce28","recordedAt":"2026-04-01T14:45:22.700Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:44.574Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144522-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T144522-c6b7ce28","recordedAt":"2026-04-01T14:45:22.700Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:46.365Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144522-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T144522-c6b7ce28","recordedAt":"2026-04-01T14:45:22.700Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:46.725Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:41.713Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:42.428Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:42.071Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:43.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:42.786Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:41.353Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:40.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:40.636Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144245-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T144245-b849edd6","recordedAt":"2026-04-01T14:42:45.627Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:39.919Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:36.697Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:36.337Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:39.560Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:39.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:38.126Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:38.484Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:37.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:37.410Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:37.055Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T144002-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T144002-c46e28d2","recordedAt":"2026-04-01T14:40:03.971Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:38.844Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T122237-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T122237-33db16bd","recordedAt":"2026-04-01T12:22:37.086Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:33.465Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T122237-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T122237-33db16bd","recordedAt":"2026-04-01T12:22:37.086Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:34.541Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T122237-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T122237-33db16bd","recordedAt":"2026-04-01T12:22:37.086Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:33.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T122237-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T122237-33db16bd","recordedAt":"2026-04-01T12:22:37.086Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:35.979Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T122237-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T122237-33db16bd","recordedAt":"2026-04-01T12:22:37.086Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:35.618Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T122237-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T122237-33db16bd","recordedAt":"2026-04-01T12:22:37.086Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:35.258Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T122237-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T122237-33db16bd","recordedAt":"2026-04-01T12:22:37.086Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:34.899Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T122237-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T122237-33db16bd","recordedAt":"2026-04-01T12:22:37.086Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:34.182Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121909-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T121909-99db93fe","recordedAt":"2026-04-01T12:19:09.623Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:31.674Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121909-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T121909-99db93fe","recordedAt":"2026-04-01T12:19:09.623Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:30.243Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121909-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T121909-99db93fe","recordedAt":"2026-04-01T12:19:09.623Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:31.317Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121909-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T121909-99db93fe","recordedAt":"2026-04-01T12:19:09.623Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:32.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121909-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T121909-99db93fe","recordedAt":"2026-04-01T12:19:09.623Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:32.391Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121909-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T121909-99db93fe","recordedAt":"2026-04-01T12:19:09.623Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:32.031Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121909-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T121909-99db93fe","recordedAt":"2026-04-01T12:19:09.623Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:30.961Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121909-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T121909-99db93fe","recordedAt":"2026-04-01T12:19:09.623Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:29.525Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121541-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T121541-c6b7ce28","recordedAt":"2026-04-01T12:15:41.197Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:29.168Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121541-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T121541-c6b7ce28","recordedAt":"2026-04-01T12:15:41.197Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:25.945Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121541-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T121541-c6b7ce28","recordedAt":"2026-04-01T12:15:41.197Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:26.659Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121541-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T121541-c6b7ce28","recordedAt":"2026-04-01T12:15:41.197Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:26.303Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121541-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T121541-c6b7ce28","recordedAt":"2026-04-01T12:15:41.197Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:27.736Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121541-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T121541-c6b7ce28","recordedAt":"2026-04-01T12:15:41.197Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:28.811Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121541-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T121541-c6b7ce28","recordedAt":"2026-04-01T12:15:41.197Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:28.093Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121541-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T121541-c6b7ce28","recordedAt":"2026-04-01T12:15:41.197Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:27.018Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:25.588Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:24.876Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:24.517Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:25.231Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:23.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:23.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:23.085Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:22.370Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T121226-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T121226-b849edd6","recordedAt":"2026-04-01T12:12:26.942Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:24.165Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:21.295Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:19.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:18.791Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:20.586Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:22.014Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:21.653Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:20.940Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:20.225Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:19.867Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T120834-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T120834-c46e28d2","recordedAt":"2026-04-01T12:08:35.880Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:19.507Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105615-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T105615-33db16bd","recordedAt":"2026-04-01T10:56:15.164Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:17.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105615-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T105615-33db16bd","recordedAt":"2026-04-01T10:56:15.164Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:15.568Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105615-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T105615-33db16bd","recordedAt":"2026-04-01T10:56:15.164Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:18.431Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105615-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T105615-33db16bd","recordedAt":"2026-04-01T10:56:15.164Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:18.074Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105615-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T105615-33db16bd","recordedAt":"2026-04-01T10:56:15.164Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:17.717Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105615-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T105615-33db16bd","recordedAt":"2026-04-01T10:56:15.164Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:17.360Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105615-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T105615-33db16bd","recordedAt":"2026-04-01T10:56:15.164Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:16.645Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105615-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T105615-33db16bd","recordedAt":"2026-04-01T10:56:15.164Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:15.928Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105253-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T105253-99db93fe","recordedAt":"2026-04-01T10:52:53.937Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:11.986Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105253-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T105253-99db93fe","recordedAt":"2026-04-01T10:52:53.937Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:14.136Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105253-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T105253-99db93fe","recordedAt":"2026-04-01T10:52:53.937Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:12.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105253-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T105253-99db93fe","recordedAt":"2026-04-01T10:52:53.937Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:13.779Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105253-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T105253-99db93fe","recordedAt":"2026-04-01T10:52:53.937Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:15.209Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105253-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T105253-99db93fe","recordedAt":"2026-04-01T10:52:53.937Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:14.852Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105253-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T105253-99db93fe","recordedAt":"2026-04-01T10:52:53.937Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:14.495Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105253-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T105253-99db93fe","recordedAt":"2026-04-01T10:52:53.937Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:13.420Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105029-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T105029-c6b7ce28","recordedAt":"2026-04-01T10:50:29.954Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:08.754Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105029-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T105029-c6b7ce28","recordedAt":"2026-04-01T10:50:29.954Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:09.113Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105029-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T105029-c6b7ce28","recordedAt":"2026-04-01T10:50:29.954Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:08.395Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105029-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T105029-c6b7ce28","recordedAt":"2026-04-01T10:50:29.954Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:09.473Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105029-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T105029-c6b7ce28","recordedAt":"2026-04-01T10:50:29.954Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:10.191Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105029-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T105029-c6b7ce28","recordedAt":"2026-04-01T10:50:29.954Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:11.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105029-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T105029-c6b7ce28","recordedAt":"2026-04-01T10:50:29.954Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:10.549Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T105029-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T105029-c6b7ce28","recordedAt":"2026-04-01T10:50:29.954Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:11.627Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:06.606Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:07.322Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:06.964Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:08.037Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:07.679Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:06.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:05.888Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:05.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104732-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T104732-b849edd6","recordedAt":"2026-04-01T10:47:32.558Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:04.813Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:01.590Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:01.232Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:03.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:04.456Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:04.098Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:03.381Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:02.662Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:02.307Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:01.948Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T104450-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T104450-c46e28d2","recordedAt":"2026-04-01T10:44:51.389Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:43:03.740Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085539-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T085539-33db16bd","recordedAt":"2026-04-01T08:55:39.643Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:58.367Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085539-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T085539-33db16bd","recordedAt":"2026-04-01T08:55:39.643Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:59.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085539-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T085539-33db16bd","recordedAt":"2026-04-01T08:55:39.643Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:58.009Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085539-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T085539-33db16bd","recordedAt":"2026-04-01T08:55:39.643Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:00.875Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085539-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T085539-33db16bd","recordedAt":"2026-04-01T08:55:39.643Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:00.517Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085539-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T085539-33db16bd","recordedAt":"2026-04-01T08:55:39.643Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:43:00.158Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085539-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T085539-33db16bd","recordedAt":"2026-04-01T08:55:39.643Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:59.802Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085539-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T085539-33db16bd","recordedAt":"2026-04-01T08:55:39.643Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:59.082Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085253-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T085253-99db93fe","recordedAt":"2026-04-01T08:52:53.563Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:56.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085253-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T085253-99db93fe","recordedAt":"2026-04-01T08:52:53.563Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:55.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085253-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T085253-99db93fe","recordedAt":"2026-04-01T08:52:53.563Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:56.220Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085253-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T085253-99db93fe","recordedAt":"2026-04-01T08:52:53.563Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:57.652Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085253-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T085253-99db93fe","recordedAt":"2026-04-01T08:52:53.563Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:57.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085253-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T085253-99db93fe","recordedAt":"2026-04-01T08:52:53.563Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:56.937Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085253-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T085253-99db93fe","recordedAt":"2026-04-01T08:52:53.563Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:55.860Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085253-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T085253-99db93fe","recordedAt":"2026-04-01T08:52:53.563Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:54.426Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085018-62102268::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T085018-62102268","recordedAt":"2026-04-01T08:50:18.750Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:54.070Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085018-62102268::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T085018-62102268","recordedAt":"2026-04-01T08:50:18.750Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:50.851Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085018-62102268::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T085018-62102268","recordedAt":"2026-04-01T08:50:18.750Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:52.640Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085018-62102268::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T085018-62102268","recordedAt":"2026-04-01T08:50:18.750Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:53.712Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085018-62102268::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T085018-62102268","recordedAt":"2026-04-01T08:50:18.750Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:52.995Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085018-62102268::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T085018-62102268","recordedAt":"2026-04-01T08:50:18.750Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:51.925Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085018-62102268::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T085018-62102268","recordedAt":"2026-04-01T08:50:18.750Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:51.569Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T085018-62102268::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T085018-62102268","recordedAt":"2026-04-01T08:50:18.750Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:51.210Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:47.985Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:49.419Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:47.267Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:49.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:50.492Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:50.134Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:48.702Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:48.343Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084748-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T084748-b849edd6","recordedAt":"2026-04-01T08:47:48.115Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:49.061Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:46.193Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:46.549Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:43.692Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:45.475Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:46.908Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:45.833Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:45.118Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:44.762Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:44.407Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T084508-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T084508-c46e28d2","recordedAt":"2026-04-01T08:45:09.656Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:44.048Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T073132-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T073132-33db16bd","recordedAt":"2026-04-01T07:31:32.585Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:43.332Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T073132-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T073132-33db16bd","recordedAt":"2026-04-01T07:31:32.585Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:42.616Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T073132-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T073132-33db16bd","recordedAt":"2026-04-01T07:31:32.585Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:40.473Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T073132-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T073132-33db16bd","recordedAt":"2026-04-01T07:31:32.585Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:42.259Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T073132-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T073132-33db16bd","recordedAt":"2026-04-01T07:31:32.585Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:41.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T073132-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T073132-33db16bd","recordedAt":"2026-04-01T07:31:32.585Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:42.974Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T073132-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T073132-33db16bd","recordedAt":"2026-04-01T07:31:32.585Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:41.545Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T073132-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T073132-33db16bd","recordedAt":"2026-04-01T07:31:32.585Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:40.830Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072848-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T072848-99db93fe","recordedAt":"2026-04-01T07:28:49.125Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:36.889Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072848-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T072848-99db93fe","recordedAt":"2026-04-01T07:28:49.125Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:38.324Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072848-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T072848-99db93fe","recordedAt":"2026-04-01T07:28:49.125Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:38.683Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072848-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T072848-99db93fe","recordedAt":"2026-04-01T07:28:49.125Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:40.115Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072848-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T072848-99db93fe","recordedAt":"2026-04-01T07:28:49.125Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:39.758Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072848-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T072848-99db93fe","recordedAt":"2026-04-01T07:28:49.125Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:39.399Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072848-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T072848-99db93fe","recordedAt":"2026-04-01T07:28:49.125Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:39.041Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072848-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T072848-99db93fe","recordedAt":"2026-04-01T07:28:49.125Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:37.605Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072625-62102268::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T072625-62102268","recordedAt":"2026-04-01T07:26:25.309Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:34.018Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072625-62102268::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T072625-62102268","recordedAt":"2026-04-01T07:26:25.309Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:33.660Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072625-62102268::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T072625-62102268","recordedAt":"2026-04-01T07:26:25.309Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:33.301Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072625-62102268::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T072625-62102268","recordedAt":"2026-04-01T07:26:25.309Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:35.096Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072625-62102268::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T072625-62102268","recordedAt":"2026-04-01T07:26:25.309Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:35.453Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072625-62102268::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T072625-62102268","recordedAt":"2026-04-01T07:26:25.309Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:36.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072625-62102268::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T072625-62102268","recordedAt":"2026-04-01T07:26:25.309Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:34.378Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072625-62102268::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T072625-62102268","recordedAt":"2026-04-01T07:26:25.309Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:36.531Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:31.508Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:30.433Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:30.791Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:29.719Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:32.225Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:31.868Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:32.943Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:32.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072347-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T072347-b849edd6","recordedAt":"2026-04-01T07:23:47.752Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:31.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:26.851Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:26.135Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:27.924Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:29.359Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:29.000Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:28.284Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:27.566Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:27.208Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:26.494Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T072107-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T072107-c46e28d2","recordedAt":"2026-04-01T07:21:08.616Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:28.642Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T055123-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T055123-33db16bd","recordedAt":"2026-04-01T05:51:23.029Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:23.269Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T055123-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T055123-33db16bd","recordedAt":"2026-04-01T05:51:23.029Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:23.987Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T055123-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T055123-33db16bd","recordedAt":"2026-04-01T05:51:23.029Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:25.776Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T055123-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T055123-33db16bd","recordedAt":"2026-04-01T05:51:23.029Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:25.418Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T055123-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T055123-33db16bd","recordedAt":"2026-04-01T05:51:23.029Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:25.062Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T055123-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T055123-33db16bd","recordedAt":"2026-04-01T05:51:23.029Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:24.705Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T055123-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T055123-33db16bd","recordedAt":"2026-04-01T05:51:23.029Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:24.346Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T055123-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T055123-33db16bd","recordedAt":"2026-04-01T05:51:23.029Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:22.914Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054918-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T054918-99db93fe","recordedAt":"2026-04-01T05:49:18.877Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:22.555Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054918-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T054918-99db93fe","recordedAt":"2026-04-01T05:49:18.877Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:22.195Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054918-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T054918-99db93fe","recordedAt":"2026-04-01T05:49:18.877Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:21.837Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054918-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T054918-99db93fe","recordedAt":"2026-04-01T05:49:18.877Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:21.480Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054918-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T054918-99db93fe","recordedAt":"2026-04-01T05:49:18.877Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:20.765Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054918-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T054918-99db93fe","recordedAt":"2026-04-01T05:49:18.877Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:20.050Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054918-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T054918-99db93fe","recordedAt":"2026-04-01T05:49:18.877Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:21.123Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054918-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T054918-99db93fe","recordedAt":"2026-04-01T05:49:18.877Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:19.334Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054656-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T054656-c6b7ce28","recordedAt":"2026-04-01T05:46:56.699Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:18.983Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054656-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T054656-c6b7ce28","recordedAt":"2026-04-01T05:46:56.699Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:16.714Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054656-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T054656-c6b7ce28","recordedAt":"2026-04-01T05:46:56.699Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:16.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054656-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T054656-c6b7ce28","recordedAt":"2026-04-01T05:46:56.699Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:15.998Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054656-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T054656-c6b7ce28","recordedAt":"2026-04-01T05:46:56.699Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:15.639Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054656-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T054656-c6b7ce28","recordedAt":"2026-04-01T05:46:56.699Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:17.787Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054656-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T054656-c6b7ce28","recordedAt":"2026-04-01T05:46:56.699Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:17.431Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054656-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T054656-c6b7ce28","recordedAt":"2026-04-01T05:46:56.699Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:18.504Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:13.144Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:12.072Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:14.573Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:14.216Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:15.282Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:14.930Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:13.501Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:12.786Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054429-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T054429-b849edd6","recordedAt":"2026-04-01T05:44:29.726Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:13.857Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::olaparib::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:10.996Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::gemcitabine::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:09.561Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:09.201Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:10.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::carboplatin::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:08.485Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::talazoparib::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:11.713Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::rucaparib::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:11.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::niraparib::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:10.638Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::paclitaxel::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:09.919Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T054147-b44315aa::cisplatin::breast_cancer","analysisId":"20260401T054147-b44315aa","recordedAt":"2026-04-01T05:41:48.627Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:08.845Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041931-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T041931-33db16bd","recordedAt":"2026-04-01T04:19:31.512Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:06.337Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041931-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T041931-33db16bd","recordedAt":"2026-04-01T04:19:31.512Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:08.125Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041931-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T041931-33db16bd","recordedAt":"2026-04-01T04:19:31.512Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:07.768Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041931-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T041931-33db16bd","recordedAt":"2026-04-01T04:19:31.512Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:07.409Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041931-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T041931-33db16bd","recordedAt":"2026-04-01T04:19:31.512Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:07.052Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041931-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T041931-33db16bd","recordedAt":"2026-04-01T04:19:31.512Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:06.693Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041931-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T041931-33db16bd","recordedAt":"2026-04-01T04:19:31.512Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:05.262Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041931-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T041931-33db16bd","recordedAt":"2026-04-01T04:19:31.512Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:05.620Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041700-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T041700-99db93fe","recordedAt":"2026-04-01T04:17:00.908Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:01.672Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041700-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T041700-99db93fe","recordedAt":"2026-04-01T04:17:00.908Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:04.903Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041700-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T041700-99db93fe","recordedAt":"2026-04-01T04:17:00.908Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:04.547Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041700-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T041700-99db93fe","recordedAt":"2026-04-01T04:17:00.908Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:04.189Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041700-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T041700-99db93fe","recordedAt":"2026-04-01T04:17:00.908Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:03.830Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041700-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T041700-99db93fe","recordedAt":"2026-04-01T04:17:00.908Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:03.110Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041700-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T041700-99db93fe","recordedAt":"2026-04-01T04:17:00.908Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:02.391Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041700-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T041700-99db93fe","recordedAt":"2026-04-01T04:17:00.908Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:03.470Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041419-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T041419-c6b7ce28","recordedAt":"2026-04-01T04:14:19.872Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:59.163Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041419-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T041419-c6b7ce28","recordedAt":"2026-04-01T04:14:19.872Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:58.804Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041419-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T041419-c6b7ce28","recordedAt":"2026-04-01T04:14:19.872Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:58.447Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041419-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T041419-c6b7ce28","recordedAt":"2026-04-01T04:14:19.872Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:58.088Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041419-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T041419-c6b7ce28","recordedAt":"2026-04-01T04:14:19.872Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:00.238Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041419-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T041419-c6b7ce28","recordedAt":"2026-04-01T04:14:19.872Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:59.881Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041419-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T041419-c6b7ce28","recordedAt":"2026-04-01T04:14:19.872Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:42:00.957Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041419-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T041419-c6b7ce28","recordedAt":"2026-04-01T04:14:19.872Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:42:01.314Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:56.301Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:55.586Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:54.507Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:57.017Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:56.657Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:57.731Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:57.375Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:55.945Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T041147-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T041147-b849edd6","recordedAt":"2026-04-01T04:11:47.783Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:55.225Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:51.634Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:50.917Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:52.714Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:54.147Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:53.789Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:53.072Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:52.353Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:51.992Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:51.272Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T040919-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T040919-c46e28d2","recordedAt":"2026-04-01T04:09:21.059Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:53.430Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031552-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T031552-33db16bd","recordedAt":"2026-04-01T03:15:53.028Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:48.059Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031552-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T031552-33db16bd","recordedAt":"2026-04-01T03:15:53.028Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:50.199Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031552-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T031552-33db16bd","recordedAt":"2026-04-01T03:15:53.028Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:50.559Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031552-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T031552-33db16bd","recordedAt":"2026-04-01T03:15:53.028Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:49.842Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031552-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T031552-33db16bd","recordedAt":"2026-04-01T03:15:53.028Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:49.491Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031552-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T031552-33db16bd","recordedAt":"2026-04-01T03:15:53.028Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:49.125Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031552-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T031552-33db16bd","recordedAt":"2026-04-01T03:15:53.028Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:48.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031552-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T031552-33db16bd","recordedAt":"2026-04-01T03:15:53.028Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:47.701Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031322-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T031322-99db93fe","recordedAt":"2026-04-01T03:13:22.079Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:47.344Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031322-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T031322-99db93fe","recordedAt":"2026-04-01T03:13:22.079Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:46.983Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031322-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T031322-99db93fe","recordedAt":"2026-04-01T03:13:22.079Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:46.625Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031322-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T031322-99db93fe","recordedAt":"2026-04-01T03:13:22.079Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:46.266Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031322-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T031322-99db93fe","recordedAt":"2026-04-01T03:13:22.079Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:45.553Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031322-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T031322-99db93fe","recordedAt":"2026-04-01T03:13:22.079Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:44.835Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031322-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T031322-99db93fe","recordedAt":"2026-04-01T03:13:22.079Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:45.909Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031322-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T031322-99db93fe","recordedAt":"2026-04-01T03:13:22.079Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:44.120Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031044-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T031044-c6b7ce28","recordedAt":"2026-04-01T03:10:44.882Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:43.765Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031044-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T031044-c6b7ce28","recordedAt":"2026-04-01T03:10:44.882Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:41.635Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031044-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T031044-c6b7ce28","recordedAt":"2026-04-01T03:10:44.882Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:41.274Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031044-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T031044-c6b7ce28","recordedAt":"2026-04-01T03:10:44.882Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:40.917Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031044-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T031044-c6b7ce28","recordedAt":"2026-04-01T03:10:44.882Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:40.559Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031044-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T031044-c6b7ce28","recordedAt":"2026-04-01T03:10:44.882Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:42.693Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031044-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T031044-c6b7ce28","recordedAt":"2026-04-01T03:10:44.882Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:42.343Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T031044-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T031044-c6b7ce28","recordedAt":"2026-04-01T03:10:44.882Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:43.408Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:38.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:36.977Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:39.484Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:39.125Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:40.201Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:39.842Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:38.409Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:37.690Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030803-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T030803-b849edd6","recordedAt":"2026-04-01T03:08:03.962Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:38.767Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:35.903Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:35.547Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:34.472Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:35.189Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:34.112Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:33.395Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:33.754Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:36.620Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:36.262Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T030511-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T030511-c46e28d2","recordedAt":"2026-04-01T03:05:12.544Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:34.830Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020411-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T020411-33db16bd","recordedAt":"2026-04-01T02:04:11.338Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:31.244Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020411-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T020411-33db16bd","recordedAt":"2026-04-01T02:04:11.338Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:33.036Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020411-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T020411-33db16bd","recordedAt":"2026-04-01T02:04:11.338Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:32.676Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020411-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T020411-33db16bd","recordedAt":"2026-04-01T02:04:11.338Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:32.318Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020411-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T020411-33db16bd","recordedAt":"2026-04-01T02:04:11.338Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:31.959Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020411-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T020411-33db16bd","recordedAt":"2026-04-01T02:04:11.338Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:31.601Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020411-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T020411-33db16bd","recordedAt":"2026-04-01T02:04:11.338Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:30.171Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020411-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T020411-33db16bd","recordedAt":"2026-04-01T02:04:11.338Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:30.531Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020123-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T020123-99db93fe","recordedAt":"2026-04-01T02:01:23.715Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:26.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020123-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T020123-99db93fe","recordedAt":"2026-04-01T02:01:23.715Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:29.812Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020123-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T020123-99db93fe","recordedAt":"2026-04-01T02:01:23.715Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:29.453Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020123-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T020123-99db93fe","recordedAt":"2026-04-01T02:01:23.715Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:29.095Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020123-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T020123-99db93fe","recordedAt":"2026-04-01T02:01:23.715Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:28.736Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020123-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T020123-99db93fe","recordedAt":"2026-04-01T02:01:23.715Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:28.021Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020123-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T020123-99db93fe","recordedAt":"2026-04-01T02:01:23.715Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:27.304Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T020123-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T020123-99db93fe","recordedAt":"2026-04-01T02:01:23.715Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:28.379Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015839-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260401T015839-c6b7ce28","recordedAt":"2026-04-01T01:58:39.784Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:24.089Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015839-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260401T015839-c6b7ce28","recordedAt":"2026-04-01T01:58:39.784Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:23.731Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015839-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260401T015839-c6b7ce28","recordedAt":"2026-04-01T01:58:39.784Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:23.374Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015839-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260401T015839-c6b7ce28","recordedAt":"2026-04-01T01:58:39.784Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:23.021Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015839-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260401T015839-c6b7ce28","recordedAt":"2026-04-01T01:58:39.784Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:25.162Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015839-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260401T015839-c6b7ce28","recordedAt":"2026-04-01T01:58:39.784Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:24.807Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015839-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260401T015839-c6b7ce28","recordedAt":"2026-04-01T01:58:39.784Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:25.876Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015839-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260401T015839-c6b7ce28","recordedAt":"2026-04-01T01:58:39.784Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:26.233Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:21.227Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:20.510Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:19.431Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:21.944Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:21.586Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:22.656Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:22.300Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:20.869Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015614-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260401T015614-b849edd6","recordedAt":"2026-04-01T01:56:14.388Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:20.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:16.561Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::carboplatin::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:15.846Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:17.638Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::talazoparib::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:19.072Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::rucaparib::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:18.713Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::niraparib::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:17.998Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:17.281Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:16.921Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::cisplatin::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:16.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T015257-c46e28d2::olaparib::breast_cancer","analysisId":"20260401T015257-c46e28d2","recordedAt":"2026-04-01T01:52:59.472Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:18.357Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000434-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260401T000434-33db16bd","recordedAt":"2026-04-01T00:04:34.752Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:12.979Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000434-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260401T000434-33db16bd","recordedAt":"2026-04-01T00:04:34.752Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:15.130Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000434-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260401T000434-33db16bd","recordedAt":"2026-04-01T00:04:34.752Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:15.489Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000434-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260401T000434-33db16bd","recordedAt":"2026-04-01T00:04:34.752Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:14.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000434-33db16bd::galantamine::alzheimers_disease","analysisId":"20260401T000434-33db16bd","recordedAt":"2026-04-01T00:04:34.752Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:14.414Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000434-33db16bd::donepezil::alzheimers_disease","analysisId":"20260401T000434-33db16bd","recordedAt":"2026-04-01T00:04:34.752Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:14.053Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000434-33db16bd::donanemab::alzheimers_disease","analysisId":"20260401T000434-33db16bd","recordedAt":"2026-04-01T00:04:34.752Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:13.694Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000434-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260401T000434-33db16bd","recordedAt":"2026-04-01T00:04:34.752Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:12.619Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000135-99db93fe::palbociclib::pan-cancer","analysisId":"20260401T000135-99db93fe","recordedAt":"2026-04-01T00:01:35.856Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:12.260Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000135-99db93fe::carboplatin::pan-cancer","analysisId":"20260401T000135-99db93fe","recordedAt":"2026-04-01T00:01:35.856Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:11.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000135-99db93fe::sirolimus::pan-cancer","analysisId":"20260401T000135-99db93fe","recordedAt":"2026-04-01T00:01:35.856Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:11.545Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000135-99db93fe::panitumumab::pan-cancer","analysisId":"20260401T000135-99db93fe","recordedAt":"2026-04-01T00:01:35.856Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:11.186Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000135-99db93fe::temozolomide::pan-cancer","analysisId":"20260401T000135-99db93fe","recordedAt":"2026-04-01T00:01:35.856Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:10.468Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000135-99db93fe::cetuximab::pan-cancer","analysisId":"20260401T000135-99db93fe","recordedAt":"2026-04-01T00:01:35.856Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:09.754Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000135-99db93fe::gemcitabine::pan-cancer","analysisId":"20260401T000135-99db93fe","recordedAt":"2026-04-01T00:01:35.856Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:10.827Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260401T000135-99db93fe::paclitaxel::pan-cancer","analysisId":"20260401T000135-99db93fe","recordedAt":"2026-04-01T00:01:35.856Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:09.036Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235857-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T235857-c6b7ce28","recordedAt":"2026-03-31T23:58:57.429Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:08.678Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235857-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T235857-c6b7ce28","recordedAt":"2026-03-31T23:58:57.429Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:06.528Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235857-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T235857-c6b7ce28","recordedAt":"2026-03-31T23:58:57.429Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:06.169Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235857-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T235857-c6b7ce28","recordedAt":"2026-03-31T23:58:57.429Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:05.810Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235857-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T235857-c6b7ce28","recordedAt":"2026-03-31T23:58:57.429Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:05.450Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235857-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T235857-c6b7ce28","recordedAt":"2026-03-31T23:58:57.429Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:07.603Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235857-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T235857-c6b7ce28","recordedAt":"2026-03-31T23:58:57.429Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:07.245Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235857-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T235857-c6b7ce28","recordedAt":"2026-03-31T23:58:57.429Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:08.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:02.938Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:01.861Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:04.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:04.018Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:05.095Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:04.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:03.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:02.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235640-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T235640-b849edd6","recordedAt":"2026-03-31T23:56:40.415Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:03.659Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:00.776Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:59.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:58.987Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:00.063Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:58.272Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:41:01.503Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:58.628Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:01.136Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:41:00.420Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T235416-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T235416-c46e28d2","recordedAt":"2026-03-31T23:54:18.257Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:59.347Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213914-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260331T213914-33db16bd","recordedAt":"2026-03-31T21:39:14.446Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:57.556Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213914-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260331T213914-33db16bd","recordedAt":"2026-03-31T21:39:14.446Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:57.912Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213914-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T213914-33db16bd","recordedAt":"2026-03-31T21:39:14.446Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:57.196Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213914-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T213914-33db16bd","recordedAt":"2026-03-31T21:39:14.446Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:56.837Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213914-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T213914-33db16bd","recordedAt":"2026-03-31T21:39:14.446Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:56.479Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213914-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T213914-33db16bd","recordedAt":"2026-03-31T21:39:14.446Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:56.118Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213914-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T213914-33db16bd","recordedAt":"2026-03-31T21:39:14.446Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:55.045Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213914-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T213914-33db16bd","recordedAt":"2026-03-31T21:39:14.446Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:55.402Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213639-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T213639-99db93fe","recordedAt":"2026-03-31T21:36:39.665Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:51.463Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213639-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T213639-99db93fe","recordedAt":"2026-03-31T21:36:39.665Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:54.685Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213639-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T213639-99db93fe","recordedAt":"2026-03-31T21:36:39.665Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:54.330Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213639-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T213639-99db93fe","recordedAt":"2026-03-31T21:36:39.665Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:53.970Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213639-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T213639-99db93fe","recordedAt":"2026-03-31T21:36:39.665Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:53.612Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213639-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T213639-99db93fe","recordedAt":"2026-03-31T21:36:39.665Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:52.897Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213639-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T213639-99db93fe","recordedAt":"2026-03-31T21:36:39.665Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:52.181Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213639-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T213639-99db93fe","recordedAt":"2026-03-31T21:36:39.665Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:53.256Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213352-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T213352-c6b7ce28","recordedAt":"2026-03-31T21:33:52.560Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:48.964Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213352-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T213352-c6b7ce28","recordedAt":"2026-03-31T21:33:52.560Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:48.608Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213352-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T213352-c6b7ce28","recordedAt":"2026-03-31T21:33:52.560Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:48.251Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213352-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T213352-c6b7ce28","recordedAt":"2026-03-31T21:33:52.560Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:47.894Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213352-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T213352-c6b7ce28","recordedAt":"2026-03-31T21:33:52.560Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:50.029Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213352-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T213352-c6b7ce28","recordedAt":"2026-03-31T21:33:52.560Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:49.673Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213352-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T213352-c6b7ce28","recordedAt":"2026-03-31T21:33:52.560Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:50.746Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213352-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T213352-c6b7ce28","recordedAt":"2026-03-31T21:33:52.560Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:51.107Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:46.104Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:45.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:44.311Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:46.821Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT04439292","NCT03668431","NCT06967155"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-03-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:46.462Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:47.539Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06026410","NCT04793958","NCT05722327","NCT06024174","NCT06764771"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-09-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:47.180Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:45.744Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T213128-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T213128-b849edd6","recordedAt":"2026-03-31T21:31:28.097Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:45.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:41.452Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:40.736Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:42.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03426254","NCT05826964","NCT03499353","NCT04755868","NCT04982848"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2018-02-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:43.951Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:43.594Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:42.889Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:42.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:41.811Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:41.093Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T212902-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T212902-c46e28d2","recordedAt":"2026-03-31T21:29:03.572Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02681562","NCT05900895","NCT06065059","NCT05826964"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-02-11","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:43.244Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202823-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T202823-33db16bd","recordedAt":"2026-03-31T20:28:23.658Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06889818","NCT05925621","NCT04468659","NCT06530732"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-10-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:37.870Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202823-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260331T202823-33db16bd","recordedAt":"2026-03-31T20:28:23.658Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:40.021Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202823-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260331T202823-33db16bd","recordedAt":"2026-03-31T20:28:23.658Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:40.380Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202823-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T202823-33db16bd","recordedAt":"2026-03-31T20:28:23.658Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:39.666Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202823-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T202823-33db16bd","recordedAt":"2026-03-31T20:28:23.658Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:39.307Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202823-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T202823-33db16bd","recordedAt":"2026-03-31T20:28:23.658Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:38.948Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202823-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T202823-33db16bd","recordedAt":"2026-03-31T20:28:23.658Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:38.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202823-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T202823-33db16bd","recordedAt":"2026-03-31T20:28:23.658Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:37.511Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202555-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T202555-99db93fe","recordedAt":"2026-03-31T20:25:55.768Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT04969731","NCT03989310","NCT05585320"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:35.716Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202555-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T202555-99db93fe","recordedAt":"2026-03-31T20:25:55.768Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:34.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202555-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T202555-99db93fe","recordedAt":"2026-03-31T20:25:55.768Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:36.792Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202555-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T202555-99db93fe","recordedAt":"2026-03-31T20:25:55.768Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:36.434Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202555-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T202555-99db93fe","recordedAt":"2026-03-31T20:25:55.768Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:37.152Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202555-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T202555-99db93fe","recordedAt":"2026-03-31T20:25:55.768Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:36.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202555-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T202555-99db93fe","recordedAt":"2026-03-31T20:25:55.768Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03899155","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:35.357Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202555-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T202555-99db93fe","recordedAt":"2026-03-31T20:25:55.768Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:33.922Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202254-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T202254-c6b7ce28","recordedAt":"2026-03-31T20:22:54.080Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01212627","NCT02438722","NCT06599502","NCT00998101"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-09-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:33.562Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202254-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T202254-c6b7ce28","recordedAt":"2026-03-31T20:22:54.080Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:31.412Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202254-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T202254-c6b7ce28","recordedAt":"2026-03-31T20:22:54.080Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:30.695Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202254-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T202254-c6b7ce28","recordedAt":"2026-03-31T20:22:54.080Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:30.336Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202254-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T202254-c6b7ce28","recordedAt":"2026-03-31T20:22:54.080Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05498428","NCT06532032","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-08-11","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:32.125Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202254-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T202254-c6b7ce28","recordedAt":"2026-03-31T20:22:54.080Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:33.204Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202254-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T202254-c6b7ce28","recordedAt":"2026-03-31T20:22:54.080Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:32.485Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202254-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T202254-c6b7ce28","recordedAt":"2026-03-31T20:22:54.080Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:31.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202031-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:27.468Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202031-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:26.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202031-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:04:03.232Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T202031-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:29.263Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202031-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:04:02.875Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T202031-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:29.977Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202031-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:28.187Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202031-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:27.828Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T202031-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T202031-b849edd6","recordedAt":"2026-03-31T20:20:31.643Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-01","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-22T19:40:28.546Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T201809-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T15:04:02.519Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T201809-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T15:04:02.162Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T201809-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:24.960Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T201809-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:26.033Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T201809-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:24.599Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T201809-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:24.247Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T201809-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:25.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T201809-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:23.889Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T201809-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:23.531Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T201809-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T201809-c46e28d2","recordedAt":"2026-03-31T20:18:11.141Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:23.173Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180323-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T180323-33db16bd","recordedAt":"2026-03-31T18:03:23.970Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:21.381Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180323-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T180323-33db16bd","recordedAt":"2026-03-31T18:03:23.970Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:19.938Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180323-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T180323-33db16bd","recordedAt":"2026-03-31T18:03:23.970Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:21.019Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180323-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T180323-33db16bd","recordedAt":"2026-03-31T18:03:23.970Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:21.736Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180323-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T180323-33db16bd","recordedAt":"2026-03-31T18:03:23.970Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:22.096Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180323-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260331T180323-33db16bd","recordedAt":"2026-03-31T18:03:23.970Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:22.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180323-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260331T180323-33db16bd","recordedAt":"2026-03-31T18:03:23.970Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:22.814Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180323-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T180323-33db16bd","recordedAt":"2026-03-31T18:03:23.970Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:04:01.805Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T180052-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T180052-99db93fe","recordedAt":"2026-03-31T18:00:52.424Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:16.357Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180052-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T180052-99db93fe","recordedAt":"2026-03-31T18:00:52.424Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:04:01.093Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T180052-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T180052-99db93fe","recordedAt":"2026-03-31T18:00:52.424Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:17.073Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180052-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T180052-99db93fe","recordedAt":"2026-03-31T18:00:52.424Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:18.862Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180052-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T180052-99db93fe","recordedAt":"2026-03-31T18:00:52.424Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:19.222Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180052-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T180052-99db93fe","recordedAt":"2026-03-31T18:00:52.424Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:19.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T180052-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T180052-99db93fe","recordedAt":"2026-03-31T18:00:52.424Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:04:00.735Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T180052-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T180052-99db93fe","recordedAt":"2026-03-31T18:00:52.424Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:04:01.449Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T175810-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T175810-c6b7ce28","recordedAt":"2026-03-31T17:58:10.919Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T15:04:00.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T175810-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T175810-c6b7ce28","recordedAt":"2026-03-31T17:58:10.919Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:12.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175810-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T175810-c6b7ce28","recordedAt":"2026-03-31T17:58:10.919Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:13.139Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175810-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T175810-c6b7ce28","recordedAt":"2026-03-31T17:58:10.919Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:13.496Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175810-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T175810-c6b7ce28","recordedAt":"2026-03-31T17:58:10.919Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:13.852Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175810-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T175810-c6b7ce28","recordedAt":"2026-03-31T17:58:10.919Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:14.925Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175810-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T175810-c6b7ce28","recordedAt":"2026-03-31T17:58:10.919Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:15.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175810-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T175810-c6b7ce28","recordedAt":"2026-03-31T17:58:10.919Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T15:04:00.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T175524-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:03:59.199Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T175524-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:10.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175524-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:03:59.631Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T175524-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:03:58.806Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T175524-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:11.703Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175524-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:12.419Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175524-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:10.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175524-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:09.908Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175524-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T175524-b849edd6","recordedAt":"2026-03-31T17:55:24.187Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:09.194Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:07.762Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:07.408Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:08.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:06.691Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T15:03:58.032Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T175232-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:07.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:06.334Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:05.975Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:40:05.618Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T175232-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T175232-c46e28d2","recordedAt":"2026-03-31T17:52:34.202Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T15:03:58.420Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T145211-4a42528b::lecanemab::alzheimers_disease","analysisId":"20260331T145211-4a42528b","recordedAt":"2026-03-31T14:52:12.025Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:03:57.628Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T145211-4a42528b::gantenerumab::alzheimers_disease","analysisId":"20260331T145211-4a42528b","recordedAt":"2026-03-31T14:52:12.025Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:52.722Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145211-4a42528b::solanezumab::alzheimers_disease","analysisId":"20260331T145211-4a42528b","recordedAt":"2026-03-31T14:52:12.025Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:53.080Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145211-4a42528b::galantamine::alzheimers_disease","analysisId":"20260331T145211-4a42528b","recordedAt":"2026-03-31T14:52:12.025Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:52.004Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145211-4a42528b::aducanumab::alzheimers_disease","analysisId":"20260331T145211-4a42528b","recordedAt":"2026-03-31T14:52:12.025Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:50.574Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145211-4a42528b::donanemab::alzheimers_disease","analysisId":"20260331T145211-4a42528b","recordedAt":"2026-03-31T14:52:12.025Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:51.291Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145211-4a42528b::donepezil::alzheimers_disease","analysisId":"20260331T145211-4a42528b","recordedAt":"2026-03-31T14:52:12.025Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:51.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145211-4a42528b::rivastigmine::alzheimers_disease","analysisId":"20260331T145211-4a42528b","recordedAt":"2026-03-31T14:52:12.025Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:52.363Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145001-40a1e933::panitumumab::pan-cancer","analysisId":"20260331T145001-40a1e933","recordedAt":"2026-03-31T14:50:01.638Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:03:56.852Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T145001-40a1e933::palbociclib::pan-cancer","analysisId":"20260331T145001-40a1e933","recordedAt":"2026-03-31T14:50:01.638Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:49.857Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145001-40a1e933::carboplatin::pan-cancer","analysisId":"20260331T145001-40a1e933","recordedAt":"2026-03-31T14:50:01.638Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:49.499Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145001-40a1e933::sirolimus::pan-cancer","analysisId":"20260331T145001-40a1e933","recordedAt":"2026-03-31T14:50:01.638Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:49.144Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145001-40a1e933::paclitaxel::pan-cancer","analysisId":"20260331T145001-40a1e933","recordedAt":"2026-03-31T14:50:01.638Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:46.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145001-40a1e933::temozolomide::pan-cancer","analysisId":"20260331T145001-40a1e933","recordedAt":"2026-03-31T14:50:01.638Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:03:56.469Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T145001-40a1e933::cetuximab::pan-cancer","analysisId":"20260331T145001-40a1e933","recordedAt":"2026-03-31T14:50:01.638Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:47.361Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T145001-40a1e933::gemcitabine::pan-cancer","analysisId":"20260331T145001-40a1e933","recordedAt":"2026-03-31T14:50:01.638Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T15:03:57.241Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144752-ee6fea68::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:45.932Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144752-ee6fea68::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:45.211Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144752-ee6fea68::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T15:03:56.082Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T144752-ee6fea68::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:44.856Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144752-ee6fea68::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:44.497Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144752-ee6fea68::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:44.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144752-ee6fea68::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:43.414Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144752-ee6fea68::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:45.576Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144752-ee6fea68::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T144752-ee6fea68","recordedAt":"2026-03-31T14:47:52.175Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:17.078Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T144731-b19043d5::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260331T144731-b19043d5","recordedAt":"2026-03-31T14:47:31.066Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:15.944Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144731-b19043d5::atezolizumab::triple-negative_breast_cancer","analysisId":"20260331T144731-b19043d5","recordedAt":"2026-03-31T14:47:31.066Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":[],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT05266937","NCT04102618","NCT04954599","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:42.687Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144731-b19043d5::afatinib::triple-negative_breast_cancer","analysisId":"20260331T144731-b19043d5","recordedAt":"2026-03-31T14:47:31.066Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:16.336Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144731-b19043d5::cisplatin::triple-negative_breast_cancer","analysisId":"20260331T144731-b19043d5","recordedAt":"2026-03-31T14:47:31.066Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01920061","NCT04491942","NCT01091454","NCT02658214","NCT01167192"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:41.957Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144731-b19043d5::osimertinib::triple-negative_breast_cancer","analysisId":"20260331T144731-b19043d5","recordedAt":"2026-03-31T14:47:31.066Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:16.722Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144731-b19043d5::carboplatin::triple-negative_breast_cancer","analysisId":"20260331T144731-b19043d5","recordedAt":"2026-03-31T14:47:31.066Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:41.607Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144731-b19043d5::erlotinib::triple-negative_breast_cancer","analysisId":"20260331T144731-b19043d5","recordedAt":"2026-03-31T14:47:31.066Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:40.541Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144550-c844c452::regorafenib::colorectal_cancer","analysisId":"20260331T144550-c844c452","recordedAt":"2026-03-31T14:45:50.273Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:36.249Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144550-c844c452::selumetinib::colorectal_cancer","analysisId":"20260331T144550-c844c452","recordedAt":"2026-03-31T14:45:50.273Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:36.966Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144550-c844c452::dabrafenib::colorectal_cancer","analysisId":"20260331T144550-c844c452","recordedAt":"2026-03-31T14:45:50.273Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:15.550Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T144550-c844c452::temsirolimus::colorectal_cancer","analysisId":"20260331T144550-c844c452","recordedAt":"2026-03-31T14:45:50.273Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:37.324Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144550-c844c452::sorafenib::colorectal_cancer","analysisId":"20260331T144550-c844c452","recordedAt":"2026-03-31T14:45:50.273Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:38.045Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144550-c844c452::adagrasib::colorectal_cancer","analysisId":"20260331T144550-c844c452","recordedAt":"2026-03-31T14:45:50.273Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:14.838Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144550-c844c452::tovorafenib::colorectal_cancer","analysisId":"20260331T144550-c844c452","recordedAt":"2026-03-31T14:45:50.273Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:15.194Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144550-c844c452::encorafenib::colorectal_cancer","analysisId":"20260331T144550-c844c452","recordedAt":"2026-03-31T14:45:50.273Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:38.759Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144337-9fad091f::paclitaxel::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:34.820Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144337-9fad091f::niraparib::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:34.095Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144337-9fad091f::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:33.380Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144337-9fad091f::gemcitabine::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:33.745Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144337-9fad091f::cisplatin::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:33.016Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144337-9fad091f::rucaparib::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:35.177Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144337-9fad091f::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:35.533Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144337-9fad091f::olaparib::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:14.477Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144337-9fad091f::talazoparib::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:14.122Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144337-9fad091f::carboplatin::breast_cancer","analysisId":"20260331T144337-9fad091f","recordedAt":"2026-03-31T14:43:37.886Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:32.652Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144249-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:13.056Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144249-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:13.411Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144249-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:32.297Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144249-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:30.502Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144249-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:30.144Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144249-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:29.784Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144249-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:29.064Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144249-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:13.766Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T144249-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T144249-b849edd6","recordedAt":"2026-03-31T14:42:49.273Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:31.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144003-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:27.270Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144003-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:12.346Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144003-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:25.479Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144003-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:28.350Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144003-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:27.631Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144003-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:12.701Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T144003-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:26.913Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144003-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:26.554Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144003-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:26.198Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T144003-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T144003-c46e28d2","recordedAt":"2026-03-31T14:40:04.561Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:25.837Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130425-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T130425-33db16bd","recordedAt":"2026-03-31T13:04:25.889Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:23.687Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130425-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T130425-33db16bd","recordedAt":"2026-03-31T13:04:25.889Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:22.257Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130425-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T130425-33db16bd","recordedAt":"2026-03-31T13:04:25.889Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:23.332Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130425-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T130425-33db16bd","recordedAt":"2026-03-31T13:04:25.889Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:24.044Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130425-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T130425-33db16bd","recordedAt":"2026-03-31T13:04:25.889Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:24.402Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130425-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260331T130425-33db16bd","recordedAt":"2026-03-31T13:04:25.889Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:24.761Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130425-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260331T130425-33db16bd","recordedAt":"2026-03-31T13:04:25.889Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:25.120Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130425-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T130425-33db16bd","recordedAt":"2026-03-31T13:04:25.889Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:11.991Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T130149-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T130149-99db93fe","recordedAt":"2026-03-31T13:01:49.538Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:10.926Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T130149-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T130149-99db93fe","recordedAt":"2026-03-31T13:01:49.538Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:11.281Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T130149-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T130149-99db93fe","recordedAt":"2026-03-31T13:01:49.538Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:21.194Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130149-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T130149-99db93fe","recordedAt":"2026-03-31T13:01:49.538Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:21.554Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130149-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T130149-99db93fe","recordedAt":"2026-03-31T13:01:49.538Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:21.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130149-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T130149-99db93fe","recordedAt":"2026-03-31T13:01:49.538Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:11.636Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T130149-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T130149-99db93fe","recordedAt":"2026-03-31T13:01:49.538Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:19.273Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T130149-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T130149-99db93fe","recordedAt":"2026-03-31T13:01:49.538Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:18.557Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125911-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T125911-c6b7ce28","recordedAt":"2026-03-31T12:59:11.147Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:10.570Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T125911-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T125911-c6b7ce28","recordedAt":"2026-03-31T12:59:11.147Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:17.843Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125911-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T125911-c6b7ce28","recordedAt":"2026-03-31T12:59:11.147Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:17.127Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125911-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T125911-c6b7ce28","recordedAt":"2026-03-31T12:59:11.147Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:16.050Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125911-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T125911-c6b7ce28","recordedAt":"2026-03-31T12:59:11.147Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:15.691Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125911-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T125911-c6b7ce28","recordedAt":"2026-03-31T12:59:11.147Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:15.332Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125911-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T125911-c6b7ce28","recordedAt":"2026-03-31T12:59:11.147Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:14.975Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125911-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T125911-c6b7ce28","recordedAt":"2026-03-31T12:59:11.147Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:10.213Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T125631-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:13.899Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125631-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:09.147Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T125631-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:14.617Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125631-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:09.858Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T125631-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:11.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125631-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:12.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125631-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:12.105Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125631-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:12.825Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125631-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T125631-b849edd6","recordedAt":"2026-03-31T12:56:31.036Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:09.502Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T125359-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:09.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125359-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:10.672Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125359-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:09.957Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125359-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:08.421Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T125359-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:08.889Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125359-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:08.533Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125359-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:08.181Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125359-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:07.828Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T125359-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:08.792Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T125359-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T125359-c46e28d2","recordedAt":"2026-03-31T12:54:00.983Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:09.606Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T113143-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T113143-33db16bd","recordedAt":"2026-03-31T11:31:43.187Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:07.468Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T113143-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T113143-33db16bd","recordedAt":"2026-03-31T11:31:43.187Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:07.110Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T113143-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T113143-33db16bd","recordedAt":"2026-03-31T11:31:43.187Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:08.065Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T113143-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T113143-33db16bd","recordedAt":"2026-03-31T11:31:43.187Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:06.752Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T113143-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T113143-33db16bd","recordedAt":"2026-03-31T11:31:43.187Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:06.394Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T113143-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T113143-33db16bd","recordedAt":"2026-03-31T11:31:43.187Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:05.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112924-65d64218::panitumumab::pan-cancer","analysisId":"20260331T112924-65d64218","recordedAt":"2026-03-31T11:29:24.457Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:07.710Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T112924-65d64218::temozolomide::pan-cancer","analysisId":"20260331T112924-65d64218","recordedAt":"2026-03-31T11:29:24.457Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:07.355Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T112924-65d64218::palbociclib::pan-cancer","analysisId":"20260331T112924-65d64218","recordedAt":"2026-03-31T11:29:24.457Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:04.962Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112924-65d64218::carboplatin::pan-cancer","analysisId":"20260331T112924-65d64218","recordedAt":"2026-03-31T11:29:24.457Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:04.606Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112924-65d64218::sirolimus::pan-cancer","analysisId":"20260331T112924-65d64218","recordedAt":"2026-03-31T11:29:24.457Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:04.247Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112924-65d64218::paclitaxel::pan-cancer","analysisId":"20260331T112924-65d64218","recordedAt":"2026-03-31T11:29:24.457Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:01.739Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112924-65d64218::gemcitabine::pan-cancer","analysisId":"20260331T112924-65d64218","recordedAt":"2026-03-31T11:29:24.457Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:07.000Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T112924-65d64218::cetuximab::pan-cancer","analysisId":"20260331T112924-65d64218","recordedAt":"2026-03-31T11:29:24.457Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:02.457Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112650-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T112650-557c91d1","recordedAt":"2026-03-31T11:26:50.578Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:59.230Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112650-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T112650-557c91d1","recordedAt":"2026-03-31T11:26:50.578Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:58.155Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112650-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T112650-557c91d1","recordedAt":"2026-03-31T11:26:50.578Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:58.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112650-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T112650-557c91d1","recordedAt":"2026-03-31T11:26:50.578Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:58.871Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112650-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T112650-557c91d1","recordedAt":"2026-03-31T11:26:50.578Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:00.304Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112650-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T112650-557c91d1","recordedAt":"2026-03-31T11:26:50.578Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:39:01.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112650-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T112650-557c91d1","recordedAt":"2026-03-31T11:26:50.578Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:06.288Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T112650-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T112650-557c91d1","recordedAt":"2026-03-31T11:26:50.578Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:06.643Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T112422-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:55.647Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112422-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:56.007Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112422-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:05.224Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T112422-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:54.575Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112422-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:57.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112422-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:05.577Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T112422-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:55.287Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112422-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:57.085Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112422-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T112422-b849edd6","recordedAt":"2026-03-31T11:24:22.437Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:05.933Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T112151-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:52.782Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112151-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:50.992Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112151-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:51.349Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112151-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:51.705Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112151-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:52.062Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112151-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:52.422Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112151-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:04.868Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T112151-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:53.855Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T112151-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:04.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T112151-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T112151-c46e28d2","recordedAt":"2026-03-31T11:21:53.355Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:53.138Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T101041-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T101041-33db16bd","recordedAt":"2026-03-31T10:10:41.715Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:49.558Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T101041-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T101041-33db16bd","recordedAt":"2026-03-31T10:10:41.715Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:50.633Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T101041-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T101041-33db16bd","recordedAt":"2026-03-31T10:10:41.715Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:50.274Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T101041-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T101041-33db16bd","recordedAt":"2026-03-31T10:10:41.715Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:04.158Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T101041-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T101041-33db16bd","recordedAt":"2026-03-31T10:10:41.715Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:49.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T101041-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T101041-33db16bd","recordedAt":"2026-03-31T10:10:41.715Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:48.487Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100815-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T100815-99db93fe","recordedAt":"2026-03-31T10:08:15.634Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:47.413Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100815-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T100815-99db93fe","recordedAt":"2026-03-31T10:08:15.634Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:03.419Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T100815-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T100815-99db93fe","recordedAt":"2026-03-31T10:08:15.634Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:03.063Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T100815-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T100815-99db93fe","recordedAt":"2026-03-31T10:08:15.634Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:48.130Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100815-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T100815-99db93fe","recordedAt":"2026-03-31T10:08:15.634Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:47.770Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100815-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T100815-99db93fe","recordedAt":"2026-03-31T10:08:15.634Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:44.920Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100815-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T100815-99db93fe","recordedAt":"2026-03-31T10:08:15.634Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:03.803Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T100815-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T100815-99db93fe","recordedAt":"2026-03-31T10:08:15.634Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:45.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100546-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T100546-557c91d1","recordedAt":"2026-03-31T10:05:46.790Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:43.484Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100546-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T100546-557c91d1","recordedAt":"2026-03-31T10:05:46.790Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:02.313Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T100546-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T100546-557c91d1","recordedAt":"2026-03-31T10:05:46.790Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:41.344Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100546-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T100546-557c91d1","recordedAt":"2026-03-31T10:05:46.790Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:41.702Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100546-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T100546-557c91d1","recordedAt":"2026-03-31T10:05:46.790Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:42.058Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100546-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T100546-557c91d1","recordedAt":"2026-03-31T10:05:46.790Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:42.416Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100546-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T100546-557c91d1","recordedAt":"2026-03-31T10:05:46.790Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:44.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100546-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T100546-557c91d1","recordedAt":"2026-03-31T10:05:46.790Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:02.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T100320-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:38.836Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100320-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:38.475Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100320-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:40.986Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100320-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:01.496Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T100320-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:37.756Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100320-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:39.193Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100320-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:40.268Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100320-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:01.913Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T100320-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T100320-b849edd6","recordedAt":"2026-03-31T10:03:20.495Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:49:01.111Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T100028-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:35.968Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100028-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:00.326Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T100028-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:34.536Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100028-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:35.249Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100028-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:35.609Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100028-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:36.324Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100028-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:37.041Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100028-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:49:00.723Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T100028-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:34.175Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T100028-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T100028-c46e28d2","recordedAt":"2026-03-31T10:00:30.356Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:34.892Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090638-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T090638-33db16bd","recordedAt":"2026-03-31T09:06:38.688Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:33.458Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090638-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T090638-33db16bd","recordedAt":"2026-03-31T09:06:38.688Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:33.815Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090638-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T090638-33db16bd","recordedAt":"2026-03-31T09:06:38.688Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:48:59.923Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T090638-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T090638-33db16bd","recordedAt":"2026-03-31T09:06:38.688Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:31.673Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090638-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T090638-33db16bd","recordedAt":"2026-03-31T09:06:38.688Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:32.743Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090638-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T090638-33db16bd","recordedAt":"2026-03-31T09:06:38.688Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:33.102Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090404-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T090404-99db93fe","recordedAt":"2026-03-31T09:04:04.203Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:30.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090404-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T090404-99db93fe","recordedAt":"2026-03-31T09:04:04.203Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:30.954Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090404-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T090404-99db93fe","recordedAt":"2026-03-31T09:04:04.203Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:28.088Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090404-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T090404-99db93fe","recordedAt":"2026-03-31T09:04:04.203Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:48:59.140Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T090404-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T090404-99db93fe","recordedAt":"2026-03-31T09:04:04.203Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:48:59.532Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T090404-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T090404-99db93fe","recordedAt":"2026-03-31T09:04:04.203Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:31.312Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090404-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T090404-99db93fe","recordedAt":"2026-03-31T09:04:04.203Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:48.087Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T090404-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T090404-99db93fe","recordedAt":"2026-03-31T09:04:04.203Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:28.807Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090144-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T090144-557c91d1","recordedAt":"2026-03-31T09:01:44.753Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:24.867Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090144-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T090144-557c91d1","recordedAt":"2026-03-31T09:01:44.753Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:25.583Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090144-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T090144-557c91d1","recordedAt":"2026-03-31T09:01:44.753Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:47.380Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T090144-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T090144-557c91d1","recordedAt":"2026-03-31T09:01:44.753Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:26.658Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090144-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T090144-557c91d1","recordedAt":"2026-03-31T09:01:44.753Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:27.370Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090144-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T090144-557c91d1","recordedAt":"2026-03-31T09:01:44.753Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:47.734Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T090144-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T090144-557c91d1","recordedAt":"2026-03-31T09:01:44.753Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:24.509Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T090144-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T090144-557c91d1","recordedAt":"2026-03-31T09:01:44.753Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:25.224Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085851-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:20.934Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085851-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:21.650Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085851-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:22.007Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085851-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:22.362Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085851-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:24.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085851-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:47.027Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T085851-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:46.674Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T085851-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:23.437Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085851-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T085851-b849edd6","recordedAt":"2026-03-31T08:58:51.140Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:46.320Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T085622-b44315aa::olaparib::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:45.967Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T085622-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:18.063Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085622-b44315aa::rucaparib::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:20.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085622-b44315aa::niraparib::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:19.501Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085622-b44315aa::paclitaxel::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:18.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085622-b44315aa::gemcitabine::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:18.424Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085622-b44315aa::talazoparib::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:45.613Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T085622-b44315aa::cisplatin::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:17.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085622-b44315aa::carboplatin::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:17.346Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T085622-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T085622-b44315aa","recordedAt":"2026-03-31T08:56:23.850Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:19.142Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T080034-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T080034-33db16bd","recordedAt":"2026-03-31T08:00:34.465Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:14.844Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T080034-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T080034-33db16bd","recordedAt":"2026-03-31T08:00:34.465Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:15.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T080034-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T080034-33db16bd","recordedAt":"2026-03-31T08:00:34.465Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:16.274Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T080034-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T080034-33db16bd","recordedAt":"2026-03-31T08:00:34.465Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:16.631Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T080034-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T080034-33db16bd","recordedAt":"2026-03-31T08:00:34.465Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:16.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T080034-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T080034-33db16bd","recordedAt":"2026-03-31T08:00:34.465Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:45.260Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T075726-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T075726-99db93fe","recordedAt":"2026-03-31T07:57:26.122Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:11.968Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075726-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T075726-99db93fe","recordedAt":"2026-03-31T07:57:26.122Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:44.552Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T075726-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T075726-99db93fe","recordedAt":"2026-03-31T07:57:26.122Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:44.198Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T075726-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T075726-99db93fe","recordedAt":"2026-03-31T07:57:26.122Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:44.907Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T075726-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T075726-99db93fe","recordedAt":"2026-03-31T07:57:26.122Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:14.487Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075726-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T075726-99db93fe","recordedAt":"2026-03-31T07:57:26.122Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:14.127Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075726-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T075726-99db93fe","recordedAt":"2026-03-31T07:57:26.122Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:13.769Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075726-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T075726-99db93fe","recordedAt":"2026-03-31T07:57:26.122Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:11.252Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075503-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T075503-557c91d1","recordedAt":"2026-03-31T07:55:03.252Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:07.654Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075503-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T075503-557c91d1","recordedAt":"2026-03-31T07:55:03.252Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:08.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075503-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T075503-557c91d1","recordedAt":"2026-03-31T07:55:03.252Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:08.372Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075503-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T075503-557c91d1","recordedAt":"2026-03-31T07:55:03.252Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:08.730Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075503-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T075503-557c91d1","recordedAt":"2026-03-31T07:55:03.252Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:09.804Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075503-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T075503-557c91d1","recordedAt":"2026-03-31T07:55:03.252Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:43.491Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T075503-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T075503-557c91d1","recordedAt":"2026-03-31T07:55:03.252Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:10.522Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075503-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T075503-557c91d1","recordedAt":"2026-03-31T07:55:03.252Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:43.845Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T075211-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:05.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075211-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:04.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075211-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:07.296Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075211-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:42.781Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T075211-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:04.068Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075211-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:05.502Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075211-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:42.428Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T075211-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:06.581Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T075211-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T075211-b849edd6","recordedAt":"2026-03-31T07:52:11.441Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:43.137Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T074918-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:42.074Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T074918-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:01.200Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T074918-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:01.913Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T074918-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:01.555Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T074918-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:02.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T074918-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:03.350Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T074918-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:00.482Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T074918-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:02.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T074918-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:41.722Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T074918-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T074918-c46e28d2","recordedAt":"2026-03-31T07:49:20.269Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:00.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061436-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T061436-33db16bd","recordedAt":"2026-03-31T06:14:36.944Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:59.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061436-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T061436-33db16bd","recordedAt":"2026-03-31T06:14:36.944Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:59.410Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061436-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T061436-33db16bd","recordedAt":"2026-03-31T06:14:36.944Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:38:00.124Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061436-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T061436-33db16bd","recordedAt":"2026-03-31T06:14:36.944Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:59.768Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061436-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T061436-33db16bd","recordedAt":"2026-03-31T06:14:36.944Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:57.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061436-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T061436-33db16bd","recordedAt":"2026-03-31T06:14:36.944Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:41.368Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T061207-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T061207-99db93fe","recordedAt":"2026-03-31T06:12:07.873Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:54.390Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061207-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T061207-99db93fe","recordedAt":"2026-03-31T06:12:07.873Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:41.010Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T061207-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T061207-99db93fe","recordedAt":"2026-03-31T06:12:07.873Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:56.901Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061207-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T061207-99db93fe","recordedAt":"2026-03-31T06:12:07.873Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:57.261Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061207-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T061207-99db93fe","recordedAt":"2026-03-31T06:12:07.873Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:55.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061207-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T061207-99db93fe","recordedAt":"2026-03-31T06:12:07.873Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:40.298Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T061207-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T061207-99db93fe","recordedAt":"2026-03-31T06:12:07.873Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:57.622Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T061207-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T061207-99db93fe","recordedAt":"2026-03-31T06:12:07.873Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:40.651Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T060914-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T060914-557c91d1","recordedAt":"2026-03-31T06:09:14.276Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:51.175Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060914-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T060914-557c91d1","recordedAt":"2026-03-31T06:09:14.276Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:52.956Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060914-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T060914-557c91d1","recordedAt":"2026-03-31T06:09:14.276Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:53.670Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060914-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T060914-557c91d1","recordedAt":"2026-03-31T06:09:14.276Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:51.881Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060914-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T060914-557c91d1","recordedAt":"2026-03-31T06:09:14.276Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:51.527Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060914-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T060914-557c91d1","recordedAt":"2026-03-31T06:09:14.276Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:50.823Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060914-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T060914-557c91d1","recordedAt":"2026-03-31T06:09:14.276Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:39.946Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T060914-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T060914-557c91d1","recordedAt":"2026-03-31T06:09:14.276Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:39.593Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T060649-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:49.745Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060649-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:48.304Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060649-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:47.230Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060649-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:47.946Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060649-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:48.664Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060649-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:50.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060649-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:38.886Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T060649-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:39.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T060649-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T060649-b849edd6","recordedAt":"2026-03-31T06:06:49.729Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:38.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T060422-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:45.440Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060422-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:45.798Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060422-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:45.082Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060422-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:44.724Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060422-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:46.514Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060422-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:44.366Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060422-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:44.008Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060422-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:43.649Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T060422-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:38.176Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T060422-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T060422-c46e28d2","recordedAt":"2026-03-31T06:04:23.770Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:37.823Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T043010-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T043010-33db16bd","recordedAt":"2026-03-31T04:30:10.254Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:37.470Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T043010-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T043010-33db16bd","recordedAt":"2026-03-31T04:30:10.254Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:42.934Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T043010-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T043010-33db16bd","recordedAt":"2026-03-31T04:30:10.254Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:42.578Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T043010-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T043010-33db16bd","recordedAt":"2026-03-31T04:30:10.254Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:42.220Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T043010-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T043010-33db16bd","recordedAt":"2026-03-31T04:30:10.254Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:41.145Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T043010-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T043010-33db16bd","recordedAt":"2026-03-31T04:30:10.254Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:43.291Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042737-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T042737-99db93fe","recordedAt":"2026-03-31T04:27:37.969Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:40.070Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042737-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T042737-99db93fe","recordedAt":"2026-03-31T04:27:37.969Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:38.275Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042737-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T042737-99db93fe","recordedAt":"2026-03-31T04:27:37.969Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:40.785Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042737-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T042737-99db93fe","recordedAt":"2026-03-31T04:27:37.969Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:36.738Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T042737-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T042737-99db93fe","recordedAt":"2026-03-31T04:27:37.969Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:36.384Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T042737-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T042737-99db93fe","recordedAt":"2026-03-31T04:27:37.969Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:37.557Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042737-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T042737-99db93fe","recordedAt":"2026-03-31T04:27:37.969Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:40.427Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042737-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T042737-99db93fe","recordedAt":"2026-03-31T04:27:37.969Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:37.091Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T042524-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T042524-557c91d1","recordedAt":"2026-03-31T04:25:24.179Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:36.031Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T042524-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T042524-557c91d1","recordedAt":"2026-03-31T04:25:24.179Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:34.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042524-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T042524-557c91d1","recordedAt":"2026-03-31T04:25:24.179Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:35.677Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T042524-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T042524-557c91d1","recordedAt":"2026-03-31T04:25:24.179Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:36.839Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042524-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T042524-557c91d1","recordedAt":"2026-03-31T04:25:24.179Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:36.124Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042524-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T042524-557c91d1","recordedAt":"2026-03-31T04:25:24.179Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:35.047Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042524-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T042524-557c91d1","recordedAt":"2026-03-31T04:25:24.179Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:34.689Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042524-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T042524-557c91d1","recordedAt":"2026-03-31T04:25:24.179Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:33.973Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042259-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:31.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042259-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:33.613Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042259-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:34.617Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T042259-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:31.823Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042259-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:35.324Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T042259-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:34.970Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T042259-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:30.391Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042259-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:31.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042259-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T042259-b849edd6","recordedAt":"2026-03-31T04:22:59.163Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:32.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042038-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:28.592Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042038-b44315aa::olaparib::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:33.867Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T042038-b44315aa::talazoparib::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:34.263Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T042038-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:27.515Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042038-b44315aa::carboplatin::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:26.800Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042038-b44315aa::gemcitabine::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:27.874Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042038-b44315aa::rucaparib::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:29.669Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042038-b44315aa::paclitaxel::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:28.233Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042038-b44315aa::cisplatin::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:27.158Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T042038-b44315aa::niraparib::breast_cancer","analysisId":"20260331T042038-b44315aa","recordedAt":"2026-03-31T04:20:39.421Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:28.951Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012903-d2b73aa4::sirolimus::pan-cancer","analysisId":"20260331T012903-d2b73aa4","recordedAt":"2026-03-31T01:29:03.277Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:18.551Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012903-d2b73aa4::palbociclib::pan-cancer","analysisId":"20260331T012903-d2b73aa4","recordedAt":"2026-03-31T01:29:03.277Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:19.267Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012903-d2b73aa4::carboplatin::pan-cancer","analysisId":"20260331T012903-d2b73aa4","recordedAt":"2026-03-31T01:29:03.277Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:18.907Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012903-d2b73aa4::temozolomide::pan-cancer","analysisId":"20260331T012903-d2b73aa4","recordedAt":"2026-03-31T01:29:03.277Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:32.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T012903-d2b73aa4::paclitaxel::pan-cancer","analysisId":"20260331T012903-d2b73aa4","recordedAt":"2026-03-31T01:29:03.277Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:16.039Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012903-d2b73aa4::cetuximab::pan-cancer","analysisId":"20260331T012903-d2b73aa4","recordedAt":"2026-03-31T01:29:03.277Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:16.757Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012903-d2b73aa4::gemcitabine::pan-cancer","analysisId":"20260331T012903-d2b73aa4","recordedAt":"2026-03-31T01:29:03.277Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:33.125Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T012903-d2b73aa4::panitumumab::pan-cancer","analysisId":"20260331T012903-d2b73aa4","recordedAt":"2026-03-31T01:29:03.277Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:33.514Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T012219-a8f122bc::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T012219-a8f122bc","recordedAt":"2026-03-31T01:22:19.144Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:32.359Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T012219-a8f122bc::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T012219-a8f122bc","recordedAt":"2026-03-31T01:22:19.144Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:15.324Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012219-a8f122bc::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260331T012219-a8f122bc","recordedAt":"2026-03-31T01:22:19.144Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:14.967Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012219-a8f122bc::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T012219-a8f122bc","recordedAt":"2026-03-31T01:22:19.144Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:14.609Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012219-a8f122bc::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T012219-a8f122bc","recordedAt":"2026-03-31T01:22:19.144Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:14.251Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012219-a8f122bc::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T012219-a8f122bc","recordedAt":"2026-03-31T01:22:19.144Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:13.892Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012219-a8f122bc::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T012219-a8f122bc","recordedAt":"2026-03-31T01:22:19.144Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:13.178Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T012219-a8f122bc::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T012219-a8f122bc","recordedAt":"2026-03-31T01:22:19.144Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:31.973Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T011836-e74d9a6f::regorafenib::colorectal_cancer","analysisId":"20260331T011836-e74d9a6f","recordedAt":"2026-03-31T01:18:36.300Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:10.636Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011836-e74d9a6f::selumetinib::colorectal_cancer","analysisId":"20260331T011836-e74d9a6f","recordedAt":"2026-03-31T01:18:36.300Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:09.558Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011836-e74d9a6f::temsirolimus::colorectal_cancer","analysisId":"20260331T011836-e74d9a6f","recordedAt":"2026-03-31T01:18:36.300Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:09.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011836-e74d9a6f::sorafenib::colorectal_cancer","analysisId":"20260331T011836-e74d9a6f","recordedAt":"2026-03-31T01:18:36.300Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:10.993Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011836-e74d9a6f::adagrasib::colorectal_cancer","analysisId":"20260331T011836-e74d9a6f","recordedAt":"2026-03-31T01:18:36.300Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:30.813Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T011836-e74d9a6f::tovorafenib::colorectal_cancer","analysisId":"20260331T011836-e74d9a6f","recordedAt":"2026-03-31T01:18:36.300Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:31.193Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T011836-e74d9a6f::encorafenib::colorectal_cancer","analysisId":"20260331T011836-e74d9a6f","recordedAt":"2026-03-31T01:18:36.300Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:11.709Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011836-e74d9a6f::dabrafenib::colorectal_cancer","analysisId":"20260331T011836-e74d9a6f","recordedAt":"2026-03-31T01:18:36.300Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:42:31.587Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T011352-22c3d67f::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:08.483Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011352-22c3d67f::paclitaxel::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:07.764Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011352-22c3d67f::talazoparib::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:24.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T011352-22c3d67f::niraparib::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:07.047Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011352-22c3d67f::rucaparib::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:08.123Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011352-22c3d67f::gemcitabine::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:06.687Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011352-22c3d67f::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:06.327Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011352-22c3d67f::cisplatin::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:05.968Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011352-22c3d67f::carboplatin::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:05.611Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T011352-22c3d67f::olaparib::breast_cancer","analysisId":"20260331T011352-22c3d67f","recordedAt":"2026-03-31T01:13:52.316Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:42:30.431Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T010353-33db16bd::galantamine::alzheimers_disease","analysisId":"20260331T010353-33db16bd","recordedAt":"2026-03-31T01:03:53.353Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:04.894Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010353-33db16bd::donepezil::alzheimers_disease","analysisId":"20260331T010353-33db16bd","recordedAt":"2026-03-31T01:03:53.353Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:04.535Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010353-33db16bd::donanemab::alzheimers_disease","analysisId":"20260331T010353-33db16bd","recordedAt":"2026-03-31T01:03:53.353Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:04.175Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010353-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260331T010353-33db16bd","recordedAt":"2026-03-31T01:03:53.353Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:03.100Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010353-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260331T010353-33db16bd","recordedAt":"2026-03-31T01:03:53.353Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:05.252Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010353-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260331T010353-33db16bd","recordedAt":"2026-03-31T01:03:53.353Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:24.510Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T010110-99db93fe::paclitaxel::pan-cancer","analysisId":"20260331T010110-99db93fe","recordedAt":"2026-03-31T01:01:10.823Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:59.516Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010110-99db93fe::sirolimus::pan-cancer","analysisId":"20260331T010110-99db93fe","recordedAt":"2026-03-31T01:01:10.823Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:02.026Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010110-99db93fe::palbociclib::pan-cancer","analysisId":"20260331T010110-99db93fe","recordedAt":"2026-03-31T01:01:10.823Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:02.741Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010110-99db93fe::panitumumab::pan-cancer","analysisId":"20260331T010110-99db93fe","recordedAt":"2026-03-31T01:01:10.823Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:23.802Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T010110-99db93fe::temozolomide::pan-cancer","analysisId":"20260331T010110-99db93fe","recordedAt":"2026-03-31T01:01:10.823Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:23.447Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T010110-99db93fe::gemcitabine::pan-cancer","analysisId":"20260331T010110-99db93fe","recordedAt":"2026-03-31T01:01:10.823Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:24.156Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T010110-99db93fe::carboplatin::pan-cancer","analysisId":"20260331T010110-99db93fe","recordedAt":"2026-03-31T01:01:10.823Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:02.383Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T010110-99db93fe::cetuximab::pan-cancer","analysisId":"20260331T010110-99db93fe","recordedAt":"2026-03-31T01:01:10.823Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:37:00.234Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005833-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260331T005833-557c91d1","recordedAt":"2026-03-31T00:58:33.331Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:57.007Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005833-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260331T005833-557c91d1","recordedAt":"2026-03-31T00:58:33.331Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:23.092Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260331T005833-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260331T005833-557c91d1","recordedAt":"2026-03-31T00:58:33.331Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:58.796Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005833-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260331T005833-557c91d1","recordedAt":"2026-03-31T00:58:33.331Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:58.078Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005833-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260331T005833-557c91d1","recordedAt":"2026-03-31T00:58:33.331Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:56.647Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005833-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260331T005833-557c91d1","recordedAt":"2026-03-31T00:58:33.331Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:56.289Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005833-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260331T005833-557c91d1","recordedAt":"2026-03-31T00:58:33.331Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:55.931Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005833-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260331T005833-557c91d1","recordedAt":"2026-03-31T00:58:33.331Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:22.737Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260331T005602-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:22.382Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T005602-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:53.422Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005602-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:53.064Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005602-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:22.028Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T005602-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:21.673Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260331T005602-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:54.856Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005602-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:55.574Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005602-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:52.344Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005602-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260331T005602-b849edd6","recordedAt":"2026-03-31T00:56:02.731Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:53.781Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:49.832Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:50.548Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::rucaparib::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:51.625Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::niraparib::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:50.907Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:50.192Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:49.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::cisplatin::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:49.118Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::carboplatin::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:48.765Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260331T005259-c46e28d2::talazoparib::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:20.964Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260331T005259-c46e28d2::olaparib::breast_cancer","analysisId":"20260331T005259-c46e28d2","recordedAt":"2026-03-31T00:53:00.640Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:21.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T220808-28a2f925::lecanemab::alzheimers_disease","analysisId":"20260330T220808-28a2f925","recordedAt":"2026-03-30T22:08:08.600Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:20.610Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T220808-28a2f925::aducanumab::alzheimers_disease","analysisId":"20260330T220808-28a2f925","recordedAt":"2026-03-30T22:08:08.600Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:46.254Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220808-28a2f925::rivastigmine::alzheimers_disease","analysisId":"20260330T220808-28a2f925","recordedAt":"2026-03-30T22:08:08.600Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:48.408Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220808-28a2f925::galantamine::alzheimers_disease","analysisId":"20260330T220808-28a2f925","recordedAt":"2026-03-30T22:08:08.600Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:48.049Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220808-28a2f925::donanemab::alzheimers_disease","analysisId":"20260330T220808-28a2f925","recordedAt":"2026-03-30T22:08:08.600Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:47.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220808-28a2f925::donepezil::alzheimers_disease","analysisId":"20260330T220808-28a2f925","recordedAt":"2026-03-30T22:08:08.600Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:47.688Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220515-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T220515-99db93fe","recordedAt":"2026-03-30T22:05:15.487Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:19.595Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T220515-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T220515-99db93fe","recordedAt":"2026-03-30T22:05:15.487Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:20.256Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T220515-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T220515-99db93fe","recordedAt":"2026-03-30T22:05:15.487Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:19.208Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T220515-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T220515-99db93fe","recordedAt":"2026-03-30T22:05:15.487Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:45.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220515-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T220515-99db93fe","recordedAt":"2026-03-30T22:05:15.487Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:45.537Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220515-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T220515-99db93fe","recordedAt":"2026-03-30T22:05:15.487Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:45.182Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220515-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T220515-99db93fe","recordedAt":"2026-03-30T22:05:15.487Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:43.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220515-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T220515-99db93fe","recordedAt":"2026-03-30T22:05:15.487Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:42.666Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220250-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T220250-557c91d1","recordedAt":"2026-03-30T22:02:50.024Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:41.949Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220250-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T220250-557c91d1","recordedAt":"2026-03-30T22:02:50.024Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:41.228Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220250-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T220250-557c91d1","recordedAt":"2026-03-30T22:02:50.024Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:40.153Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220250-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T220250-557c91d1","recordedAt":"2026-03-30T22:02:50.024Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:39.796Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220250-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T220250-557c91d1","recordedAt":"2026-03-30T22:02:50.024Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:39.077Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220250-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T220250-557c91d1","recordedAt":"2026-03-30T22:02:50.024Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:39.437Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220250-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T220250-557c91d1","recordedAt":"2026-03-30T22:02:50.024Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:18.820Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T220250-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T220250-557c91d1","recordedAt":"2026-03-30T22:02:50.024Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:18.424Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T220002-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:38.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220002-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:17.268Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T220002-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:36.928Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220002-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:36.568Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220002-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:17.652Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T220002-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:35.490Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220002-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:36.208Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T220002-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:18.038Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T220002-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T220002-b849edd6","recordedAt":"2026-03-30T22:00:02.741Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:38.717Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:34.773Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:31.904Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:16.866Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T215725-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:33.697Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:34.056Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:32.621Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:32.980Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:33.337Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:32.261Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T215725-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T215725-c46e28d2","recordedAt":"2026-03-30T21:57:27.207Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:39:16.471Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T205436-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T205436-33db16bd","recordedAt":"2026-03-30T20:54:36.728Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:39:16.082Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T205436-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T205436-33db16bd","recordedAt":"2026-03-30T20:54:36.728Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:30.471Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205436-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T205436-33db16bd","recordedAt":"2026-03-30T20:54:36.728Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:31.546Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205436-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T205436-33db16bd","recordedAt":"2026-03-30T20:54:36.728Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:31.188Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205436-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T205436-33db16bd","recordedAt":"2026-03-30T20:54:36.728Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:29.398Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205436-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T205436-33db16bd","recordedAt":"2026-03-30T20:54:36.728Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:30.829Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205138-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T205138-99db93fe","recordedAt":"2026-03-30T20:51:38.985Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:25.812Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205138-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T205138-99db93fe","recordedAt":"2026-03-30T20:51:38.985Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:28.682Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205138-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T205138-99db93fe","recordedAt":"2026-03-30T20:51:38.985Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:29.041Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205138-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T205138-99db93fe","recordedAt":"2026-03-30T20:51:38.985Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:12.485Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T205138-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T205138-99db93fe","recordedAt":"2026-03-30T20:51:38.985Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:28.322Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T205138-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T205138-99db93fe","recordedAt":"2026-03-30T20:51:38.985Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:12.840Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T205138-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T205138-99db93fe","recordedAt":"2026-03-30T20:51:38.985Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:12.130Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T205138-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T205138-99db93fe","recordedAt":"2026-03-30T20:51:38.985Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:26.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204809-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T204809-557c91d1","recordedAt":"2026-03-30T20:48:09.951Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:11.775Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T204809-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T204809-557c91d1","recordedAt":"2026-03-30T20:48:09.951Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:11.421Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T204809-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T204809-557c91d1","recordedAt":"2026-03-30T20:48:09.951Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:25.096Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204809-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T204809-557c91d1","recordedAt":"2026-03-30T20:48:09.951Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:22.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204809-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T204809-557c91d1","recordedAt":"2026-03-30T20:48:09.951Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:22.946Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204809-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T204809-557c91d1","recordedAt":"2026-03-30T20:48:09.951Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:23.305Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204809-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T204809-557c91d1","recordedAt":"2026-03-30T20:48:09.951Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:24.382Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204809-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T204809-557c91d1","recordedAt":"2026-03-30T20:48:09.951Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:22.229Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204429-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:19.235Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204429-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:19.595Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204429-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:19.952Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204429-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:21.874Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204429-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:10.349Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T204429-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:11.064Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T204429-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:10.710Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T204429-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:18.520Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204429-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T204429-b849edd6","recordedAt":"2026-03-30T20:44:29.113Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:21.157Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::olaparib::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:09.639Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T204142-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:16.724Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::carboplatin::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:14.949Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::rucaparib::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:17.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::niraparib::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:17.084Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::paclitaxel::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:16.366Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::gemcitabine::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:16.008Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:15.655Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::cisplatin::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:15.301Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T204142-b44315aa::talazoparib::breast_cancer","analysisId":"20260330T204142-b44315aa","recordedAt":"2026-03-30T20:41:44.168Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:09.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T203543-0e1206a5::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:11.719Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203543-0e1206a5::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:14.232Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203543-0e1206a5::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:13.872Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203543-0e1206a5::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:13.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203543-0e1206a5::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:13.153Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203543-0e1206a5::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:12.794Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203543-0e1206a5::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:12.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203543-0e1206a5::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:09.284Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T203543-0e1206a5::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T203543-0e1206a5","recordedAt":"2026-03-30T20:35:43.506Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:08.928Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T203209-5256fd4f::dabrafenib::colorectal_cancer","analysisId":"20260330T203209-5256fd4f","recordedAt":"2026-03-30T20:32:09.784Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:08.219Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T203209-5256fd4f::encorafenib::colorectal_cancer","analysisId":"20260330T203209-5256fd4f","recordedAt":"2026-03-30T20:32:09.784Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:10.645Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203209-5256fd4f::adagrasib::colorectal_cancer","analysisId":"20260330T203209-5256fd4f","recordedAt":"2026-03-30T20:32:09.784Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:07.862Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T203209-5256fd4f::tovorafenib::colorectal_cancer","analysisId":"20260330T203209-5256fd4f","recordedAt":"2026-03-30T20:32:09.784Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:08.574Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T203209-5256fd4f::selumetinib::colorectal_cancer","analysisId":"20260330T203209-5256fd4f","recordedAt":"2026-03-30T20:32:09.784Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:08.495Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203209-5256fd4f::temsirolimus::colorectal_cancer","analysisId":"20260330T203209-5256fd4f","recordedAt":"2026-03-30T20:32:09.784Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:08.855Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203209-5256fd4f::regorafenib::colorectal_cancer","analysisId":"20260330T203209-5256fd4f","recordedAt":"2026-03-30T20:32:09.784Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:09.573Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T203209-5256fd4f::sorafenib::colorectal_cancer","analysisId":"20260330T203209-5256fd4f","recordedAt":"2026-03-30T20:32:09.784Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:09.926Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::rucaparib::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:07.061Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::carboplatin::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:04.555Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::cisplatin::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:04.913Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:05.272Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::gemcitabine::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:05.631Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::niraparib::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:05.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::paclitaxel::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:06.700Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:07.418Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T202447-a10b045e::talazoparib::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:07.151Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T202447-a10b045e::olaparib::breast_cancer","analysisId":"20260330T202447-a10b045e","recordedAt":"2026-03-30T20:24:47.758Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:07.506Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T184349-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T184349-33db16bd","recordedAt":"2026-03-30T18:43:49.689Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:03.839Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184349-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T184349-33db16bd","recordedAt":"2026-03-30T18:43:49.689Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:03.481Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184349-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T184349-33db16bd","recordedAt":"2026-03-30T18:43:49.689Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:06.796Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T184349-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T184349-33db16bd","recordedAt":"2026-03-30T18:43:49.689Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:02.048Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184349-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T184349-33db16bd","recordedAt":"2026-03-30T18:43:49.689Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:03.123Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184349-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T184349-33db16bd","recordedAt":"2026-03-30T18:43:49.689Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:04.197Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184123-65d64218::sirolimus::pan-cancer","analysisId":"20260330T184123-65d64218","recordedAt":"2026-03-30T18:41:23.169Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:00.970Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184123-65d64218::temozolomide::pan-cancer","analysisId":"20260330T184123-65d64218","recordedAt":"2026-03-30T18:41:23.169Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:06.085Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T184123-65d64218::panitumumab::pan-cancer","analysisId":"20260330T184123-65d64218","recordedAt":"2026-03-30T18:41:23.169Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:05.730Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T184123-65d64218::palbociclib::pan-cancer","analysisId":"20260330T184123-65d64218","recordedAt":"2026-03-30T18:41:23.169Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:01.687Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184123-65d64218::carboplatin::pan-cancer","analysisId":"20260330T184123-65d64218","recordedAt":"2026-03-30T18:41:23.169Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:36:01.329Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184123-65d64218::paclitaxel::pan-cancer","analysisId":"20260330T184123-65d64218","recordedAt":"2026-03-30T18:41:23.169Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:58.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T184123-65d64218::gemcitabine::pan-cancer","analysisId":"20260330T184123-65d64218","recordedAt":"2026-03-30T18:41:23.169Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:06.441Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T184123-65d64218::cetuximab::pan-cancer","analysisId":"20260330T184123-65d64218","recordedAt":"2026-03-30T18:41:23.169Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:59.181Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183857-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T183857-557c91d1","recordedAt":"2026-03-30T18:38:57.560Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:05.020Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T183857-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T183857-557c91d1","recordedAt":"2026-03-30T18:38:57.560Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:55.238Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183857-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T183857-557c91d1","recordedAt":"2026-03-30T18:38:57.560Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:54.882Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183857-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T183857-557c91d1","recordedAt":"2026-03-30T18:38:57.560Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:55.599Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183857-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T183857-557c91d1","recordedAt":"2026-03-30T18:38:57.560Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:55.957Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183857-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T183857-557c91d1","recordedAt":"2026-03-30T18:38:57.560Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:57.038Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183857-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T183857-557c91d1","recordedAt":"2026-03-30T18:38:57.560Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:57.750Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183857-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T183857-557c91d1","recordedAt":"2026-03-30T18:38:57.560Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:05.375Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T183542-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:52.011Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183542-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:52.729Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183542-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:04.665Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T183542-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:54.522Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183542-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:51.295Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183542-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:52.371Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183542-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:04.309Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T183542-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:03.954Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T183542-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T183542-b849edd6","recordedAt":"2026-03-30T18:35:42.485Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:53.808Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:49.507Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::carboplatin::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:47.723Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::olaparib::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:03.598Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T183242-b44315aa::rucaparib::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:50.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::niraparib::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:49.865Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::paclitaxel::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:49.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::gemcitabine::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:48.796Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:48.440Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::cisplatin::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:48.081Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T183242-b44315aa::talazoparib::breast_cancer","analysisId":"20260330T183242-b44315aa","recordedAt":"2026-03-30T18:32:44.209Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:03.243Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T164310-1f1ae2bb::donanemab::alzheimers_disease","analysisId":"20260330T164310-1f1ae2bb","recordedAt":"2026-03-30T16:43:10.651Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:46.288Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164310-1f1ae2bb::aducanumab::alzheimers_disease","analysisId":"20260330T164310-1f1ae2bb","recordedAt":"2026-03-30T16:43:10.651Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:45.574Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164310-1f1ae2bb::donepezil::alzheimers_disease","analysisId":"20260330T164310-1f1ae2bb","recordedAt":"2026-03-30T16:43:10.651Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:46.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164310-1f1ae2bb::rivastigmine::alzheimers_disease","analysisId":"20260330T164310-1f1ae2bb","recordedAt":"2026-03-30T16:43:10.651Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:47.365Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164310-1f1ae2bb::lecanemab::alzheimers_disease","analysisId":"20260330T164310-1f1ae2bb","recordedAt":"2026-03-30T16:43:10.651Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:02.888Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T164310-1f1ae2bb::galantamine::alzheimers_disease","analysisId":"20260330T164310-1f1ae2bb","recordedAt":"2026-03-30T16:43:10.651Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:47.006Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164027-c2761458::palbociclib::pan-cancer","analysisId":"20260330T164027-c2761458","recordedAt":"2026-03-30T16:40:27.602Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:44.857Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164027-c2761458::sirolimus::pan-cancer","analysisId":"20260330T164027-c2761458","recordedAt":"2026-03-30T16:40:27.602Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:44.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164027-c2761458::paclitaxel::pan-cancer","analysisId":"20260330T164027-c2761458","recordedAt":"2026-03-30T16:40:27.602Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:41.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164027-c2761458::temozolomide::pan-cancer","analysisId":"20260330T164027-c2761458","recordedAt":"2026-03-30T16:40:27.602Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:02.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T164027-c2761458::carboplatin::pan-cancer","analysisId":"20260330T164027-c2761458","recordedAt":"2026-03-30T16:40:27.602Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:44.500Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164027-c2761458::gemcitabine::pan-cancer","analysisId":"20260330T164027-c2761458","recordedAt":"2026-03-30T16:40:27.602Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:01.819Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T164027-c2761458::cetuximab::pan-cancer","analysisId":"20260330T164027-c2761458","recordedAt":"2026-03-30T16:40:27.602Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:42.357Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T164027-c2761458::panitumumab::pan-cancer","analysisId":"20260330T164027-c2761458","recordedAt":"2026-03-30T16:40:27.602Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:33:02.174Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T163634-fcc440b4::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:39.129Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163634-fcc440b4::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:01.464Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T163634-fcc440b4::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:01.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T163634-fcc440b4::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:40.929Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163634-fcc440b4::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:40.564Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163634-fcc440b4::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:40.198Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163634-fcc440b4::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:39.843Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163634-fcc440b4::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:39.484Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163634-fcc440b4::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T163634-fcc440b4","recordedAt":"2026-03-30T16:36:34.882Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:38.412Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163107-68cb23d2::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T163107-68cb23d2","recordedAt":"2026-03-30T16:31:07.899Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:00.754Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T163107-68cb23d2::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T163107-68cb23d2","recordedAt":"2026-03-30T16:31:07.899Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:33.033Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163107-68cb23d2::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T163107-68cb23d2","recordedAt":"2026-03-30T16:31:07.899Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:33.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163107-68cb23d2::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T163107-68cb23d2","recordedAt":"2026-03-30T16:31:07.899Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:34.107Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163107-68cb23d2::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260330T163107-68cb23d2","recordedAt":"2026-03-30T16:31:07.899Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:34.826Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163107-68cb23d2::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T163107-68cb23d2","recordedAt":"2026-03-30T16:31:07.899Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:35.184Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163107-68cb23d2::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T163107-68cb23d2","recordedAt":"2026-03-30T16:31:07.899Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:35.542Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T163107-68cb23d2::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T163107-68cb23d2","recordedAt":"2026-03-30T16:31:07.899Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:00.399Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T162732-22c3d67f::rucaparib::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:31.595Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T162732-22c3d67f::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:31.955Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T162732-22c3d67f::gemcitabine::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:30.169Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T162732-22c3d67f::paclitaxel::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:31.240Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T162732-22c3d67f::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:29.810Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T162732-22c3d67f::cisplatin::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:29.453Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T162732-22c3d67f::carboplatin::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:29.099Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T162732-22c3d67f::olaparib::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:33:00.043Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T162732-22c3d67f::talazoparib::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:32:59.685Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T162732-22c3d67f::niraparib::breast_cancer","analysisId":"20260330T162732-22c3d67f","recordedAt":"2026-03-30T16:27:32.393Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:30.526Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151836-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T151836-33db16bd","recordedAt":"2026-03-30T15:18:36.615Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:26.590Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151836-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T151836-33db16bd","recordedAt":"2026-03-30T15:18:36.615Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:28.382Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151836-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T151836-33db16bd","recordedAt":"2026-03-30T15:18:36.615Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:28.023Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151836-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T151836-33db16bd","recordedAt":"2026-03-30T15:18:36.615Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:27.665Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151836-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T151836-33db16bd","recordedAt":"2026-03-30T15:18:36.615Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:32:59.330Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T151836-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T151836-33db16bd","recordedAt":"2026-03-30T15:18:36.615Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:28.743Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151549-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T151549-99db93fe","recordedAt":"2026-03-30T15:15:49.904Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:23.009Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151549-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T151549-99db93fe","recordedAt":"2026-03-30T15:15:49.904Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:26.234Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151549-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T151549-99db93fe","recordedAt":"2026-03-30T15:15:49.904Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:25.875Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151549-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T151549-99db93fe","recordedAt":"2026-03-30T15:15:49.904Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:32:58.975Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T151549-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T151549-99db93fe","recordedAt":"2026-03-30T15:15:49.904Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:32:58.197Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T151549-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T151549-99db93fe","recordedAt":"2026-03-30T15:15:49.904Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:25.516Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151549-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T151549-99db93fe","recordedAt":"2026-03-30T15:15:49.904Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:32:58.585Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T151549-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T151549-99db93fe","recordedAt":"2026-03-30T15:15:49.904Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:23.723Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151254-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T151254-557c91d1","recordedAt":"2026-03-30T15:12:54.406Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:20.504Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151254-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T151254-557c91d1","recordedAt":"2026-03-30T15:12:54.406Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:22.296Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151254-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T151254-557c91d1","recordedAt":"2026-03-30T15:12:54.406Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:32:57.423Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T151254-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T151254-557c91d1","recordedAt":"2026-03-30T15:12:54.406Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:21.579Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151254-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T151254-557c91d1","recordedAt":"2026-03-30T15:12:54.406Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:20.147Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151254-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T151254-557c91d1","recordedAt":"2026-03-30T15:12:54.406Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:19.795Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151254-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T151254-557c91d1","recordedAt":"2026-03-30T15:12:54.406Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:19.430Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151254-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T151254-557c91d1","recordedAt":"2026-03-30T15:12:54.406Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:32:57.813Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T151002-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:15.842Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151002-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:19.073Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151002-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:32:56.251Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T151002-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:16.919Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151002-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:16.559Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151002-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:17.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151002-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:32:56.633Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T151002-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:18.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T151002-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T151002-b849edd6","recordedAt":"2026-03-30T15:10:02.505Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:32:57.033Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T150713-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:32:55.862Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T150713-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:13.691Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T150713-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:13.334Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T150713-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:12.616Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T150713-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:12.975Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T150713-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:12.258Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T150713-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:32:55.471Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T150713-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:14.050Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T150713-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:15.127Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T150713-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T150713-c46e28d2","recordedAt":"2026-03-30T15:07:14.349Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:14.409Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T135123-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T135123-33db16bd","recordedAt":"2026-03-30T13:51:23.339Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:10.823Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T135123-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T135123-33db16bd","recordedAt":"2026-03-30T13:51:23.339Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:10.106Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T135123-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T135123-33db16bd","recordedAt":"2026-03-30T13:51:23.339Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:09.031Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T135123-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260330T135123-33db16bd","recordedAt":"2026-03-30T13:51:23.339Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:11.899Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T135123-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260330T135123-33db16bd","recordedAt":"2026-03-30T13:51:23.339Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:11.539Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T135123-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T135123-33db16bd","recordedAt":"2026-03-30T13:51:23.339Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:11.181Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T135123-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T135123-33db16bd","recordedAt":"2026-03-30T13:51:23.339Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:32:55.069Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T135123-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T135123-33db16bd","recordedAt":"2026-03-30T13:51:23.339Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:10.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134819-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T134819-99db93fe","recordedAt":"2026-03-30T13:48:19.519Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:08.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134819-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T134819-99db93fe","recordedAt":"2026-03-30T13:48:19.519Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:05.451Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134819-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T134819-99db93fe","recordedAt":"2026-03-30T13:48:19.519Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:07.958Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134819-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T134819-99db93fe","recordedAt":"2026-03-30T13:48:19.519Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:47.615Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T134819-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T134819-99db93fe","recordedAt":"2026-03-30T13:48:19.519Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:47.970Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T134819-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T134819-99db93fe","recordedAt":"2026-03-30T13:48:19.519Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:08.672Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134819-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T134819-99db93fe","recordedAt":"2026-03-30T13:48:19.519Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:06.168Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134819-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T134819-99db93fe","recordedAt":"2026-03-30T13:48:19.519Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:47.260Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T134444-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T134444-426e9227","recordedAt":"2026-03-30T13:44:44.904Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:46.543Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T134444-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T134444-426e9227","recordedAt":"2026-03-30T13:44:44.904Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:04.733Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134444-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T134444-426e9227","recordedAt":"2026-03-30T13:44:44.904Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:04.018Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134444-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T134444-426e9227","recordedAt":"2026-03-30T13:44:44.904Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:02.950Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134444-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T134444-426e9227","recordedAt":"2026-03-30T13:44:44.904Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:02.592Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134444-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T134444-426e9227","recordedAt":"2026-03-30T13:44:44.904Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:02.231Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134444-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T134444-426e9227","recordedAt":"2026-03-30T13:44:44.904Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:01.875Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134444-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T134444-426e9227","recordedAt":"2026-03-30T13:44:44.904Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:46.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T134149-181452b6::regorafenib::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:58.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134149-181452b6::adagrasib::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:45.478Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T134149-181452b6::atezolizumab::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:01.518Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134149-181452b6::temsirolimus::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:59.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134149-181452b6::sorafenib::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:59.370Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134149-181452b6::selumetinib::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:59.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134149-181452b6::dabrafenib::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:45.833Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T134149-181452b6::encorafenib::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:35:00.801Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T134149-181452b6::tovorafenib::colorectal_cancer","analysisId":"20260330T134149-181452b6","recordedAt":"2026-03-30T13:41:49.217Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:46.188Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T133803-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:45.122Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T133803-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:56.152Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T133803-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:56.869Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T133803-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:56.511Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T133803-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:55.076Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T133803-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:55.434Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T133803-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:57.586Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T133803-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:54.717Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T133803-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:55.792Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T133803-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T133803-c46e28d2","recordedAt":"2026-03-30T13:38:04.850Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:44.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T120155-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T120155-33db16bd","recordedAt":"2026-03-30T12:01:55.935Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:53.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T120155-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T120155-33db16bd","recordedAt":"2026-03-30T12:01:55.935Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:52.569Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T120155-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T120155-33db16bd","recordedAt":"2026-03-30T12:01:55.935Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:51.490Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T120155-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260330T120155-33db16bd","recordedAt":"2026-03-30T12:01:55.935Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:53.997Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T120155-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T120155-33db16bd","recordedAt":"2026-03-30T12:01:55.935Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:53.284Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T120155-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T120155-33db16bd","recordedAt":"2026-03-30T12:01:55.935Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:52.928Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T120155-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T120155-33db16bd","recordedAt":"2026-03-30T12:01:55.935Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:44.413Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T120155-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260330T120155-33db16bd","recordedAt":"2026-03-30T12:01:55.935Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:54.358Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115840-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T115840-99db93fe","recordedAt":"2026-03-30T11:58:41.009Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:43.703Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T115840-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T115840-99db93fe","recordedAt":"2026-03-30T11:58:41.009Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:51.134Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115840-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T115840-99db93fe","recordedAt":"2026-03-30T11:58:41.009Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:50.774Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115840-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T115840-99db93fe","recordedAt":"2026-03-30T11:58:41.009Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:43.348Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T115840-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T115840-99db93fe","recordedAt":"2026-03-30T11:58:41.009Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:50.415Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115840-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T115840-99db93fe","recordedAt":"2026-03-30T11:58:41.009Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:47.917Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115840-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T115840-99db93fe","recordedAt":"2026-03-30T11:58:41.009Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:48.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115840-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T115840-99db93fe","recordedAt":"2026-03-30T11:58:41.009Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:44.058Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T115526-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T115526-426e9227","recordedAt":"2026-03-30T11:55:26.848Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:42.639Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T115526-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T115526-426e9227","recordedAt":"2026-03-30T11:55:26.848Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:45.055Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115526-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T115526-426e9227","recordedAt":"2026-03-30T11:55:26.848Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:44.696Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115526-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T115526-426e9227","recordedAt":"2026-03-30T11:55:26.848Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:44.335Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115526-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T115526-426e9227","recordedAt":"2026-03-30T11:55:26.848Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:42.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T115526-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T115526-426e9227","recordedAt":"2026-03-30T11:55:26.848Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:47.203Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115526-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T115526-426e9227","recordedAt":"2026-03-30T11:55:26.848Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:46.485Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115526-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T115526-426e9227","recordedAt":"2026-03-30T11:55:26.848Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:45.414Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115244-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:41.574Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T115244-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:41.929Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T115244-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:40.753Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115244-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:41.470Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115244-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:41.825Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115244-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:42.185Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115244-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:43.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T115244-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:42.284Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T115244-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T115244-b849edd6","recordedAt":"2026-03-30T11:52:44.613Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:43.258Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T114959-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:41.219Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T114959-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:39.321Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T114959-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:40.033Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T114959-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:40.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T114959-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:38.961Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T114959-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:37.171Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T114959-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:37.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T114959-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:37.889Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T114959-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:38.246Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T114959-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T114959-c46e28d2","recordedAt":"2026-03-30T11:50:00.718Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:38.605Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093946-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260330T093946-33db16bd","recordedAt":"2026-03-30T09:39:46.511Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:36.452Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093946-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260330T093946-33db16bd","recordedAt":"2026-03-30T09:39:46.511Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:36.812Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093946-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T093946-33db16bd","recordedAt":"2026-03-30T09:39:46.511Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:40.509Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T093946-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T093946-33db16bd","recordedAt":"2026-03-30T09:39:46.511Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:33.943Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093946-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T093946-33db16bd","recordedAt":"2026-03-30T09:39:46.511Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:35.018Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093946-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T093946-33db16bd","recordedAt":"2026-03-30T09:39:46.511Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:35.377Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093946-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T093946-33db16bd","recordedAt":"2026-03-30T09:39:46.511Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:35.736Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093946-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T093946-33db16bd","recordedAt":"2026-03-30T09:39:46.511Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:36.093Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093708-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T093708-99db93fe","recordedAt":"2026-03-30T09:37:08.347Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:32.876Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093708-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T093708-99db93fe","recordedAt":"2026-03-30T09:37:08.347Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:40.154Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T093708-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T093708-99db93fe","recordedAt":"2026-03-30T09:37:08.347Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:39.444Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T093708-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T093708-99db93fe","recordedAt":"2026-03-30T09:37:08.347Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:30.374Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093708-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T093708-99db93fe","recordedAt":"2026-03-30T09:37:08.347Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:33.231Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093708-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T093708-99db93fe","recordedAt":"2026-03-30T09:37:08.347Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:33.584Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093708-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T093708-99db93fe","recordedAt":"2026-03-30T09:37:08.347Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:31.083Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093708-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T093708-99db93fe","recordedAt":"2026-03-30T09:37:08.347Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:39.799Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T093400-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T093400-426e9227","recordedAt":"2026-03-30T09:34:00.701Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:39.089Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T093400-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T093400-426e9227","recordedAt":"2026-03-30T09:34:00.701Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:27.148Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093400-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T093400-426e9227","recordedAt":"2026-03-30T09:34:00.701Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:26.790Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093400-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T093400-426e9227","recordedAt":"2026-03-30T09:34:00.701Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:29.662Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093400-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T093400-426e9227","recordedAt":"2026-03-30T09:34:00.701Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:38.732Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T093400-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T093400-426e9227","recordedAt":"2026-03-30T09:34:00.701Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:28.942Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093400-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T093400-426e9227","recordedAt":"2026-03-30T09:34:00.701Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:27.865Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093400-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T093400-426e9227","recordedAt":"2026-03-30T09:34:00.701Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:27.508Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093051-181452b6::regorafenib::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:23.205Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093051-181452b6::adagrasib::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:38.377Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T093051-181452b6::atezolizumab::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:26.431Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093051-181452b6::temsirolimus::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:24.642Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093051-181452b6::sorafenib::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:24.282Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093051-181452b6::selumetinib::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:23.923Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093051-181452b6::encorafenib::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:25.715Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T093051-181452b6::dabrafenib::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:38.022Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T093051-181452b6::tovorafenib::colorectal_cancer","analysisId":"20260330T093051-181452b6","recordedAt":"2026-03-30T09:30:51.290Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:37.667Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T092714-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:37.312Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T092714-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:20.698Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T092714-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:21.058Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T092714-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:21.774Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T092714-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:21.416Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T092714-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:22.493Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T092714-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:36.957Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T092714-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:19.625Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T092714-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:19.981Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T092714-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T092714-c46e28d2","recordedAt":"2026-03-30T09:27:16.104Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:20.339Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080709-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T080709-33db16bd","recordedAt":"2026-03-30T08:07:09.253Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:17.834Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080709-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T080709-33db16bd","recordedAt":"2026-03-30T08:07:09.253Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:18.191Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080709-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T080709-33db16bd","recordedAt":"2026-03-30T08:07:09.253Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:16.407Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080709-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T080709-33db16bd","recordedAt":"2026-03-30T08:07:09.253Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:18.550Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080709-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260330T080709-33db16bd","recordedAt":"2026-03-30T08:07:09.253Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:18.908Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080709-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T080709-33db16bd","recordedAt":"2026-03-30T08:07:09.253Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:36.602Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T080709-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260330T080709-33db16bd","recordedAt":"2026-03-30T08:07:09.253Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:19.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080709-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T080709-33db16bd","recordedAt":"2026-03-30T08:07:09.253Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:17.477Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080430-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T080430-99db93fe","recordedAt":"2026-03-30T08:04:30.940Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:15.692Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080430-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T080430-99db93fe","recordedAt":"2026-03-30T08:04:30.940Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:35.866Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T080430-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T080430-99db93fe","recordedAt":"2026-03-30T08:04:30.940Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:15.338Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080430-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T080430-99db93fe","recordedAt":"2026-03-30T08:04:30.940Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:12.839Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080430-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T080430-99db93fe","recordedAt":"2026-03-30T08:04:30.940Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:16.050Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080430-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T080430-99db93fe","recordedAt":"2026-03-30T08:04:30.940Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:36.248Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T080430-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T080430-99db93fe","recordedAt":"2026-03-30T08:04:30.940Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:35.480Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T080430-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T080430-99db93fe","recordedAt":"2026-03-30T08:04:30.940Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:13.558Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080109-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T080109-426e9227","recordedAt":"2026-03-30T08:01:09.166Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:09.969Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080109-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T080109-426e9227","recordedAt":"2026-03-30T08:01:09.166Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:35.094Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T080109-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T080109-426e9227","recordedAt":"2026-03-30T08:01:09.166Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:12.123Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080109-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T080109-426e9227","recordedAt":"2026-03-30T08:01:09.166Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:34.708Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T080109-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T080109-426e9227","recordedAt":"2026-03-30T08:01:09.166Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:09.613Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080109-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T080109-426e9227","recordedAt":"2026-03-30T08:01:09.166Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:11.405Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080109-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T080109-426e9227","recordedAt":"2026-03-30T08:01:09.166Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:10.331Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T080109-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T080109-426e9227","recordedAt":"2026-03-30T08:01:09.166Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:09.255Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075839-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:06.387Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075839-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:07.107Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075839-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:08.898Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075839-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:34.319Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T075839-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:05.671Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075839-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:06.747Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075839-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:08.183Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075839-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:33.933Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T075839-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T075839-b849edd6","recordedAt":"2026-03-30T07:58:39.590Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:33.547Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T075610-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:02.802Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075610-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:02.086Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075610-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:02.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075610-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:03.161Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075610-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:03.519Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075610-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:04.235Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075610-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:04.952Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075610-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:03.878Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T075610-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:32.758Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T075610-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T075610-c46e28d2","recordedAt":"2026-03-30T07:56:12.137Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:23:33.148Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T070319-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T070319-33db16bd","recordedAt":"2026-03-30T07:03:19.135Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:59.940Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070319-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T070319-33db16bd","recordedAt":"2026-03-30T07:03:19.135Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:00.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070319-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T070319-33db16bd","recordedAt":"2026-03-30T07:03:19.135Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:23:32.368Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T070319-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260330T070319-33db16bd","recordedAt":"2026-03-30T07:03:19.135Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:01.727Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070319-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260330T070319-33db16bd","recordedAt":"2026-03-30T07:03:19.135Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:01.368Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070319-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T070319-33db16bd","recordedAt":"2026-03-30T07:03:19.135Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:01.010Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070319-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T070319-33db16bd","recordedAt":"2026-03-30T07:03:19.135Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:58.862Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070319-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T070319-33db16bd","recordedAt":"2026-03-30T07:03:19.135Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:34:00.652Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070019-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T070019-99db93fe","recordedAt":"2026-03-30T07:00:19.807Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:58.504Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070019-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T070019-99db93fe","recordedAt":"2026-03-30T07:00:19.807Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:32.083Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T070019-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T070019-99db93fe","recordedAt":"2026-03-30T07:00:19.807Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:32.438Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T070019-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T070019-99db93fe","recordedAt":"2026-03-30T07:00:19.807Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:58.146Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070019-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T070019-99db93fe","recordedAt":"2026-03-30T07:00:19.807Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:55.284Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070019-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T070019-99db93fe","recordedAt":"2026-03-30T07:00:19.807Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:57.788Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T070019-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T070019-99db93fe","recordedAt":"2026-03-30T07:00:19.807Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:31.729Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T070019-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T070019-99db93fe","recordedAt":"2026-03-30T07:00:19.807Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:56.001Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065808-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T065808-426e9227","recordedAt":"2026-03-30T06:58:08.134Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:52.411Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065808-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T065808-426e9227","recordedAt":"2026-03-30T06:58:08.134Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:52.056Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065808-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T065808-426e9227","recordedAt":"2026-03-30T06:58:08.134Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:51.696Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065808-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T065808-426e9227","recordedAt":"2026-03-30T06:58:08.134Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:31.363Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T065808-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T065808-426e9227","recordedAt":"2026-03-30T06:58:08.134Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:31.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T065808-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T065808-426e9227","recordedAt":"2026-03-30T06:58:08.134Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:54.564Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065808-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T065808-426e9227","recordedAt":"2026-03-30T06:58:08.134Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:52.772Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065808-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T065808-426e9227","recordedAt":"2026-03-30T06:58:08.134Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:53.846Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065541-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:30.290Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T065541-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:49.539Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065541-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:51.337Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065541-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:30.645Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T065541-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:49.179Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065541-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:48.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065541-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:48.821Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065541-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:50.617Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065541-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T065541-b849edd6","recordedAt":"2026-03-30T06:55:41.720Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:29.933Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T065305-b44315aa::olaparib::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:29.222Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T065305-b44315aa::talazoparib::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:29.578Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T065305-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:46.322Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065305-b44315aa::rucaparib::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:47.395Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065305-b44315aa::niraparib::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:46.680Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065305-b44315aa::paclitaxel::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:45.962Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065305-b44315aa::gemcitabine::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:45.606Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065305-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:45.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065305-b44315aa::cisplatin::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:44.890Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T065305-b44315aa::carboplatin::breast_cancer","analysisId":"20260330T065305-b44315aa","recordedAt":"2026-03-30T06:53:06.606Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:44.534Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T045203-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T045203-33db16bd","recordedAt":"2026-03-30T04:52:03.838Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:41.310Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T045203-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T045203-33db16bd","recordedAt":"2026-03-30T04:52:03.838Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:28.864Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T045203-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260330T045203-33db16bd","recordedAt":"2026-03-30T04:52:03.838Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:44.176Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T045203-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260330T045203-33db16bd","recordedAt":"2026-03-30T04:52:03.838Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:43.816Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T045203-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T045203-33db16bd","recordedAt":"2026-03-30T04:52:03.838Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:43.459Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T045203-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T045203-33db16bd","recordedAt":"2026-03-30T04:52:03.838Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:43.100Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T045203-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T045203-33db16bd","recordedAt":"2026-03-30T04:52:03.838Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:42.742Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T045203-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T045203-33db16bd","recordedAt":"2026-03-30T04:52:03.838Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:42.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044933-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T044933-99db93fe","recordedAt":"2026-03-30T04:49:33.308Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:27.794Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T044933-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T044933-99db93fe","recordedAt":"2026-03-30T04:49:33.308Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:37.721Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044933-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T044933-99db93fe","recordedAt":"2026-03-30T04:49:33.308Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:40.231Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044933-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T044933-99db93fe","recordedAt":"2026-03-30T04:49:33.308Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:40.591Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044933-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T044933-99db93fe","recordedAt":"2026-03-30T04:49:33.308Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:40.950Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044933-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T044933-99db93fe","recordedAt":"2026-03-30T04:49:33.308Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:28.152Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T044933-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T044933-99db93fe","recordedAt":"2026-03-30T04:49:33.308Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:28.507Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T044933-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T044933-99db93fe","recordedAt":"2026-03-30T04:49:33.308Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:38.440Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044721-231146b2::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T044721-231146b2","recordedAt":"2026-03-30T04:47:21.253Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:37.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044721-231146b2::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T044721-231146b2","recordedAt":"2026-03-30T04:47:21.253Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:34.502Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044721-231146b2::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T044721-231146b2","recordedAt":"2026-03-30T04:47:21.253Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:34.145Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044721-231146b2::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T044721-231146b2","recordedAt":"2026-03-30T04:47:21.253Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:34.860Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044721-231146b2::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T044721-231146b2","recordedAt":"2026-03-30T04:47:21.253Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:35.218Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044721-231146b2::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T044721-231146b2","recordedAt":"2026-03-30T04:47:21.253Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:36.291Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044721-231146b2::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T044721-231146b2","recordedAt":"2026-03-30T04:47:21.253Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:27.084Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T044721-231146b2::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T044721-231146b2","recordedAt":"2026-03-30T04:47:21.253Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:27.439Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T044451-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:31.637Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044451-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:31.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044451-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:30.564Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044451-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:33.786Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044451-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:31.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044451-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:26.002Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T044451-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:33.067Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044451-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:26.722Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T044451-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T044451-b849edd6","recordedAt":"2026-03-30T04:44:51.223Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:26.358Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T044236-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:25.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T044236-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:29.846Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044236-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:28.771Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044236-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:29.130Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044236-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:28.416Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044236-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:28.056Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044236-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:27.697Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044236-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:27.340Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044236-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:26.982Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T044236-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T044236-c46e28d2","recordedAt":"2026-03-30T04:42:38.208Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:25.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T025910-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T025910-33db16bd","recordedAt":"2026-03-30T02:59:10.707Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:25.921Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025910-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T025910-33db16bd","recordedAt":"2026-03-30T02:59:10.707Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:25.563Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025910-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260330T025910-33db16bd","recordedAt":"2026-03-30T02:59:10.707Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:26.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025910-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260330T025910-33db16bd","recordedAt":"2026-03-30T02:59:10.707Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:26.628Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025910-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T025910-33db16bd","recordedAt":"2026-03-30T02:59:10.707Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:24.937Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T025910-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T025910-33db16bd","recordedAt":"2026-03-30T02:59:10.707Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:25.205Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025910-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T025910-33db16bd","recordedAt":"2026-03-30T02:59:10.707Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:24.847Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025910-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T025910-33db16bd","recordedAt":"2026-03-30T02:59:10.707Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:23.768Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025629-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T025629-99db93fe","recordedAt":"2026-03-30T02:56:29.229Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:20.087Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025629-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T025629-99db93fe","recordedAt":"2026-03-30T02:56:29.229Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:23.410Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025629-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T025629-99db93fe","recordedAt":"2026-03-30T02:56:29.229Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:23.052Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025629-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T025629-99db93fe","recordedAt":"2026-03-30T02:56:29.229Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:24.226Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T025629-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T025629-99db93fe","recordedAt":"2026-03-30T02:56:29.229Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:24.582Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T025629-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T025629-99db93fe","recordedAt":"2026-03-30T02:56:29.229Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:23.872Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T025629-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T025629-99db93fe","recordedAt":"2026-03-30T02:56:29.229Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:22.693Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025629-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T025629-99db93fe","recordedAt":"2026-03-30T02:56:29.229Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:20.795Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025412-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T025412-426e9227","recordedAt":"2026-03-30T02:54:12.042Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:16.883Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025412-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T025412-426e9227","recordedAt":"2026-03-30T02:54:12.042Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:16.525Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025412-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T025412-426e9227","recordedAt":"2026-03-30T02:54:12.042Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:17.241Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025412-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T025412-426e9227","recordedAt":"2026-03-30T02:54:12.042Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:17.599Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025412-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T025412-426e9227","recordedAt":"2026-03-30T02:54:12.042Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:18.663Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025412-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T025412-426e9227","recordedAt":"2026-03-30T02:54:12.042Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:19.374Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025412-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T025412-426e9227","recordedAt":"2026-03-30T02:54:12.042Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:23.163Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T025412-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T025412-426e9227","recordedAt":"2026-03-30T02:54:12.042Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:23.517Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T025123-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:13.659Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025123-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:14.376Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025123-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:22.095Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T025123-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:16.171Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025123-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:14.016Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025123-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:12.941Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T025123-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:22.452Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T025123-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:22.808Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T025123-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T025123-b849edd6","recordedAt":"2026-03-30T02:51:23.092Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:15.457Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T024840-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:21.381Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T024840-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:09.720Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T024840-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:09.360Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T024840-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:12.224Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T024840-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:21.739Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T024840-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:11.507Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T024840-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:10.794Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T024840-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:10.437Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T024840-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:10.078Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T024840-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T024840-c46e28d2","recordedAt":"2026-03-30T02:48:42.053Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:11.153Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011613-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260330T011613-33db16bd","recordedAt":"2026-03-30T01:16:13.812Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:08.284Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011613-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260330T011613-33db16bd","recordedAt":"2026-03-30T01:16:13.812Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:09.003Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011613-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260330T011613-33db16bd","recordedAt":"2026-03-30T01:16:13.812Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:06.132Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011613-33db16bd::donanemab::alzheimers_disease","analysisId":"20260330T011613-33db16bd","recordedAt":"2026-03-30T01:16:13.812Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:07.207Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011613-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260330T011613-33db16bd","recordedAt":"2026-03-30T01:16:13.812Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:21.026Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T011613-33db16bd::donepezil::alzheimers_disease","analysisId":"20260330T011613-33db16bd","recordedAt":"2026-03-30T01:16:13.812Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:07.567Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011613-33db16bd::galantamine::alzheimers_disease","analysisId":"20260330T011613-33db16bd","recordedAt":"2026-03-30T01:16:13.812Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:07.925Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011613-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260330T011613-33db16bd","recordedAt":"2026-03-30T01:16:13.812Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:08.643Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011340-99db93fe::carboplatin::pan-cancer","analysisId":"20260330T011340-99db93fe","recordedAt":"2026-03-30T01:13:40.613Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:05.415Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011340-99db93fe::gemcitabine::pan-cancer","analysisId":"20260330T011340-99db93fe","recordedAt":"2026-03-30T01:13:40.613Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:20.313Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T011340-99db93fe::temozolomide::pan-cancer","analysisId":"20260330T011340-99db93fe","recordedAt":"2026-03-30T01:13:40.613Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:20.670Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T011340-99db93fe::panitumumab::pan-cancer","analysisId":"20260330T011340-99db93fe","recordedAt":"2026-03-30T01:13:40.613Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:19.958Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T011340-99db93fe::palbociclib::pan-cancer","analysisId":"20260330T011340-99db93fe","recordedAt":"2026-03-30T01:13:40.613Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:05.776Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011340-99db93fe::sirolimus::pan-cancer","analysisId":"20260330T011340-99db93fe","recordedAt":"2026-03-30T01:13:40.613Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:05.058Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011340-99db93fe::paclitaxel::pan-cancer","analysisId":"20260330T011340-99db93fe","recordedAt":"2026-03-30T01:13:40.613Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:02.553Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011340-99db93fe::cetuximab::pan-cancer","analysisId":"20260330T011340-99db93fe","recordedAt":"2026-03-30T01:13:40.613Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:03.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011107-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260330T011107-426e9227","recordedAt":"2026-03-30T01:11:07.364Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:59.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011107-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260330T011107-426e9227","recordedAt":"2026-03-30T01:11:07.364Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:19.247Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260330T011107-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260330T011107-426e9227","recordedAt":"2026-03-30T01:11:07.364Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:59.362Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011107-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260330T011107-426e9227","recordedAt":"2026-03-30T01:11:07.364Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:59.721Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011107-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260330T011107-426e9227","recordedAt":"2026-03-30T01:11:07.364Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:00.078Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011107-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260330T011107-426e9227","recordedAt":"2026-03-30T01:11:07.364Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:01.136Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011107-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260330T011107-426e9227","recordedAt":"2026-03-30T01:11:07.364Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:33:01.838Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T011107-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260330T011107-426e9227","recordedAt":"2026-03-30T01:11:07.364Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:19.602Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260330T010838-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:18.489Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T010838-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:56.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010838-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:55.428Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010838-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:58.647Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010838-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:56.146Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010838-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:56.505Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010838-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:18.892Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T010838-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:57.934Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010838-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260330T010838-b849edd6","recordedAt":"2026-03-30T01:08:38.322Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:18.133Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260330T010600-c46e28d2::olaparib::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:17.273Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T010600-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:53.635Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010600-c46e28d2::carboplatin::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:51.846Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010600-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:53.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010600-c46e28d2::talazoparib::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:17.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260330T010600-c46e28d2::cisplatin::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:52.203Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010600-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:52.562Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010600-c46e28d2::rucaparib::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:54.710Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010600-c46e28d2::niraparib::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:53.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260330T010600-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260330T010600-c46e28d2","recordedAt":"2026-03-30T01:06:02.313Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:52.921Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T194050-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T194050-33db16bd","recordedAt":"2026-03-29T19:40:50.810Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:48.623Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T194050-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T194050-33db16bd","recordedAt":"2026-03-29T19:40:50.810Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:50.416Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T194050-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T194050-33db16bd","recordedAt":"2026-03-29T19:40:50.810Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:50.775Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T194050-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T194050-33db16bd","recordedAt":"2026-03-29T19:40:50.810Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:51.132Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T194050-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T194050-33db16bd","recordedAt":"2026-03-29T19:40:50.810Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:51.491Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T194050-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T194050-33db16bd","recordedAt":"2026-03-29T19:40:50.810Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:50.058Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T194050-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T194050-33db16bd","recordedAt":"2026-03-29T19:40:50.810Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:16.854Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T194050-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T194050-33db16bd","recordedAt":"2026-03-29T19:40:50.810Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:49.699Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193826-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T193826-99db93fe","recordedAt":"2026-03-29T19:38:26.917Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:47.533Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193826-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T193826-99db93fe","recordedAt":"2026-03-29T19:38:26.917Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:45.041Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193826-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T193826-99db93fe","recordedAt":"2026-03-29T19:38:26.917Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:16.461Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T193826-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T193826-99db93fe","recordedAt":"2026-03-29T19:38:26.917Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:15.675Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T193826-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T193826-99db93fe","recordedAt":"2026-03-29T19:38:26.917Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:48.262Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193826-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T193826-99db93fe","recordedAt":"2026-03-29T19:38:26.917Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:47.892Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193826-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T193826-99db93fe","recordedAt":"2026-03-29T19:38:26.917Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:45.750Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193826-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T193826-99db93fe","recordedAt":"2026-03-29T19:38:26.917Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:16.078Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T193609-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T193609-426e9227","recordedAt":"2026-03-29T19:36:09.584Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:41.451Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193609-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T193609-426e9227","recordedAt":"2026-03-29T19:36:09.584Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:42.528Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193609-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T193609-426e9227","recordedAt":"2026-03-29T19:36:09.584Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:44.323Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193609-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T193609-426e9227","recordedAt":"2026-03-29T19:36:09.584Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:15.270Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T193609-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T193609-426e9227","recordedAt":"2026-03-29T19:36:09.584Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T14:06:14.844Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T193609-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T193609-426e9227","recordedAt":"2026-03-29T19:36:09.584Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:43.607Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193609-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T193609-426e9227","recordedAt":"2026-03-29T19:36:09.584Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:42.169Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193609-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T193609-426e9227","recordedAt":"2026-03-29T19:36:09.584Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:41.809Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193349-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T14:06:14.437Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T193349-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:41.093Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193349-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:39.307Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193349-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:38.953Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193349-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:38.595Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193349-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:37.882Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193349-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:40.376Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193349-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:05.764Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T193349-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T193349-b849edd6","recordedAt":"2026-03-29T19:33:49.917Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:06.118Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T193138-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:47:05.055Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T193138-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:35.364Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193138-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:36.086Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193138-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:37.163Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193138-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:36.446Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193138-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:35.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193138-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:34.999Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193138-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:34.635Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193138-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:34.272Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T193138-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T193138-c46e28d2","recordedAt":"2026-03-29T19:31:39.600Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:47:05.410Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T181451-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T181451-33db16bd","recordedAt":"2026-03-29T18:14:51.153Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:32.812Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181451-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T181451-33db16bd","recordedAt":"2026-03-29T18:14:51.153Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:32.447Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181451-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T181451-33db16bd","recordedAt":"2026-03-29T18:14:51.153Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:32.082Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181451-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T181451-33db16bd","recordedAt":"2026-03-29T18:14:51.153Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:31.002Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181451-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T181451-33db16bd","recordedAt":"2026-03-29T18:14:51.153Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:04.701Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T181451-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T181451-33db16bd","recordedAt":"2026-03-29T18:14:51.153Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:33.907Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181451-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T181451-33db16bd","recordedAt":"2026-03-29T18:14:51.153Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:33.542Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181451-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T181451-33db16bd","recordedAt":"2026-03-29T18:14:51.153Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:33.177Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181205-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T181205-99db93fe","recordedAt":"2026-03-29T18:12:05.924Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:03.991Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T181205-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T181205-99db93fe","recordedAt":"2026-03-29T18:12:05.924Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:30.273Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181205-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T181205-99db93fe","recordedAt":"2026-03-29T18:12:05.924Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:29.907Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181205-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T181205-99db93fe","recordedAt":"2026-03-29T18:12:05.924Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:03.635Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T181205-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T181205-99db93fe","recordedAt":"2026-03-29T18:12:05.924Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:30.638Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181205-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T181205-99db93fe","recordedAt":"2026-03-29T18:12:05.924Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:27.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181205-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T181205-99db93fe","recordedAt":"2026-03-29T18:12:05.924Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:28.112Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T181205-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T181205-99db93fe","recordedAt":"2026-03-29T18:12:05.924Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:04.345Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T180931-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T180931-426e9227","recordedAt":"2026-03-29T18:09:31.980Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:47:03.281Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T180931-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T180931-426e9227","recordedAt":"2026-03-29T18:09:31.980Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:47:02.926Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T180931-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T180931-426e9227","recordedAt":"2026-03-29T18:09:31.980Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:26.653Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180931-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T180931-426e9227","recordedAt":"2026-03-29T18:09:31.980Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:25.938Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180931-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T180931-426e9227","recordedAt":"2026-03-29T18:09:31.980Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:24.887Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180931-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T180931-426e9227","recordedAt":"2026-03-29T18:09:31.980Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:24.536Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180931-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T180931-426e9227","recordedAt":"2026-03-29T18:09:31.980Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:24.170Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180931-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T180931-426e9227","recordedAt":"2026-03-29T18:09:31.980Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:23.806Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180640-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:21.643Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180640-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:20.914Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180640-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:01.863Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T180640-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:20.184Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180640-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:21.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180640-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:23.440Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180640-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:22.725Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180640-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:02.572Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T180640-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T180640-b849edd6","recordedAt":"2026-03-29T18:06:40.291Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:02.217Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T180400-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:47:01.509Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T180400-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:17.642Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180400-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:17.291Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180400-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:16.926Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180400-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:47:01.155Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T180400-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:16.575Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180400-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:18.372Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180400-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:19.468Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180400-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:18.738Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T180400-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T180400-c46e28d2","recordedAt":"2026-03-29T18:04:01.649Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:18.007Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165233-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T165233-33db16bd","recordedAt":"2026-03-29T16:52:33.591Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:15.170Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165233-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T165233-33db16bd","recordedAt":"2026-03-29T16:52:33.591Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:14.456Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165233-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T165233-33db16bd","recordedAt":"2026-03-29T16:52:33.591Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:13.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165233-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T165233-33db16bd","recordedAt":"2026-03-29T16:52:33.591Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:16.223Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165233-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T165233-33db16bd","recordedAt":"2026-03-29T16:52:33.591Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:15.872Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165233-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T165233-33db16bd","recordedAt":"2026-03-29T16:52:33.591Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:15.520Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165233-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T165233-33db16bd","recordedAt":"2026-03-29T16:52:33.591Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:14.816Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165233-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T165233-33db16bd","recordedAt":"2026-03-29T16:52:33.591Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:00.801Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T165026-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T165026-99db93fe","recordedAt":"2026-03-29T16:50:26.596Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:10.472Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165026-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T165026-99db93fe","recordedAt":"2026-03-29T16:50:26.596Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:13.019Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165026-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T165026-99db93fe","recordedAt":"2026-03-29T16:50:26.596Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:12.291Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165026-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T165026-99db93fe","recordedAt":"2026-03-29T16:50:26.596Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:09.745Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T165026-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T165026-99db93fe","recordedAt":"2026-03-29T16:50:26.596Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:00.446Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T165026-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T165026-99db93fe","recordedAt":"2026-03-29T16:50:26.596Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:47:00.092Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T165026-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T165026-99db93fe","recordedAt":"2026-03-29T16:50:26.596Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:59.735Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T165026-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T165026-99db93fe","recordedAt":"2026-03-29T16:50:26.596Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:12.655Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164823-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T164823-426e9227","recordedAt":"2026-03-29T16:48:23.755Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:06.881Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164823-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T164823-426e9227","recordedAt":"2026-03-29T16:48:23.755Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:59.026Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T164823-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T164823-426e9227","recordedAt":"2026-03-29T16:48:23.755Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:59.381Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T164823-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T164823-426e9227","recordedAt":"2026-03-29T16:48:23.755Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:06.164Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164823-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T164823-426e9227","recordedAt":"2026-03-29T16:48:23.755Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:09.017Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164823-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T164823-426e9227","recordedAt":"2026-03-29T16:48:23.755Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:08.307Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164823-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T164823-426e9227","recordedAt":"2026-03-29T16:48:23.755Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:07.239Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164823-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T164823-426e9227","recordedAt":"2026-03-29T16:48:23.755Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:06.529Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164605-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:04.020Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164605-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:02.585Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164605-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:03.296Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164605-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:03.660Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164605-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:57.952Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T164605-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:05.805Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164605-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:58.318Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T164605-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:58.672Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T164605-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T164605-b849edd6","recordedAt":"2026-03-29T16:46:05.885Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:05.079Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164357-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:57.244Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T164357-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:00.439Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164357-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:01.154Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164357-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:00.084Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164357-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:59.724Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164357-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:57.598Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T164357-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:00.801Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164357-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:32:01.871Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164357-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:59.365Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T164357-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T164357-c46e28d2","recordedAt":"2026-03-29T16:43:58.778Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:59.001Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T152142-1f1ae2bb::gantenerumab::alzheimers_disease","analysisId":"20260329T152142-1f1ae2bb","recordedAt":"2026-03-29T15:21:42.294Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:58.285Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T152142-1f1ae2bb::solanezumab::alzheimers_disease","analysisId":"20260329T152142-1f1ae2bb","recordedAt":"2026-03-29T15:21:42.294Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:58.643Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T152142-1f1ae2bb::rivastigmine::alzheimers_disease","analysisId":"20260329T152142-1f1ae2bb","recordedAt":"2026-03-29T15:21:42.294Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:57.920Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T152142-1f1ae2bb::galantamine::alzheimers_disease","analysisId":"20260329T152142-1f1ae2bb","recordedAt":"2026-03-29T15:21:42.294Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:57.555Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T152142-1f1ae2bb::donepezil::alzheimers_disease","analysisId":"20260329T152142-1f1ae2bb","recordedAt":"2026-03-29T15:21:42.294Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:57.195Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T152142-1f1ae2bb::donanemab::alzheimers_disease","analysisId":"20260329T152142-1f1ae2bb","recordedAt":"2026-03-29T15:21:42.294Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:56.830Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T152142-1f1ae2bb::aducanumab::alzheimers_disease","analysisId":"20260329T152142-1f1ae2bb","recordedAt":"2026-03-29T15:21:42.294Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:56.122Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T152142-1f1ae2bb::lecanemab::alzheimers_disease","analysisId":"20260329T152142-1f1ae2bb","recordedAt":"2026-03-29T15:21:42.294Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:56.889Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T151842-d2b73aa4::gemcitabine::pan-cancer","analysisId":"20260329T151842-d2b73aa4","recordedAt":"2026-03-29T15:18:42.094Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:56.535Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T151842-d2b73aa4::paclitaxel::pan-cancer","analysisId":"20260329T151842-d2b73aa4","recordedAt":"2026-03-29T15:18:42.094Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:52.177Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151842-d2b73aa4::cetuximab::pan-cancer","analysisId":"20260329T151842-d2b73aa4","recordedAt":"2026-03-29T15:18:42.094Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:52.905Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151842-d2b73aa4::panitumumab::pan-cancer","analysisId":"20260329T151842-d2b73aa4","recordedAt":"2026-03-29T15:18:42.094Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:56.181Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T151842-d2b73aa4::temozolomide::pan-cancer","analysisId":"20260329T151842-d2b73aa4","recordedAt":"2026-03-29T15:18:42.094Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:55.827Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T151842-d2b73aa4::sirolimus::pan-cancer","analysisId":"20260329T151842-d2b73aa4","recordedAt":"2026-03-29T15:18:42.094Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:54.693Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151842-d2b73aa4::palbociclib::pan-cancer","analysisId":"20260329T151842-d2b73aa4","recordedAt":"2026-03-29T15:18:42.094Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:55.417Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151842-d2b73aa4::carboplatin::pan-cancer","analysisId":"20260329T151842-d2b73aa4","recordedAt":"2026-03-29T15:18:42.094Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:55.058Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151453-0e1206a5::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T151453-0e1206a5","recordedAt":"2026-03-29T15:14:53.401Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:48.979Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151453-0e1206a5::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T151453-0e1206a5","recordedAt":"2026-03-29T15:14:53.401Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:50.408Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151453-0e1206a5::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T151453-0e1206a5","recordedAt":"2026-03-29T15:14:53.401Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:50.764Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151453-0e1206a5::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260329T151453-0e1206a5","recordedAt":"2026-03-29T15:14:53.401Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:51.115Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151453-0e1206a5::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T151453-0e1206a5","recordedAt":"2026-03-29T15:14:53.401Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:55.119Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T151453-0e1206a5::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T151453-0e1206a5","recordedAt":"2026-03-29T15:14:53.401Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:50.042Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151453-0e1206a5::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T151453-0e1206a5","recordedAt":"2026-03-29T15:14:53.401Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:49.691Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151453-0e1206a5::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T151453-0e1206a5","recordedAt":"2026-03-29T15:14:53.401Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:55.473Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T151155-e74d9a6f::tovorafenib::colorectal_cancer","analysisId":"20260329T151155-e74d9a6f","recordedAt":"2026-03-29T15:11:55.743Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:54.765Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T151155-e74d9a6f::adagrasib::colorectal_cancer","analysisId":"20260329T151155-e74d9a6f","recordedAt":"2026-03-29T15:11:55.743Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:54.411Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T151155-e74d9a6f::dabrafenib::colorectal_cancer","analysisId":"20260329T151155-e74d9a6f","recordedAt":"2026-03-29T15:11:55.743Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:54.056Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T151155-e74d9a6f::encorafenib::colorectal_cancer","analysisId":"20260329T151155-e74d9a6f","recordedAt":"2026-03-29T15:11:55.743Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:47.551Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151155-e74d9a6f::temsirolimus::colorectal_cancer","analysisId":"20260329T151155-e74d9a6f","recordedAt":"2026-03-29T15:11:55.743Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:46.840Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151155-e74d9a6f::selumetinib::colorectal_cancer","analysisId":"20260329T151155-e74d9a6f","recordedAt":"2026-03-29T15:11:55.743Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:46.488Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151155-e74d9a6f::sorafenib::colorectal_cancer","analysisId":"20260329T151155-e74d9a6f","recordedAt":"2026-03-29T15:11:55.743Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:46.135Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T151155-e74d9a6f::regorafenib::colorectal_cancer","analysisId":"20260329T151155-e74d9a6f","recordedAt":"2026-03-29T15:11:55.743Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:45.423Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T150852-22c3d67f::gemcitabine::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:42.914Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T150852-22c3d67f::olaparib::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:53.347Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T150852-22c3d67f::carboplatin::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:41.842Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T150852-22c3d67f::cisplatin::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:42.200Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T150852-22c3d67f::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:42.554Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T150852-22c3d67f::niraparib::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:43.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T150852-22c3d67f::paclitaxel::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:43.989Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T150852-22c3d67f::rucaparib::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:44.347Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T150852-22c3d67f::talazoparib::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:53.701Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T150852-22c3d67f::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T150852-22c3d67f","recordedAt":"2026-03-29T15:08:52.112Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:44.709Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143749-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T143749-33db16bd","recordedAt":"2026-03-29T14:37:49.108Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:52.991Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T143749-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T143749-33db16bd","recordedAt":"2026-03-29T14:37:49.108Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:38.626Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143749-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T143749-33db16bd","recordedAt":"2026-03-29T14:37:49.108Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:39.708Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143749-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T143749-33db16bd","recordedAt":"2026-03-29T14:37:49.108Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:40.067Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143749-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T143749-33db16bd","recordedAt":"2026-03-29T14:37:49.108Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:40.421Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143749-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T143749-33db16bd","recordedAt":"2026-03-29T14:37:49.108Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:40.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143749-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T143749-33db16bd","recordedAt":"2026-03-29T14:37:49.108Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:41.138Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143749-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T143749-33db16bd","recordedAt":"2026-03-29T14:37:49.108Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:41.488Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143553-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T143553-99db93fe","recordedAt":"2026-03-29T14:35:53.209Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:38.262Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143553-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T143553-99db93fe","recordedAt":"2026-03-29T14:35:53.209Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:52.253Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T143553-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T143553-99db93fe","recordedAt":"2026-03-29T14:35:53.209Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:52.636Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T143553-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T143553-99db93fe","recordedAt":"2026-03-29T14:35:53.209Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:51.899Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T143553-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T143553-99db93fe","recordedAt":"2026-03-29T14:35:53.209Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:35.732Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143553-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T143553-99db93fe","recordedAt":"2026-03-29T14:35:53.209Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:37.538Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143553-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T143553-99db93fe","recordedAt":"2026-03-29T14:35:53.209Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:37.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143553-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T143553-99db93fe","recordedAt":"2026-03-29T14:35:53.209Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:35.007Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143335-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T143335-426e9227","recordedAt":"2026-03-29T14:33:36.001Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:32.161Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143335-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T143335-426e9227","recordedAt":"2026-03-29T14:33:36.001Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:31.453Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143335-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T143335-426e9227","recordedAt":"2026-03-29T14:33:36.001Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:33.594Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143335-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T143335-426e9227","recordedAt":"2026-03-29T14:33:36.001Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:34.304Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143335-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T143335-426e9227","recordedAt":"2026-03-29T14:33:36.001Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:51.118Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T143335-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T143335-426e9227","recordedAt":"2026-03-29T14:33:36.001Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:51.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T143335-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T143335-426e9227","recordedAt":"2026-03-29T14:33:36.001Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:32.514Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143335-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T143335-426e9227","recordedAt":"2026-03-29T14:33:36.001Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:31.809Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143126-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:29.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143126-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:50.722Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T143126-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:49.928Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T143126-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:28.582Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143126-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:30.377Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143126-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:27.868Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143126-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:31.099Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143126-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:28.942Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T143126-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T143126-b849edd6","recordedAt":"2026-03-29T14:31:26.165Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:50.318Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T142911-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:26.445Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T142911-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:26.080Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T142911-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:49.539Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T142911-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:27.157Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T142911-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:25.728Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T142911-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:25.377Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T142911-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:25.016Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T142911-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:24.663Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T142911-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:24.309Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T142911-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T142911-c46e28d2","recordedAt":"2026-03-29T14:29:13.219Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T13:46:49.132Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T132714-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T132714-33db16bd","recordedAt":"2026-03-29T13:27:14.559Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:23.581Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132714-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T132714-33db16bd","recordedAt":"2026-03-29T13:27:14.559Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:23.223Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132714-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T132714-33db16bd","recordedAt":"2026-03-29T13:27:14.559Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:23.946Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132714-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T132714-33db16bd","recordedAt":"2026-03-29T13:27:14.559Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:22.861Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132714-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T132714-33db16bd","recordedAt":"2026-03-29T13:27:14.559Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:22.510Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132714-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T132714-33db16bd","recordedAt":"2026-03-29T13:27:14.559Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:22.153Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132714-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T132714-33db16bd","recordedAt":"2026-03-29T13:27:14.559Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:21.073Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132714-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T132714-33db16bd","recordedAt":"2026-03-29T13:27:14.559Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:48.736Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T132516-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T132516-99db93fe","recordedAt":"2026-03-29T13:25:16.209Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:17.507Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132516-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T132516-99db93fe","recordedAt":"2026-03-29T13:25:16.209Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:20.716Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132516-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T132516-99db93fe","recordedAt":"2026-03-29T13:25:16.209Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:20.362Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132516-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T132516-99db93fe","recordedAt":"2026-03-29T13:25:16.209Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:20.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132516-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T132516-99db93fe","recordedAt":"2026-03-29T13:25:16.209Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:18.226Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132516-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T132516-99db93fe","recordedAt":"2026-03-29T13:25:16.209Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:16.486Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T132516-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T132516-99db93fe","recordedAt":"2026-03-29T13:25:16.209Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:16.132Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T132516-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T132516-99db93fe","recordedAt":"2026-03-29T13:25:16.209Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T13:46:48.350Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T132311-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T132311-426e9227","recordedAt":"2026-03-29T13:23:11.860Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:16.076Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132311-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T132311-426e9227","recordedAt":"2026-03-29T13:23:11.860Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:14.625Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132311-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T132311-426e9227","recordedAt":"2026-03-29T13:23:11.860Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:13.900Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132311-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T132311-426e9227","recordedAt":"2026-03-29T13:23:11.860Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:14.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132311-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T132311-426e9227","recordedAt":"2026-03-29T13:23:11.860Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:15.423Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T132311-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T132311-426e9227","recordedAt":"2026-03-29T13:23:11.860Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:16.792Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132311-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T132311-426e9227","recordedAt":"2026-03-29T13:23:11.860Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:14.999Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132311-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T132311-426e9227","recordedAt":"2026-03-29T13:23:11.860Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:15.777Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T132107-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:14.356Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T132107-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:15.068Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T132107-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:12.824Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132107-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:13.541Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132107-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:14.713Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T132107-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:11.757Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132107-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:11.394Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132107-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:11.035Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T132107-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T132107-b849edd6","recordedAt":"2026-03-29T13:21:07.134Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:10.317Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:06.727Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:08.520Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:14.002Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T131904-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:09.604Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:08.874Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:08.168Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:07.811Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:07.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:07.094Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T131904-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T131904-c46e28d2","recordedAt":"2026-03-29T13:19:05.656Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:13.648Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T115934-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T115934-33db16bd","recordedAt":"2026-03-29T11:59:34.498Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:13.293Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T115934-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T115934-33db16bd","recordedAt":"2026-03-29T11:59:34.498Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:05.299Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115934-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T115934-33db16bd","recordedAt":"2026-03-29T11:59:34.498Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:04.586Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115934-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T115934-33db16bd","recordedAt":"2026-03-29T11:59:34.498Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:03.502Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115934-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T115934-33db16bd","recordedAt":"2026-03-29T11:59:34.498Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:06.368Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115934-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T115934-33db16bd","recordedAt":"2026-03-29T11:59:34.498Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:06.013Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115934-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T115934-33db16bd","recordedAt":"2026-03-29T11:59:34.498Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:05.658Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115934-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T115934-33db16bd","recordedAt":"2026-03-29T11:59:34.498Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:04.943Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115733-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T115733-99db93fe","recordedAt":"2026-03-29T11:57:33.752Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:02.423Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115733-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T115733-99db93fe","recordedAt":"2026-03-29T11:57:33.752Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:00.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115733-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T115733-99db93fe","recordedAt":"2026-03-29T11:57:33.752Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:02.785Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115733-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T115733-99db93fe","recordedAt":"2026-03-29T11:57:33.752Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:31:03.145Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115733-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T115733-99db93fe","recordedAt":"2026-03-29T11:57:33.752Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:12.229Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T115733-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T115733-99db93fe","recordedAt":"2026-03-29T11:57:33.752Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:12.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T115733-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T115733-99db93fe","recordedAt":"2026-03-29T11:57:33.752Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:12.938Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T115733-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T115733-99db93fe","recordedAt":"2026-03-29T11:57:33.752Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:59.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115538-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T115538-426e9227","recordedAt":"2026-03-29T11:55:38.557Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:11.875Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T115538-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T115538-426e9227","recordedAt":"2026-03-29T11:55:38.557Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:57.040Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115538-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T115538-426e9227","recordedAt":"2026-03-29T11:55:38.557Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:56.680Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115538-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T115538-426e9227","recordedAt":"2026-03-29T11:55:38.557Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:56.321Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115538-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T115538-426e9227","recordedAt":"2026-03-29T11:55:38.557Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:57.403Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115538-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T115538-426e9227","recordedAt":"2026-03-29T11:55:38.557Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:11.520Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T115538-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T115538-426e9227","recordedAt":"2026-03-29T11:55:38.557Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:59.197Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115538-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T115538-426e9227","recordedAt":"2026-03-29T11:55:38.557Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:58.483Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115323-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:55.962Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115323-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:10.811Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T115323-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:10.457Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T115323-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:54.170Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115323-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:53.807Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115323-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:53.456Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115323-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:52.734Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115323-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:55.250Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115323-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T115323-b849edd6","recordedAt":"2026-03-29T11:53:23.062Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:11.166Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T115122-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:09.749Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T115122-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:10.103Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T115122-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:52.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115122-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:51.311Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115122-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:50.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115122-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:50.235Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115122-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:49.884Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115122-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:49.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115122-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:49.176Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T115122-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T115122-c46e28d2","recordedAt":"2026-03-29T11:51:23.479Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:50.954Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T105111-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T105111-33db16bd","recordedAt":"2026-03-29T10:51:12.012Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:48.458Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T105111-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T105111-33db16bd","recordedAt":"2026-03-29T10:51:12.012Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:48.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T105111-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T105111-33db16bd","recordedAt":"2026-03-29T10:51:12.012Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:47.753Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T105111-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T105111-33db16bd","recordedAt":"2026-03-29T10:51:12.012Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:48.815Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T105111-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T105111-33db16bd","recordedAt":"2026-03-29T10:51:12.012Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:47.398Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T105111-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T105111-33db16bd","recordedAt":"2026-03-29T10:51:12.012Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:47.044Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T105111-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T105111-33db16bd","recordedAt":"2026-03-29T10:51:12.012Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:45.968Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T105111-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T105111-33db16bd","recordedAt":"2026-03-29T10:51:12.012Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:09.394Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T104904-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T104904-99db93fe","recordedAt":"2026-03-29T10:49:04.309Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:42.400Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104904-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T104904-99db93fe","recordedAt":"2026-03-29T10:49:04.309Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:08.330Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T104904-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T104904-99db93fe","recordedAt":"2026-03-29T10:49:04.309Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:45.615Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104904-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T104904-99db93fe","recordedAt":"2026-03-29T10:49:04.309Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:45.259Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104904-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T104904-99db93fe","recordedAt":"2026-03-29T10:49:04.309Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:44.905Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104904-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T104904-99db93fe","recordedAt":"2026-03-29T10:49:04.309Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:43.125Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104904-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T104904-99db93fe","recordedAt":"2026-03-29T10:49:04.309Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:08.685Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T104904-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T104904-99db93fe","recordedAt":"2026-03-29T10:49:04.309Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:09.039Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T104652-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T104652-426e9227","recordedAt":"2026-03-29T10:46:52.796Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:40.958Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104652-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T104652-426e9227","recordedAt":"2026-03-29T10:46:52.796Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:39.153Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104652-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T104652-426e9227","recordedAt":"2026-03-29T10:46:52.796Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:39.516Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104652-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T104652-426e9227","recordedAt":"2026-03-29T10:46:52.796Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:38.795Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104652-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T104652-426e9227","recordedAt":"2026-03-29T10:46:52.796Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:07.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T104652-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T104652-426e9227","recordedAt":"2026-03-29T10:46:52.796Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:39.880Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104652-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T104652-426e9227","recordedAt":"2026-03-29T10:46:52.796Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:41.681Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104652-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T104652-426e9227","recordedAt":"2026-03-29T10:46:52.796Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:07.621Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T104405-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:07.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T104405-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:36.658Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104405-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:38.440Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104405-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:36.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104405-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:35.938Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104405-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:35.218Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104405-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:06.912Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T104405-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:37.723Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104405-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T104405-b849edd6","recordedAt":"2026-03-29T10:44:05.933Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:06.558Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T104056-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:33.431Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104056-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:06.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T104056-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:34.504Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104056-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:33.789Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104056-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:32.357Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104056-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:05.839Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T104056-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:32.002Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104056-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:33.072Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104056-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:31.649Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T104056-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T104056-c46e28d2","recordedAt":"2026-03-29T10:40:58.307Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:32.717Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080550-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T080550-33db16bd","recordedAt":"2026-03-29T08:05:50.546Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:30.223Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080550-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T080550-33db16bd","recordedAt":"2026-03-29T08:05:50.546Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:28.439Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080550-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T080550-33db16bd","recordedAt":"2026-03-29T08:05:50.546Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:31.292Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080550-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T080550-33db16bd","recordedAt":"2026-03-29T08:05:50.546Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:29.518Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080550-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T080550-33db16bd","recordedAt":"2026-03-29T08:05:50.546Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:30.932Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080550-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T080550-33db16bd","recordedAt":"2026-03-29T08:05:50.546Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:30.581Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080550-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T080550-33db16bd","recordedAt":"2026-03-29T08:05:50.546Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:29.872Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080550-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T080550-33db16bd","recordedAt":"2026-03-29T08:05:50.546Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:05.483Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T080347-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T080347-99db93fe","recordedAt":"2026-03-29T08:03:47.507Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:24.851Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080347-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T080347-99db93fe","recordedAt":"2026-03-29T08:03:47.507Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:28.074Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080347-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T080347-99db93fe","recordedAt":"2026-03-29T08:03:47.507Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:05.128Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T080347-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T080347-99db93fe","recordedAt":"2026-03-29T08:03:47.507Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:04.774Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T080347-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T080347-99db93fe","recordedAt":"2026-03-29T08:03:47.507Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:04.419Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T080347-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T080347-99db93fe","recordedAt":"2026-03-29T08:03:47.507Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:27.710Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080347-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T080347-99db93fe","recordedAt":"2026-03-29T08:03:47.507Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:27.355Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080347-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T080347-99db93fe","recordedAt":"2026-03-29T08:03:47.507Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:25.563Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080128-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T080128-426e9227","recordedAt":"2026-03-29T08:01:28.073Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:22.370Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080128-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T080128-426e9227","recordedAt":"2026-03-29T08:01:28.073Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:22.014Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080128-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T080128-426e9227","recordedAt":"2026-03-29T08:01:28.073Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:21.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080128-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T080128-426e9227","recordedAt":"2026-03-29T08:01:28.073Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:21.561Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080128-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T080128-426e9227","recordedAt":"2026-03-29T08:01:28.073Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:24.140Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080128-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T080128-426e9227","recordedAt":"2026-03-29T08:01:28.073Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:04.065Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T080128-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T080128-426e9227","recordedAt":"2026-03-29T08:01:28.073Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:23.438Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T080128-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T080128-426e9227","recordedAt":"2026-03-29T08:01:28.073Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:03.710Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T075929-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:02.646Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T075929-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:03.356Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T075929-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:20.124Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075929-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:03.001Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T075929-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:20.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075929-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:19.061Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075929-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:18.703Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075929-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:18.338Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075929-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T075929-b849edd6","recordedAt":"2026-03-29T07:59:29.647Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:17.623Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:15.101Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:15.831Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:14.022Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:14.389Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:01.538Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T075656-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:14.748Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:16.905Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:16.191Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:15.467Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T075656-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T075656-c46e28d2","recordedAt":"2026-03-29T07:56:57.686Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T12:00:02.252Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T061621-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T061621-33db16bd","recordedAt":"2026-03-29T06:16:21.600Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:01.129Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T061621-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T061621-33db16bd","recordedAt":"2026-03-29T06:16:21.600Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:12.935Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061621-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T061621-33db16bd","recordedAt":"2026-03-29T06:16:21.600Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:10.773Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061621-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T061621-33db16bd","recordedAt":"2026-03-29T06:16:21.600Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:11.847Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061621-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T061621-33db16bd","recordedAt":"2026-03-29T06:16:21.600Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:12.211Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061621-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T061621-33db16bd","recordedAt":"2026-03-29T06:16:21.600Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:12.569Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061621-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T061621-33db16bd","recordedAt":"2026-03-29T06:16:21.600Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:13.296Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061621-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T061621-33db16bd","recordedAt":"2026-03-29T06:16:21.600Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:13.656Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061429-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T061429-99db93fe","recordedAt":"2026-03-29T06:14:29.586Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:00.432Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T061429-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T061429-99db93fe","recordedAt":"2026-03-29T06:14:29.586Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:07.878Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061429-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T061429-99db93fe","recordedAt":"2026-03-29T06:14:29.586Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:10.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061429-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T061429-99db93fe","recordedAt":"2026-03-29T06:14:29.586Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T11:59:59.663Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T061429-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T061429-99db93fe","recordedAt":"2026-03-29T06:14:29.586Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T12:00:00.042Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T061429-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T061429-99db93fe","recordedAt":"2026-03-29T06:14:29.586Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:10.414Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061429-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T061429-99db93fe","recordedAt":"2026-03-29T06:14:29.586Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:09.691Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061429-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T061429-99db93fe","recordedAt":"2026-03-29T06:14:29.586Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:07.170Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061234-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T061234-426e9227","recordedAt":"2026-03-29T06:12:34.606Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T11:59:58.872Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T061234-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T061234-426e9227","recordedAt":"2026-03-29T06:12:34.606Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:03.598Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061234-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T061234-426e9227","recordedAt":"2026-03-29T06:12:34.606Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T11:59:59.272Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T061234-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T061234-426e9227","recordedAt":"2026-03-29T06:12:34.606Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:06.461Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061234-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T061234-426e9227","recordedAt":"2026-03-29T06:12:34.606Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:05.742Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061234-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T061234-426e9227","recordedAt":"2026-03-29T06:12:34.606Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:04.672Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061234-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T061234-426e9227","recordedAt":"2026-03-29T06:12:34.606Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:04.313Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061234-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T061234-426e9227","recordedAt":"2026-03-29T06:12:34.606Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:03.962Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061029-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:01.467Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061029-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:01.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061029-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:00.747Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061029-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T11:59:58.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T061029-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:02.531Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061029-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:00.032Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061029-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:30:03.239Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T061029-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T11:59:58.483Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T061029-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T061029-b849edd6","recordedAt":"2026-03-29T06:10:29.287Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:19.890Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T060830-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:19.171Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T060830-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:56.477Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T060830-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:59.324Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T060830-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:58.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T060830-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:19.529Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T060830-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:58.601Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T060830-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:57.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T060830-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:57.544Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T060830-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:57.181Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T060830-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T060830-c46e28d2","recordedAt":"2026-03-29T06:08:31.784Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:56.830Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021540-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260329T021540-33db16bd","recordedAt":"2026-03-29T02:15:40.329Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:55.764Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021540-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260329T021540-33db16bd","recordedAt":"2026-03-29T02:15:40.329Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:56.123Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021540-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260329T021540-33db16bd","recordedAt":"2026-03-29T02:15:40.329Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:55.404Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021540-33db16bd::galantamine::alzheimers_disease","analysisId":"20260329T021540-33db16bd","recordedAt":"2026-03-29T02:15:40.329Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:55.045Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021540-33db16bd::donepezil::alzheimers_disease","analysisId":"20260329T021540-33db16bd","recordedAt":"2026-03-29T02:15:40.329Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:54.682Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021540-33db16bd::donanemab::alzheimers_disease","analysisId":"20260329T021540-33db16bd","recordedAt":"2026-03-29T02:15:40.329Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:54.327Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021540-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260329T021540-33db16bd","recordedAt":"2026-03-29T02:15:40.329Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:53.258Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021540-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260329T021540-33db16bd","recordedAt":"2026-03-29T02:15:40.329Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:18.817Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T021335-99db93fe::paclitaxel::pan-cancer","analysisId":"20260329T021335-99db93fe","recordedAt":"2026-03-29T02:13:35.020Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:49.681Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021335-99db93fe::gemcitabine::pan-cancer","analysisId":"20260329T021335-99db93fe","recordedAt":"2026-03-29T02:13:35.020Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:18.462Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T021335-99db93fe::cetuximab::pan-cancer","analysisId":"20260329T021335-99db93fe","recordedAt":"2026-03-29T02:13:35.020Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:50.395Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021335-99db93fe::panitumumab::pan-cancer","analysisId":"20260329T021335-99db93fe","recordedAt":"2026-03-29T02:13:35.020Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:18.108Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T021335-99db93fe::temozolomide::pan-cancer","analysisId":"20260329T021335-99db93fe","recordedAt":"2026-03-29T02:13:35.020Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:17.755Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T021335-99db93fe::sirolimus::pan-cancer","analysisId":"20260329T021335-99db93fe","recordedAt":"2026-03-29T02:13:35.020Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:52.182Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021335-99db93fe::carboplatin::pan-cancer","analysisId":"20260329T021335-99db93fe","recordedAt":"2026-03-29T02:13:35.020Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:52.539Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021335-99db93fe::palbociclib::pan-cancer","analysisId":"20260329T021335-99db93fe","recordedAt":"2026-03-29T02:13:35.020Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:52.895Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021131-426e9227::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260329T021131-426e9227","recordedAt":"2026-03-29T02:11:31.680Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:48.240Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021131-426e9227::amivantamab::non-small_cell_lung_cancer","analysisId":"20260329T021131-426e9227","recordedAt":"2026-03-29T02:11:31.680Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:17.047Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260329T021131-426e9227::crizotinib::non-small_cell_lung_cancer","analysisId":"20260329T021131-426e9227","recordedAt":"2026-03-29T02:11:31.680Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:46.462Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021131-426e9227::alectinib::non-small_cell_lung_cancer","analysisId":"20260329T021131-426e9227","recordedAt":"2026-03-29T02:11:31.680Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:46.826Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021131-426e9227::brigatinib::non-small_cell_lung_cancer","analysisId":"20260329T021131-426e9227","recordedAt":"2026-03-29T02:11:31.680Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:46.099Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021131-426e9227::ceritinib::non-small_cell_lung_cancer","analysisId":"20260329T021131-426e9227","recordedAt":"2026-03-29T02:11:31.680Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:47.182Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021131-426e9227::tepotinib::non-small_cell_lung_cancer","analysisId":"20260329T021131-426e9227","recordedAt":"2026-03-29T02:11:31.680Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:48.957Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T021131-426e9227::cetuximab::non-small_cell_lung_cancer","analysisId":"20260329T021131-426e9227","recordedAt":"2026-03-29T02:11:31.680Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:17.401Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260329T020915-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:15.985Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T020915-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:45.021Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020915-b849edd6::dabrafenib::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:16.693Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260329T020915-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:42.504Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020915-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:43.227Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020915-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:43.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020915-b849edd6::temsirolimus::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:43.948Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020915-b849edd6::atezolizumab::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:45.739Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020915-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260329T020915-b849edd6","recordedAt":"2026-03-29T02:09:15.126Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:16.339Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T020705-c46e28d2::rucaparib::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:41.795Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020705-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:40.727Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020705-c46e28d2::niraparib::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:41.079Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020705-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:40.367Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020705-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:40.015Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020705-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:39.655Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020705-c46e28d2::cisplatin::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:39.297Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020705-c46e28d2::carboplatin::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:38.946Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T020705-c46e28d2::talazoparib::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01286987","NCT04591431","NCT01945775","NCT02286687","NCT05141708"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:15.630Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T020705-c46e28d2::olaparib::breast_cancer","analysisId":"20260329T020705-c46e28d2","recordedAt":"2026-03-29T02:07:06.762Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04421963","NCT00494234","NCT04024254","NCT02484404"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:15.236Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260329T001726-a119bc50::afatinib_dimaleate::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:38.225Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001726-a119bc50::gefitinib::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:37.872Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001726-a119bc50::sunitinib::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:35.366Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001726-a119bc50::cetuximab::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05929456","NCT01884740","NCT05956821","NCT02861898","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:36.084Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001726-a119bc50::regorafenib::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:36.436Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001726-a119bc50::erlotinib::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:36.797Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001726-a119bc50::vandetanib::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:37.160Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001726-a119bc50::amivantamab::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"AMIVANTAMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06632236"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-09","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:14.847Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"HEALTH_SERVICES_RESEARCH"},{"id":"20260329T001726-a119bc50::afatinib::glioblastoma","analysisId":"20260329T001726-a119bc50","recordedAt":"2026-03-29T00:17:26.268Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:37.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001026-94b3f16c::riluzole::amyotrophic_lateral_sclerosis","analysisId":"20260329T001026-94b3f16c","recordedAt":"2026-03-29T00:10:26.222Z","drug":"RILUZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04518540","NCT03127267","NCT00231140","NCT03693781","NCT00694941"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-08-18","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:34.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260329T001026-94b3f16c::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260329T001026-94b3f16c","recordedAt":"2026-03-29T00:10:26.222Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070119","NCT05852418"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:35.006Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T234247-6eaf8c73::inclisiran::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04873934","NCT05192941","NCT06494501","NCT06813911","NCT06507852"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2021-05-05","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:14.493Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T234247-6eaf8c73::mipomersen::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"MIPOMERSEN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01598948"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-05-14","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:31.594Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T234247-6eaf8c73::lovastatin::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000477","NCT00000553","NCT00651391","NCT00116870","NCT00125593"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:31.171Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T234247-6eaf8c73::cholestyramine_resin::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"CHOLESTYRAMINE RESIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000461","NCT06501443","NCT01053065"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:32.020Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T234247-6eaf8c73::alirocumab::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03559309","NCT01663402","NCT03067844","NCT05001984","NCT03355027"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:32.911Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T234247-6eaf8c73::dexamethasone::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"DEXAMETHASONE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02807779","NCT03942601","NCT01507558","NCT01983449"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-06-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:33.364Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T234247-6eaf8c73::rivaroxaban::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"RIVAROXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05797376","NCT02544932","NCT04305028","NCT05009862","NCT04753372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-04-03","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:33.843Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T234247-6eaf8c73::alprostadil::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"ALPROSTADIL","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04312555","NCT01758874","NCT04197323"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-03-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:34.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T234247-6eaf8c73::pravastatin_sodium::atherosclerosis","analysisId":"20260328T234247-6eaf8c73","recordedAt":"2026-03-28T23:42:47.730Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00000461","NCT01634906","NCT00054938","NCT06501443","NCT06856772"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:32.452Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T230943-f274096f::adagrasib::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:13.400Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T230943-f274096f::temsirolimus::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:28.053Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T230943-f274096f::sorafenib::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:27.692Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T230943-f274096f::selumetinib::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:26.979Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T230943-f274096f::regorafenib::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:26.627Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T230943-f274096f::dabrafenib::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:14.108Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260328T230943-f274096f::sotorasib::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06645236","NCT05198934","NCT06252649"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:13.754Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T230943-f274096f::tovorafenib::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:13.046Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T230943-f274096f::encorafenib::colorectal_cancer","analysisId":"20260328T230943-f274096f","recordedAt":"2026-03-28T23:09:43.366Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:28.761Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T222833-3de3aa36::adalimumab::rheumatoid_arthritis","analysisId":"20260328T222833-3de3aa36","recordedAt":"2026-03-28T22:28:33.615Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02565810","NCT03938701","NCT01078402","NCT02353780","NCT00650026"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-30","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:26.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T222833-3de3aa36::pentoxifylline::rheumatoid_arthritis","analysisId":"20260328T222833-3de3aa36","recordedAt":"2026-03-28T22:28:33.615Z","drug":"PENTOXIFYLLINE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06998628"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-05-31","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:12.684Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T222833-3de3aa36::infliximab::rheumatoid_arthritis","analysisId":"20260328T222833-3de3aa36","recordedAt":"2026-03-28T22:28:33.615Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01299545","NCT02353780","NCT00705289","NCT02925338","NCT05379049"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-02-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:22.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T222833-3de3aa36::etanercept::rheumatoid_arthritis","analysisId":"20260328T222833-3de3aa36","recordedAt":"2026-03-28T22:28:33.615Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00244556","NCT00346294","NCT00445770","NCT00706797","NCT02353780"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:25.362Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T214238-8611a511::galantamine::alzheimer's_disease","analysisId":"20260328T214238-8611a511","recordedAt":"2026-03-28T21:42:38.709Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:21.664Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T214238-8611a511::donepezil::alzheimer's_disease","analysisId":"20260328T214238-8611a511","recordedAt":"2026-03-28T21:42:38.709Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:21.310Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T214238-8611a511::donanemab::alzheimer's_disease","analysisId":"20260328T214238-8611a511","recordedAt":"2026-03-28T21:42:38.709Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:20.952Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T214238-8611a511::aducanumab::alzheimer's_disease","analysisId":"20260328T214238-8611a511","recordedAt":"2026-03-28T21:42:38.709Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:20.248Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T214238-8611a511::lecanemab::alzheimer's_disease","analysisId":"20260328T214238-8611a511","recordedAt":"2026-03-28T21:42:38.709Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:12.301Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260328T214238-8611a511::rivastigmine::alzheimer's_disease","analysisId":"20260328T214238-8611a511","recordedAt":"2026-03-28T21:42:38.709Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:22.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204543-eecedaba::solanezumab::alzheimers_disease","analysisId":"20260328T204543-eecedaba","recordedAt":"2026-03-28T20:45:43.472Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:19.895Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204543-eecedaba::aducanumab::alzheimers_disease","analysisId":"20260328T204543-eecedaba","recordedAt":"2026-03-28T20:45:43.472Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:17.392Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204543-eecedaba::gantenerumab::alzheimers_disease","analysisId":"20260328T204543-eecedaba","recordedAt":"2026-03-28T20:45:43.472Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:19.536Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204543-eecedaba::rivastigmine::alzheimers_disease","analysisId":"20260328T204543-eecedaba","recordedAt":"2026-03-28T20:45:43.472Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:19.175Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204543-eecedaba::galantamine::alzheimers_disease","analysisId":"20260328T204543-eecedaba","recordedAt":"2026-03-28T20:45:43.472Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:18.818Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204543-eecedaba::donepezil::alzheimers_disease","analysisId":"20260328T204543-eecedaba","recordedAt":"2026-03-28T20:45:43.472Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:18.464Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204543-eecedaba::donanemab::alzheimers_disease","analysisId":"20260328T204543-eecedaba","recordedAt":"2026-03-28T20:45:43.472Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:18.107Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204543-eecedaba::lecanemab::alzheimers_disease","analysisId":"20260328T204543-eecedaba","recordedAt":"2026-03-28T20:45:43.472Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:11.947Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260328T204322-04055287::palbociclib::pan-cancer","analysisId":"20260328T204322-04055287","recordedAt":"2026-03-28T20:43:22.223Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:16.688Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204322-04055287::sirolimus::pan-cancer","analysisId":"20260328T204322-04055287","recordedAt":"2026-03-28T20:43:22.223Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:15.974Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204322-04055287::cetuximab::pan-cancer","analysisId":"20260328T204322-04055287","recordedAt":"2026-03-28T20:43:22.223Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:14.189Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204322-04055287::paclitaxel::pan-cancer","analysisId":"20260328T204322-04055287","recordedAt":"2026-03-28T20:43:22.223Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:13.469Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204322-04055287::temozolomide::pan-cancer","analysisId":"20260328T204322-04055287","recordedAt":"2026-03-28T20:43:22.223Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:10.885Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T204322-04055287::gemcitabine::pan-cancer","analysisId":"20260328T204322-04055287","recordedAt":"2026-03-28T20:43:22.223Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:11.593Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T204322-04055287::panitumumab::pan-cancer","analysisId":"20260328T204322-04055287","recordedAt":"2026-03-28T20:43:22.223Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:11.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T204322-04055287::carboplatin::pan-cancer","analysisId":"20260328T204322-04055287","recordedAt":"2026-03-28T20:43:22.223Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:16.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204022-a8f2f46e::tepotinib::non-small_cell_lung_cancer","analysisId":"20260328T204022-a8f2f46e","recordedAt":"2026-03-28T20:40:22.264Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:10.968Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204022-a8f2f46e::alectinib::non-small_cell_lung_cancer","analysisId":"20260328T204022-a8f2f46e","recordedAt":"2026-03-28T20:40:22.264Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:11.327Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204022-a8f2f46e::brigatinib::non-small_cell_lung_cancer","analysisId":"20260328T204022-a8f2f46e","recordedAt":"2026-03-28T20:40:22.264Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:11.689Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204022-a8f2f46e::ceritinib::non-small_cell_lung_cancer","analysisId":"20260328T204022-a8f2f46e","recordedAt":"2026-03-28T20:40:22.264Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:12.040Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204022-a8f2f46e::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260328T204022-a8f2f46e","recordedAt":"2026-03-28T20:40:22.264Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:12.405Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T204022-a8f2f46e::amivantamab::non-small_cell_lung_cancer","analysisId":"20260328T204022-a8f2f46e","recordedAt":"2026-03-28T20:40:22.264Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:10.531Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260328T204022-a8f2f46e::cetuximab::non-small_cell_lung_cancer","analysisId":"20260328T204022-a8f2f46e","recordedAt":"2026-03-28T20:40:22.264Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:10.177Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260328T204022-a8f2f46e::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260328T204022-a8f2f46e","recordedAt":"2026-03-28T20:40:22.264Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:10.266Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T203717-5256fd4f::regorafenib::colorectal_cancer","analysisId":"20260328T203717-5256fd4f","recordedAt":"2026-03-28T20:37:17.269Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:03.076Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T203717-5256fd4f::adagrasib::colorectal_cancer","analysisId":"20260328T203717-5256fd4f","recordedAt":"2026-03-28T20:37:17.269Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:09.469Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T203717-5256fd4f::tovorafenib::colorectal_cancer","analysisId":"20260328T203717-5256fd4f","recordedAt":"2026-03-28T20:37:17.269Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:09.115Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T203717-5256fd4f::temsirolimus::colorectal_cancer","analysisId":"20260328T203717-5256fd4f","recordedAt":"2026-03-28T20:37:17.269Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:04.489Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T203717-5256fd4f::selumetinib::colorectal_cancer","analysisId":"20260328T203717-5256fd4f","recordedAt":"2026-03-28T20:37:17.269Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:04.138Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T203717-5256fd4f::sorafenib::colorectal_cancer","analysisId":"20260328T203717-5256fd4f","recordedAt":"2026-03-28T20:37:17.269Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:03.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T203717-5256fd4f::encorafenib::colorectal_cancer","analysisId":"20260328T203717-5256fd4f","recordedAt":"2026-03-28T20:37:17.269Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:05.205Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T203717-5256fd4f::dabrafenib::colorectal_cancer","analysisId":"20260328T203717-5256fd4f","recordedAt":"2026-03-28T20:37:17.269Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:09.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260328T190428-3e00d7eb::amivantamab::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"AMIVANTAMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06632236"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-09","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:08.761Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"HEALTH_SERVICES_RESEARCH"},{"id":"20260328T190428-3e00d7eb::sunitinib::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:59.453Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T190428-3e00d7eb::cetuximab::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05929456","NCT01884740","NCT05956821","NCT02861898","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:00.157Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T190428-3e00d7eb::regorafenib::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:00.508Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T190428-3e00d7eb::erlotinib::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:00.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T190428-3e00d7eb::vandetanib::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:01.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T190428-3e00d7eb::afatinib::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:01.568Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T190428-3e00d7eb::gefitinib::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:01.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T190428-3e00d7eb::afatinib_dimaleate::glioblastoma","analysisId":"20260328T190428-3e00d7eb","recordedAt":"2026-03-28T19:04:28.475Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:29:02.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T013222-0afbf512::sorafenib::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:56.978Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T013222-0afbf512::temsirolimus::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:57.336Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T013222-0afbf512::tovorafenib::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:08.031Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T013222-0afbf512::adagrasib::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:08.384Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T013222-0afbf512::regorafenib::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:55.914Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T013222-0afbf512::selumetinib::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:56.267Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T013222-0afbf512::dabrafenib::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:07.323Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260328T013222-0afbf512::encorafenib::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:58.047Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T013222-0afbf512::sotorasib::colorectal_cancer","analysisId":"20260328T013222-0afbf512","recordedAt":"2026-03-28T01:32:22.739Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06645236","NCT05198934","NCT06252649"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:07.677Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T002230-b19043d5::cisplatin::triple-negative_breast_cancer","analysisId":"20260328T002230-b19043d5","recordedAt":"2026-03-28T00:22:30.834Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01920061","NCT04491942","NCT01091454","NCT02658214","NCT01167192"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:54.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T002230-b19043d5::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260328T002230-b19043d5","recordedAt":"2026-03-28T00:22:30.834Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:06.583Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T002230-b19043d5::carboplatin::triple-negative_breast_cancer","analysisId":"20260328T002230-b19043d5","recordedAt":"2026-03-28T00:22:30.834Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:54.396Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T002230-b19043d5::erlotinib::triple-negative_breast_cancer","analysisId":"20260328T002230-b19043d5","recordedAt":"2026-03-28T00:22:30.834Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:53.330Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T002230-b19043d5::atezolizumab::triple-negative_breast_cancer","analysisId":"20260328T002230-b19043d5","recordedAt":"2026-03-28T00:22:30.834Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":[],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT05266937","NCT04102618","NCT04954599","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:55.557Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T002230-b19043d5::osimertinib::triple-negative_breast_cancer","analysisId":"20260328T002230-b19043d5","recordedAt":"2026-03-28T00:22:30.834Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:06.194Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T002230-b19043d5::afatinib::triple-negative_breast_cancer","analysisId":"20260328T002230-b19043d5","recordedAt":"2026-03-28T00:22:30.834Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:06.969Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260328T000459-ef3ba940::lecanemab::alzheimer's_disease","analysisId":"20260328T000459-ef3ba940","recordedAt":"2026-03-28T00:04:59.831Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:05.807Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260328T000459-ef3ba940::aducanumab::alzheimer's_disease","analysisId":"20260328T000459-ef3ba940","recordedAt":"2026-03-28T00:04:59.831Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:50.119Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T000459-ef3ba940::donanemab::alzheimer's_disease","analysisId":"20260328T000459-ef3ba940","recordedAt":"2026-03-28T00:04:59.831Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:50.835Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T000459-ef3ba940::donepezil::alzheimer's_disease","analysisId":"20260328T000459-ef3ba940","recordedAt":"2026-03-28T00:04:59.831Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:51.195Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T000459-ef3ba940::galantamine::alzheimer's_disease","analysisId":"20260328T000459-ef3ba940","recordedAt":"2026-03-28T00:04:59.831Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:51.549Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260328T000459-ef3ba940::rivastigmine::alzheimer's_disease","analysisId":"20260328T000459-ef3ba940","recordedAt":"2026-03-28T00:04:59.831Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:51.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235646-fb50242d::galantamine::alzheimers_disease","analysisId":"20260327T235646-fb50242d","recordedAt":"2026-03-27T23:56:46.441Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:48.703Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235646-fb50242d::donanemab::alzheimers_disease","analysisId":"20260327T235646-fb50242d","recordedAt":"2026-03-27T23:56:46.441Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:48.001Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235646-fb50242d::aducanumab::alzheimers_disease","analysisId":"20260327T235646-fb50242d","recordedAt":"2026-03-27T23:56:46.441Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:47.295Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235646-fb50242d::donepezil::alzheimers_disease","analysisId":"20260327T235646-fb50242d","recordedAt":"2026-03-27T23:56:46.441Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:48.352Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235646-fb50242d::rivastigmine::alzheimers_disease","analysisId":"20260327T235646-fb50242d","recordedAt":"2026-03-27T23:56:46.441Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:49.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235646-fb50242d::solanezumab::alzheimers_disease","analysisId":"20260327T235646-fb50242d","recordedAt":"2026-03-27T23:56:46.441Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:49.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235646-fb50242d::gantenerumab::alzheimers_disease","analysisId":"20260327T235646-fb50242d","recordedAt":"2026-03-27T23:56:46.441Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:49.416Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235646-fb50242d::lecanemab::alzheimers_disease","analysisId":"20260327T235646-fb50242d","recordedAt":"2026-03-27T23:56:46.441Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06992804","NCT06285448"],"trialFound":true,"trialCompleted":false,"trialStatus":"ENROLLING_BY_INVITATION","trialFirstPostedDate":"2024-02-29","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:05.424Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260327T235152-c2761458::paclitaxel::pan-cancer","analysisId":"20260327T235152-c2761458","recordedAt":"2026-03-27T23:51:52.650Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:43.365Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235152-c2761458::cetuximab::pan-cancer","analysisId":"20260327T235152-c2761458","recordedAt":"2026-03-27T23:51:52.650Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:44.069Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235152-c2761458::gemcitabine::pan-cancer","analysisId":"20260327T235152-c2761458","recordedAt":"2026-03-27T23:51:52.650Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT04004234","NCT05585320","NCT06991491","NCT03989310"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:05.038Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T235152-c2761458::temozolomide::pan-cancer","analysisId":"20260327T235152-c2761458","recordedAt":"2026-03-27T23:51:52.650Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT04566380","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:04.652Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T235152-c2761458::panitumumab::pan-cancer","analysisId":"20260327T235152-c2761458","recordedAt":"2026-03-27T23:51:52.650Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:04.269Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T235152-c2761458::palbociclib::pan-cancer","analysisId":"20260327T235152-c2761458","recordedAt":"2026-03-27T23:51:52.650Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:46.575Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235152-c2761458::carboplatin::pan-cancer","analysisId":"20260327T235152-c2761458","recordedAt":"2026-03-27T23:51:52.650Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:46.220Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T235152-c2761458::sirolimus::pan-cancer","analysisId":"20260327T235152-c2761458","recordedAt":"2026-03-27T23:51:52.650Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:45.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234703-e9fd8e59::tepotinib::non-small_cell_lung_cancer","analysisId":"20260327T234703-e9fd8e59","recordedAt":"2026-03-27T23:47:03.567Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:40.871Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234703-e9fd8e59::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260327T234703-e9fd8e59","recordedAt":"2026-03-27T23:47:03.567Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:42.285Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234703-e9fd8e59::ceritinib::non-small_cell_lung_cancer","analysisId":"20260327T234703-e9fd8e59","recordedAt":"2026-03-27T23:47:03.567Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:41.935Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234703-e9fd8e59::brigatinib::non-small_cell_lung_cancer","analysisId":"20260327T234703-e9fd8e59","recordedAt":"2026-03-27T23:47:03.567Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:41.582Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234703-e9fd8e59::alectinib::non-small_cell_lung_cancer","analysisId":"20260327T234703-e9fd8e59","recordedAt":"2026-03-27T23:47:03.567Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:41.223Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234703-e9fd8e59::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260327T234703-e9fd8e59","recordedAt":"2026-03-27T23:47:03.567Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:40.167Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234703-e9fd8e59::amivantamab::non-small_cell_lung_cancer","analysisId":"20260327T234703-e9fd8e59","recordedAt":"2026-03-27T23:47:03.567Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04599712","NCT06120140"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2020-10-23","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:03.499Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260327T234703-e9fd8e59::cetuximab::non-small_cell_lung_cancer","analysisId":"20260327T234703-e9fd8e59","recordedAt":"2026-03-27T23:47:03.567Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101348","NCT00207116","NCT00097227","NCT03319459","NCT05069935"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:03.887Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260327T234217-93f35f69::temsirolimus::colorectal_cancer","analysisId":"20260327T234217-93f35f69","recordedAt":"2026-03-27T23:42:17.750Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:38.014Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-93f35f69::encorafenib::colorectal_cancer","analysisId":"20260327T234217-93f35f69","recordedAt":"2026-03-27T23:42:17.750Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:38.718Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-93f35f69::regorafenib::colorectal_cancer","analysisId":"20260327T234217-93f35f69","recordedAt":"2026-03-27T23:42:17.750Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:36.585Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-93f35f69::sorafenib::colorectal_cancer","analysisId":"20260327T234217-93f35f69","recordedAt":"2026-03-27T23:42:17.750Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:37.300Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-93f35f69::selumetinib::colorectal_cancer","analysisId":"20260327T234217-93f35f69","recordedAt":"2026-03-27T23:42:17.750Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:37.651Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-93f35f69::tovorafenib::colorectal_cancer","analysisId":"20260327T234217-93f35f69","recordedAt":"2026-03-27T23:42:17.750Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:02.711Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T234217-93f35f69::adagrasib::colorectal_cancer","analysisId":"20260327T234217-93f35f69","recordedAt":"2026-03-27T23:42:17.750Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05578092","NCT05722327","NCT06024174","NCT03785249"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:02.329Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T234217-93f35f69::dabrafenib::colorectal_cancer","analysisId":"20260327T234217-93f35f69","recordedAt":"2026-03-27T23:42:17.750Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03668431","NCT02465060","NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-05-01T03:43:03.109Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260327T234217-8412cb7d::sorafenib::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:33.983Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-8412cb7d::adagrasib::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:29.234Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T234217-8412cb7d::regorafenib::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:32.914Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-8412cb7d::selumetinib::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:33.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-8412cb7d::encorafenib::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:35.064Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-8412cb7d::temsirolimus::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:34.333Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T234217-8412cb7d::tovorafenib::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:28.880Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T234217-8412cb7d::sotorasib::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06645236","NCT05198934","NCT06252649"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-05-01T03:43:01.940Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T234217-8412cb7d::dabrafenib::colorectal_cancer","analysisId":"20260327T234217-8412cb7d","recordedAt":"2026-03-27T23:42:17.485Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06967155","NCT01750918","NCT05963087"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:28.525Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T233739-9fad091f::olaparib::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:27.814Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260327T233739-9fad091f::sacituzumab_govitecan::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:32.197Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T233739-9fad091f::paclitaxel::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:31.483Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T233739-9fad091f::rucaparib::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:31.835Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T233739-9fad091f::talazoparib::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:28.169Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260327T233739-9fad091f::carboplatin::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:29.337Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T233739-9fad091f::cisplatin::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:29.699Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T233739-9fad091f::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:30.050Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T233739-9fad091f::gemcitabine::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:30.416Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T233739-9fad091f::niraparib::breast_cancer","analysisId":"20260327T233739-9fad091f","recordedAt":"2026-03-27T23:37:39.627Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:30.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T232441-7a209d0a::ceritinib::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:26.632Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T232441-7a209d0a::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:27.833Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T232441-7a209d0a::repotrectinib::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"REPOTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04772235","NCT06552234","NCT06315010","NCT03093116","NCT06140836"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2017-03-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:27.459Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T232441-7a209d0a::crizotinib::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:25.556Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T232441-7a209d0a::brigatinib::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:25.917Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T232441-7a209d0a::alectinib::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:26.270Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T232441-7a209d0a::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:27.128Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T232441-7a209d0a::amivantamab::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:27.105Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T232441-7a209d0a::cetuximab::non-small_cell_lung_cancer","analysisId":"20260327T232441-7a209d0a","recordedAt":"2026-03-27T23:24:41.472Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:26.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260327T230237-ad3a6610::atezolizumab::triple-negative_breast_cancer","analysisId":"20260327T230237-ad3a6610","recordedAt":"2026-03-27T23:02:37.505Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT05266937","NCT04102618","NCT04954599","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:23.769Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T230237-ad3a6610::cisplatin::triple-negative_breast_cancer","analysisId":"20260327T230237-ad3a6610","recordedAt":"2026-03-27T23:02:37.505Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01920061","NCT04491942","NCT01091454","NCT02658214","NCT01167192"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:24.850Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T230237-ad3a6610::carboplatin::triple-negative_breast_cancer","analysisId":"20260327T230237-ad3a6610","recordedAt":"2026-03-27T23:02:37.505Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:24.485Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T230237-ad3a6610::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260327T230237-ad3a6610","recordedAt":"2026-03-27T23:02:37.505Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:26.397Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T230237-ad3a6610::afatinib::triple-negative_breast_cancer","analysisId":"20260327T230237-ad3a6610","recordedAt":"2026-03-27T23:02:37.505Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:26.042Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T230237-ad3a6610::cetuximab::triple-negative_breast_cancer","analysisId":"20260327T230237-ad3a6610","recordedAt":"2026-03-27T23:02:37.505Z","drug":"CETUXIMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00600249","NCT04464967","NCT05069935","NCT00463788"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-23","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:25.203Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T230237-ad3a6610::erlotinib::triple-negative_breast_cancer","analysisId":"20260327T230237-ad3a6610","recordedAt":"2026-03-27T23:02:37.505Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:22.697Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T171423-9905738a::riluzole::amyotrophic_lateral_sclerosis","analysisId":"20260327T171423-9905738a","recordedAt":"2026-03-27T17:14:23.365Z","drug":"RILUZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04518540","NCT03127267","NCT00231140","NCT03693781","NCT00694941"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-08-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:21.198Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T171423-9905738a::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260327T171423-9905738a","recordedAt":"2026-03-27T17:14:23.365Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070119","NCT05852418"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:21.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T170835-5b46876f::erlotinib::triple-negative_breast_cancer","analysisId":"20260327T170835-5b46876f","recordedAt":"2026-03-27T17:08:35.130Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:17.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T170835-5b46876f::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260327T170835-5b46876f","recordedAt":"2026-03-27T17:08:35.130Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:25.688Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T170835-5b46876f::afatinib::triple-negative_breast_cancer","analysisId":"20260327T170835-5b46876f","recordedAt":"2026-03-27T17:08:35.130Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:25.300Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260327T170835-5b46876f::cetuximab::triple-negative_breast_cancer","analysisId":"20260327T170835-5b46876f","recordedAt":"2026-03-27T17:08:35.130Z","drug":"CETUXIMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00600249","NCT04464967","NCT05069935","NCT00463788"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-23","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:20.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T170835-5b46876f::carboplatin::triple-negative_breast_cancer","analysisId":"20260327T170835-5b46876f","recordedAt":"2026-03-27T17:08:35.130Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:19.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T170835-5b46876f::cisplatin::triple-negative_breast_cancer","analysisId":"20260327T170835-5b46876f","recordedAt":"2026-03-27T17:08:35.130Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01920061","NCT04491942","NCT01091454","NCT02658214","NCT01167192"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:20.338Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260327T170835-5b46876f::atezolizumab::triple-negative_breast_cancer","analysisId":"20260327T170835-5b46876f","recordedAt":"2026-03-27T17:08:35.130Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT05266937","NCT04102618","NCT04954599","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:18.807Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260326T204317-b1cf2389::erlotinib::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:13.308Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260326T204317-b1cf2389::gefitinib::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:13.672Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260326T204317-b1cf2389::afatinib::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:12.950Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260326T204317-b1cf2389::atezolizumab::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"ATEZOLIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06328036","NCT03673787","NCT03973879","NCT05039281"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-09-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:24.556Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"HEALTH_SERVICES_RESEARCH"},{"id":"20260326T204317-b1cf2389::amivantamab::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"AMIVANTAMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06632236"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-09","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:24.911Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"HEALTH_SERVICES_RESEARCH"},{"id":"20260326T204317-b1cf2389::afatinib_dimaleate::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:15.828Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260326T204317-b1cf2389::sunitinib::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:15.466Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260326T204317-b1cf2389::regorafenib::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:15.104Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260326T204317-b1cf2389::cetuximab::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05929456","NCT01884740","NCT05956821","NCT02861898","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:14.746Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260326T204317-b1cf2389::vandetanib::glioblastoma","analysisId":"20260326T204317-b1cf2389","recordedAt":"2026-03-26T20:43:17.064Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:14.030Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002453-9d1a1093::donanemab::alzheimers_disease","analysisId":"20260324T002453-9d1a1093","recordedAt":"2026-03-24T00:24:53.304Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:10.802Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002453-9d1a1093::lecanemab::alzheimers_disease","analysisId":"20260324T002453-9d1a1093","recordedAt":"2026-03-24T00:24:53.304Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:24.201Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260324T002453-9d1a1093::solanezumab::alzheimers_disease","analysisId":"20260324T002453-9d1a1093","recordedAt":"2026-03-24T00:24:53.304Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:12.598Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002453-9d1a1093::gantenerumab::alzheimers_disease","analysisId":"20260324T002453-9d1a1093","recordedAt":"2026-03-24T00:24:53.304Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:12.233Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002453-9d1a1093::rivastigmine::alzheimers_disease","analysisId":"20260324T002453-9d1a1093","recordedAt":"2026-03-24T00:24:53.304Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:11.880Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002453-9d1a1093::galantamine::alzheimers_disease","analysisId":"20260324T002453-9d1a1093","recordedAt":"2026-03-24T00:24:53.304Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:11.518Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002453-9d1a1093::donepezil::alzheimers_disease","analysisId":"20260324T002453-9d1a1093","recordedAt":"2026-03-24T00:24:53.304Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:11.158Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002453-9d1a1093::aducanumab::alzheimers_disease","analysisId":"20260324T002453-9d1a1093","recordedAt":"2026-03-24T00:24:53.304Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:09.627Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002045-60fd7a13::carboplatin::pan-cancer","analysisId":"20260324T002045-60fd7a13","recordedAt":"2026-03-24T00:20:45.109Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:08.908Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002045-60fd7a13::palbociclib::pan-cancer","analysisId":"20260324T002045-60fd7a13","recordedAt":"2026-03-24T00:20:45.109Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:09.267Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002045-60fd7a13::temozolomide::pan-cancer","analysisId":"20260324T002045-60fd7a13","recordedAt":"2026-03-24T00:20:45.109Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:23.846Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260324T002045-60fd7a13::panitumumab::pan-cancer","analysisId":"20260324T002045-60fd7a13","recordedAt":"2026-03-24T00:20:45.109Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:23.134Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260324T002045-60fd7a13::sirolimus::pan-cancer","analysisId":"20260324T002045-60fd7a13","recordedAt":"2026-03-24T00:20:45.109Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:08.550Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002045-60fd7a13::paclitaxel::pan-cancer","analysisId":"20260324T002045-60fd7a13","recordedAt":"2026-03-24T00:20:45.109Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:06.023Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260324T002045-60fd7a13::gemcitabine::pan-cancer","analysisId":"20260324T002045-60fd7a13","recordedAt":"2026-03-24T00:20:45.109Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:23.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260324T002045-60fd7a13::cetuximab::pan-cancer","analysisId":"20260324T002045-60fd7a13","recordedAt":"2026-03-24T00:20:45.109Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:06.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T220109-1e6c099a::decitabine::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06651866","NCT05190471","NCT04282187","NCT04083911","NCT06778187"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-09-10","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T19:44:22.779Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T220109-1e6c099a::quizartinib::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"QUIZARTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03723681","NCT01390337","NCT04107727"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-10-28","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:04.354Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T220109-1e6c099a::azacitidine::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05448599","NCT03769532","NCT05190471","NCT06177067","NCT04266795"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-12-07","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T19:44:21.877Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T220109-1e6c099a::ponatinib::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"PONATINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04188405","NCT01424982","NCT02629692","NCT01667133","NCT02779283"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-12-04","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:02.177Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T220109-1e6c099a::idarubicin::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"IDARUBICIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04897490","NCT01018069","NCT00878722","NCT00382954","NCT00840346"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2021-05-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:04.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T220109-1e6c099a::midostaurin::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01174888","NCT00866281","NCT03280030","NCT01830361","NCT02078609"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:03.920Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T220109-1e6c099a::gilteritinib::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05312112","NCT02421939","NCT03922100","NCT06317649","NCT06713837"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2022-04-04","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:03.493Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T220109-1e6c099a::sunitinib::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"SUNITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00890747","NCT02779283","NCT00783653","NCT00387426","NCT01620216"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-04-29","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:03.053Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T220109-1e6c099a::sorafenib::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"SORAFENIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02270788","NCT00875745","NCT01371981","NCT00908167","NCT01398501"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-10-20","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:02.629Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T220109-1e6c099a::pacritinib::acute_myeloid_leukemia","analysisId":"20260323T220109-1e6c099a","recordedAt":"2026-03-23T22:01:09.326Z","drug":"PACRITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01620216","NCT02323607","NCT02532010","NCT04282187"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2012-06-14","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:01.741Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::erlotinib::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:57.862Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::afatinib::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:57.420Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::gefitinib::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:58.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::vandetanib::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:58.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::amivantamab::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"AMIVANTAMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06632236"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-09","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:07:02.083Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"HEALTH_SERVICES_RESEARCH"},{"id":"20260323T212205-b1cf2389::cetuximab::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05929456","NCT01884740","NCT05956821","NCT02861898","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:59.569Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::regorafenib::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:00.005Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::sunitinib::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:00.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::afatinib_dimaleate::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:28:00.873Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T212205-b1cf2389::atezolizumab::glioblastoma","analysisId":"20260323T212205-b1cf2389","recordedAt":"2026-03-23T21:22:05.763Z","drug":"ATEZOLIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06328036","NCT03673787","NCT03973879","NCT05039281"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-09-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:07:02.471Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"HEALTH_SERVICES_RESEARCH"},{"id":"20260323T211212-843e6b62::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T211212-843e6b62","recordedAt":"2026-03-23T21:12:12.618Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:54.032Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T211212-843e6b62::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T211212-843e6b62","recordedAt":"2026-03-23T21:12:12.618Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:54.735Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T211212-843e6b62::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T211212-843e6b62","recordedAt":"2026-03-23T21:12:12.618Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:55.886Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T211212-843e6b62::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T211212-843e6b62","recordedAt":"2026-03-23T21:12:12.618Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:56.604Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T211212-843e6b62::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T211212-843e6b62","recordedAt":"2026-03-23T21:12:12.618Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:53.682Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T211212-843e6b62::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T211212-843e6b62","recordedAt":"2026-03-23T21:12:12.618Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:07:01.350Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T211212-843e6b62::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T211212-843e6b62","recordedAt":"2026-03-23T21:12:12.618Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:07:01.705Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T211212-843e6b62::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T211212-843e6b62","recordedAt":"2026-03-23T21:12:12.618Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:54.383Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210812-5e774562::sorafenib::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:51.191Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210812-5e774562::selumetinib::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:50.828Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210812-5e774562::atezolizumab::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:53.316Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210812-5e774562::regorafenib::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:50.099Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210812-5e774562::adagrasib::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:07:00.995Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T210812-5e774562::temsirolimus::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:51.545Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210812-5e774562::tovorafenib::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:07:00.286Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T210812-5e774562::dabrafenib::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06967155","NCT01750918","NCT05963087"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:07:00.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T210812-5e774562::encorafenib::colorectal_cancer","analysisId":"20260323T210812-5e774562","recordedAt":"2026-03-23T21:08:12.426Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:52.600Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210650-fb19acbf::encorafenib::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:48.959Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210650-fb19acbf::dabrafenib::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06967155","NCT01750918","NCT05963087"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:59.219Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T210650-fb19acbf::tovorafenib::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:59.932Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T210650-fb19acbf::adagrasib::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:59.577Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T210650-fb19acbf::temsirolimus::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:47.804Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210650-fb19acbf::sorafenib::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:47.381Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210650-fb19acbf::selumetinib::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:47.015Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210650-fb19acbf::regorafenib::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:46.305Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210650-fb19acbf::atezolizumab::colorectal_cancer","analysisId":"20260323T210650-fb19acbf","recordedAt":"2026-03-23T21:06:50.740Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT03845166","NCT02876224","NCT05482516","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:49.737Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::rucaparib::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:45.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::niraparib::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:44.865Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::paclitaxel::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:44.148Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::gemcitabine::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:43.792Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::talazoparib::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:58.474Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T210455-aeb0f5c3::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:43.350Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::carboplatin::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:42.517Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:44.500Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::cisplatin::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:42.988Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T210455-aeb0f5c3::olaparib::breast_cancer","analysisId":"20260323T210455-aeb0f5c3","recordedAt":"2026-03-23T21:04:57.791Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:58.829Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T205920-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260323T205920-33db16bd","recordedAt":"2026-03-23T20:59:20.931Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:58.119Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T205920-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260323T205920-33db16bd","recordedAt":"2026-03-23T20:59:20.931Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:41.784Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205920-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260323T205920-33db16bd","recordedAt":"2026-03-23T20:59:20.931Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:42.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205920-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260323T205920-33db16bd","recordedAt":"2026-03-23T20:59:20.931Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:41.433Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205920-33db16bd::galantamine::alzheimers_disease","analysisId":"20260323T205920-33db16bd","recordedAt":"2026-03-23T20:59:20.931Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:41.069Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205920-33db16bd::donepezil::alzheimers_disease","analysisId":"20260323T205920-33db16bd","recordedAt":"2026-03-23T20:59:20.931Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:40.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205920-33db16bd::donanemab::alzheimers_disease","analysisId":"20260323T205920-33db16bd","recordedAt":"2026-03-23T20:59:20.931Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:40.350Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205920-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260323T205920-33db16bd","recordedAt":"2026-03-23T20:59:20.931Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:39.633Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205637-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T205637-99db93fe","recordedAt":"2026-03-23T20:56:37.753Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:36.071Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205637-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T205637-99db93fe","recordedAt":"2026-03-23T20:56:37.753Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:38.550Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205637-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T205637-99db93fe","recordedAt":"2026-03-23T20:56:37.753Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:57.017Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T205637-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T205637-99db93fe","recordedAt":"2026-03-23T20:56:37.753Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:36.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205637-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T205637-99db93fe","recordedAt":"2026-03-23T20:56:37.753Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:38.917Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205637-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T205637-99db93fe","recordedAt":"2026-03-23T20:56:37.753Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:57.764Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T205637-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T205637-99db93fe","recordedAt":"2026-03-23T20:56:37.753Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:39.268Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205637-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T205637-99db93fe","recordedAt":"2026-03-23T20:56:37.753Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:57.403Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T205346-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:32.500Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205346-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:56.244Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T205346-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:35.360Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205346-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:34.634Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205346-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:33.920Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205346-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:33.567Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205346-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:33.204Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205346-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:32.850Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205346-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T205346-557c91d1","recordedAt":"2026-03-23T20:53:46.872Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:56.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T205024-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:31.782Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205024-b849edd6::capecitabine::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:30.348Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205024-b849edd6::cetuximab::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:30.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205024-b849edd6::bevacizumab::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:29.997Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205024-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:28.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205024-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:55.854Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T205024-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:55.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T205024-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:31.421Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T205024-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260323T205024-b849edd6","recordedAt":"2026-03-23T20:50:24.811Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:29.284Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::olaparib::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:54.698Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T204722-c46e28d2::rucaparib::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:28.212Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::niraparib::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:27.505Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:27.153Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:26.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:26.087Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:25.723Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::carboplatin::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:25.368Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:26.449Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T204722-c46e28d2::talazoparib::breast_cancer","analysisId":"20260323T204722-c46e28d2","recordedAt":"2026-03-23T20:47:24.296Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:06:55.092Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T173448-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260323T173448-33db16bd","recordedAt":"2026-03-23T17:34:48.229Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:18.255Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173448-33db16bd::donanemab::alzheimers_disease","analysisId":"20260323T173448-33db16bd","recordedAt":"2026-03-23T17:34:48.229Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:18.977Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173448-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260323T173448-33db16bd","recordedAt":"2026-03-23T17:34:48.229Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:20.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173448-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260323T173448-33db16bd","recordedAt":"2026-03-23T17:34:48.229Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:20.032Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173448-33db16bd::galantamine::alzheimers_disease","analysisId":"20260323T173448-33db16bd","recordedAt":"2026-03-23T17:34:48.229Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:19.682Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173448-33db16bd::donepezil::alzheimers_disease","analysisId":"20260323T173448-33db16bd","recordedAt":"2026-03-23T17:34:48.229Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:19.332Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173448-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260323T173448-33db16bd","recordedAt":"2026-03-23T17:34:48.229Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:20.738Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173448-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260323T173448-33db16bd","recordedAt":"2026-03-23T17:34:48.229Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:54.308Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T173039-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T173039-99db93fe","recordedAt":"2026-03-23T17:30:39.381Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:15.301Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173039-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T173039-99db93fe","recordedAt":"2026-03-23T17:30:39.381Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:34.407Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T173039-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T173039-99db93fe","recordedAt":"2026-03-23T17:30:39.381Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:17.178Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173039-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T173039-99db93fe","recordedAt":"2026-03-23T17:30:39.381Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:17.899Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173039-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T173039-99db93fe","recordedAt":"2026-03-23T17:30:39.381Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:34.762Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T173039-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T173039-99db93fe","recordedAt":"2026-03-23T17:30:39.381Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:06:53.919Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T173039-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T173039-99db93fe","recordedAt":"2026-03-23T17:30:39.381Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:14.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T173039-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T173039-99db93fe","recordedAt":"2026-03-23T17:30:39.381Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:17.533Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172733-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:13.865Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172733-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:33.696Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T172733-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:11.009Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172733-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:11.360Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172733-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:11.718Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172733-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:12.078Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172733-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:12.438Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172733-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:13.146Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172733-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T172733-557c91d1","recordedAt":"2026-03-23T17:27:33.685Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:34.051Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T172436-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:33.340Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T172436-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:09.942Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172436-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:07.794Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172436-b849edd6::cetuximab::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:09.217Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172436-b849edd6::capecitabine::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:08.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172436-b849edd6::bevacizumab::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:08.504Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172436-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:07.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172436-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:32.985Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T172436-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260323T172436-b849edd6","recordedAt":"2026-03-23T17:24:36.269Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:10.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172024-c46e28d2::talazoparib::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:32.629Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T172024-c46e28d2::rucaparib::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:06.727Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172024-c46e28d2::niraparib::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:06.011Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172024-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:05.660Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172024-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:05.296Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172024-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:04.583Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172024-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:04.219Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172024-c46e28d2::carboplatin::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:03.859Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T172024-c46e28d2::olaparib::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:32.272Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T172024-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T172024-c46e28d2","recordedAt":"2026-03-23T17:20:25.698Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:27:04.935Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T145127-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260323T145127-33db16bd","recordedAt":"2026-03-23T14:51:27.683Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:31.917Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T145127-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260323T145127-33db16bd","recordedAt":"2026-03-23T14:51:27.683Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:56.650Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T145127-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260323T145127-33db16bd","recordedAt":"2026-03-23T14:51:27.683Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:59.162Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T145127-33db16bd::donanemab::alzheimers_disease","analysisId":"20260323T145127-33db16bd","recordedAt":"2026-03-23T14:51:27.683Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:57.376Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T145127-33db16bd::donepezil::alzheimers_disease","analysisId":"20260323T145127-33db16bd","recordedAt":"2026-03-23T14:51:27.683Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:57.728Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T145127-33db16bd::galantamine::alzheimers_disease","analysisId":"20260323T145127-33db16bd","recordedAt":"2026-03-23T14:51:27.683Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:58.082Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T145127-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260323T145127-33db16bd","recordedAt":"2026-03-23T14:51:27.683Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:58.801Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T145127-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260323T145127-33db16bd","recordedAt":"2026-03-23T14:51:27.683Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:58.444Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144732-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T144732-99db93fe","recordedAt":"2026-03-23T14:47:32.452Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:56.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144732-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T144732-99db93fe","recordedAt":"2026-03-23T14:47:32.452Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:55.583Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144732-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T144732-99db93fe","recordedAt":"2026-03-23T14:47:32.452Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:31.206Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T144732-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T144732-99db93fe","recordedAt":"2026-03-23T14:47:32.452Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:31.562Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T144732-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T144732-99db93fe","recordedAt":"2026-03-23T14:47:32.452Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:30.850Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T144732-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T144732-99db93fe","recordedAt":"2026-03-23T14:47:32.452Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:55.946Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144732-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T144732-99db93fe","recordedAt":"2026-03-23T14:47:32.452Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:53.093Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144732-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T144732-99db93fe","recordedAt":"2026-03-23T14:47:32.452Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:53.808Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144331-a00acae8::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:50.214Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144331-a00acae8::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:50.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144331-a00acae8::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:30.139Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T144331-a00acae8::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:30.495Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T144331-a00acae8::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:50.939Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144331-a00acae8::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:51.653Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144331-a00acae8::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:49.511Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144331-a00acae8::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:49.862Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T144331-a00acae8::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T144331-a00acae8","recordedAt":"2026-03-23T14:43:31.219Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:52.375Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143917-b849edd6::cetuximab::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:47.722Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143917-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:29.784Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T143917-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:45.939Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143917-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:29.425Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T143917-b849edd6::bevacizumab::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:47.008Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143917-b849edd6::capecitabine::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:47.365Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143917-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:48.799Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143917-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:48.434Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143917-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260323T143917-b849edd6","recordedAt":"2026-03-23T14:39:17.855Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:46.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143501-c46e28d2::olaparib::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:29.070Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T143501-c46e28d2::niraparib::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:44.519Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143501-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:44.167Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143501-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:43.805Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143501-c46e28d2::talazoparib::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:28.713Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T143501-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:43.450Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143501-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:42.737Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143501-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:43.087Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143501-c46e28d2::carboplatin::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:42.378Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T143501-c46e28d2::rucaparib::breast_cancer","analysisId":"20260323T143501-c46e28d2","recordedAt":"2026-03-23T14:35:02.745Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:45.230Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T132323-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260323T132323-33db16bd","recordedAt":"2026-03-23T13:23:23.860Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:41.298Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T132323-33db16bd::donepezil::alzheimers_disease","analysisId":"20260323T132323-33db16bd","recordedAt":"2026-03-23T13:23:23.860Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:40.582Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T132323-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260323T132323-33db16bd","recordedAt":"2026-03-23T13:23:23.860Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:39.514Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T132323-33db16bd::donanemab::alzheimers_disease","analysisId":"20260323T132323-33db16bd","recordedAt":"2026-03-23T13:23:23.860Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:40.230Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T132323-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260323T132323-33db16bd","recordedAt":"2026-03-23T13:23:23.860Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:42.013Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T132323-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260323T132323-33db16bd","recordedAt":"2026-03-23T13:23:23.860Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:41.661Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T132323-33db16bd::galantamine::alzheimers_disease","analysisId":"20260323T132323-33db16bd","recordedAt":"2026-03-23T13:23:23.860Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:40.946Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T132323-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260323T132323-33db16bd","recordedAt":"2026-03-23T13:23:23.860Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:28.357Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T131937-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T131937-99db93fe","recordedAt":"2026-03-23T13:19:37.221Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:27.647Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T131937-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T131937-99db93fe","recordedAt":"2026-03-23T13:19:37.221Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:35.946Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131937-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T131937-99db93fe","recordedAt":"2026-03-23T13:19:37.221Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:36.656Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131937-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T131937-99db93fe","recordedAt":"2026-03-23T13:19:37.221Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:38.798Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131937-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T131937-99db93fe","recordedAt":"2026-03-23T13:19:37.221Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:39.162Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131937-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T131937-99db93fe","recordedAt":"2026-03-23T13:19:37.221Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:28.002Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T131937-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T131937-99db93fe","recordedAt":"2026-03-23T13:19:37.221Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:27.292Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T131937-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T131937-99db93fe","recordedAt":"2026-03-23T13:19:37.221Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:38.444Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131637-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:32.383Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131637-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:33.091Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131637-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:33.444Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131637-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:33.808Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131637-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:34.518Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131637-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:35.233Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131637-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:26.581Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T131637-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:26.937Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T131637-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T131637-557c91d1","recordedAt":"2026-03-23T13:16:37.934Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:32.741Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131332-b849edd6::sorafenib::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:31.664Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131332-b849edd6::adagrasib::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:25.870Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T131332-b849edd6::tovorafenib::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:26.226Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T131332-b849edd6::regorafenib::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:28.801Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131332-b849edd6::selumetinib::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:31.313Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131332-b849edd6::cetuximab::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:30.594Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131332-b849edd6::capecitabine::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:30.236Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131332-b849edd6::bevacizumab::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:29.881Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T131332-b849edd6::encorafenib::colorectal_cancer","analysisId":"20260323T131332-b849edd6","recordedAt":"2026-03-23T13:13:32.105Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:29.159Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T130924-5bea43da::olaparib::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:25.515Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T130924-5bea43da::carboplatin::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:25.215Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T130924-5bea43da::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:25.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T130924-5bea43da::paclitaxel::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:25.943Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T130924-5bea43da::tamoxifen::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:26.654Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T130924-5bea43da::vinorelbine::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:27.019Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T130924-5bea43da::talazoparib::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:25.159Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T130924-5bea43da::niraparib::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:27.372Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T130924-5bea43da::rucaparib::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:28.084Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T130924-5bea43da::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T130924-5bea43da","recordedAt":"2026-03-23T13:09:26.074Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:26.304Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111326-33db16bd::galantamine::alzheimers_disease","analysisId":"20260323T111326-33db16bd","recordedAt":"2026-03-23T11:13:26.341Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:23.789Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111326-33db16bd::donepezil::alzheimers_disease","analysisId":"20260323T111326-33db16bd","recordedAt":"2026-03-23T11:13:26.341Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:23.430Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111326-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260323T111326-33db16bd","recordedAt":"2026-03-23T11:13:26.341Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:22.345Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111326-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260323T111326-33db16bd","recordedAt":"2026-03-23T11:13:26.341Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:24.803Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T111326-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260323T111326-33db16bd","recordedAt":"2026-03-23T11:13:26.341Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:24.861Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111326-33db16bd::donanemab::alzheimers_disease","analysisId":"20260323T111326-33db16bd","recordedAt":"2026-03-23T11:13:26.341Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:23.068Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111326-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260323T111326-33db16bd","recordedAt":"2026-03-23T11:13:26.341Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:24.500Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111326-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260323T111326-33db16bd","recordedAt":"2026-03-23T11:13:26.341Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:24.144Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111017-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T111017-99db93fe","recordedAt":"2026-03-23T11:10:17.193Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:23.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T111017-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T111017-99db93fe","recordedAt":"2026-03-23T11:10:17.193Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:21.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111017-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T111017-99db93fe","recordedAt":"2026-03-23T11:10:17.193Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:21.635Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111017-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T111017-99db93fe","recordedAt":"2026-03-23T11:10:17.193Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:24.093Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T111017-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T111017-99db93fe","recordedAt":"2026-03-23T11:10:17.193Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:21.993Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111017-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T111017-99db93fe","recordedAt":"2026-03-23T11:10:17.193Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:18.791Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T111017-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T111017-99db93fe","recordedAt":"2026-03-23T11:10:17.193Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:24.448Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T111017-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T111017-99db93fe","recordedAt":"2026-03-23T11:10:17.193Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:19.501Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110716-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:15.197Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110716-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:15.553Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110716-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:15.907Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110716-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:16.989Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110716-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:16.263Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110716-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:23.381Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T110716-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:23.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T110716-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:18.069Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110716-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T110716-557c91d1","recordedAt":"2026-03-23T11:07:16.765Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:17.707Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110419-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:22.313Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T110419-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:22.669Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T110419-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:12.680Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110419-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:13.400Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110419-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:14.474Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110419-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:14.123Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110419-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:11.616Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110419-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:11.969Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110419-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260323T110419-5b7100d5","recordedAt":"2026-03-23T11:04:19.136Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:13.040Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:09.460Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::olaparib::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:21.601Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T110019-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:09.096Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::rucaparib::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:10.899Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::niraparib::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:10.180Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:09.820Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:08.736Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:08.382Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::carboplatin::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:08.024Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T110019-c46e28d2::talazoparib::breast_cancer","analysisId":"20260323T110019-c46e28d2","recordedAt":"2026-03-23T11:00:21.039Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:21.957Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T093539-b7825793::donepezil::alzheimers_disease","analysisId":"20260323T093539-b7825793","recordedAt":"2026-03-23T09:35:39.840Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:06.233Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093539-b7825793::donanemab::alzheimers_disease","analysisId":"20260323T093539-b7825793","recordedAt":"2026-03-23T09:35:39.840Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:05.873Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093539-b7825793::gantenerumab::alzheimers_disease","analysisId":"20260323T093539-b7825793","recordedAt":"2026-03-23T09:35:39.840Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:07.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093539-b7825793::aducanumab::alzheimers_disease","analysisId":"20260323T093539-b7825793","recordedAt":"2026-03-23T09:35:39.840Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:05.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093539-b7825793::lecanemab::alzheimers_disease","analysisId":"20260323T093539-b7825793","recordedAt":"2026-03-23T09:35:39.840Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:21.246Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T093539-b7825793::galantamine::alzheimers_disease","analysisId":"20260323T093539-b7825793","recordedAt":"2026-03-23T09:35:39.840Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:06.593Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093539-b7825793::solanezumab::alzheimers_disease","analysisId":"20260323T093539-b7825793","recordedAt":"2026-03-23T09:35:39.840Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:07.671Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093539-b7825793::rivastigmine::alzheimers_disease","analysisId":"20260323T093539-b7825793","recordedAt":"2026-03-23T09:35:39.840Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:06.955Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093231-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T093231-99db93fe","recordedAt":"2026-03-23T09:32:31.433Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:02.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093231-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T093231-99db93fe","recordedAt":"2026-03-23T09:32:31.433Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:20.535Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T093231-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T093231-99db93fe","recordedAt":"2026-03-23T09:32:31.433Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:20.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T093231-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T093231-99db93fe","recordedAt":"2026-03-23T09:32:31.433Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:20.891Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T093231-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T093231-99db93fe","recordedAt":"2026-03-23T09:32:31.433Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:04.067Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093231-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T093231-99db93fe","recordedAt":"2026-03-23T09:32:31.433Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:04.431Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093231-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T093231-99db93fe","recordedAt":"2026-03-23T09:32:31.433Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:01.562Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T093231-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T093231-99db93fe","recordedAt":"2026-03-23T09:32:31.433Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:04.792Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092935-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:19.364Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T092935-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:57.966Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092935-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:58.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092935-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:58.680Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092935-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:59.043Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092935-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:59.768Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092935-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:00.492Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092935-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:26:00.846Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092935-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T092935-557c91d1","recordedAt":"2026-03-23T09:29:35.177Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:19.756Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T092640-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:57.253Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092640-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:56.897Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092640-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:54.765Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092640-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:56.184Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092640-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:18.972Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T092640-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:55.833Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092640-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:55.481Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092640-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:54.403Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092640-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260323T092640-5b7100d5","recordedAt":"2026-03-23T09:26:40.344Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:18.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T092326-c46e28d2::talazoparib::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T14:03:18.200Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T092326-c46e28d2::olaparib::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:17.810Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T092326-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:51.922Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092326-c46e28d2::rucaparib::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:53.687Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092326-c46e28d2::niraparib::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:52.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092326-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:52.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092326-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:52.273Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092326-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:51.559Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092326-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:51.194Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T092326-c46e28d2::carboplatin::breast_cancer","analysisId":"20260323T092326-c46e28d2","recordedAt":"2026-03-23T09:23:28.093Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:50.839Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074830-33db16bd::galantamine::alzheimers_disease","analysisId":"20260323T074830-33db16bd","recordedAt":"2026-03-23T07:48:30.224Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:49.392Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074830-33db16bd::donepezil::alzheimers_disease","analysisId":"20260323T074830-33db16bd","recordedAt":"2026-03-23T07:48:30.224Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:49.038Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074830-33db16bd::donanemab::alzheimers_disease","analysisId":"20260323T074830-33db16bd","recordedAt":"2026-03-23T07:48:30.224Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:48.688Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074830-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260323T074830-33db16bd","recordedAt":"2026-03-23T07:48:30.224Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:47.978Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074830-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260323T074830-33db16bd","recordedAt":"2026-03-23T07:48:30.224Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:17.422Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T074830-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260323T074830-33db16bd","recordedAt":"2026-03-23T07:48:30.224Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:50.112Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074830-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260323T074830-33db16bd","recordedAt":"2026-03-23T07:48:30.224Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:49.753Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074830-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260323T074830-33db16bd","recordedAt":"2026-03-23T07:48:30.224Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:50.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074552-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T074552-99db93fe","recordedAt":"2026-03-23T07:45:53.019Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:46.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074552-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T074552-99db93fe","recordedAt":"2026-03-23T07:45:53.019Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:44.678Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T074552-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T074552-99db93fe","recordedAt":"2026-03-23T07:45:53.019Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:44.390Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074552-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T074552-99db93fe","recordedAt":"2026-03-23T07:45:53.019Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:45.110Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074552-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T074552-99db93fe","recordedAt":"2026-03-23T07:45:53.019Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T14:03:17.030Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T074552-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T074552-99db93fe","recordedAt":"2026-03-23T07:45:53.019Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:47.625Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074552-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T074552-99db93fe","recordedAt":"2026-03-23T07:45:53.019Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:47.264Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074552-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T074552-99db93fe","recordedAt":"2026-03-23T07:45:53.019Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:44.322Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T074310-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:43.324Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074310-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:43.967Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T074310-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:43.608Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T074310-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:43.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074310-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:42.604Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074310-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:41.895Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074310-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:41.539Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074310-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:41.175Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074310-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T074310-557c91d1","recordedAt":"2026-03-23T07:43:10.927Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:40.814Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074018-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:39.723Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074018-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:40.088Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074018-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:39.002Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074018-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:38.640Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074018-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:42.897Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T074018-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:38.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074018-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:37.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074018-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:37.567Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T074018-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260323T074018-5b7100d5","recordedAt":"2026-03-23T07:40:18.159Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:43.253Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T073717-c46e28d2::talazoparib::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:42.542Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T073717-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:35.088Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T073717-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:34.727Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T073717-c46e28d2::olaparib::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:42.168Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T073717-c46e28d2::rucaparib::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:36.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T073717-c46e28d2::niraparib::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:35.799Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T073717-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:35.446Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T073717-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:34.367Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T073717-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:34.014Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T073717-c46e28d2::carboplatin::breast_cancer","analysisId":"20260323T073717-c46e28d2","recordedAt":"2026-03-23T07:37:19.222Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:33.654Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040716-b7825793::gantenerumab::alzheimers_disease","analysisId":"20260323T040716-b7825793","recordedAt":"2026-03-23T04:07:16.922Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:32.931Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040716-b7825793::lecanemab::alzheimers_disease","analysisId":"20260323T040716-b7825793","recordedAt":"2026-03-23T04:07:16.922Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:41.810Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T040716-b7825793::rivastigmine::alzheimers_disease","analysisId":"20260323T040716-b7825793","recordedAt":"2026-03-23T04:07:16.922Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:32.574Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040716-b7825793::galantamine::alzheimers_disease","analysisId":"20260323T040716-b7825793","recordedAt":"2026-03-23T04:07:16.922Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:32.218Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040716-b7825793::donepezil::alzheimers_disease","analysisId":"20260323T040716-b7825793","recordedAt":"2026-03-23T04:07:16.922Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:31.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040716-b7825793::donanemab::alzheimers_disease","analysisId":"20260323T040716-b7825793","recordedAt":"2026-03-23T04:07:16.922Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:31.501Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040716-b7825793::aducanumab::alzheimers_disease","analysisId":"20260323T040716-b7825793","recordedAt":"2026-03-23T04:07:16.922Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:30.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040716-b7825793::solanezumab::alzheimers_disease","analysisId":"20260323T040716-b7825793","recordedAt":"2026-03-23T04:07:16.922Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:33.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040421-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T040421-99db93fe","recordedAt":"2026-03-23T04:04:21.093Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:30.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040421-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T040421-99db93fe","recordedAt":"2026-03-23T04:04:21.093Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:29.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040421-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T040421-99db93fe","recordedAt":"2026-03-23T04:04:21.093Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:27.222Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040421-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T040421-99db93fe","recordedAt":"2026-03-23T04:04:21.093Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:27.939Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040421-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T040421-99db93fe","recordedAt":"2026-03-23T04:04:21.093Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:41.454Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T040421-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T040421-99db93fe","recordedAt":"2026-03-23T04:04:21.093Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:40.744Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T040421-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T040421-99db93fe","recordedAt":"2026-03-23T04:04:21.093Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:41.099Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T040421-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T040421-99db93fe","recordedAt":"2026-03-23T04:04:21.093Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:30.092Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040122-294a1f4e::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:23.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040122-294a1f4e::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:24.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040122-294a1f4e::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:40.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T040122-294a1f4e::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:23.639Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040122-294a1f4e::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:26.506Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040122-294a1f4e::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:26.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040122-294a1f4e::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:25.425Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040122-294a1f4e::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:24.717Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T040122-294a1f4e::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T040122-294a1f4e","recordedAt":"2026-03-23T04:01:22.190Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:40.030Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T035847-a1697017::adagrasib::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:39.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T035847-a1697017::cetuximab::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:21.860Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035847-a1697017::sorafenib::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:22.921Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035847-a1697017::tovorafenib::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:39.674Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T035847-a1697017::selumetinib::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:22.568Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035847-a1697017::regorafenib::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:20.067Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035847-a1697017::bevacizumab::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:21.145Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035847-a1697017::encorafenib::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:20.430Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035847-a1697017::capecitabine::colorectal_cancer","analysisId":"20260323T035847-a1697017","recordedAt":"2026-03-23T03:58:47.739Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:21.506Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::tamoxifen::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:17.902Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::paclitaxel::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:17.192Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::vinorelbine::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:18.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::niraparib::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:18.627Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::rucaparib::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:19.344Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:17.543Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::olaparib::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:38.964Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T035448-9e67b5f1::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:16.839Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::carboplatin::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:16.478Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T035448-9e67b5f1::talazoparib::breast_cancer","analysisId":"20260323T035448-9e67b5f1","recordedAt":"2026-03-23T03:54:49.821Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:38.610Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T012950-33db16bd::donanemab::alzheimers_disease","analysisId":"20260323T012950-33db16bd","recordedAt":"2026-03-23T01:29:50.068Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:14.333Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012950-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260323T012950-33db16bd","recordedAt":"2026-03-23T01:29:50.068Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:38.255Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T012950-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260323T012950-33db16bd","recordedAt":"2026-03-23T01:29:50.068Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:16.119Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012950-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260323T012950-33db16bd","recordedAt":"2026-03-23T01:29:50.068Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:15.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012950-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260323T012950-33db16bd","recordedAt":"2026-03-23T01:29:50.068Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:15.402Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012950-33db16bd::galantamine::alzheimers_disease","analysisId":"20260323T012950-33db16bd","recordedAt":"2026-03-23T01:29:50.068Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:15.048Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012950-33db16bd::donepezil::alzheimers_disease","analysisId":"20260323T012950-33db16bd","recordedAt":"2026-03-23T01:29:50.068Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:14.694Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012950-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260323T012950-33db16bd","recordedAt":"2026-03-23T01:29:50.068Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:13.606Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012656-ea8d980f::palbociclib::pan-cancer","analysisId":"20260323T012656-ea8d980f","recordedAt":"2026-03-23T01:26:56.853Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:13.245Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012656-ea8d980f::panitumumab::pan-cancer","analysisId":"20260323T012656-ea8d980f","recordedAt":"2026-03-23T01:26:56.853Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:37.182Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T012656-ea8d980f::carboplatin::pan-cancer","analysisId":"20260323T012656-ea8d980f","recordedAt":"2026-03-23T01:26:56.853Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:12.887Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012656-ea8d980f::paclitaxel::pan-cancer","analysisId":"20260323T012656-ea8d980f","recordedAt":"2026-03-23T01:26:56.853Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:10.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012656-ea8d980f::cetuximab::pan-cancer","analysisId":"20260323T012656-ea8d980f","recordedAt":"2026-03-23T01:26:56.853Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:10.728Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012656-ea8d980f::gemcitabine::pan-cancer","analysisId":"20260323T012656-ea8d980f","recordedAt":"2026-03-23T01:26:56.853Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:37.539Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T012656-ea8d980f::sirolimus::pan-cancer","analysisId":"20260323T012656-ea8d980f","recordedAt":"2026-03-23T01:26:56.853Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:12.524Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012656-ea8d980f::temozolomide::pan-cancer","analysisId":"20260323T012656-ea8d980f","recordedAt":"2026-03-23T01:26:56.853Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:37.900Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T012404-294a1f4e::crizotinib::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:06.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012404-294a1f4e::ceritinib::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:07.490Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012404-294a1f4e::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:08.205Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012404-294a1f4e::cetuximab::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:36.827Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260323T012404-294a1f4e::amivantamab::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:36.472Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T012404-294a1f4e::tepotinib::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:08.910Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012404-294a1f4e::afatinib::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:09.275Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012404-294a1f4e::brigatinib::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:06.422Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012404-294a1f4e::alectinib::non-small_cell_lung_cancer","analysisId":"20260323T012404-294a1f4e","recordedAt":"2026-03-23T01:24:04.978Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:07.132Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012125-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:04.649Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012125-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:04.293Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012125-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:03.223Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012125-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:02.866Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012125-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:03.934Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012125-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:05.711Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012125-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:05.358Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T012125-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:35.758Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T012125-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260323T012125-5b7100d5","recordedAt":"2026-03-23T01:21:25.170Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:36.114Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T011835-9e67b5f1::talazoparib::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:35.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T011835-9e67b5f1::tamoxifen::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:00.719Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T011835-9e67b5f1::paclitaxel::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:59.999Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T011835-9e67b5f1::olaparib::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:35.404Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T011835-9e67b5f1::carboplatin::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:59.278Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T011835-9e67b5f1::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:59.638Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T011835-9e67b5f1::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:00.360Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T011835-9e67b5f1::rucaparib::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:02.147Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T011835-9e67b5f1::niraparib::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:01.437Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T011835-9e67b5f1::vinorelbine::breast_cancer","analysisId":"20260323T011835-9e67b5f1","recordedAt":"2026-03-23T01:18:36.423Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:25:01.078Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T005219-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:57.502Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T005219-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:56.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T005219-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:58.576Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T005219-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:58.224Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T005219-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:34.338Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T005219-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:57.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T005219-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:56.793Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T005219-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:55.713Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T005219-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260323T005219-5b7100d5","recordedAt":"2026-03-23T00:52:19.848Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:34.693Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T004905-c46e28d2::talazoparib::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:33.627Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T004905-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:52.508Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004905-c46e28d2::carboplatin::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:52.146Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004905-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:53.227Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004905-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:53.943Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004905-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:53.582Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004905-c46e28d2::rucaparib::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:54.999Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004905-c46e28d2::olaparib::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:33.982Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260323T004905-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:52.873Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004905-c46e28d2::niraparib::breast_cancer","analysisId":"20260323T004905-c46e28d2","recordedAt":"2026-03-23T00:49:05.486Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:54.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004816-3067acf1::donanemab::alzheimer's_disease","analysisId":"20260323T004816-3067acf1","recordedAt":"2026-03-23T00:48:18.743Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:50.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004816-3067acf1::lecanemab::alzheimer's_disease","analysisId":"20260323T004816-3067acf1","recordedAt":"2026-03-23T00:48:18.743Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:33.272Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T004816-3067acf1::rivastigmine::alzheimer's_disease","analysisId":"20260323T004816-3067acf1","recordedAt":"2026-03-23T00:48:18.743Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:51.789Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004816-3067acf1::galantamine::alzheimer's_disease","analysisId":"20260323T004816-3067acf1","recordedAt":"2026-03-23T00:48:18.743Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:51.427Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004816-3067acf1::donepezil::alzheimer's_disease","analysisId":"20260323T004816-3067acf1","recordedAt":"2026-03-23T00:48:18.743Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:51.065Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T004816-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260323T004816-3067acf1","recordedAt":"2026-03-23T00:48:18.743Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:49.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000552-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260323T000552-33db16bd","recordedAt":"2026-03-23T00:05:52.044Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:32.915Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T000552-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260323T000552-33db16bd","recordedAt":"2026-03-23T00:05:52.044Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:49.633Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000552-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260323T000552-33db16bd","recordedAt":"2026-03-23T00:05:52.044Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:49.201Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000552-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260323T000552-33db16bd","recordedAt":"2026-03-23T00:05:52.044Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:48.770Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000552-33db16bd::galantamine::alzheimers_disease","analysisId":"20260323T000552-33db16bd","recordedAt":"2026-03-23T00:05:52.044Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:48.355Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000552-33db16bd::donepezil::alzheimers_disease","analysisId":"20260323T000552-33db16bd","recordedAt":"2026-03-23T00:05:52.044Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:47.929Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000552-33db16bd::donanemab::alzheimers_disease","analysisId":"20260323T000552-33db16bd","recordedAt":"2026-03-23T00:05:52.044Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:47.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000552-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260323T000552-33db16bd","recordedAt":"2026-03-23T00:05:52.044Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:46.664Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000249-99db93fe::gemcitabine::pan-cancer","analysisId":"20260323T000249-99db93fe","recordedAt":"2026-03-23T00:02:49.853Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:31.757Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T000249-99db93fe::palbociclib::pan-cancer","analysisId":"20260323T000249-99db93fe","recordedAt":"2026-03-23T00:02:49.853Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:46.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000249-99db93fe::carboplatin::pan-cancer","analysisId":"20260323T000249-99db93fe","recordedAt":"2026-03-23T00:02:49.853Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:45.825Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000249-99db93fe::sirolimus::pan-cancer","analysisId":"20260323T000249-99db93fe","recordedAt":"2026-03-23T00:02:49.853Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:45.402Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000249-99db93fe::panitumumab::pan-cancer","analysisId":"20260323T000249-99db93fe","recordedAt":"2026-03-23T00:02:49.853Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:32.143Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T000249-99db93fe::cetuximab::pan-cancer","analysisId":"20260323T000249-99db93fe","recordedAt":"2026-03-23T00:02:49.853Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:43.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260323T000249-99db93fe::temozolomide::pan-cancer","analysisId":"20260323T000249-99db93fe","recordedAt":"2026-03-23T00:02:49.853Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:32.560Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260323T000249-99db93fe::paclitaxel::pan-cancer","analysisId":"20260323T000249-99db93fe","recordedAt":"2026-03-23T00:02:49.853Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:42.458Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235943-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:40.308Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235943-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:39.028Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235943-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:38.605Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235943-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:38.174Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235943-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:30.993Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T235943-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:41.604Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235943-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:41.167Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235943-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:39.460Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235943-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T235943-557c91d1","recordedAt":"2026-03-22T23:59:43.719Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:31.400Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260322T235530-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:30.197Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T235530-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:36.318Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235530-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:34.532Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235530-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:35.608Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235530-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:30.551Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T235530-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:37.396Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235530-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:37.032Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235530-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:34.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235530-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T235530-5b7100d5","recordedAt":"2026-03-22T23:55:30.561Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:35.964Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:29.840Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T235239-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:33.760Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:32.914Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:32.481Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:32.052Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:31.191Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:30.763Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:30.340Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:31.615Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T235239-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T235239-c46e28d2","recordedAt":"2026-03-22T23:52:40.743Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:29.380Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T230635-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260322T230635-91dbcf4e","recordedAt":"2026-03-22T23:06:35.094Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05906576","NCT00791557","NCT03221166","NCT01787786","NCT05584228"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:27.410Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T230635-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260322T230635-91dbcf4e","recordedAt":"2026-03-22T23:06:35.094Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03938701","NCT01144156","NCT05394805","NCT01629628"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-05-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:27.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T230635-91dbcf4e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260322T230635-91dbcf4e","recordedAt":"2026-03-22T23:06:35.094Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03844932","NCT05112263","NCT01536535","NCT06126835"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-02-18","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:28.832Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T230635-91dbcf4e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260322T230635-91dbcf4e","recordedAt":"2026-03-22T23:06:35.094Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01418131","NCT00643071","NCT03204136","NCT01536535","NCT02954159"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-08-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:28.481Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T230635-91dbcf4e::celecoxib::inflammatory_bowel_disease","analysisId":"20260322T230635-91dbcf4e","recordedAt":"2026-03-22T23:06:35.094Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00640809","NCT01284504","NCT00808743","NCT00177866","NCT00473980"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:28.126Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T230635-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260322T230635-91dbcf4e","recordedAt":"2026-03-22T23:06:35.094Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03760003","NCT05584228","NCT05040464","NCT04304950","NCT01957423"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:27.775Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T223233-3067acf1::galantamine::alzheimer's_disease","analysisId":"20260322T223233-3067acf1","recordedAt":"2026-03-22T22:32:33.713Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:25.913Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T223233-3067acf1::donepezil::alzheimer's_disease","analysisId":"20260322T223233-3067acf1","recordedAt":"2026-03-22T22:32:33.713Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:25.492Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T223233-3067acf1::lecanemab::alzheimer's_disease","analysisId":"20260322T223233-3067acf1","recordedAt":"2026-03-22T22:32:33.713Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:28.931Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T223233-3067acf1::rivastigmine::alzheimer's_disease","analysisId":"20260322T223233-3067acf1","recordedAt":"2026-03-22T22:32:33.713Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:26.339Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T223233-3067acf1::donanemab::alzheimer's_disease","analysisId":"20260322T223233-3067acf1","recordedAt":"2026-03-22T22:32:33.713Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:25.073Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T223233-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260322T223233-3067acf1","recordedAt":"2026-03-22T22:32:33.713Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:24.210Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T212717-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:23.367Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T212717-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:20.381Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T212717-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:19.953Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T212717-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:21.236Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T212717-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:21.666Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T212717-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:22.090Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T212717-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:22.935Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T212717-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:28.518Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T212717-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T212717-5b7100d5","recordedAt":"2026-03-22T21:27:17.381Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:50:28.116Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T210403-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260322T210403-91dbcf4e","recordedAt":"2026-03-22T21:04:03.773Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03938701","NCT01144156","NCT05394805","NCT01629628"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-05-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:16.096Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T210403-91dbcf4e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260322T210403-91dbcf4e","recordedAt":"2026-03-22T21:04:03.773Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03844932","NCT05112263","NCT01536535","NCT06126835"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-02-18","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:18.264Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T210403-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260322T210403-91dbcf4e","recordedAt":"2026-03-22T21:04:03.773Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05906576","NCT00791557","NCT03221166","NCT01787786","NCT05584228"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:16.521Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T210403-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260322T210403-91dbcf4e","recordedAt":"2026-03-22T21:04:03.773Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03760003","NCT05584228","NCT05040464","NCT04304950","NCT01957423"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:16.963Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T210403-91dbcf4e::celecoxib::inflammatory_bowel_disease","analysisId":"20260322T210403-91dbcf4e","recordedAt":"2026-03-22T21:04:03.773Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00640809","NCT01284504","NCT00808743","NCT00177866","NCT00473980"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:17.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T210403-91dbcf4e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260322T210403-91dbcf4e","recordedAt":"2026-03-22T21:04:03.773Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01418131","NCT00643071","NCT03204136","NCT01536535","NCT02954159"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-08-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:24:17.827Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T202655-677edf52::etanercept::rheumatoid_arthritis","analysisId":"20260322T202655-677edf52","recordedAt":"2026-03-22T20:26:55.329Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00244556","NCT00346294","NCT00445770","NCT00706797","NCT02353780"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:22:05.175Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T202655-677edf52::adalimumab::rheumatoid_arthritis","analysisId":"20260322T202655-677edf52","recordedAt":"2026-03-22T20:26:55.329Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02565810","NCT03938701","NCT01078402","NCT02353780","NCT00650026"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-30","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:22:05.608Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T202655-677edf52::pentoxifylline::rheumatoid_arthritis","analysisId":"20260322T202655-677edf52","recordedAt":"2026-03-22T20:26:55.329Z","drug":"PENTOXIFYLLINE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06998628"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-05-31","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:27.688Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T202655-677edf52::infliximab::rheumatoid_arthritis","analysisId":"20260322T202655-677edf52","recordedAt":"2026-03-22T20:26:55.329Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01299545","NCT02353780","NCT00705289","NCT02925338","NCT05379049"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-02-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:22:04.747Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T200431-357e5474::aldesleukin::systemic_lupus_erythematosus","analysisId":"20260322T200431-357e5474","recordedAt":"2026-03-22T20:04:31.152Z","drug":"ALDESLEUKIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01988506","NCT04397107","NCT05631717","NCT02932137","NCT03312335"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-11-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:20.038Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T200431-357e5474::ustekinumab::systemic_lupus_erythematosus","analysisId":"20260322T200431-357e5474","recordedAt":"2026-03-22T20:04:31.152Z","drug":"USTEKINUMAB","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02349061","NCT03517722","NCT04060888"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-01-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:20.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T200431-357e5474::dimethyl_sulfoxide::systemic_lupus_erythematosus","analysisId":"20260322T200431-357e5474","recordedAt":"2026-03-22T20:04:31.152Z","drug":"DIMETHYL SULFOXIDE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05458622","NCT05747651"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-07-14","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:27.301Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"SUPPORTIVE_CARE"},{"id":"20260322T194739-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T194739-33db16bd","recordedAt":"2026-03-22T19:47:39.437Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:18.450Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194739-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T194739-33db16bd","recordedAt":"2026-03-22T19:47:39.437Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:17.374Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194739-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T194739-33db16bd","recordedAt":"2026-03-22T19:47:39.437Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:26.902Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T194739-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T194739-33db16bd","recordedAt":"2026-03-22T19:47:39.437Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:19.166Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194739-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T194739-33db16bd","recordedAt":"2026-03-22T19:47:39.437Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:18.806Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194739-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T194739-33db16bd","recordedAt":"2026-03-22T19:47:39.437Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:18.085Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194443-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T194443-99db93fe","recordedAt":"2026-03-22T19:44:43.947Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:14.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194443-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T194443-99db93fe","recordedAt":"2026-03-22T19:44:43.947Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:34.559Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T194443-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T194443-99db93fe","recordedAt":"2026-03-22T19:44:43.947Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:50:26.482Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T194443-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T194443-99db93fe","recordedAt":"2026-03-22T19:44:43.947Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:17.014Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194443-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T194443-99db93fe","recordedAt":"2026-03-22T19:44:43.947Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:16.663Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194443-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T194443-99db93fe","recordedAt":"2026-03-22T19:44:43.947Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:16.300Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194443-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T194443-99db93fe","recordedAt":"2026-03-22T19:44:43.947Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:13.821Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194443-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T194443-99db93fe","recordedAt":"2026-03-22T19:44:43.947Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:34.204Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T194150-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:33.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T194150-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:13.101Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194150-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:12.746Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194150-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:12.033Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194150-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:11.316Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194150-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:10.954Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194150-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:10.603Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194150-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:10.242Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T194150-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T194150-557c91d1","recordedAt":"2026-03-22T19:41:50.241Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:33.848Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260322T193828-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:09.166Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193828-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:32.777Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T193828-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:08.454Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193828-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:08.099Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193828-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:07.742Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193828-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:06.656Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193828-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:07.020Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193828-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:09.532Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193828-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T193828-5b7100d5","recordedAt":"2026-03-22T19:38:28.749Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:33.133Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T193812-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:05.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193812-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:03.433Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193812-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:04.865Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193812-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:32.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T193812-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:04.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193812-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:04.148Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193812-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:03.076Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193812-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:32.422Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T193812-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T193812-5b7100d5","recordedAt":"2026-03-22T19:38:12.263Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:05.941Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:01.652Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:00.575Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:02.372Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:31.711Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T193651-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:01.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:00.931Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:21:00.215Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:59.851Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:59.486Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T193651-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T193651-c46e28d2","recordedAt":"2026-03-22T19:36:53.848Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:31.355Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T190714-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T190714-33db16bd","recordedAt":"2026-03-22T19:07:14.158Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:30.999Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T190714-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T190714-33db16bd","recordedAt":"2026-03-22T19:07:14.158Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:56.602Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190714-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T190714-33db16bd","recordedAt":"2026-03-22T19:07:14.158Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:57.687Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190714-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T190714-33db16bd","recordedAt":"2026-03-22T19:07:14.158Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:58.049Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190714-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T190714-33db16bd","recordedAt":"2026-03-22T19:07:14.158Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:58.402Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190714-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260322T190714-33db16bd","recordedAt":"2026-03-22T19:07:14.158Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:58.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190714-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260322T190714-33db16bd","recordedAt":"2026-03-22T19:07:14.158Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:59.123Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190714-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T190714-33db16bd","recordedAt":"2026-03-22T19:07:14.158Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:57.321Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190450-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T190450-99db93fe","recordedAt":"2026-03-22T19:04:50.359Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:55.532Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190450-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T190450-99db93fe","recordedAt":"2026-03-22T19:04:50.359Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:55.895Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190450-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T190450-99db93fe","recordedAt":"2026-03-22T19:04:50.359Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:56.247Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190450-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T190450-99db93fe","recordedAt":"2026-03-22T19:04:50.359Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:29.931Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T190450-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T190450-99db93fe","recordedAt":"2026-03-22T19:04:50.359Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:30.287Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T190450-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T190450-99db93fe","recordedAt":"2026-03-22T19:04:50.359Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:53.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190450-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T190450-99db93fe","recordedAt":"2026-03-22T19:04:50.359Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:53.034Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190450-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T190450-99db93fe","recordedAt":"2026-03-22T19:04:50.359Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:30.643Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T190232-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:29.219Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260322T190232-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:52.318Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190232-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:51.958Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190232-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:51.230Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190232-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:50.507Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190232-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:50.147Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190232-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:49.789Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190232-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:49.428Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190232-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T190232-557c91d1","recordedAt":"2026-03-22T19:02:32.292Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:29.575Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T190012-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:46.210Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190012-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:46.924Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190012-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:47.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190012-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:47.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190012-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:48.346Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190012-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:28.508Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T190012-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:48.709Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T190012-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:28.864Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T190012-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T190012-5b7100d5","recordedAt":"2026-03-22T19:00:12.211Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:45.860Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:43.014Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:28.152Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T185748-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:45.146Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:44.433Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:44.076Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:43.719Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:42.660Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:42.308Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:43.365Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T185748-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T185748-c46e28d2","recordedAt":"2026-03-22T18:57:50.131Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:27.756Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T174246-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T174246-33db16bd","recordedAt":"2026-03-22T17:42:46.244Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:40.514Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174246-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T174246-33db16bd","recordedAt":"2026-03-22T17:42:46.244Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:40.163Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174246-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T174246-33db16bd","recordedAt":"2026-03-22T17:42:46.244Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:40.880Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174246-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T174246-33db16bd","recordedAt":"2026-03-22T17:42:46.244Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:41.232Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174246-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260322T174246-33db16bd","recordedAt":"2026-03-22T17:42:46.244Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:41.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174246-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260322T174246-33db16bd","recordedAt":"2026-03-22T17:42:46.244Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:41.955Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174246-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T174246-33db16bd","recordedAt":"2026-03-22T17:42:46.244Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:39.449Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174246-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T174246-33db16bd","recordedAt":"2026-03-22T17:42:46.244Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:27.361Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T174021-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T174021-99db93fe","recordedAt":"2026-03-22T17:40:21.569Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:26.969Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T174021-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T174021-99db93fe","recordedAt":"2026-03-22T17:40:21.569Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:39.081Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174021-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T174021-99db93fe","recordedAt":"2026-03-22T17:40:21.569Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:38.717Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174021-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T174021-99db93fe","recordedAt":"2026-03-22T17:40:21.569Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:38.352Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174021-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T174021-99db93fe","recordedAt":"2026-03-22T17:40:21.569Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:35.877Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174021-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T174021-99db93fe","recordedAt":"2026-03-22T17:40:21.569Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:36.578Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T174021-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T174021-99db93fe","recordedAt":"2026-03-22T17:40:21.569Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:26.571Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T174021-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T174021-99db93fe","recordedAt":"2026-03-22T17:40:21.569Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:26.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T173813-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:25.390Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260322T173813-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:34.806Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173813-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:34.095Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173813-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:33.031Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173813-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:32.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173813-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:32.674Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173813-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:33.382Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173813-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:25.781Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T173813-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T173813-557c91d1","recordedAt":"2026-03-22T17:38:13.117Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:35.170Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173531-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:30.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173531-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:33:25.001Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T173531-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:29.146Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173531-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:31.616Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173531-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:31.265Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173531-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:30.558Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173531-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:33:24.615Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T173531-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:29.850Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173531-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T173531-5b7100d5","recordedAt":"2026-03-22T17:35:31.232Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:28.796Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:27.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:28.083Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:25.226Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:26.298Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:25.578Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:25.930Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:26.660Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:27.369Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T173310-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:46.809Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T173310-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T173310-c46e28d2","recordedAt":"2026-03-22T17:33:12.264Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:47.167Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T163009-ae6826c9::decitabine::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06113289","NCT04093570","NCT06713837","NCT03813186","NCT04822766"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-01-23","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:46.063Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260322T163009-ae6826c9::midostaurin::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01174888","NCT00866281","NCT03280030","NCT01830361","NCT02078609"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:21.404Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T163009-ae6826c9::azacitidine::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02543879","NCT04102020","NCT01912274","NCT06571825"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-07-31","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:46.452Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T163009-ae6826c9::quizartinib::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"QUIZARTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03723681","NCT01390337","NCT04107727"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-10-28","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:22.254Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T163009-ae6826c9::sunitinib::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"SUNITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00890747","NCT02779283","NCT00783653","NCT00387426","NCT01620216"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-04-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:24.874Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T163009-ae6826c9::sorafenib::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"SORAFENIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02270788","NCT00875745","NCT01371981","NCT00908167","NCT01398501"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-10-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:24.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T163009-ae6826c9::pacritinib::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"PACRITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01620216","NCT02323607","NCT02532010","NCT04282187"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2012-06-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:23.990Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T163009-ae6826c9::idarubicin::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"IDARUBICIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04897490","NCT01018069","NCT00878722","NCT00382954","NCT00840346"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2021-05-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:22.697Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T163009-ae6826c9::ponatinib::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"PONATINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04188405","NCT01424982","NCT02629692","NCT01667133","NCT02779283"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-12-04","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:21.833Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T163009-ae6826c9::gilteritinib::acute_myeloid_leukemia","analysisId":"20260322T163009-ae6826c9","recordedAt":"2026-03-22T16:30:09.758Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05312112","NCT02421939","NCT03922100","NCT06317649","NCT06713837"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2022-04-04","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:20.981Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T162713-677edf52::infliximab::rheumatoid_arthritis","analysisId":"20260322T162713-677edf52","recordedAt":"2026-03-22T16:27:13.861Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01299545","NCT02353780","NCT00705289","NCT02925338","NCT05379049"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-02-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:16.740Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T162713-677edf52::adalimumab::rheumatoid_arthritis","analysisId":"20260322T162713-677edf52","recordedAt":"2026-03-22T16:27:13.861Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02565810","NCT03938701","NCT01078402","NCT02353780","NCT00650026"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-30","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:17.606Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T162713-677edf52::etanercept::rheumatoid_arthritis","analysisId":"20260322T162713-677edf52","recordedAt":"2026-03-22T16:27:13.861Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00244556","NCT00346294","NCT00445770","NCT00706797","NCT02353780"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:17.171Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T162713-677edf52::pentoxifylline::rheumatoid_arthritis","analysisId":"20260322T162713-677edf52","recordedAt":"2026-03-22T16:27:13.861Z","drug":"PENTOXIFYLLINE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06998628"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-05-31","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:45.672Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T151659-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T151659-33db16bd","recordedAt":"2026-03-22T15:16:59.395Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:45.289Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T151659-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T151659-33db16bd","recordedAt":"2026-03-22T15:16:59.395Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:09.618Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151659-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260322T151659-33db16bd","recordedAt":"2026-03-22T15:16:59.395Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:12.105Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151659-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260322T151659-33db16bd","recordedAt":"2026-03-22T15:16:59.395Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:11.741Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151659-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T151659-33db16bd","recordedAt":"2026-03-22T15:16:59.395Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:11.034Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151659-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T151659-33db16bd","recordedAt":"2026-03-22T15:16:59.395Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:11.388Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151659-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T151659-33db16bd","recordedAt":"2026-03-22T15:16:59.395Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:10.681Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151659-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T151659-33db16bd","recordedAt":"2026-03-22T15:16:59.395Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:10.326Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151447-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T151447-99db93fe","recordedAt":"2026-03-22T15:14:47.914Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:08.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151447-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T151447-99db93fe","recordedAt":"2026-03-22T15:14:47.914Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:06.062Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151447-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T151447-99db93fe","recordedAt":"2026-03-22T15:14:47.914Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:44.933Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T151447-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T151447-99db93fe","recordedAt":"2026-03-22T15:14:47.914Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:44.576Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T151447-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T151447-99db93fe","recordedAt":"2026-03-22T15:14:47.914Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:06.768Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151447-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T151447-99db93fe","recordedAt":"2026-03-22T15:14:47.914Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:09.267Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151447-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T151447-99db93fe","recordedAt":"2026-03-22T15:14:47.914Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:08.548Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151447-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T151447-99db93fe","recordedAt":"2026-03-22T15:14:47.914Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:44.219Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T151236-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:43.507Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T151236-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:43.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260322T151236-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:05.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151236-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:04.980Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151236-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:04.265Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151236-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:03.545Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151236-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:03.191Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151236-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:02.839Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T151236-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T151236-557c91d1","recordedAt":"2026-03-22T15:12:36.196Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:02.481Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150955-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:00.346Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150955-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:58.932Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150955-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:00.700Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150955-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:59.282Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150955-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:01.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150955-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:20:01.412Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150955-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:42.794Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T150955-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:59.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150955-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T150955-5b7100d5","recordedAt":"2026-03-22T15:09:55.547Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:43.151Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T150742-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:42.438Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T150742-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:58.228Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150742-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:56.802Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150742-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:56.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150742-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:57.163Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150742-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:55.365Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150742-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:55.731Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150742-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:56.082Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T150742-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:42.081Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T150742-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T150742-c46e28d2","recordedAt":"2026-03-22T15:07:43.912Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:57.515Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T143203-68e7fb0c::tamoxifen::breast_cancer_precision_medicine","analysisId":"20260322T143203-68e7fb0c","recordedAt":"2026-03-22T14:32:03.202Z","drug":"TAMOXIFEN","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06630325","NCT02624973"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-12-09","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:39.404Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260322T143203-68e7fb0c::docetaxel_anhydrous::breast_cancer_precision_medicine","analysisId":"20260322T143203-68e7fb0c","recordedAt":"2026-03-22T14:32:03.202Z","drug":"DOCETAXEL ANHYDROUS","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299999","NCT02624973"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:40.954Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T143203-68e7fb0c::fulvestrant::breast_cancer_precision_medicine","analysisId":"20260322T143203-68e7fb0c","recordedAt":"2026-03-22T14:32:03.202Z","drug":"FULVESTRANT","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06561022"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2024-08-19","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:41.724Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T143203-68e7fb0c::abemaciclib::breast_cancer_precision_medicine","analysisId":"20260322T143203-68e7fb0c","recordedAt":"2026-03-22T14:32:03.202Z","drug":"ABEMACICLIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06561022","NCT06630325"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2024-08-19","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:39.793Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T143203-68e7fb0c::capecitabine::breast_cancer_precision_medicine","analysisId":"20260322T143203-68e7fb0c","recordedAt":"2026-03-22T14:32:03.202Z","drug":"CAPECITABINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299999","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:40.567Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T143203-68e7fb0c::carboplatin::breast_cancer_precision_medicine","analysisId":"20260322T143203-68e7fb0c","recordedAt":"2026-03-22T14:32:03.202Z","drug":"CARBOPLATIN","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299999","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:40.182Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T143203-68e7fb0c::estradiol_valerate::breast_cancer_precision_medicine","analysisId":"20260322T143203-68e7fb0c","recordedAt":"2026-03-22T14:32:03.202Z","drug":"ESTRADIOL VALERATE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ESR1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06561022"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2024-08-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:41.340Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T142721-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T142721-33db16bd","recordedAt":"2026-03-22T14:27:21.104Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:39.011Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T142721-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T142721-33db16bd","recordedAt":"2026-03-22T14:27:21.104Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:48.848Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142721-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260322T142721-33db16bd","recordedAt":"2026-03-22T14:27:21.104Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:50.631Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142721-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260322T142721-33db16bd","recordedAt":"2026-03-22T14:27:21.104Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:50.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142721-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T142721-33db16bd","recordedAt":"2026-03-22T14:27:21.104Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:49.929Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142721-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T142721-33db16bd","recordedAt":"2026-03-22T14:27:21.104Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:49.565Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142721-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T142721-33db16bd","recordedAt":"2026-03-22T14:27:21.104Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:49.206Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142721-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T142721-33db16bd","recordedAt":"2026-03-22T14:27:21.104Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:48.139Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142531-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T142531-99db93fe","recordedAt":"2026-03-22T14:25:31.041Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:44.581Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142531-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T142531-99db93fe","recordedAt":"2026-03-22T14:25:31.041Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:45.293Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142531-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T142531-99db93fe","recordedAt":"2026-03-22T14:25:31.041Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:47.425Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142531-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T142531-99db93fe","recordedAt":"2026-03-22T14:25:31.041Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:47.776Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142531-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T142531-99db93fe","recordedAt":"2026-03-22T14:25:31.041Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:47.074Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142531-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T142531-99db93fe","recordedAt":"2026-03-22T14:25:31.041Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:37.943Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T142531-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T142531-99db93fe","recordedAt":"2026-03-22T14:25:31.041Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:38.299Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T142531-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T142531-99db93fe","recordedAt":"2026-03-22T14:25:31.041Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:38.655Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T142338-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:41.026Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142338-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:37.587Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260322T142338-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:43.517Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142338-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:42.805Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142338-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:42.086Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142338-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:41.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142338-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:41.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142338-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:43.872Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142338-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T142338-557c91d1","recordedAt":"2026-03-22T14:23:38.399Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:37.231Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T142148-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:39.937Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142148-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:36.874Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T142148-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:37.429Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142148-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:38.495Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142148-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:38.859Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142148-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:39.213Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142148-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:37.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142148-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:40.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142148-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T142148-5b7100d5","recordedAt":"2026-03-22T14:21:48.324Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:36.518Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T142000-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:35.633Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142000-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:35.276Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142000-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:34.550Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142000-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:34.193Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142000-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:33.830Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142000-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:36.162Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T142000-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:34.911Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142000-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:36.720Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142000-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:35.998Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T142000-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T142000-c46e28d2","recordedAt":"2026-03-22T14:20:00.839Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:35.806Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T141941-ac05ef48::gefitinib::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"GEFITINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01732276"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2012-11-22","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:34.662Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T141941-ac05ef48::cetuximab::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"CETUXIMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00600249","NCT04464967","NCT05069935","NCT00463788"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-23","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:31.764Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141941-ac05ef48::paclitaxel::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT03057600","NCT03997123","NCT05763992"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:30.893Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141941-ac05ef48::carboplatin::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:30.470Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141941-ac05ef48::atezolizumab::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03289962","NCT05266937","NCT04102618","NCT04954599","NCT03256344"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:30.035Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141941-ac05ef48::lapatinib::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01426880","NCT02158507","NCT01272141"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-08-31","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:29.597Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141941-ac05ef48::afatinib::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:35.450Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T141941-ac05ef48::pembrolizumab::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"PEMBROLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02644369","NCT02657889","NCT04024800","NCT02178722","NCT05208762"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:35.065Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T141941-ac05ef48::erlotinib::triple-negative_breast_cancer","analysisId":"20260322T141941-ac05ef48","recordedAt":"2026-03-22T14:19:43.747Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:32.620Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141003-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T141003-33db16bd","recordedAt":"2026-03-22T14:10:03.475Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:28.422Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141003-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T141003-33db16bd","recordedAt":"2026-03-22T14:10:03.475Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:27.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141003-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T141003-33db16bd","recordedAt":"2026-03-22T14:10:03.475Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:27.340Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141003-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T141003-33db16bd","recordedAt":"2026-03-22T14:10:03.475Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:26.628Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141003-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T141003-33db16bd","recordedAt":"2026-03-22T14:10:03.475Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:34.278Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T141003-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260322T141003-33db16bd","recordedAt":"2026-03-22T14:10:03.475Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:29.131Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141003-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260322T141003-33db16bd","recordedAt":"2026-03-22T14:10:03.475Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:28.780Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T141003-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T141003-33db16bd","recordedAt":"2026-03-22T14:10:03.475Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:28.059Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140755-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T140755-99db93fe","recordedAt":"2026-03-22T14:07:55.574Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:23.777Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140755-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T140755-99db93fe","recordedAt":"2026-03-22T14:07:55.574Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:33.209Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T140755-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T140755-99db93fe","recordedAt":"2026-03-22T14:07:55.574Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:23.064Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140755-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T140755-99db93fe","recordedAt":"2026-03-22T14:07:55.574Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:33.565Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T140755-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T140755-99db93fe","recordedAt":"2026-03-22T14:07:55.574Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:26.269Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140755-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T140755-99db93fe","recordedAt":"2026-03-22T14:07:55.574Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:25.911Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140755-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T140755-99db93fe","recordedAt":"2026-03-22T14:07:55.574Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:25.559Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140755-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T140755-99db93fe","recordedAt":"2026-03-22T14:07:55.574Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:33.921Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T140533-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:20.548Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140533-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:20.198Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140533-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:19.832Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140533-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:22.351Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140533-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:21.997Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140533-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:19.479Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140533-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:21.281Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140533-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:32.853Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260322T140533-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T140533-557c91d1","recordedAt":"2026-03-22T14:05:33.097Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05241873","NCT05388669","NCT05299125","NCT06083857"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-02-16","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:32.497Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T140330-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:18.749Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140330-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:15.881Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140330-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:16.965Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140330-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:17.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140330-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:17.693Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140330-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:18.396Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140330-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04330664","NCT03785249","NCT06412198","NCT05722327"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-12-24","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:31.716Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T140330-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:16.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140330-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T140330-5b7100d5","recordedAt":"2026-03-22T14:03:30.405Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:32.100Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T140103-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04703920","NCT03330405","NCT03911973","NCT02567396","NCT04991480"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:31.325Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T140103-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06488378","NCT05332561","NCT05536128","NCT02498613","NCT05203445"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:30.924Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"OTHER","primaryPurpose":"TREATMENT"},{"id":"20260322T140103-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:12.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140103-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:13.013Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140103-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:13.729Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140103-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:14.081Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140103-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:14.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140103-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:15.164Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140103-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:13.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T140103-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T140103-c46e28d2","recordedAt":"2026-03-22T14:01:04.677Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:12.284Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130730-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T130730-33db16bd","recordedAt":"2026-03-22T13:07:30.932Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05269394","NCT05469009","NCT05999084","NCT01760005"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2013-01-03","trialPhase":"Phase 2/PHASE3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:30.525Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T130730-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260322T130730-33db16bd","recordedAt":"2026-03-22T13:07:30.932Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:11.563Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130730-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T130730-33db16bd","recordedAt":"2026-03-22T13:07:30.932Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:11.198Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130730-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T130730-33db16bd","recordedAt":"2026-03-22T13:07:30.932Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:10.840Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130730-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T130730-33db16bd","recordedAt":"2026-03-22T13:07:30.932Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:10.480Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130730-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T130730-33db16bd","recordedAt":"2026-03-22T13:07:30.932Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:10.115Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130730-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T130730-33db16bd","recordedAt":"2026-03-22T13:07:30.932Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:09.409Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130730-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260322T130730-33db16bd","recordedAt":"2026-03-22T13:07:30.932Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:11.924Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130456-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T130456-99db93fe","recordedAt":"2026-03-22T13:04:56.037Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT06739395","NCT04566380"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:30.126Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T130456-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T130456-99db93fe","recordedAt":"2026-03-22T13:04:56.037Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:09.054Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130456-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T130456-99db93fe","recordedAt":"2026-03-22T13:04:56.037Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:08.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130456-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T130456-99db93fe","recordedAt":"2026-03-22T13:04:56.037Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT06607185","NCT06991491","NCT04969731","NCT04004234"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:29.347Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T130456-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T130456-99db93fe","recordedAt":"2026-03-22T13:04:56.037Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:08.695Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130456-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T130456-99db93fe","recordedAt":"2026-03-22T13:04:56.037Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:06.532Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130456-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T130456-99db93fe","recordedAt":"2026-03-22T13:04:56.037Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:05.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130456-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T130456-99db93fe","recordedAt":"2026-03-22T13:04:56.037Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-30T13:20:29.733Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T130150-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:32.179Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T130150-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00124618","NCT00622674","NCT04449874","NCT04464967","NCT00397384"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-30T13:20:28.954Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260322T130150-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:05.111Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130150-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:04.761Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130150-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:04.047Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130150-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:03.333Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130150-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:02.983Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130150-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:02.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T130150-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T130150-557c91d1","recordedAt":"2026-03-22T13:01:50.396Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:02.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125914-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:59.038Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125914-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:00.495Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125914-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:01.204Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125914-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:31.466Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T125914-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:00.130Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125914-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:59.764Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125914-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:58.682Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125914-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:31.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T125914-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T125914-5b7100d5","recordedAt":"2026-03-22T12:59:14.705Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:19:01.564Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:55.814Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:55.446Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:57.965Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:31.110Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T125604-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:56.167Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:55.081Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:57.248Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:56.886Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:56.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T125604-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T125604-c46e28d2","recordedAt":"2026-03-22T12:56:05.600Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:30.754Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114707-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T114707-33db16bd","recordedAt":"2026-03-22T11:47:07.447Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:53.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114707-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260322T114707-33db16bd","recordedAt":"2026-03-22T11:47:07.447Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:54.731Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114707-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260322T114707-33db16bd","recordedAt":"2026-03-22T11:47:07.447Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:54.367Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114707-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T114707-33db16bd","recordedAt":"2026-03-22T11:47:07.447Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:54.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114707-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T114707-33db16bd","recordedAt":"2026-03-22T11:47:07.447Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:53.645Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114707-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T114707-33db16bd","recordedAt":"2026-03-22T11:47:07.447Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:52.931Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114707-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T114707-33db16bd","recordedAt":"2026-03-22T11:47:07.447Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:52.214Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114707-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T114707-33db16bd","recordedAt":"2026-03-22T11:47:07.447Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:30.398Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114450-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T114450-99db93fe","recordedAt":"2026-03-22T11:44:51.001Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:51.857Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114450-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T114450-99db93fe","recordedAt":"2026-03-22T11:44:51.001Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:51.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114450-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T114450-99db93fe","recordedAt":"2026-03-22T11:44:51.001Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:51.498Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114450-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T114450-99db93fe","recordedAt":"2026-03-22T11:44:51.001Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:48.616Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114450-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T114450-99db93fe","recordedAt":"2026-03-22T11:44:51.001Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:49.332Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114450-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T114450-99db93fe","recordedAt":"2026-03-22T11:44:51.001Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:29.331Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114450-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T114450-99db93fe","recordedAt":"2026-03-22T11:44:51.001Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:30.043Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114450-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T114450-99db93fe","recordedAt":"2026-03-22T11:44:51.001Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:29.687Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114233-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:47.547Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114233-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:46.130Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114233-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05395052"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-05-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:28.976Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114233-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:45.776Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114233-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:45.424Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114233-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:45.070Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114233-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:46.844Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114233-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:47.898Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114233-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T114233-557c91d1","recordedAt":"2026-03-22T11:42:33.255Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:28.620Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114020-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:27.908Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114020-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:44.369Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114020-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:42.928Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114020-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:42.571Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114020-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:41.497Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114020-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:41.853Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114020-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:44.005Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T114020-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:28.264Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T114020-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T114020-5b7100d5","recordedAt":"2026-03-22T11:40:20.836Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:43.289Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:38.648Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:37.943Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:38.297Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:39.352Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:39.711Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:40.076Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:40.781Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:38.999Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T113812-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:27.552Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T113812-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T113812-c46e28d2","recordedAt":"2026-03-22T11:38:14.045Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:27.197Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T064558-33db16bd::donepezil::alzheimers_disease","analysisId":"20260322T064558-33db16bd","recordedAt":"2026-03-22T06:45:58.216Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:35.861Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064558-33db16bd::donanemab::alzheimers_disease","analysisId":"20260322T064558-33db16bd","recordedAt":"2026-03-22T06:45:58.216Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:35.433Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064558-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260322T064558-33db16bd","recordedAt":"2026-03-22T06:45:58.216Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:34.575Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064558-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260322T064558-33db16bd","recordedAt":"2026-03-22T06:45:58.216Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:26.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T064558-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260322T064558-33db16bd","recordedAt":"2026-03-22T06:45:58.216Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT04339413","NCT04374253","NCT01656525","NCT03444870","NCT04592341"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2020-04-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:37.152Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064558-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260322T064558-33db16bd","recordedAt":"2026-03-22T06:45:58.216Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01399125","NCT01948791","NCT00766363","NCT00627848","NCT01696591"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-20","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:36.719Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064558-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260322T064558-33db16bd","recordedAt":"2026-03-22T06:45:58.216Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01900665","NCT00749216","NCT01148498","NCT01127633","NCT00905372"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:37.583Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064558-33db16bd::galantamine::alzheimers_disease","analysisId":"20260322T064558-33db16bd","recordedAt":"2026-03-22T06:45:58.216Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00240695","NCT00216515","NCT00236574","NCT01696591","NCT00035204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:36.290Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064356-99db93fe::carboplatin::pan-cancer","analysisId":"20260322T064356-99db93fe","recordedAt":"2026-03-22T06:43:56.139Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03989336","NCT06297811","NCT06333314","NCT06607185","NCT02476955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:33.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064356-99db93fe::paclitaxel::pan-cancer","analysisId":"20260322T064356-99db93fe","recordedAt":"2026-03-22T06:43:56.139Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06991491","NCT03989336","NCT01608009","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-05-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:29.945Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064356-99db93fe::panitumumab::pan-cancer","analysisId":"20260322T064356-99db93fe","recordedAt":"2026-03-22T06:43:56.139Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:26.485Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T064356-99db93fe::temozolomide::pan-cancer","analysisId":"20260322T064356-99db93fe","recordedAt":"2026-03-22T06:43:56.139Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:25.774Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T064356-99db93fe::cetuximab::pan-cancer","analysisId":"20260322T064356-99db93fe","recordedAt":"2026-03-22T06:43:56.139Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-10-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:30.802Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064356-99db93fe::palbociclib::pan-cancer","analysisId":"20260322T064356-99db93fe","recordedAt":"2026-03-22T06:43:56.139Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT06126276","NCT03065387","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-17","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:33.812Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064356-99db93fe::sirolimus::pan-cancer","analysisId":"20260322T064356-99db93fe","recordedAt":"2026-03-22T06:43:56.139Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-16","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:32.950Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064356-99db93fe::gemcitabine::pan-cancer","analysisId":"20260322T064356-99db93fe","recordedAt":"2026-03-22T06:43:56.139Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:26.130Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T064147-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:25.418Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T064147-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:26.062Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064147-557c91d1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:26.935Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064147-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04129502","NCT04576208","NCT04051827","NCT02716116","NCT05863819"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-10-15","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:27.807Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064147-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03940703","NCT06083857","NCT06106802","NCT06031688","NCT03531762"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-05-06","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:28.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064147-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:29.079Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064147-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05395052"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-05-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:25.018Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T064147-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:25.620Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T064147-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260322T064147-557c91d1","recordedAt":"2026-03-22T06:41:47.969Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:26.494Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063945-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06107413","NCT06997497","NCT00973557","NCT00623805","NCT00070122"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2023-10-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:22.599Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063945-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06940388","NCT00081289","NCT06884670","NCT06520683"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:23.038Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063945-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00954876","NCT06997497","NCT01212627","NCT01287130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2009-08-06","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:23.470Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063945-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:24.619Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T063945-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02188264","NCT01217450","NCT01116271","NCT01134601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-01-31","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:24.321Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063945-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:24.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063945-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:24.264Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T063945-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:21.750Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063945-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260322T063945-5b7100d5","recordedAt":"2026-03-22T06:39:45.471Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:21.318Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05770531","NCT03424005","NCT03901339"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:18.324Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::olaparib::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:23.501Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260322T063705-c46e28d2::carboplatin::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:16.997Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:17.882Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03879174","NCT01384526","NCT06120595","NCT03493854","NCT06449027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-03-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:18.747Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03839823","NCT00430001","NCT04963595","NCT03423849","NCT00193089"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:19.167Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::niraparib::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT02657889","NCT06535893","NCT05238831","NCT03368729"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-04-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:19.601Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::rucaparib::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT03542175","NCT03911453","NCT02505048","NCT01074970"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-11-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:20.455Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-22T19:18:17.441Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260322T063705-c46e28d2::talazoparib::breast_cancer","analysisId":"20260322T063705-c46e28d2","recordedAt":"2026-03-22T06:37:06.687Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:23.909Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T013214-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260321T013214-3067acf1","recordedAt":"2026-03-21T01:32:15.003Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-29T00:07:35.013Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T013214-3067acf1::galantamine::alzheimer's_disease","analysisId":"20260321T013214-3067acf1","recordedAt":"2026-03-21T01:32:15.003Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-29T00:07:36.610Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012633-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260321T012633-33db16bd","recordedAt":"2026-03-21T01:26:33.061Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-29T00:07:32.981Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012633-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260321T012633-33db16bd","recordedAt":"2026-03-21T01:26:33.061Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT01760005","NCT00329082","NCT02614131","NCT02008357","NCT00749216"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-29T00:07:34.513Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012633-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260321T012633-33db16bd","recordedAt":"2026-03-21T01:26:33.061Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 2","mechanism":"","trialNctIds":["NCT03443973","NCT01760005","NCT03444870","NCT04339413","NCT01656525"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-29T00:07:34.001Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012633-33db16bd::galantamine::alzheimers_disease","analysisId":"20260321T012633-33db16bd","recordedAt":"2026-03-21T01:26:33.061Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-29T00:07:32.630Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012633-33db16bd::donepezil::alzheimers_disease","analysisId":"20260321T012633-33db16bd","recordedAt":"2026-03-21T01:26:33.061Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-29T00:07:32.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012633-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260321T012633-33db16bd","recordedAt":"2026-03-21T01:26:33.061Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-29T00:07:31.578Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012633-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260321T012633-33db16bd","recordedAt":"2026-03-21T01:26:33.061Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:23.107Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T012129-99db93fe::sapanisertib::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:43:06.408Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012129-99db93fe::temozolomide::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:22.751Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T012129-99db93fe::panitumumab::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:22.039Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T012129-99db93fe::sirolimus::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:07.809Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012129-99db93fe::cetuximab::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:06.057Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012129-99db93fe::paclitaxel::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:22.395Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T012129-99db93fe::vemurafenib::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:43:05.707Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012129-99db93fe::carboplatin::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:08.160Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012129-99db93fe::palbociclib::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:08.511Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T012129-99db93fe::gemcitabine::pan-cancer","analysisId":"20260321T012129-99db93fe","recordedAt":"2026-03-21T01:21:29.763Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:21.683Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T011717-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:02.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:04.656Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:04.307Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:43:03.956Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:03.604Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:03.253Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01871805","NCT05014464","NCT03535740","NCT06765109","NCT05525338"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:02.552Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:02.903Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:05.007Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011717-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260321T011717-557c91d1","recordedAt":"2026-03-21T01:17:20.771Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:43:01.852Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:42:57.234Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::genistein::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"GENISTEIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:42:59.497Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::sorbitol::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"SORBITOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:42:58.085Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::procarbazine_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"PROCARBAZINE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:42:59.063Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:42:57.656Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::melatonin::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"MELATONIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:43:01.067Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::interleukin-11::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"INTERLEUKIN-11","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:43:01.501Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::pioglitazone_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:43:00.507Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:43:00.016Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011216-5021da0e::lithium::neurodegeneration_biomarker_panel","analysisId":"20260321T011216-5021da0e","recordedAt":"2026-03-21T01:12:17.029Z","drug":"LITHIUM","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:42:58.567Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:10:10.162Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:11.566Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:11.918Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:20.972Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T011005-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:09.111Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:09.461Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:10.512Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:10.865Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:12.268Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T011005-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260321T011005-5b7100d5","recordedAt":"2026-03-21T01:10:05.441Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:21.327Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T010630-c46e28d2::rucaparib::breast_cancer","analysisId":"20260321T010630-c46e28d2","recordedAt":"2026-03-21T01:06:33.353Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:07.006Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T010630-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260321T010630-c46e28d2","recordedAt":"2026-03-21T01:06:33.353Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:08.759Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T010630-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260321T010630-c46e28d2","recordedAt":"2026-03-21T01:06:33.353Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:08.409Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T010630-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260321T010630-c46e28d2","recordedAt":"2026-03-21T01:06:33.353Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:08.059Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T010630-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260321T010630-c46e28d2","recordedAt":"2026-03-21T01:06:33.353Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:07.707Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T010630-c46e28d2::olaparib::breast_cancer","analysisId":"20260321T010630-c46e28d2","recordedAt":"2026-03-21T01:06:33.353Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:06.306Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T010630-c46e28d2::niraparib::breast_cancer","analysisId":"20260321T010630-c46e28d2","recordedAt":"2026-03-21T01:06:33.353Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:06.656Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T010630-c46e28d2::talazoparib::breast_cancer","analysisId":"20260321T010630-c46e28d2","recordedAt":"2026-03-21T01:06:33.353Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:07.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::alteplase::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"ALTEPLASE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:10:03.108Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::ibudilast::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"IBUDILAST","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:10:04.188Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::gallium_nitrate::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"GALLIUM NITRATE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:10:04.615Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::echinacea_preparation::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"ECHINACEA PREPARATION","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:10:05.058Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::insulin,_regular,_human::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"INSULIN, REGULAR, HUMAN","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:10:05.493Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::midostaurin::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"MIDOSTAURIN","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:10:05.956Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::pentoxifylline::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"PENTOXIFYLLINE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06998628"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-05-31","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:20.616Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T005657-677edf52::infliximab::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00036387","NCT01295151","NCT01571219","NCT01936181","NCT03478111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:01.679Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::etanercept::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00837434","NCT03100734","NCT03332719","NCT05891600","NCT06016517"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:02.128Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T005657-677edf52::adalimumab::rheumatoid_arthritis","analysisId":"20260321T005657-677edf52","recordedAt":"2026-03-21T00:57:01.104Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00497614","NCT00837434","NCT00603993","NCT00650156","NCT02640612"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:02.677Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::brigatinib::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:25.971Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::cetuximab::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:10:00.638Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::amivantamab::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:27.798Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::crizotinib::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:26.322Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::alectinib::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01871805","NCT05014464","NCT03535740","NCT06765109","NCT05525338"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:27.447Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:27.518Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::afatinib::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:27.868Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:06:28.298Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:06:28.648Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T003455-78e027ed::repotrectinib::non-small_cell_lung_cancer","analysisId":"20260321T003455-78e027ed","recordedAt":"2026-03-21T00:34:57.999Z","drug":"REPOTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06140836","NCT04772235","NCT06315010","NCT03093116","NCT06552234"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2017-03-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:20.232Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T001753-bf3608f6::neratinib::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:19.832Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260321T001753-bf3608f6::lapatinib::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01591577","NCT02101905","NCT00107003","NCT04135807","NCT00095940"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:25.269Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T001753-bf3608f6::vandetanib::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00995007","NCT00821080","NCT00441142","NCT00613223","NCT00613054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:24.738Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T001753-bf3608f6::gefitinib::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00014170","NCT00042991","NCT00085566","NCT00238797","NCT00132158"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:24.224Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T001753-bf3608f6::erlotinib::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01257594","NCT00039494","NCT00525525","NCT00301418","NCT00671970"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:23.874Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T001753-bf3608f6::afatinib_dimaleate::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00977431","NCT00727506","NCT00875433","NCT05432518","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:23.367Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T001753-bf3608f6::afatinib::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00977431","NCT00727506","NCT00875433","NCT05432518","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:22.824Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T001753-bf3608f6::sunitinib::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00606008","NCT03025893","NCT01100177","NCT03275558","NCT00864864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:22.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T001753-bf3608f6::cetuximab::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02800486","NCT01238237","NCT05929456","NCT00463073","NCT01884740"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:21.246Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260321T001753-bf3608f6::regorafenib::glioblastoma","analysisId":"20260321T001753-bf3608f6","recordedAt":"2026-03-21T00:17:55.739Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06047379","NCT06095375","NCT03970447","NCT05759195","NCT02926222"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:21.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222558-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T222558-33db16bd","recordedAt":"2026-03-20T22:25:58.589Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:18.874Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222558-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T222558-33db16bd","recordedAt":"2026-03-20T22:25:58.589Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:19.575Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222558-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T222558-33db16bd","recordedAt":"2026-03-20T22:25:58.589Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:19.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222558-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T222558-33db16bd","recordedAt":"2026-03-20T22:25:58.589Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:20.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222558-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T222558-33db16bd","recordedAt":"2026-03-20T22:25:58.589Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:19.450Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T222342-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:18.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T222342-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:16.069Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222342-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:18.522Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222342-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:17.820Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222342-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:06:16.419Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222342-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:06:15.718Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222342-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:18.570Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T222342-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:18.171Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222342-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:18.923Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T222342-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T222342-99db93fe","recordedAt":"2026-03-20T22:23:42.287Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:19.278Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T222100-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:54.635Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:54.985Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:55.686Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:56.036Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:02:56.386Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:56.737Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:57.088Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:55.336Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:57.439Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T222100-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T222100-557c91d1","recordedAt":"2026-03-20T22:21:00.565Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:06:15.017Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:54.284Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:17.861Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T221846-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:53.934Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:53.583Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:51.127Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:51.477Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T23:02:52.178Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:52.529Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:52.879Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221846-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T221846-5b7100d5","recordedAt":"2026-03-20T22:18:46.875Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:17.670Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T221610-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T221610-c46e28d2","recordedAt":"2026-03-20T22:16:12.049Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:50.424Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221610-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T221610-c46e28d2","recordedAt":"2026-03-20T22:16:12.049Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:50.072Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221610-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T221610-c46e28d2","recordedAt":"2026-03-20T22:16:12.049Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:49.722Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221610-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T221610-c46e28d2","recordedAt":"2026-03-20T22:16:12.049Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:49.371Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221610-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T221610-c46e28d2","recordedAt":"2026-03-20T22:16:12.049Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:49.020Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221610-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T221610-c46e28d2","recordedAt":"2026-03-20T22:16:12.049Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:48.670Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221610-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T221610-c46e28d2","recordedAt":"2026-03-20T22:16:12.049Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:48.319Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T221610-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T221610-c46e28d2","recordedAt":"2026-03-20T22:16:12.049Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:50.775Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T191028-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T191028-33db16bd","recordedAt":"2026-03-20T19:10:28.126Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:17.151Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T191028-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T191028-33db16bd","recordedAt":"2026-03-20T19:10:28.126Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:56.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T191028-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T191028-33db16bd","recordedAt":"2026-03-20T19:10:28.126Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:47.267Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T191028-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T191028-33db16bd","recordedAt":"2026-03-20T19:10:28.126Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:47.618Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T191028-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T191028-33db16bd","recordedAt":"2026-03-20T19:10:28.126Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T23:02:47.968Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190817-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:55.684Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190817-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:55.333Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190817-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T22:28:53.931Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190817-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T22:28:53.230Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190817-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:53.580Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190817-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:16.603Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T190817-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:56.035Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190817-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:16.409Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T190817-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:16.798Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T190817-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T190817-99db93fe","recordedAt":"2026-03-20T19:08:17.154Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:16.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T190548-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:50.779Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T22:28:51.129Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:51.480Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:52.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:52.179Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:49.771Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:51.830Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:48.838Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:49.318Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190548-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T190548-557c91d1","recordedAt":"2026-03-20T19:05:48.952Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:50.341Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190327-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:43:02.939Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190327-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:48.343Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190327-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-27T11:52:15.033Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T190327-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:15.232Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T190327-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:47.394Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190327-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:47.846Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190327-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:45.866Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190327-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T22:28:46.341Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190327-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T22:28:45.421Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190327-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T190327-5b7100d5","recordedAt":"2026-03-20T19:03:27.261Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:43:02.462Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190114-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T190114-c46e28d2","recordedAt":"2026-03-20T19:01:15.461Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:58.647Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190114-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T190114-c46e28d2","recordedAt":"2026-03-20T19:01:15.461Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:43:00.600Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190114-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T190114-c46e28d2","recordedAt":"2026-03-20T19:01:15.461Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:43:00.050Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190114-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T190114-c46e28d2","recordedAt":"2026-03-20T19:01:15.461Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:59.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190114-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T190114-c46e28d2","recordedAt":"2026-03-20T19:01:15.461Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:59.095Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190114-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T190114-c46e28d2","recordedAt":"2026-03-20T19:01:15.461Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:43:01.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190114-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T190114-c46e28d2","recordedAt":"2026-03-20T19:01:15.461Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:43:01.515Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T190114-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T190114-c46e28d2","recordedAt":"2026-03-20T19:01:15.461Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:43:01.060Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T180022-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T180022-33db16bd","recordedAt":"2026-03-20T18:00:22.797Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:58.179Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T180022-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T180022-33db16bd","recordedAt":"2026-03-20T18:00:22.797Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:57.683Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T180022-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T180022-33db16bd","recordedAt":"2026-03-20T18:00:22.797Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:57.218Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T180022-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T180022-33db16bd","recordedAt":"2026-03-20T18:00:22.797Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:56.232Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T180022-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T180022-33db16bd","recordedAt":"2026-03-20T18:00:22.797Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-27T11:52:14.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T175758-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:13.205Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T175758-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:55.301Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175758-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:52.373Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175758-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T21:42:51.930Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175758-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T21:42:52.851Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175758-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:54.838Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175758-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:55.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175758-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:13.562Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T175758-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:13.917Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T175758-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T175758-99db93fe","recordedAt":"2026-03-20T17:57:58.569Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:14.272Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T175555-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:40:02.163Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T21:42:49.092Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:49.621Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:50.138Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:51.059Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:40:01.813Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T21:42:50.598Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:40:01.112Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:40:01.462Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175555-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T175555-557c91d1","recordedAt":"2026-03-20T17:55:55.449Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:40:02.514Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175333-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:40:00.761Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175333-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T20:39:58.658Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175333-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:57.870Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175333-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:57.520Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175333-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:59.008Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175333-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:40:00.061Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175333-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:40:00.410Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175333-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:12.492Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T175333-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:12.848Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T175333-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T175333-5b7100d5","recordedAt":"2026-03-20T17:53:33.469Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:59.359Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175116-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T175116-c46e28d2","recordedAt":"2026-03-20T17:51:18.021Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:55.539Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175116-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T175116-c46e28d2","recordedAt":"2026-03-20T17:51:18.021Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:56.467Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175116-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T175116-c46e28d2","recordedAt":"2026-03-20T17:51:18.021Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:57.168Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175116-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T175116-c46e28d2","recordedAt":"2026-03-20T17:51:18.021Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:56.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175116-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T175116-c46e28d2","recordedAt":"2026-03-20T17:51:18.021Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:54.117Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175116-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T175116-c46e28d2","recordedAt":"2026-03-20T17:51:18.021Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:54.617Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175116-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T175116-c46e28d2","recordedAt":"2026-03-20T17:51:18.021Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:55.083Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T175116-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T175116-c46e28d2","recordedAt":"2026-03-20T17:51:18.021Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:55.997Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T162103-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T162103-33db16bd","recordedAt":"2026-03-20T16:21:03.571Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:52.770Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T162103-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T162103-33db16bd","recordedAt":"2026-03-20T16:21:03.571Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:12.137Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T162103-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T162103-33db16bd","recordedAt":"2026-03-20T16:21:03.571Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:53.668Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T162103-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T162103-33db16bd","recordedAt":"2026-03-20T16:21:03.571Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:53.222Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T162103-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T162103-33db16bd","recordedAt":"2026-03-20T16:21:03.571Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:51.845Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161836-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:11.426Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T161836-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:11.069Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T161836-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:11.782Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T161836-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:36:08.186Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161836-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:51.256Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161836-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:39:50.742Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161836-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:36:13.215Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161836-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T20:36:09.040Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161836-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T20:36:07.576Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161836-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T161836-99db93fe","recordedAt":"2026-03-20T16:18:36.209Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:10.714Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T161615-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:36:03.703Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:52.986Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:36:02.876Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:36:01.983Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T20:35:59.642Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:59.154Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:55.459Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:57.988Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:54.657Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161615-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T161615-557c91d1","recordedAt":"2026-03-20T16:16:15.833Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:36:06.137Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161338-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:50.708Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161338-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:10.359Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T161338-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:39.835Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161338-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:51.535Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161338-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:48.277Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161338-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:46.586Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161338-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T20:35:46.073Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161338-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:41.368Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161338-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:10.003Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T161338-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T161338-5b7100d5","recordedAt":"2026-03-20T16:13:38.479Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:50.028Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161123-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T161123-c46e28d2","recordedAt":"2026-03-20T16:11:25.128Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:21.056Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161123-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T161123-c46e28d2","recordedAt":"2026-03-20T16:11:25.128Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:39.082Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161123-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T161123-c46e28d2","recordedAt":"2026-03-20T16:11:25.128Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:19.304Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161123-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T161123-c46e28d2","recordedAt":"2026-03-20T16:11:25.128Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:19.654Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161123-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T161123-c46e28d2","recordedAt":"2026-03-20T16:11:25.128Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:20.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161123-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T161123-c46e28d2","recordedAt":"2026-03-20T16:11:25.128Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:20.355Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161123-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T161123-c46e28d2","recordedAt":"2026-03-20T16:11:25.128Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:20.705Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T161123-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T161123-c46e28d2","recordedAt":"2026-03-20T16:11:25.128Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T20:35:35.426Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151411-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T151411-33db16bd","recordedAt":"2026-03-20T15:14:11.593Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:18.252Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151411-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T151411-33db16bd","recordedAt":"2026-03-20T15:14:11.593Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:18.953Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151411-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T151411-33db16bd","recordedAt":"2026-03-20T15:14:11.593Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:18.602Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151411-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T151411-33db16bd","recordedAt":"2026-03-20T15:14:11.593Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:17.551Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151411-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T151411-33db16bd","recordedAt":"2026-03-20T15:14:11.593Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:09.647Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T151200-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:08.223Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T151200-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T19:50:14.395Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151200-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:14.746Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151200-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T19:50:15.096Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151200-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:09.291Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T151200-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:08.935Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T151200-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:08.580Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T151200-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:16.499Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151200-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:16.849Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T151200-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T151200-99db93fe","recordedAt":"2026-03-20T15:12:00.492Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:17.200Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:13.343Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:13.694Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:11.942Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:11.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:10.887Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:04.380Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T19:50:12.292Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:12.643Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:12.993Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150932-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T150932-557c91d1","recordedAt":"2026-03-20T15:09:32.894Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:50:11.239Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:00.872Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:01.222Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:04.029Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:02.627Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T19:05:01.924Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:07.869Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T150656-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:03.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:03.328Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:02.275Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150656-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T150656-5b7100d5","recordedAt":"2026-03-20T15:06:56.541Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:07.514Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T150412-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T150412-c46e28d2","recordedAt":"2026-03-20T15:04:14.094Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:58.770Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150412-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T150412-c46e28d2","recordedAt":"2026-03-20T15:04:14.094Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:00.522Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150412-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T150412-c46e28d2","recordedAt":"2026-03-20T15:04:14.094Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:05:00.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150412-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T150412-c46e28d2","recordedAt":"2026-03-20T15:04:14.094Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:59.822Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150412-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T150412-c46e28d2","recordedAt":"2026-03-20T15:04:14.094Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:59.471Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150412-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T150412-c46e28d2","recordedAt":"2026-03-20T15:04:14.094Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:59.120Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150412-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T150412-c46e28d2","recordedAt":"2026-03-20T15:04:14.094Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:58.420Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T150412-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T150412-c46e28d2","recordedAt":"2026-03-20T15:04:14.094Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:58.070Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134638-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T134638-33db16bd","recordedAt":"2026-03-20T13:46:38.243Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:57.720Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134638-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T134638-33db16bd","recordedAt":"2026-03-20T13:46:38.243Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:07.159Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T134638-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T134638-33db16bd","recordedAt":"2026-03-20T13:46:38.243Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:57.369Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134638-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T134638-33db16bd","recordedAt":"2026-03-20T13:46:38.243Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:57.018Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134638-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T134638-33db16bd","recordedAt":"2026-03-20T13:46:38.243Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:56.317Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134413-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:06.804Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T134413-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:55.615Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134413-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:55.265Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134413-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T19:01:22.228Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134413-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T19:01:21.512Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134413-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:21.877Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134413-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:06.093Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T134413-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:06.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T134413-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:04:55.965Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134413-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T134413-99db93fe","recordedAt":"2026-03-20T13:44:13.706Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:05.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T134159-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:19.443Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T19:01:19.794Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:20.144Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:18.742Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:20.765Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:21.115Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:18.391Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:18.042Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:20.494Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T134159-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T134159-c6b7ce28","recordedAt":"2026-03-20T13:41:59.783Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:19.092Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133942-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T19:01:15.587Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133942-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:17.691Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133942-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:16.288Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133942-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:15.937Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133942-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:14.885Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133942-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:14.535Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133942-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:05.383Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T133942-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:05.024Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T133942-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:17.340Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133942-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T133942-5b7100d5","recordedAt":"2026-03-20T13:39:42.381Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:16.989Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133736-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T133736-c46e28d2","recordedAt":"2026-03-20T13:37:37.878Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:12.432Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133736-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T133736-c46e28d2","recordedAt":"2026-03-20T13:37:37.878Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:12.081Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133736-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T133736-c46e28d2","recordedAt":"2026-03-20T13:37:37.878Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:11.731Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133736-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T133736-c46e28d2","recordedAt":"2026-03-20T13:37:37.878Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:14.184Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133736-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T133736-c46e28d2","recordedAt":"2026-03-20T13:37:37.878Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:13.834Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133736-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T133736-c46e28d2","recordedAt":"2026-03-20T13:37:37.878Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:13.484Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133736-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T133736-c46e28d2","recordedAt":"2026-03-20T13:37:37.878Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:13.133Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T133736-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T133736-c46e28d2","recordedAt":"2026-03-20T13:37:37.878Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:12.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T123131-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T123131-33db16bd","recordedAt":"2026-03-20T12:31:31.454Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:11.380Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T123131-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T123131-33db16bd","recordedAt":"2026-03-20T12:31:31.454Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:10.680Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T123131-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T123131-33db16bd","recordedAt":"2026-03-20T12:31:31.454Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T19:01:11.031Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T123131-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T123131-33db16bd","recordedAt":"2026-03-20T12:31:31.454Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:44.640Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T123131-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T123131-33db16bd","recordedAt":"2026-03-20T12:31:31.454Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:04.665Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T122848-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:03.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T122848-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:03.953Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T122848-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:43.939Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122848-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T02:35:41.487Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122848-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T02:35:42.188Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122848-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:43.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122848-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:44.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122848-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:41.837Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122848-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:04.309Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T122848-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T122848-99db93fe","recordedAt":"2026-03-20T12:28:48.485Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:03.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T122621-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:39.033Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:40.084Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:39.734Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T02:35:39.384Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:38.682Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:37.980Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:37.629Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:40.785Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:40.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122621-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T122621-c6b7ce28","recordedAt":"2026-03-20T12:26:21.710Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:38.332Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122338-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:35.732Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122338-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:34.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122338-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:34.681Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122338-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:36.578Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122338-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:36.929Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122338-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:02.884Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T122338-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:02.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T122338-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T02:35:35.382Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122338-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:36.082Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122338-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T122338-5b7100d5","recordedAt":"2026-03-20T12:23:38.758Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:37.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122122-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T122122-c46e28d2","recordedAt":"2026-03-20T12:21:23.629Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:31.525Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122122-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T122122-c46e28d2","recordedAt":"2026-03-20T12:21:23.629Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:31.876Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122122-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T122122-c46e28d2","recordedAt":"2026-03-20T12:21:23.629Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:32.226Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122122-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T122122-c46e28d2","recordedAt":"2026-03-20T12:21:23.629Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:32.577Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122122-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T122122-c46e28d2","recordedAt":"2026-03-20T12:21:23.629Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:32.927Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122122-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T122122-c46e28d2","recordedAt":"2026-03-20T12:21:23.629Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:33.279Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122122-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T122122-c46e28d2","recordedAt":"2026-03-20T12:21:23.629Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:33.629Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T122122-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T122122-c46e28d2","recordedAt":"2026-03-20T12:21:23.629Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:33.980Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T110031-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T110031-33db16bd","recordedAt":"2026-03-20T11:00:31.099Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:30.824Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T110031-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T110031-33db16bd","recordedAt":"2026-03-20T11:00:31.099Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:02.174Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T110031-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T110031-33db16bd","recordedAt":"2026-03-20T11:00:31.099Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:29.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T110031-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T110031-33db16bd","recordedAt":"2026-03-20T11:00:31.099Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:30.473Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T110031-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T110031-33db16bd","recordedAt":"2026-03-20T11:00:31.099Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:31.175Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105807-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:28.721Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105807-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:26.968Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105807-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T02:35:26.618Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105807-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T02:35:27.318Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105807-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:29.071Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105807-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:29.422Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105807-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:01.463Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T105807-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:01.818Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T105807-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:01.107Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T105807-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T105807-99db93fe","recordedAt":"2026-03-20T10:58:07.849Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:00.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T105543-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:30.028Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T02:35:25.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:32.132Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:29.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:29.327Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:30.729Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:30.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:31.781Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:31.430Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105543-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T105543-c6b7ce28","recordedAt":"2026-03-20T10:55:43.346Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T01:43:31.080Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T01:43:26.874Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:25.822Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:28.276Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:26:00.394Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T105303-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:28.626Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:28.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:27.575Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:27.225Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:26.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105303-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T105303-5b7100d5","recordedAt":"2026-03-20T10:53:03.563Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:26:00.034Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T105044-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T105044-c46e28d2","recordedAt":"2026-03-20T10:50:45.791Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:23.369Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105044-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T105044-c46e28d2","recordedAt":"2026-03-20T10:50:45.791Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:23.018Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105044-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T105044-c46e28d2","recordedAt":"2026-03-20T10:50:45.791Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:25.472Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105044-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T105044-c46e28d2","recordedAt":"2026-03-20T10:50:45.791Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:25.121Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105044-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T105044-c46e28d2","recordedAt":"2026-03-20T10:50:45.791Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:24.771Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105044-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T105044-c46e28d2","recordedAt":"2026-03-20T10:50:45.791Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:24.421Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105044-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T105044-c46e28d2","recordedAt":"2026-03-20T10:50:45.791Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:24.070Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T105044-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T105044-c46e28d2","recordedAt":"2026-03-20T10:50:45.791Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:23.720Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075854-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T075854-33db16bd","recordedAt":"2026-03-20T07:58:54.736Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:22.668Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075854-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T075854-33db16bd","recordedAt":"2026-03-20T07:58:54.736Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:21.967Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075854-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T075854-33db16bd","recordedAt":"2026-03-20T07:58:54.736Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:43:22.317Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075854-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T075854-33db16bd","recordedAt":"2026-03-20T07:58:54.736Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:56.977Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075854-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T075854-33db16bd","recordedAt":"2026-03-20T07:58:54.736Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:25:59.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T075640-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:25:58.558Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T075640-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:25:58.157Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T075640-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:54.173Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075640-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:25:59.322Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T075640-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:55.926Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075640-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:56.627Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075640-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:56.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075640-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:25:58.915Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T075640-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T01:32:54.524Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075640-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T075640-99db93fe","recordedAt":"2026-03-20T07:56:40.830Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T01:32:53.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T01:32:51.718Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:51.017Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:50.317Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:49.966Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:50.666Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:52.770Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:53.121Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:52.420Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:52.069Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075422-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T075422-c6b7ce28","recordedAt":"2026-03-20T07:54:22.273Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:51.368Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:25:57.350Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T075203-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:49.265Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:48.915Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:49.616Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:48.214Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T01:32:47.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T01:32:47.513Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:23:00.511Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:23:00.161Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T075203-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T075203-5b7100d5","recordedAt":"2026-03-20T07:52:03.054Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:25:57.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T074927-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T074927-c46e28d2","recordedAt":"2026-03-20T07:49:28.759Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:59.811Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T074927-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T074927-c46e28d2","recordedAt":"2026-03-20T07:49:28.759Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:57.708Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T074927-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T074927-c46e28d2","recordedAt":"2026-03-20T07:49:28.759Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:58.059Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T074927-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T074927-c46e28d2","recordedAt":"2026-03-20T07:49:28.759Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:58.409Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T074927-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T074927-c46e28d2","recordedAt":"2026-03-20T07:49:28.759Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:58.760Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T074927-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T074927-c46e28d2","recordedAt":"2026-03-20T07:49:28.759Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:59.460Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T074927-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T074927-c46e28d2","recordedAt":"2026-03-20T07:49:28.759Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:59.110Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T074927-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T074927-c46e28d2","recordedAt":"2026-03-20T07:49:28.759Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:57.357Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045419-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T045419-33db16bd","recordedAt":"2026-03-20T04:54:19.997Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:57.007Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045419-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T045419-33db16bd","recordedAt":"2026-03-20T04:54:19.997Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:56.656Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045419-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T045419-33db16bd","recordedAt":"2026-03-20T04:54:19.997Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T19:25:56.956Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T045419-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T045419-33db16bd","recordedAt":"2026-03-20T04:54:19.997Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:56.306Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045419-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T045419-33db16bd","recordedAt":"2026-03-20T04:54:19.997Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:55.605Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045159-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:55.255Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045159-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:12.741Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T045159-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T00:22:53.153Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045159-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:54.554Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045159-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T00:22:52.451Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045159-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:52.802Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045159-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:54.904Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T045159-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:12.386Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T045159-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:13.095Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T045159-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T045159-99db93fe","recordedAt":"2026-03-20T04:51:59.823Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T19:25:56.543Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T044942-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:51.401Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:28.341Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:51.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:27.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:50.700Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T00:22:50.350Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:29.042Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:28.692Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:27.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044942-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T044942-c6b7ce28","recordedAt":"2026-03-20T04:49:42.157Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:22:51.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:26.939Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:11.675Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T044720-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:26.589Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:27.291Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:25.887Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:25.536Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-28T00:05:25.097Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:24.231Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:23.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044720-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T044720-5b7100d5","recordedAt":"2026-03-20T04:47:20.446Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:12.030Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T044458-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T044458-c46e28d2","recordedAt":"2026-03-20T04:44:59.867Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:20.877Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044458-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T044458-c46e28d2","recordedAt":"2026-03-20T04:44:59.867Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:20.409Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044458-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T044458-c46e28d2","recordedAt":"2026-03-20T04:44:59.867Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:19.955Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044458-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T044458-c46e28d2","recordedAt":"2026-03-20T04:44:59.867Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:23.314Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044458-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T044458-c46e28d2","recordedAt":"2026-03-20T04:44:59.867Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:22.802Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044458-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T044458-c46e28d2","recordedAt":"2026-03-20T04:44:59.867Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:22.365Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044458-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T044458-c46e28d2","recordedAt":"2026-03-20T04:44:59.867Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:21.898Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T044458-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T044458-c46e28d2","recordedAt":"2026-03-20T04:44:59.867Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:21.347Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033351-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T033351-33db16bd","recordedAt":"2026-03-20T03:33:51.195Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:19.514Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033351-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T033351-33db16bd","recordedAt":"2026-03-20T03:33:51.195Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:19.067Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033351-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T033351-33db16bd","recordedAt":"2026-03-20T03:33:51.195Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:18.628Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033351-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T033351-33db16bd","recordedAt":"2026-03-20T03:33:51.195Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:17.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033351-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T033351-33db16bd","recordedAt":"2026-03-20T03:33:51.195Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:11.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T033133-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:16.836Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033133-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:10.966Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T033133-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:10.610Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T033133-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:43:03.715Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033133-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:43:04.574Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033133-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:10.254Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T033133-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:43:04.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033133-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-28T00:05:17.300Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033133-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:43:06.314Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T033133-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T033133-99db93fe","recordedAt":"2026-03-20T03:31:33.423Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:09.899Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T032852-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:43:00.570Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:43:02.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:42:59.623Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:43:01.943Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:43:01.477Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:43:01.007Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:43:02.844Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:43:00.133Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:42:59.181Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032852-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T032852-c6b7ce28","recordedAt":"2026-03-20T03:28:52.414Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:42:58.727Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032628-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:09.544Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T032628-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:09.190Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T032628-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01896856","NCT02310477","NCT02316340","NCT02656524","NCT02465502"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:05.607Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032628-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:03:06.895Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032628-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06640166","NCT01436656","NCT05743036","NCT03803553","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:06.034Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032628-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:42:57.797Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032628-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:42:56.441Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032628-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:42:58.264Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032628-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:07.332Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032628-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T032628-5b7100d5","recordedAt":"2026-03-20T03:26:28.795Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:42:57.352Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032403-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T032403-c46e28d2","recordedAt":"2026-03-20T03:24:04.359Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04655183","NCT04178460","NCT05238831","NCT04240106","NCT04641247"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:02.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032403-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T032403-c46e28d2","recordedAt":"2026-03-20T03:24:04.359Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00544765","NCT06533722","NCT05856383","NCT00146549","NCT00140140"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:05.180Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032403-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T032403-c46e28d2","recordedAt":"2026-03-20T03:24:04.359Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003016","NCT01249456","NCT02313051","NCT06548919","NCT00002967"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:04.751Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032403-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T032403-c46e28d2","recordedAt":"2026-03-20T03:24:04.359Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00070564","NCT06135493","NCT01320111","NCT00656669","NCT02672475"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:04.315Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032403-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T032403-c46e28d2","recordedAt":"2026-03-20T03:24:04.359Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02953184","NCT06291064","NCT00093834","NCT00070564","NCT01569087"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:03.879Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032403-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T032403-c46e28d2","recordedAt":"2026-03-20T03:24:04.359Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04987931","NCT03911973","NCT04755868","NCT04550494","NCT03343054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:03.451Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032403-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T032403-c46e28d2","recordedAt":"2026-03-20T03:24:04.359Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT02505048","NCT03992131","NCT03542175","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:03.020Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T032403-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T032403-c46e28d2","recordedAt":"2026-03-20T03:24:04.359Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06298084","NCT05900895","NCT05340413","NCT06130254","NCT03205761"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:02.159Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021441-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T021441-33db16bd","recordedAt":"2026-03-20T02:14:41.873Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00236574","NCT00297362","NCT00551161","NCT00369603","NCT01009476"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:01.302Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021441-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T021441-33db16bd","recordedAt":"2026-03-20T02:14:41.873Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT02782975","NCT05310071","NCT01397539"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:02:59.949Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021441-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T021441-33db16bd","recordedAt":"2026-03-20T02:14:41.873Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02860065","NCT06840054","NCT01125683","NCT03221894","NCT00165724"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:00.872Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021441-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T021441-33db16bd","recordedAt":"2026-03-20T02:14:41.873Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00551161","NCT00219232","NCT05102045","NCT01047579","NCT01677754"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:03:01.729Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021441-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T021441-33db16bd","recordedAt":"2026-03-20T02:14:41.873Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:08.835Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T021220-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:07.415Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T021220-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:07.770Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T021220-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:02:58.642Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021220-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T17:14:49.668Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021220-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T17:14:48.825Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021220-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT02476955","NCT06297811","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:02:59.077Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021220-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT06739395","NCT03238196","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T23:02:59.508Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021220-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:08.480Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T021220-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:49.247Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T021220-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T021220-99db93fe","recordedAt":"2026-03-20T02:12:20.243Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:08.126Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T020954-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03531762","NCT03492437","NCT06083857","NCT02864992","NCT06031688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:46.716Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT02716116","NCT05207423","NCT04535557"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:45.864Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04926831","NCT05435846","NCT04460729","NCT05642572","NCT01911507"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:45.441Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02568267","NCT04317651","NCT01871805","NCT05014464","NCT02824094"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:44.590Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03535740","NCT01449461","NCT04322890","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:44.159Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04965090","NCT05663866","NCT05241873"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:45.014Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00203931","NCT00406302"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:47.563Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06268210","NCT04965090","NCT04248829","NCT05663866"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:47.986Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02795156","NCT02208843","NCT02424617","NCT03370770","NCT04179890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:47.138Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020954-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T020954-c6b7ce28","recordedAt":"2026-03-20T02:09:54.226Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T17:14:46.291Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020738-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00308516","NCT04737187","NCT02271464","NCT04761614"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:42.889Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020738-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:06.651Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T020738-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:07.060Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T020738-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02560298","NCT02935309","NCT02271464","NCT04833387"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:43.315Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020738-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT00614393","NCT05019534","NCT01380262","NCT00784667"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:43.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020738-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01471353","NCT00989469","NCT01376453","NCT00826540","NCT00780169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:42.049Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020738-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT01287130","NCT02450656","NCT02586987","NCT01217450"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-27T17:14:41.629Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020738-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T17:14:41.208Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020738-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT01436656","NCT03693170","NCT05217446","NCT04800822"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:45.026Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020738-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T020738-5b7100d5","recordedAt":"2026-03-20T02:07:38.862Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05900648","NCT04503694","NCT05942768","NCT04996355","NCT01538680"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:44.589Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020514-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T020514-c46e28d2","recordedAt":"2026-03-20T02:05:15.301Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04837209","NCT03154281","NCT03329937","NCT05169437","NCT05232006"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:41.554Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020514-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T020514-c46e28d2","recordedAt":"2026-03-20T02:05:15.301Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00516724","NCT02498613","NCT03931551","NCT04191135","NCT02684318"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:41.128Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020514-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T020514-c46e28d2","recordedAt":"2026-03-20T02:05:15.301Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02040857","NCT00295100","NCT01192308","NCT03541863","NCT03065621"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:43.717Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020514-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T020514-c46e28d2","recordedAt":"2026-03-20T02:05:15.301Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00068757","NCT05840211","NCT05555706","NCT06942234","NCT00629499"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:43.286Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020514-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T020514-c46e28d2","recordedAt":"2026-03-20T02:05:15.301Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00309920","NCT02229084","NCT01415336","NCT01378533","NCT00331552"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:42.847Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020514-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T020514-c46e28d2","recordedAt":"2026-03-20T02:05:15.301Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04134884","NCT05141708","NCT02034916","NCT04591431","NCT03911973"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:42.416Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020514-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T020514-c46e28d2","recordedAt":"2026-03-20T02:05:15.301Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06230055","NCT05901935","NCT03541863","NCT00480597","NCT02628613"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:44.161Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T020514-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T020514-c46e28d2","recordedAt":"2026-03-20T02:05:15.301Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04171700","NCT02505048","NCT03542175","NCT03840200","NCT03911453"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:41.985Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005545-33db16bd::galantamine::alzheimers_disease","analysisId":"20260320T005545-33db16bd","recordedAt":"2026-03-20T00:55:45.843Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00291421","NCT03454646","NCT00253214","NCT00338117","NCT00216593"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:40.251Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005545-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260320T005545-33db16bd","recordedAt":"2026-03-20T00:55:45.843Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05108922","NCT04241068","NCT02477800","NCT01677572","NCT05469009"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:38.962Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005545-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260320T005545-33db16bd","recordedAt":"2026-03-20T00:55:45.843Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00291421","NCT00622713","NCT01025466","NCT00104442","NCT03454646"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:40.683Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005545-33db16bd::donepezil::alzheimers_disease","analysisId":"20260320T005545-33db16bd","recordedAt":"2026-03-20T00:55:45.843Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01972204","NCT00291421","NCT00467766","NCT00165659","NCT04661280"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:39.820Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005545-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260320T005545-33db16bd","recordedAt":"2026-03-20T00:55:45.843Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:06.272Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T005335-99db93fe::temozolomide::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:05.500Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T005335-99db93fe::vemurafenib::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T21:22:37.474Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005335-99db93fe::sapanisertib::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-26T20:43:35.926Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005335-99db93fe::sirolimus::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:37.648Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005335-99db93fe::carboplatin::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT03989336","NCT02476955","NCT06297811","NCT06333314"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:38.072Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005335-99db93fe::palbociclib::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT06126276","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:38.537Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005335-99db93fe::panitumumab::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:04.729Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T005335-99db93fe::paclitaxel::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:37:05.116Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T005335-99db93fe::gemcitabine::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:37:05.883Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T005335-99db93fe::cetuximab::pan-cancer","analysisId":"20260320T005335-99db93fe","recordedAt":"2026-03-20T00:53:35.410Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06607185","NCT01816984","NCT06585488"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-26T20:43:35.499Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005116-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05388669","NCT05326425","NCT04248829","NCT02609776","NCT04965090"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-11-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:30.912Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T005116-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04576208","NCT04051827","NCT04535557","NCT02716116","NCT05207423"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:34.311Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005116-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T21:22:34.736Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005116-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04591431","NCT06106802","NCT06908993","NCT02864992","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:35.201Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005116-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01828112","NCT06140836","NCT02277457","NCT03737994","NCT04317651"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:32.964Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005116-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04591431","NCT04074993","NCT04592523","NCT03737994","NCT03389399"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:32.516Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005116-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05642572","NCT04575025","NCT02414139","NCT02750215","NCT03240393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:33.874Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005116-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04750824","NCT03827070","NCT04356118","NCT05445791"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:35.642Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T005116-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05395052"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-05-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:31.268Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T005116-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260320T005116-c6b7ce28","recordedAt":"2026-03-20T00:51:16.504Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:30.557Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T004904-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04215731","NCT00444041","NCT05945901","NCT06415851"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:31.218Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004904-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:29.847Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T004904-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02830139","NCT04215731","NCT04418895","NCT02641691"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:31.643Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004904-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06207656","NCT05725200","NCT05004350","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:27.852Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004904-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02287025","NCT02465502","NCT05485909","NCT06543836"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:27.418Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004904-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T21:22:28.706Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004904-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT02188264","NCT01134601","NCT01287130","NCT02450656"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:29.130Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004904-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT00839111","NCT00869570","NCT00703638","NCT03251612"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:29.624Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004904-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:29.493Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T004904-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260320T004904-5b7100d5","recordedAt":"2026-03-20T00:49:04.338Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:30.202Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T004646-c46e28d2::olaparib::breast_cancer","analysisId":"20260320T004646-c46e28d2","recordedAt":"2026-03-20T00:46:48.073Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03742245","NCT04053322","NCT04024254","NCT05238831","NCT03685331"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:10.907Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004646-c46e28d2::niraparib::breast_cancer","analysisId":"20260320T004646-c46e28d2","recordedAt":"2026-03-20T00:46:48.073Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:29.138Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260320T004646-c46e28d2::rucaparib::breast_cancer","analysisId":"20260320T004646-c46e28d2","recordedAt":"2026-03-20T00:46:48.073Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03101280","NCT03992131","NCT03542175","NCT04171700","NCT02505048"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:11.778Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004646-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260320T004646-c46e28d2","recordedAt":"2026-03-20T00:46:48.073Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00075673","NCT04605575","NCT00022152","NCT00503750","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:22:26.987Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004646-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260320T004646-c46e28d2","recordedAt":"2026-03-20T00:46:48.073Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06548919","NCT00543829","NCT01196936","NCT00003972","NCT06346457"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:13.779Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004646-c46e28d2::talazoparib::breast_cancer","analysisId":"20260320T004646-c46e28d2","recordedAt":"2026-03-20T00:46:48.073Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05141708","NCT04591431","NCT02034916","NCT02282345","NCT03990896"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:12.204Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004646-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260320T004646-c46e28d2","recordedAt":"2026-03-20T00:46:48.073Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00146588","NCT01210768","NCT00027989","NCT00346229","NCT06802757"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:12.637Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260320T004646-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260320T004646-c46e28d2","recordedAt":"2026-03-20T00:46:48.073Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:28.741Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260319T235329-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T235329-33db16bd","recordedAt":"2026-03-19T23:53:29.300Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01677572","NCT02484547","NCT01397539","NCT05469009","NCT03639987"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:08.412Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235329-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T235329-33db16bd","recordedAt":"2026-03-19T23:53:29.300Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00299676","NCT00236431","NCT01677754","NCT00297414","NCT00234637"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:10.045Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235329-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T235329-33db16bd","recordedAt":"2026-03-19T23:53:29.300Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:28.385Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T235329-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T235329-33db16bd","recordedAt":"2026-03-19T23:53:29.300Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00134953","NCT00506415","NCT01380288","NCT01677754","NCT01948791"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:10.469Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235329-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T235329-33db16bd","recordedAt":"2026-03-19T23:53:29.300Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05592678","NCT00777608","NCT01039701","NCT05538507","NCT03438604"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:09.624Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235106-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01473095","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:07.116Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235106-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:27.289Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T235106-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T21:07:05.301Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235106-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T21:07:04.456Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235106-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03238196","NCT06126276","NCT06739395","NCT03065387"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:07.981Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235106-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT03989336","NCT05585320","NCT04004234"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:27.676Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T235106-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:26.935Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T235106-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT01816984","NCT06607185"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:04.887Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T235106-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:28.030Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T235106-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T235106-99db93fe","recordedAt":"2026-03-19T23:51:06.964Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06297811","NCT02476955","NCT06333314","NCT06607185","NCT03989336"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T21:07:07.545Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234833-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05388669","NCT05326425","NCT04248829","NCT02609776","NCT04965090"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-11-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:26.580Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T234833-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04591431","NCT06106802","NCT06908993","NCT02864992","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:49.039Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234833-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T17:44:48.657Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234833-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04576208","NCT04051827","NCT04535557","NCT02716116","NCT05207423"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:48.274Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234833-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04591431","NCT04074993","NCT04592523","NCT03737994","NCT03389399"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:46.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234833-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05642572","NCT04575025","NCT02414139","NCT02750215","NCT03240393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:47.887Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234833-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01828112","NCT06140836","NCT02277457","NCT03737994","NCT04317651"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:47.123Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234833-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04750824","NCT03827070","NCT04356118","NCT05445791"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:49.420Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234833-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05395052"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-05-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:25.815Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T234833-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T234833-c6b7ce28","recordedAt":"2026-03-19T23:48:33.077Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:26.174Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T234612-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:25.424Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T234612-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02287025","NCT02465502","NCT05485909","NCT06543836"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:42.957Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234612-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:25.069Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T234612-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T17:44:44.092Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234612-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01116271","NCT02188264","NCT01134601","NCT01287130","NCT02450656"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:44.471Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234612-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT00839111","NCT00869570","NCT00703638","NCT03251612"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:44.849Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234612-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06207656","NCT05725200","NCT05004350","NCT05039177"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:43.335Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234612-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02830139","NCT04215731","NCT04418895","NCT02641691"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:45.986Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234612-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04215731","NCT00444041","NCT05945901","NCT06415851"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:45.603Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234612-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260319T234612-5b7100d5","recordedAt":"2026-03-19T23:46:12.646Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:24.714Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T234354-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T234354-c46e28d2","recordedAt":"2026-03-19T23:43:55.688Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:22.250Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234354-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T234354-c46e28d2","recordedAt":"2026-03-19T23:43:55.688Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:21.866Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234354-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T234354-c46e28d2","recordedAt":"2026-03-19T23:43:55.688Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:21.487Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234354-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T234354-c46e28d2","recordedAt":"2026-03-19T23:43:55.688Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:24.360Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T234354-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T234354-c46e28d2","recordedAt":"2026-03-19T23:43:55.688Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00075673","NCT04605575","NCT00022152","NCT00503750","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:42.575Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234354-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T234354-c46e28d2","recordedAt":"2026-03-19T23:43:55.688Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06548919","NCT00543829","NCT01196936","NCT00003972","NCT06346457"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:42.198Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234354-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T234354-c46e28d2","recordedAt":"2026-03-19T23:43:55.688Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00146588","NCT01210768","NCT00027989","NCT00346229","NCT06802757"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T17:44:41.435Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T234354-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T234354-c46e28d2","recordedAt":"2026-03-19T23:43:55.688Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:24.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260319T223953-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T223953-33db16bd","recordedAt":"2026-03-19T22:39:53.311Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:23.605Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T223953-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T223953-33db16bd","recordedAt":"2026-03-19T22:39:53.311Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:21.106Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223953-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T223953-33db16bd","recordedAt":"2026-03-19T22:39:53.311Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:20.726Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223953-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T223953-33db16bd","recordedAt":"2026-03-19T22:39:53.311Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:20.348Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223953-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T223953-33db16bd","recordedAt":"2026-03-19T22:39:53.311Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:19.590Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223704-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:16.557Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223704-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:19.210Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223704-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:18.831Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223704-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:23.250Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T223704-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T15:25:16.174Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223704-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T15:25:16.933Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223704-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:15.796Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223704-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:22.539Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T223704-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:22.894Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T223704-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T223704-99db93fe","recordedAt":"2026-03-19T22:37:04.522Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:18.451Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T00:49:27.015Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:15.415Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:14.647Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:14.258Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:26.570Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:26.132Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:25.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:24.795Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T15:25:15.033Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223421-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T223421-c6b7ce28","recordedAt":"2026-03-19T22:34:21.101Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:22.183Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T223140-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:21.472Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T223140-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:23.898Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223140-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:23.454Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223140-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:21.828Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T223140-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:22.577Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223140-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:22.130Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223140-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:21.117Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T223140-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-23T00:49:21.531Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223140-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:20.622Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T223140-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260319T223140-17ab599a","recordedAt":"2026-03-19T22:31:40.489Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:20.134Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T222852-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T222852-c46e28d2","recordedAt":"2026-03-19T22:28:53.481Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:19.701Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T222852-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T222852-c46e28d2","recordedAt":"2026-03-19T22:28:53.481Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:18.778Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T222852-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T222852-c46e28d2","recordedAt":"2026-03-19T22:28:53.481Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:18.332Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T222852-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T222852-c46e28d2","recordedAt":"2026-03-19T22:28:53.481Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:17.437Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T222852-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T222852-c46e28d2","recordedAt":"2026-03-19T22:28:53.481Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-23T00:49:16.956Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T222852-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T222852-c46e28d2","recordedAt":"2026-03-19T22:28:53.481Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:37.983Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T222852-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T222852-c46e28d2","recordedAt":"2026-03-19T22:28:53.481Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:20.407Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T222852-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T222852-c46e28d2","recordedAt":"2026-03-19T22:28:53.481Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:20.762Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T212352-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T212352-33db16bd","recordedAt":"2026-03-19T21:23:52.705Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:35.746Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212352-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T212352-33db16bd","recordedAt":"2026-03-19T21:23:52.705Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:37.547Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212352-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T212352-33db16bd","recordedAt":"2026-03-19T21:23:52.705Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:37.115Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212352-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T212352-33db16bd","recordedAt":"2026-03-19T21:23:52.705Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:20.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T212352-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T212352-33db16bd","recordedAt":"2026-03-19T21:23:52.705Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:36.682Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212120-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T23:14:32.645Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212120-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:19.696Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T212120-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:35.317Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212120-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:34.872Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212120-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:34.430Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212120-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T23:14:31.693Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212120-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:31.248Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212120-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:18.986Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T212120-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:32.204Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T212120-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T212120-99db93fe","recordedAt":"2026-03-19T21:21:20.529Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:19.341Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T211834-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:18.628Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T211834-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T23:14:29.044Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211834-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:28.604Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211834-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:28.167Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211834-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:07:01.780Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211834-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:07:01.336Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211834-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:30.803Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211834-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:30.366Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211834-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:29.929Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211834-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T211834-c6b7ce28","recordedAt":"2026-03-19T21:18:34.695Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:14:29.495Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211601-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T23:06:58.197Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211601-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:57.321Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211601-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:56.869Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211601-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:17.919Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T211601-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:18.273Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T211601-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:07:00.403Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211601-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:59.949Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211601-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:59.069Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211601-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:58.638Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211601-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260319T211601-17ab599a","recordedAt":"2026-03-19T21:16:01.199Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:17.563Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T211322-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T211322-c46e28d2","recordedAt":"2026-03-19T21:13:23.232Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:53.587Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211322-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T211322-c46e28d2","recordedAt":"2026-03-19T21:13:23.232Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:17.208Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T211322-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T211322-c46e28d2","recordedAt":"2026-03-19T21:13:23.232Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:53.154Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211322-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T211322-c46e28d2","recordedAt":"2026-03-19T21:13:23.232Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:54.101Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211322-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T211322-c46e28d2","recordedAt":"2026-03-19T21:13:23.232Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:55.023Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211322-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T211322-c46e28d2","recordedAt":"2026-03-19T21:13:23.232Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:16.853Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T211322-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T211322-c46e28d2","recordedAt":"2026-03-19T21:13:23.232Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:55.482Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T211322-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T211322-c46e28d2","recordedAt":"2026-03-19T21:13:23.232Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:56.385Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195726-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T195726-33db16bd","recordedAt":"2026-03-19T19:57:26.114Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:52.242Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195726-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T195726-33db16bd","recordedAt":"2026-03-19T19:57:26.114Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T23:06:52.680Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195726-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T195726-33db16bd","recordedAt":"2026-03-19T19:57:26.114Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:33:01.680Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195726-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T195726-33db16bd","recordedAt":"2026-03-19T19:57:26.114Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:33:02.576Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195726-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T195726-33db16bd","recordedAt":"2026-03-19T19:57:26.114Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:16.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T195444-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:15.675Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T195444-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:15.287Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T195444-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:58.147Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195444-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:57.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195444-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T22:32:57.710Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195444-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:33:00.364Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195444-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T22:32:58.577Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195444-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:33:00.806Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195444-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:33:01.237Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195444-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T195444-99db93fe","recordedAt":"2026-03-19T19:54:44.818Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:16.057Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T195219-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:53.098Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195219-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:56.810Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195219-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:56.354Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195219-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:55.462Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195219-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T22:32:55.006Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195219-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:54.575Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195219-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:14.900Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T195219-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:52.613Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195219-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:55.902Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T195219-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T195219-c6b7ce28","recordedAt":"2026-03-19T19:52:20.013Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:32:54.128Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194931-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:14.499Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T194931-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:55.591Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194931-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:51.958Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194931-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:52.497Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194931-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T22:06:53.364Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194931-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:53.796Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194931-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:54.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194931-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:55.155Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194931-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:14.112Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T194931-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260319T194931-17ab599a","recordedAt":"2026-03-19T19:49:31.675Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:34:13.725Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T194642-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T194642-c46e28d2","recordedAt":"2026-03-19T19:46:44.087Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:43.807Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T194642-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T194642-c46e28d2","recordedAt":"2026-03-19T19:46:44.087Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:34:13.337Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T194642-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T194642-c46e28d2","recordedAt":"2026-03-19T19:46:44.087Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:48.439Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194642-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T194642-c46e28d2","recordedAt":"2026-03-19T19:46:44.087Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:51.522Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194642-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T194642-c46e28d2","recordedAt":"2026-03-19T19:46:44.087Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:50.641Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194642-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T194642-c46e28d2","recordedAt":"2026-03-19T19:46:44.087Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:50.205Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194642-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T194642-c46e28d2","recordedAt":"2026-03-19T19:46:44.087Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:49.338Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T194642-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T194642-c46e28d2","recordedAt":"2026-03-19T19:46:44.087Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:48.882Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:48.669Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:46.887Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:47.325Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:48.221Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:47.533Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T22:06:46.104Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:46.619Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:47.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T22:06:47.980Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184624-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T184624-c6b7ce28","recordedAt":"2026-03-19T18:46:24.559Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:43.452Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T184338-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:42.488Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184338-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:42.390Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T184338-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:46.016Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184338-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:45.559Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184338-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:43.099Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T184338-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:44.690Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184338-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:44.253Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184338-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T21:27:43.813Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184338-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:42.932Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184338-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260319T184338-17ab599a","recordedAt":"2026-03-19T18:43:38.656Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:42.744Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T184052-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T184052-c46e28d2","recordedAt":"2026-03-19T18:40:54.023Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:41.161Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184052-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T184052-c46e28d2","recordedAt":"2026-03-19T18:40:54.023Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:38.992Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184052-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T184052-c46e28d2","recordedAt":"2026-03-19T18:40:54.023Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:39.423Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184052-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T184052-c46e28d2","recordedAt":"2026-03-19T18:40:54.023Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:39.869Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184052-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T184052-c46e28d2","recordedAt":"2026-03-19T18:40:54.023Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:40.732Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184052-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T184052-c46e28d2","recordedAt":"2026-03-19T18:40:54.023Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:27:42.034Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T184052-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T184052-c46e28d2","recordedAt":"2026-03-19T18:40:54.023Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:41.681Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T184052-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T184052-c46e28d2","recordedAt":"2026-03-19T18:40:54.023Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:42.035Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T174925-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T174925-33db16bd","recordedAt":"2026-03-19T17:49:25.188Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:41.326Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T174925-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T174925-33db16bd","recordedAt":"2026-03-19T17:49:25.188Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:27.591Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174925-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T174925-33db16bd","recordedAt":"2026-03-19T17:49:25.188Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:28.550Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174925-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T174925-33db16bd","recordedAt":"2026-03-19T17:49:25.188Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:28.984Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174925-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T174925-33db16bd","recordedAt":"2026-03-19T17:49:25.188Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:29.935Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174647-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:24.023Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174647-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:40.262Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T174647-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:40.972Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T174647-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:27.133Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174647-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:26.682Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174647-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:26.233Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174647-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T21:04:24.456Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174647-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T21:04:23.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174647-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:23.140Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174647-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T174647-99db93fe","recordedAt":"2026-03-19T17:46:47.330Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:40.618Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T174329-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:21.822Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174329-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:22.699Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174329-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:22.255Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174329-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:21.384Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174329-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:23.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174329-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:39.908Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T174329-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:23.096Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174329-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T21:04:20.949Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174329-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:20.421Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174329-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T174329-c6b7ce28","recordedAt":"2026-03-19T17:43:29.827Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T21:04:19.962Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174030-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:19.011Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174030-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:22.217Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174030-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:21.665Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174030-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:20.788Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174030-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:39.199Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T174030-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:38.845Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T174030-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:20.345Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174030-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T20:27:19.898Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174030-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:18.547Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T174030-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260319T174030-17ab599a","recordedAt":"2026-03-19T17:40:30.317Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:39.554Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T173743-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T173743-c46e28d2","recordedAt":"2026-03-19T17:37:44.687Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:15.434Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T173743-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T173743-c46e28d2","recordedAt":"2026-03-19T17:37:44.687Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:38.491Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T173743-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T173743-c46e28d2","recordedAt":"2026-03-19T17:37:44.687Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:18.107Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T173743-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T173743-c46e28d2","recordedAt":"2026-03-19T17:37:44.687Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:17.207Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T173743-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T173743-c46e28d2","recordedAt":"2026-03-19T17:37:44.687Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:38.137Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T173743-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T173743-c46e28d2","recordedAt":"2026-03-19T17:37:44.687Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:16.761Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T173743-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T173743-c46e28d2","recordedAt":"2026-03-19T17:37:44.687Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:15.874Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T173743-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T173743-c46e28d2","recordedAt":"2026-03-19T17:37:44.687Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:14.985Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T161044-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T161044-33db16bd","recordedAt":"2026-03-19T16:10:45.052Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:14.094Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T161044-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T161044-33db16bd","recordedAt":"2026-03-19T16:10:45.052Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:14.534Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T161044-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T161044-33db16bd","recordedAt":"2026-03-19T16:10:45.052Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:27:13.657Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T161044-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T161044-33db16bd","recordedAt":"2026-03-19T16:10:45.052Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:59.320Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T161044-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T161044-33db16bd","recordedAt":"2026-03-19T16:10:45.052Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:37.782Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T160805-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:58.850Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160805-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:54.814Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160805-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:57.945Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160805-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:37.426Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T160805-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T20:04:56.182Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160805-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T20:04:55.241Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160805-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:58.398Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160805-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:55.701Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160805-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:36.717Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T160805-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T160805-99db93fe","recordedAt":"2026-03-19T16:08:05.490Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:37.072Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T160456-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:53.441Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160456-c6b7ce28::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:53.926Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160456-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:36.362Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T160456-c6b7ce28::lazertinib::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:54.371Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160456-c6b7ce28::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:52.982Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160456-c6b7ce28::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T20:04:52.537Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160456-c6b7ce28::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:51.968Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160456-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:51.513Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160456-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:50.636Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160456-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T160456-c6b7ce28","recordedAt":"2026-03-19T16:04:56.358Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T20:04:50.188Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160151-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T19:38:54.189Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160151-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:53.279Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160151-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:36.008Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T160151-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:56.398Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160151-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:35.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T160151-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:55.956Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160151-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:55.080Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160151-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:54.634Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160151-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:52.841Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T160151-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260319T160151-17ab599a","recordedAt":"2026-03-19T16:01:51.638Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:35.654Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T155849-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T155849-c46e28d2","recordedAt":"2026-03-19T15:58:50.873Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:34.942Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T155849-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T155849-c46e28d2","recordedAt":"2026-03-19T15:58:50.873Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:51.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T155849-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T155849-c46e28d2","recordedAt":"2026-03-19T15:58:50.873Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:49.160Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T155849-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T155849-c46e28d2","recordedAt":"2026-03-19T15:58:50.873Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:49.669Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T155849-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T155849-c46e28d2","recordedAt":"2026-03-19T15:58:50.873Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:50.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T155849-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T155849-c46e28d2","recordedAt":"2026-03-19T15:58:50.873Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:51.514Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T155849-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T155849-c46e28d2","recordedAt":"2026-03-19T15:58:50.873Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:52.391Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T155849-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T155849-c46e28d2","recordedAt":"2026-03-19T15:58:50.873Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:34.588Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T145936-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T145936-33db16bd","recordedAt":"2026-03-19T14:59:36.174Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:48.718Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145936-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T145936-33db16bd","recordedAt":"2026-03-19T14:59:36.174Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:47.834Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145936-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T145936-33db16bd","recordedAt":"2026-03-19T14:59:36.174Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:46.954Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145936-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T145936-33db16bd","recordedAt":"2026-03-19T14:59:36.174Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:48.281Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145936-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T145936-33db16bd","recordedAt":"2026-03-19T14:59:36.174Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:34.233Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T145642-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:33.524Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T145642-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:37.306Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145642-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T19:38:46.479Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145642-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:33.171Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T145642-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:33.878Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T145642-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T16:30:34.220Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145642-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:33.794Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145642-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:36.859Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145642-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T16:30:35.092Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145642-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T145642-99db93fe","recordedAt":"2026-03-19T14:56:42.279Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:34.668Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:31.142Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:32.453Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T16:30:32.018Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:30.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:29.793Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:32.816Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T145328-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:31.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:29.352Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:33.349Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145328-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T145328-557c91d1","recordedAt":"2026-03-19T14:53:28.782Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:32.910Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145027-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:28.463Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145027-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:32.462Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T145027-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:30:28.009Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145027-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:32.108Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T145027-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:08.065Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145027-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:07.605Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145027-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T16:23:07.154Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145027-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:06.301Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145027-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:05.867Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T145027-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260319T145027-17ab599a","recordedAt":"2026-03-19T14:50:27.122Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:31.752Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T144720-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T144720-c46e28d2","recordedAt":"2026-03-19T14:47:21.732Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:31.398Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T144720-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T144720-c46e28d2","recordedAt":"2026-03-19T14:47:21.732Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:02.335Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T144720-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T144720-c46e28d2","recordedAt":"2026-03-19T14:47:21.732Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:02.764Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T144720-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T144720-c46e28d2","recordedAt":"2026-03-19T14:47:21.732Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:03.200Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T144720-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T144720-c46e28d2","recordedAt":"2026-03-19T14:47:21.732Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:04.098Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T144720-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T144720-c46e28d2","recordedAt":"2026-03-19T14:47:21.732Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:04.543Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T144720-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T144720-c46e28d2","recordedAt":"2026-03-19T14:47:21.732Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:05.433Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T144720-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T144720-c46e28d2","recordedAt":"2026-03-19T14:47:21.732Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:31.043Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T134419-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T134419-33db16bd","recordedAt":"2026-03-19T13:44:19.479Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:30.689Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T134419-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T134419-33db16bd","recordedAt":"2026-03-19T13:44:19.479Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:01.900Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134419-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T134419-33db16bd","recordedAt":"2026-03-19T13:44:19.479Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:01.465Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134419-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T134419-33db16bd","recordedAt":"2026-03-19T13:44:19.479Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:00.969Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134419-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T134419-33db16bd","recordedAt":"2026-03-19T13:44:19.479Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:23:00.076Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134215-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:29.979Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T134215-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:29.587Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T134215-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:22:59.633Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134215-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:30.334Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T134215-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:22:59.198Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134215-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T16:02:12.312Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134215-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:12.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134215-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:11.869Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134215-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:22:58.760Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T134215-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T134215-99db93fe","recordedAt":"2026-03-19T13:42:15.725Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T16:02:13.174Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:10.965Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:06.877Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:10.527Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T16:02:10.075Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:09.633Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:09.194Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:08.309Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:07.780Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:11.427Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133943-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T133943-557c91d1","recordedAt":"2026-03-19T13:39:43.442Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:29.233Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T133718-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:28.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T133718-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:06.000Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133718-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:05.516Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133718-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:04.639Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133718-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T16:02:04.193Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133718-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T16:02:03.746Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133718-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:32.965Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133718-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:32.402Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133718-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:28.022Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T133718-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260319T133718-5b7100d5","recordedAt":"2026-03-19T13:37:18.816Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:28.422Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T133450-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T133450-c46e28d2","recordedAt":"2026-03-19T13:34:51.481Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:28.354Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133450-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T133450-c46e28d2","recordedAt":"2026-03-19T13:34:51.481Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:30.650Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133450-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T133450-c46e28d2","recordedAt":"2026-03-19T13:34:51.481Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:31.946Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133450-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T133450-c46e28d2","recordedAt":"2026-03-19T13:34:51.481Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:29.247Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133450-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T133450-c46e28d2","recordedAt":"2026-03-19T13:34:51.481Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:30.133Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133450-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T133450-c46e28d2","recordedAt":"2026-03-19T13:34:51.481Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:28.800Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T133450-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T133450-c46e28d2","recordedAt":"2026-03-19T13:34:51.481Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:27.638Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T133450-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T133450-c46e28d2","recordedAt":"2026-03-19T13:34:51.481Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:27.231Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T110542-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T110542-33db16bd","recordedAt":"2026-03-19T11:05:42.780Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:26.152Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110542-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T110542-33db16bd","recordedAt":"2026-03-19T11:05:42.780Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:27.915Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110542-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T110542-33db16bd","recordedAt":"2026-03-19T11:05:42.780Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:27.480Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110542-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T110542-33db16bd","recordedAt":"2026-03-19T11:05:42.780Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T18:15:26.831Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T110542-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T110542-33db16bd","recordedAt":"2026-03-19T11:05:42.780Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:27.047Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110327-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T14:20:05.634Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110327-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:06.093Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110327-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:26.039Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T110327-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T14:32:23.013Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110327-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:25.278Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110327-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T18:15:26.426Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T110327-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:25.712Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110327-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:32:24.789Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110327-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:05.204Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110327-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T110327-99db93fe","recordedAt":"2026-03-19T11:03:27.361Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:37.083Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T110053-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:04.312Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110053-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:00.138Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110053-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:00.588Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110053-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:01.043Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110053-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:36.727Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T110053-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:01.913Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110053-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:02.546Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110053-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T14:20:03.276Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110053-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:03.869Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T110053-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T110053-557c91d1","recordedAt":"2026-03-19T11:00:53.828Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:20:04.761Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105815-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:19:55.399Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105815-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:19:54.158Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105815-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-22T14:19:53.647Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105815-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:36.016Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T105815-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:36.371Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T105815-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:19:52.296Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105815-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:19:52.748Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105815-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:19:59.204Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105815-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-22T14:19:58.255Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105815-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260319T105815-5b7100d5","recordedAt":"2026-03-19T10:58:15.858Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:35.660Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T105527-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T105527-c46e28d2","recordedAt":"2026-03-19T10:55:28.858Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:35.305Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T105527-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T105527-c46e28d2","recordedAt":"2026-03-19T10:55:28.858Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:52.783Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105527-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T105527-c46e28d2","recordedAt":"2026-03-19T10:55:28.858Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:34.949Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T105527-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T105527-c46e28d2","recordedAt":"2026-03-19T10:55:28.858Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:54.920Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105527-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T105527-c46e28d2","recordedAt":"2026-03-19T10:55:28.858Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:53.641Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105527-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T105527-c46e28d2","recordedAt":"2026-03-19T10:55:28.858Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:51.924Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105527-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T105527-c46e28d2","recordedAt":"2026-03-19T10:55:28.858Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:54.061Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T105527-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T105527-c46e28d2","recordedAt":"2026-03-19T10:55:28.858Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:52.352Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090319-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T090319-33db16bd","recordedAt":"2026-03-19T09:03:19.368Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:51.485Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090319-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T090319-33db16bd","recordedAt":"2026-03-19T09:03:19.368Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:50.614Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090319-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T090319-33db16bd","recordedAt":"2026-03-19T09:03:19.368Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:51.048Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090319-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T090319-33db16bd","recordedAt":"2026-03-19T09:03:19.368Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:34.594Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T090319-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T090319-33db16bd","recordedAt":"2026-03-19T09:03:19.368Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:49.761Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090026-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T23:37:45.869Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090026-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:33.527Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T090026-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:46.302Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090026-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:34.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T090026-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:49.323Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090026-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:48.878Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090026-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:48.444Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090026-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T23:37:46.726Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090026-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T23:37:45.446Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T090026-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T090026-99db93fe","recordedAt":"2026-03-19T09:00:26.274Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:33.883Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T085527-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:48.513Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085527-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:50.240Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085527-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:47.224Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085527-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:49.805Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085527-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:33.172Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T085527-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:49.374Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085527-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:54:48.943Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085527-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:48.083Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085527-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:46.789Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085527-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T085527-557c91d1","recordedAt":"2026-03-19T08:55:27.354Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:46.362Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085310-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:54:43.363Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085310-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:42.510Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085310-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:42.084Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085310-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:43.790Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085310-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:32.105Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T085310-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:32.460Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T085310-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:45.499Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085310-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:45.071Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085310-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:44.214Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085310-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260319T085310-5b7100d5","recordedAt":"2026-03-19T08:53:10.059Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:32.816Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T085046-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T085046-c46e28d2","recordedAt":"2026-03-19T08:50:47.548Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:31.395Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T085046-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T085046-c46e28d2","recordedAt":"2026-03-19T08:50:47.548Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:31.750Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T085046-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T085046-c46e28d2","recordedAt":"2026-03-19T08:50:47.548Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:41.651Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085046-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T085046-c46e28d2","recordedAt":"2026-03-19T08:50:47.548Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:54:40.774Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085046-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T085046-c46e28d2","recordedAt":"2026-03-19T08:50:47.548Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:30.672Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085046-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T085046-c46e28d2","recordedAt":"2026-03-19T08:50:47.548Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:29.813Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085046-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T085046-c46e28d2","recordedAt":"2026-03-19T08:50:47.548Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:29.378Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T085046-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T085046-c46e28d2","recordedAt":"2026-03-19T08:50:47.548Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:28.949Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T052009-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T052009-33db16bd","recordedAt":"2026-03-19T05:20:09.961Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:27.646Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T052009-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T052009-33db16bd","recordedAt":"2026-03-19T05:20:09.961Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:28.092Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T052009-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T052009-33db16bd","recordedAt":"2026-03-19T05:20:09.961Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:28.518Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T052009-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T052009-33db16bd","recordedAt":"2026-03-19T05:20:09.961Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:31.040Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T052009-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T052009-33db16bd","recordedAt":"2026-03-19T05:20:09.961Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:26.786Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051747-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:22.506Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051747-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:23.364Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051747-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:30.329Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T051747-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:26.353Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051747-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:25.923Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051747-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:25.495Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051747-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:44:23.785Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051747-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:44:22.936Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051747-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:29.973Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T051747-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T051747-99db93fe","recordedAt":"2026-03-19T05:17:47.094Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:30.685Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T051507-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:29.618Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T051507-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:27.558Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051507-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:21.197Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051507-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:21.626Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051507-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:44:22.057Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051507-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:29.288Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051507-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:29.719Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051507-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:25:30.144Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051507-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:28.425Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051507-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T051507-557c91d1","recordedAt":"2026-03-19T05:15:07.501Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:27.991Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051045-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:28.552Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T051045-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:29.263Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T051045-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:26.687Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051045-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:26.246Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051045-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:25.376Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051045-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:24.946Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051045-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:25:24.519Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051045-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:23.662Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051045-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:23.235Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T051045-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260319T051045-5b7100d5","recordedAt":"2026-03-19T05:10:45.849Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:28.908Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T050835-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T050835-c46e28d2","recordedAt":"2026-03-19T05:08:36.890Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:28.196Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T050835-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T050835-c46e28d2","recordedAt":"2026-03-19T05:08:36.890Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:16:03.012Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T050835-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T050835-c46e28d2","recordedAt":"2026-03-19T05:08:36.890Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:22.803Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T050835-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T050835-c46e28d2","recordedAt":"2026-03-19T05:08:36.890Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:21.936Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T050835-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T050835-c46e28d2","recordedAt":"2026-03-19T05:08:36.890Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:21.504Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T050835-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T050835-c46e28d2","recordedAt":"2026-03-19T05:08:36.890Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:25:20.642Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T050835-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T050835-c46e28d2","recordedAt":"2026-03-19T05:08:36.890Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:16:03.435Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T050835-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T050835-c46e28d2","recordedAt":"2026-03-19T05:08:36.890Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:27.840Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T035144-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T035144-33db16bd","recordedAt":"2026-03-19T03:51:44.863Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:16:02.146Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T035144-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T035144-33db16bd","recordedAt":"2026-03-19T03:51:44.863Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:16:01.722Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T035144-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T035144-33db16bd","recordedAt":"2026-03-19T03:51:44.863Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:16:00.825Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T035144-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T035144-33db16bd","recordedAt":"2026-03-19T03:51:44.863Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:27.485Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T035144-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T035144-33db16bd","recordedAt":"2026-03-19T03:51:44.863Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:16:02.581Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034934-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:59.537Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034934-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:15:56.951Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034934-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:56.526Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034934-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:26.419Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T034934-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:16:00.389Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034934-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:27.129Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T034934-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:26.774Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T034934-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:57.380Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034934-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:59.960Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034934-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T034934-99db93fe","recordedAt":"2026-03-19T03:49:34.635Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:15:57.817Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:55.671Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:28.260Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:26.063Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T034702-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:28.688Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:29.116Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:53.938Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:54.366Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:15:54.794Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:55.235Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034702-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T034702-557c91d1","recordedAt":"2026-03-19T03:47:02.584Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:15:56.097Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034444-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:27.396Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034444-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:25.708Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T034444-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:25.352Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T034444-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:26.971Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034444-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:26.117Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034444-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:25.693Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034444-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T22:00:25.271Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034444-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:24.424Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034444-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:23.995Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034444-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260319T034444-5b7100d5","recordedAt":"2026-03-19T03:44:44.827Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:24.996Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T034108-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T034108-c46e28d2","recordedAt":"2026-03-19T03:41:09.976Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:24.640Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T034108-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T034108-c46e28d2","recordedAt":"2026-03-19T03:41:09.976Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:24.285Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T034108-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T034108-c46e28d2","recordedAt":"2026-03-19T03:41:09.976Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:22.277Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034108-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T034108-c46e28d2","recordedAt":"2026-03-19T03:41:09.976Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:21.420Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034108-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T034108-c46e28d2","recordedAt":"2026-03-19T03:41:09.976Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:20.994Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034108-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T034108-c46e28d2","recordedAt":"2026-03-19T03:41:09.976Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:20.568Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034108-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T034108-c46e28d2","recordedAt":"2026-03-19T03:41:09.976Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:23.574Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T034108-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T034108-c46e28d2","recordedAt":"2026-03-19T03:41:09.976Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:22.707Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T015018-33db16bd::galantamine::alzheimers_disease","analysisId":"20260319T015018-33db16bd","recordedAt":"2026-03-19T01:50:18.611Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:53:04.362Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T015018-33db16bd::donepezil::alzheimers_disease","analysisId":"20260319T015018-33db16bd","recordedAt":"2026-03-19T01:50:18.611Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:53:03.935Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T015018-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260319T015018-33db16bd","recordedAt":"2026-03-19T01:50:18.611Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:53:03.079Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T015018-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260319T015018-33db16bd","recordedAt":"2026-03-19T01:50:18.611Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:23.930Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T015018-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260319T015018-33db16bd","recordedAt":"2026-03-19T01:50:18.611Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T22:00:20.137Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014801-99db93fe::paclitaxel::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:58.408Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014801-99db93fe::temozolomide::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:23.575Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T014801-99db93fe::panitumumab::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:23.187Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T014801-99db93fe::gemcitabine::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:22.832Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T014801-99db93fe::palbociclib::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:53:02.648Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014801-99db93fe::carboplatin::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:53:02.206Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014801-99db93fe::sirolimus::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:53:01.775Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014801-99db93fe::sapanisertib::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:52:59.836Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014801-99db93fe::vemurafenib::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:52:58.849Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014801-99db93fe::cetuximab::pan-cancer","analysisId":"20260319T014801-99db93fe","recordedAt":"2026-03-19T01:48:02.013Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:59.416Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:57.946Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:12.970Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:53.956Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:54.391Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:55.310Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:55.742Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:52:56.463Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:56.975Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:52:57.507Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014554-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260319T014554-557c91d1","recordedAt":"2026-03-19T01:45:54.125Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:22.476Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T014331-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:12.048Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014331-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:21.310Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T014331-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:21.698Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T014331-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:09.011Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014331-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:08.536Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014331-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:22.080Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260319T014331-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:39:09.883Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014331-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:10.332Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014331-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:10.759Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014331-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260319T014331-5b7100d5","recordedAt":"2026-03-19T01:43:31.968Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:11.614Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014121-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260319T014121-c46e28d2","recordedAt":"2026-03-19T01:41:22.554Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:20.519Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260319T014121-c46e28d2::olaparib::breast_cancer","analysisId":"20260319T014121-c46e28d2","recordedAt":"2026-03-19T01:41:22.554Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:04.811Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014121-c46e28d2::rucaparib::breast_cancer","analysisId":"20260319T014121-c46e28d2","recordedAt":"2026-03-19T01:41:22.554Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:05.779Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014121-c46e28d2::niraparib::breast_cancer","analysisId":"20260319T014121-c46e28d2","recordedAt":"2026-03-19T01:41:22.554Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:05.291Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014121-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260319T014121-c46e28d2","recordedAt":"2026-03-19T01:41:22.554Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:06.673Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014121-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260319T014121-c46e28d2","recordedAt":"2026-03-19T01:41:22.554Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:07.136Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014121-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260319T014121-c46e28d2","recordedAt":"2026-03-19T01:41:22.554Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:08.056Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260319T014121-c46e28d2::talazoparib::breast_cancer","analysisId":"20260319T014121-c46e28d2","recordedAt":"2026-03-19T01:41:22.554Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:20.922Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T233845-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260318T233845-33db16bd","recordedAt":"2026-03-18T23:38:45.073Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:48.022Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233845-33db16bd::galantamine::alzheimers_disease","analysisId":"20260318T233845-33db16bd","recordedAt":"2026-03-18T23:38:45.073Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:03.893Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233845-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260318T233845-33db16bd","recordedAt":"2026-03-18T23:38:45.073Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T17:52:20.126Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T233845-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260318T233845-33db16bd","recordedAt":"2026-03-18T23:38:45.073Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:04.320Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233845-33db16bd::donepezil::alzheimers_disease","analysisId":"20260318T233845-33db16bd","recordedAt":"2026-03-18T23:38:45.073Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:39:03.416Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233601-99db93fe::cetuximab::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:44.525Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233601-99db93fe::palbociclib::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:47.577Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233601-99db93fe::carboplatin::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:47.132Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233601-99db93fe::sirolimus::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:46.706Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233601-99db93fe::sapanisertib::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:34:44.955Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233601-99db93fe::paclitaxel::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:43.606Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233601-99db93fe::panitumumab::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:19.738Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T233601-99db93fe::vemurafenib::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:34:44.066Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233601-99db93fe::temozolomide::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:20.723Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T233601-99db93fe::gemcitabine::pan-cancer","analysisId":"20260318T233601-99db93fe","recordedAt":"2026-03-18T23:36:01.131Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T17:52:19.348Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T233242-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:34:41.857Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233242-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:40.072Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233242-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:39.640Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233242-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:39.204Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233242-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:20.367Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T233242-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:42.736Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233242-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:42.305Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233242-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:43.171Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233242-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:41.421Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T233242-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T233242-557c91d1","recordedAt":"2026-03-18T23:32:42.563Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:40.991Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232950-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:34:38.330Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232950-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:19.654Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T232950-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:09.441Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232950-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:08.583Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232950-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:08.146Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232950-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:23:07.675Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232950-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:06.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232950-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:06.396Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232950-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:20.011Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T232950-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260318T232950-17ab599a","recordedAt":"2026-03-18T23:29:50.235Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:19.298Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T232657-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260318T232657-c46e28d2","recordedAt":"2026-03-18T23:26:58.462Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:18.941Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260318T232657-c46e28d2::talazoparib::breast_cancer","analysisId":"20260318T232657-c46e28d2","recordedAt":"2026-03-18T23:26:58.462Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:18.585Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T232657-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260318T232657-c46e28d2","recordedAt":"2026-03-18T23:26:58.462Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:05.097Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232657-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260318T232657-c46e28d2","recordedAt":"2026-03-18T23:26:58.462Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:05.966Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232657-c46e28d2::olaparib::breast_cancer","analysisId":"20260318T232657-c46e28d2","recordedAt":"2026-03-18T23:26:58.462Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:02.921Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232657-c46e28d2::niraparib::breast_cancer","analysisId":"20260318T232657-c46e28d2","recordedAt":"2026-03-18T23:26:58.462Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:03.355Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232657-c46e28d2::rucaparib::breast_cancer","analysisId":"20260318T232657-c46e28d2","recordedAt":"2026-03-18T23:26:58.462Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:03.790Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T232657-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260318T232657-c46e28d2","recordedAt":"2026-03-18T23:26:58.462Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:04.656Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220320-33db16bd::donepezil::alzheimers_disease","analysisId":"20260318T220320-33db16bd","recordedAt":"2026-03-18T22:03:20.990Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:01.629Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220320-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260318T220320-33db16bd","recordedAt":"2026-03-18T22:03:20.990Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:00.779Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220320-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260318T220320-33db16bd","recordedAt":"2026-03-18T22:03:20.990Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:02.494Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220320-33db16bd::galantamine::alzheimers_disease","analysisId":"20260318T220320-33db16bd","recordedAt":"2026-03-18T22:03:20.990Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:02.057Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220320-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260318T220320-33db16bd","recordedAt":"2026-03-18T22:03:20.990Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:18.228Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T220019-99db93fe::temozolomide::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:17.158Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T220019-99db93fe::panitumumab::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:17.871Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T220019-99db93fe::vemurafenib::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:09:43.766Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220019-99db93fe::gemcitabine::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:17.515Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T220019-99db93fe::sapanisertib::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:09:44.680Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220019-99db93fe::sirolimus::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:46.629Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220019-99db93fe::carboplatin::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:22:59.921Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220019-99db93fe::palbociclib::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:23:00.354Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220019-99db93fe::paclitaxel::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:43.275Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T220019-99db93fe::cetuximab::pan-cancer","analysisId":"20260318T220019-99db93fe","recordedAt":"2026-03-18T22:00:19.777Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:44.194Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:41.873Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:39.053Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:39.534Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:40.485Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:40.942Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T21:09:41.426Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:38.561Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:42.304Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:42.790Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215724-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T215724-557c91d1","recordedAt":"2026-03-18T21:57:24.397Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:16.802Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T215405-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:15.733Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T215405-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:16.090Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T215405-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:31.117Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215405-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:31.549Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215405-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T20:48:32.421Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215405-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:32.859Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215405-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:36.344Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215405-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:37.205Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215405-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T21:09:37.633Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215405-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260318T215405-17ab599a","recordedAt":"2026-03-18T21:54:05.880Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:16.446Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T215108-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260318T215108-c46e28d2","recordedAt":"2026-03-18T21:51:09.565Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:15.020Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260318T215108-c46e28d2::talazoparib::breast_cancer","analysisId":"20260318T215108-c46e28d2","recordedAt":"2026-03-18T21:51:09.565Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:15.377Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T215108-c46e28d2::rucaparib::breast_cancer","analysisId":"20260318T215108-c46e28d2","recordedAt":"2026-03-18T21:51:09.565Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:27.931Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215108-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260318T215108-c46e28d2","recordedAt":"2026-03-18T21:51:09.565Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:28.893Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215108-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260318T215108-c46e28d2","recordedAt":"2026-03-18T21:51:09.565Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:29.365Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215108-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260318T215108-c46e28d2","recordedAt":"2026-03-18T21:51:09.565Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:30.639Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215108-c46e28d2::olaparib::breast_cancer","analysisId":"20260318T215108-c46e28d2","recordedAt":"2026-03-18T21:51:09.565Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:27.068Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T215108-c46e28d2::niraparib::breast_cancer","analysisId":"20260318T215108-c46e28d2","recordedAt":"2026-03-18T21:51:09.565Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:27.496Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201710-d91daa29::donepezil::alzheimers_disease","analysisId":"20260318T201710-d91daa29","recordedAt":"2026-03-18T20:17:10.931Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:25.752Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201710-d91daa29::galantamine::alzheimers_disease","analysisId":"20260318T201710-d91daa29","recordedAt":"2026-03-18T20:17:10.931Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:26.191Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201710-d91daa29::lecanemab::alzheimers_disease","analysisId":"20260318T201710-d91daa29","recordedAt":"2026-03-18T20:17:10.931Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:14.663Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T201710-d91daa29::rivastigmine::alzheimers_disease","analysisId":"20260318T201710-d91daa29","recordedAt":"2026-03-18T20:17:10.931Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:26.634Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201710-d91daa29::aducanumab::alzheimers_disease","analysisId":"20260318T201710-d91daa29","recordedAt":"2026-03-18T20:17:10.931Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:24.879Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201415-99db93fe::cetuximab::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:07.196Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201415-99db93fe::sapanisertib::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T19:58:07.630Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201415-99db93fe::vemurafenib::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T19:58:06.765Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201415-99db93fe::paclitaxel::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:06.340Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201415-99db93fe::panitumumab::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:13.595Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T201415-99db93fe::temozolomide::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:13.951Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T201415-99db93fe::carboplatin::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:24.003Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201415-99db93fe::palbociclib::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:24.432Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201415-99db93fe::sirolimus::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T20:48:23.525Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201415-99db93fe::gemcitabine::pan-cancer","analysisId":"20260318T201415-99db93fe","recordedAt":"2026-03-18T20:14:15.282Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:14.307Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T201131-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:04.187Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201131-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T19:58:04.619Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201131-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:05.055Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201131-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:02.024Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201131-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:02.453Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201131-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:05.912Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201131-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:05.481Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201131-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:13.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T201131-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:02.887Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T201131-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T201131-557c91d1","recordedAt":"2026-03-18T20:11:31.404Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:03.757Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200817-17ab599a::selumetinib::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:57:59.430Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200817-17ab599a::sorafenib::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:57:59.868Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200817-17ab599a::bevacizumab::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:00.734Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200817-17ab599a::capecitabine::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T19:58:01.164Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200817-17ab599a::tovorafenib::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:12.526Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T200817-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:11.650Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200817-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:12.092Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200817-17ab599a::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T19:57:59.001Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200817-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:12.168Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T200817-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260318T200817-17ab599a","recordedAt":"2026-03-18T20:08:17.480Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:12.882Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T200513-c46e28d2::talazoparib::breast_cancer","analysisId":"20260318T200513-c46e28d2","recordedAt":"2026-03-18T20:05:14.314Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:11.812Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T200513-c46e28d2::rucaparib::breast_cancer","analysisId":"20260318T200513-c46e28d2","recordedAt":"2026-03-18T20:05:14.314Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:08.910Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200513-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260318T200513-c46e28d2","recordedAt":"2026-03-18T20:05:14.314Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:09.825Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200513-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260318T200513-c46e28d2","recordedAt":"2026-03-18T20:05:14.314Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:10.295Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200513-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260318T200513-c46e28d2","recordedAt":"2026-03-18T20:05:14.314Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:11.217Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200513-c46e28d2::niraparib::breast_cancer","analysisId":"20260318T200513-c46e28d2","recordedAt":"2026-03-18T20:05:14.314Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:08.418Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200513-c46e28d2::olaparib::breast_cancer","analysisId":"20260318T200513-c46e28d2","recordedAt":"2026-03-18T20:05:14.314Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:07.989Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T200513-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260318T200513-c46e28d2","recordedAt":"2026-03-18T20:05:14.314Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:11.455Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260318T184003-d91daa29::galantamine::alzheimers_disease","analysisId":"20260318T184003-d91daa29","recordedAt":"2026-03-18T18:40:03.607Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:07.125Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T184003-d91daa29::aducanumab::alzheimers_disease","analysisId":"20260318T184003-d91daa29","recordedAt":"2026-03-18T18:40:03.607Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:05.829Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T184003-d91daa29::lecanemab::alzheimers_disease","analysisId":"20260318T184003-d91daa29","recordedAt":"2026-03-18T18:40:03.607Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:11.099Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T184003-d91daa29::donepezil::alzheimers_disease","analysisId":"20260318T184003-d91daa29","recordedAt":"2026-03-18T18:40:03.607Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:06.691Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T184003-d91daa29::rivastigmine::alzheimers_disease","analysisId":"20260318T184003-d91daa29","recordedAt":"2026-03-18T18:40:03.607Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:07.552Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183749-99db93fe::gemcitabine::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:10.030Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T183749-99db93fe::cetuximab::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:02.136Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183749-99db93fe::panitumumab::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:10.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T183749-99db93fe::temozolomide::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:10.386Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T183749-99db93fe::palbociclib::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:05.379Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183749-99db93fe::carboplatin::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:04.926Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183749-99db93fe::sirolimus::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:38:04.460Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183749-99db93fe::vemurafenib::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T15:35:08.973Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183749-99db93fe::paclitaxel::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:08.549Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183749-99db93fe::sapanisertib::pan-cancer","analysisId":"20260318T183749-99db93fe","recordedAt":"2026-03-18T18:37:49.832Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T15:38:02.593Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:05.360Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:03.990Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:08.121Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:07.158Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:06.713Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T15:35:06.269Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:05.814Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:07.643Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:04.439Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183539-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T183539-557c91d1","recordedAt":"2026-03-18T18:35:39.709Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:09.667Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T183316-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:09.311Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T183316-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:08.955Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T183316-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:08.598Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T183316-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:03.046Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183316-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:02.621Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183316-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:01.738Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183316-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:35:01.281Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183316-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T15:35:00.845Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183316-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:59.999Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183316-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260318T183316-5b7100d5","recordedAt":"2026-03-18T18:33:16.412Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:59.571Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183102-c46e28d2::rucaparib::breast_cancer","analysisId":"20260318T183102-c46e28d2","recordedAt":"2026-03-18T18:31:04.168Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:34.402Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183102-c46e28d2::niraparib::breast_cancer","analysisId":"20260318T183102-c46e28d2","recordedAt":"2026-03-18T18:31:04.168Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:33.968Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183102-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260318T183102-c46e28d2","recordedAt":"2026-03-18T18:31:04.168Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:59.132Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183102-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260318T183102-c46e28d2","recordedAt":"2026-03-18T18:31:04.168Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:35.691Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183102-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260318T183102-c46e28d2","recordedAt":"2026-03-18T18:31:04.168Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:35.263Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183102-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260318T183102-c46e28d2","recordedAt":"2026-03-18T18:31:04.168Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:07.885Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260318T183102-c46e28d2::olaparib::breast_cancer","analysisId":"20260318T183102-c46e28d2","recordedAt":"2026-03-18T18:31:04.168Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:33.531Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T183102-c46e28d2::talazoparib::breast_cancer","analysisId":"20260318T183102-c46e28d2","recordedAt":"2026-03-18T18:31:04.168Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:08.242Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T170314-33db16bd::donepezil::alzheimers_disease","analysisId":"20260318T170314-33db16bd","recordedAt":"2026-03-18T17:03:14.172Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:32.200Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170314-33db16bd::galantamine::alzheimers_disease","analysisId":"20260318T170314-33db16bd","recordedAt":"2026-03-18T17:03:14.172Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:32.656Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170314-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260318T170314-33db16bd","recordedAt":"2026-03-18T17:03:14.172Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:33.098Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170314-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260318T170314-33db16bd","recordedAt":"2026-03-18T17:03:14.172Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:07.529Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T170314-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260318T170314-33db16bd","recordedAt":"2026-03-18T17:03:14.172Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:31.345Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170051-99db93fe::carboplatin::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:29.986Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170051-99db93fe::sapanisertib::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T15:34:27.723Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170051-99db93fe::vemurafenib::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T15:34:26.871Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170051-99db93fe::paclitaxel::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:26.449Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170051-99db93fe::cetuximab::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:27.298Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170051-99db93fe::temozolomide::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:07.172Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T170051-99db93fe::palbociclib::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:30.908Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170051-99db93fe::sirolimus::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:29.542Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T170051-99db93fe::gemcitabine::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:06.458Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T170051-99db93fe::panitumumab::pan-cancer","analysisId":"20260318T170051-99db93fe","recordedAt":"2026-03-18T17:00:51.229Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:06.815Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T165821-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:57.230Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165821-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:57.700Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165821-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:58.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165821-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:59.052Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165821-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:06.073Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T165821-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T15:23:59.516Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165821-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:59.985Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165821-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:34:26.016Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165821-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:24:00.443Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165821-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T165821-557c91d1","recordedAt":"2026-03-18T16:58:21.727Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:24:00.913Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165559-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:04.895Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T165559-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:05.675Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T165559-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:52.701Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165559-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:53.130Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165559-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T15:23:54.014Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165559-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:54.482Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165559-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:54.938Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165559-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:55.859Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165559-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:56.324Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165559-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260318T165559-5b7100d5","recordedAt":"2026-03-18T16:55:59.625Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:05.289Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T165343-c46e28d2::talazoparib::breast_cancer","analysisId":"20260318T165343-c46e28d2","recordedAt":"2026-03-18T16:53:44.775Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:04.509Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T165343-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260318T165343-c46e28d2","recordedAt":"2026-03-18T16:53:44.775Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:51.350Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165343-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260318T165343-c46e28d2","recordedAt":"2026-03-18T16:53:44.775Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:04.109Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260318T165343-c46e28d2::olaparib::breast_cancer","analysisId":"20260318T165343-c46e28d2","recordedAt":"2026-03-18T16:53:44.775Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:57:01.637Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165343-c46e28d2::niraparib::breast_cancer","analysisId":"20260318T165343-c46e28d2","recordedAt":"2026-03-18T16:53:44.775Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:57:02.072Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165343-c46e28d2::rucaparib::breast_cancer","analysisId":"20260318T165343-c46e28d2","recordedAt":"2026-03-18T16:53:44.775Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:57:02.514Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165343-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260318T165343-c46e28d2","recordedAt":"2026-03-18T16:53:44.775Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:50.907Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T165343-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260318T165343-c46e28d2","recordedAt":"2026-03-18T16:53:44.775Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T15:23:52.274Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::ruxolitinib::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"RUXOLITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:57:00.702Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::tretinoin::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"TRETINOIN","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:57:00.235Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::ketoconazole::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:56:59.768Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:56:59.340Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::mycophenolate::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:56:58.875Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::gentian_violet_cation::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:56:58.431Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::entrectinib::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:56:57.958Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::vandetanib::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:56:57.487Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::tofacitinib::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"TOFACITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:57:01.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T152757-da593734::palbociclib::parkinson's_disease","analysisId":"20260318T152757-da593734","recordedAt":"2026-03-18T15:27:57.298Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:56:57.017Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151839-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260318T151839-33db16bd","recordedAt":"2026-03-18T15:18:39.580Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:56:56.581Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151839-33db16bd::galantamine::alzheimers_disease","analysisId":"20260318T151839-33db16bd","recordedAt":"2026-03-18T15:18:39.580Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:56:56.146Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151839-33db16bd::donepezil::alzheimers_disease","analysisId":"20260318T151839-33db16bd","recordedAt":"2026-03-18T15:18:39.580Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:56:55.680Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151839-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260318T151839-33db16bd","recordedAt":"2026-03-18T15:18:39.580Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:56:54.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151839-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260318T151839-33db16bd","recordedAt":"2026-03-18T15:18:39.580Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:36:03.714Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T151553-99db93fe::gemcitabine::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:46.441Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T151553-99db93fe::panitumumab::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:03.327Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T151553-99db93fe::temozolomide::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:36:02.948Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T151553-99db93fe::palbociclib::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:56:54.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151553-99db93fe::carboplatin::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:56:53.713Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151553-99db93fe::sirolimus::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:56:53.280Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151553-99db93fe::sapanisertib::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:53.850Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151553-99db93fe::vemurafenib::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:52.990Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151553-99db93fe::paclitaxel::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:52.569Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151553-99db93fe::cetuximab::pan-cancer","analysisId":"20260318T151553-99db93fe","recordedAt":"2026-03-18T15:15:53.032Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:53.426Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:50.849Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:50.410Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:49.990Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:51.713Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:52.142Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:49.557Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:48.695Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:48.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T14:31:51.278Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151308-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T151308-557c91d1","recordedAt":"2026-03-18T15:13:08.391Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:46.087Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T151122-357e5474::dimethyl_sulfoxide::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"DIMETHYL SULFOXIDE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05747651","NCT05458622"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-07-14","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:45.734Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"SUPPORTIVE_CARE"},{"id":"20260318T151122-357e5474::hydrocortisone_butyrate::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"HYDROCORTISONE BUTYRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:46.569Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151122-357e5474::ustekinumab::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"USTEKINUMAB","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03517722","NCT02349061","NCT04060888"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:51.596Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151122-357e5474::theophylline::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"THEOPHYLLINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:47.413Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151122-357e5474::phenylephrine::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"PHENYLEPHRINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:46.990Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151122-357e5474::paregoric::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"PAREGORIC","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:46.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151122-357e5474::fentanyl_citrate::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"FENTANYL CITRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:45.728Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151122-357e5474::clarithromycin::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"CLARITHROMYCIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T14:31:45.302Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151122-357e5474::aldesleukin::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"ALDESLEUKIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02932137","NCT05631717","NCT04397107","NCT03312335","NCT02084238"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:51.154Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151122-357e5474::atorvastatin_calcium_trihydrate::systemic_lupus_erythematosus","analysisId":"20260318T151122-357e5474","recordedAt":"2026-03-18T15:11:22.655Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:50.720Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::procarbazine_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"PROCARBAZINE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:48.066Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:46.772Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:46.336Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::melatonin::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"MELATONIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:49.858Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::pioglitazone_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:49.349Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::interleukin-11::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"INTERLEUKIN-11","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:50.287Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:48.922Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::genistein::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"GENISTEIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:48.496Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::lithium::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"LITHIUM","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:47.639Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151121-5021da0e::sorbitol::neurodegeneration_biomarker_panel","analysisId":"20260318T151121-5021da0e","recordedAt":"2026-03-18T15:11:21.886Z","drug":"SORBITOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:08:47.200Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151015-c46e28d2::niraparib::breast_cancer","analysisId":"20260318T151015-c46e28d2","recordedAt":"2026-03-18T15:10:15.476Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:43.251Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151015-c46e28d2::rucaparib::breast_cancer","analysisId":"20260318T151015-c46e28d2","recordedAt":"2026-03-18T15:10:15.476Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:43.696Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151015-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260318T151015-c46e28d2","recordedAt":"2026-03-18T15:10:15.476Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:44.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151015-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260318T151015-c46e28d2","recordedAt":"2026-03-18T15:10:15.476Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:45.010Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151015-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260318T151015-c46e28d2","recordedAt":"2026-03-18T15:10:15.476Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:45.897Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151015-c46e28d2::olaparib::breast_cancer","analysisId":"20260318T151015-c46e28d2","recordedAt":"2026-03-18T15:10:15.476Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:42.819Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T151015-c46e28d2::talazoparib::breast_cancer","analysisId":"20260318T151015-c46e28d2","recordedAt":"2026-03-18T15:10:15.476Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:45.357Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T151015-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260318T151015-c46e28d2","recordedAt":"2026-03-18T15:10:15.476Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:45.003Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260318T150750-99db93fe::temozolomide::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:43.942Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150750-99db93fe::cetuximab::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:19.757Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150750-99db93fe::paclitaxel::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:18.426Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150750-99db93fe::vemurafenib::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:02:19.058Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150750-99db93fe::sapanisertib::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:02:20.540Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150750-99db93fe::sirolimus::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:23.268Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150750-99db93fe::carboplatin::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:41.925Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150750-99db93fe::palbociclib::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:08:42.377Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150750-99db93fe::panitumumab::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:44.296Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150750-99db93fe::gemcitabine::pan-cancer","analysisId":"20260318T150750-99db93fe","recordedAt":"2026-03-18T15:07:50.944Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:44.649Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150535-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:16.295Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150535-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:43.589Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150535-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:15.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150535-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T06:02:15.178Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150535-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:14.429Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150535-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:13.703Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150535-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:12.303Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150535-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:11.858Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150535-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:16.974Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150535-557c91d1::lazertinib::non-small_cell_lung_cancer","analysisId":"20260318T150535-557c91d1","recordedAt":"2026-03-18T15:05:35.195Z","drug":"LAZERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04075396","NCT04248829","NCT06106802","NCT04077463","NCT05338619"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:17.652Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150242-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:08.163Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150242-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:42.883Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150242-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:43.236Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150242-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:10.303Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150242-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T06:02:09.210Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150242-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:58:00.537Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150242-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:58:00.086Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150242-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:59.227Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150242-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:58.788Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150242-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260318T150242-5b7100d5","recordedAt":"2026-03-18T15:02:42.826Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:42.529Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150154-c2b1d328::inclisiran::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisiran utilizes the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation.","trialNctIds":["NCT05888103","NCT06501443","NCT05639218","NCT06126367","NCT02597127"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:55.273Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150154-c2b1d328::alirocumab::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02959047","NCT04847752","NCT06083961","NCT05129241","NCT03507374"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:54.390Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150154-c2b1d328::lovastatin::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03771053","NCT00474123","NCT06501443","NCT00120289","NCT00461630"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:57.471Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150154-c2b1d328::rivaroxaban::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"RIVAROXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04847752","NCT02376010","NCT04753372","NCT06986369"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:58.359Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150154-c2b1d328::apixaban::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"APIXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04229264"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-01-18","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:41.790Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150154-c2b1d328::pravastatin_sodium::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872845","NCT06501443","NCT00147797","NCT00054938","NCT01634906"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:57.902Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150154-c2b1d328::dabigatran::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"DABIGATRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02544932","NCT01352702","NCT06058130","NCT04847752"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-05-12","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:42.175Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T150154-c2b1d328::edoxaban::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"EDOXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01802775","NCT04010955"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:56.999Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150154-c2b1d328::atorvastatin_calcium_trihydrate::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:57:56.132Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150154-c2b1d328::evolocumab::atherosclerosis","analysisId":"20260318T150154-c2b1d328","recordedAt":"2026-03-18T15:01:54.754Z","drug":"EVOLOCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06295679","NCT04847752","NCT03096288","NCT06700720","NCT04141579"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:54.825Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150027-c46e28d2::rucaparib::breast_cancer","analysisId":"20260318T150027-c46e28d2","recordedAt":"2026-03-18T15:00:28.283Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:51.700Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150027-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260318T150027-c46e28d2","recordedAt":"2026-03-18T15:00:28.283Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:53.933Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150027-c46e28d2::niraparib::breast_cancer","analysisId":"20260318T150027-c46e28d2","recordedAt":"2026-03-18T15:00:28.283Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:51.263Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150027-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260318T150027-c46e28d2","recordedAt":"2026-03-18T15:00:28.283Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:41.410Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260318T150027-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260318T150027-c46e28d2","recordedAt":"2026-03-18T15:00:28.283Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:52.575Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150027-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260318T150027-c46e28d2","recordedAt":"2026-03-18T15:00:28.283Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:53.036Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150027-c46e28d2::olaparib::breast_cancer","analysisId":"20260318T150027-c46e28d2","recordedAt":"2026-03-18T15:00:28.283Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:57:50.832Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T150027-c46e28d2::talazoparib::breast_cancer","analysisId":"20260318T150027-c46e28d2","recordedAt":"2026-03-18T15:00:28.283Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:41.057Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T145613-8c5b9a71::pravastatin_sodium::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872845","NCT06501443","NCT00147797","NCT00054938","NCT01634906"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:27.508Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::inclisiran::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05888103","NCT06501443","NCT05639218","NCT06126367","NCT02597127"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:25.152Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::lomitapide_mesylate::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"LOMITAPIDE MESYLATE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:38:25.716Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::lovastatin::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03771053","NCT00474123","NCT06501443","NCT00120289","NCT00461630"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:26.176Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::mipomersen::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"MIPOMERSEN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01598948"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:26.605Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::cholestyramine_resin::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"CHOLESTYRAMINE RESIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06501443","NCT01053065","NCT00000461"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:27.071Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::rivaroxaban::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"RIVAROXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04847752","NCT02376010","NCT04753372","NCT06986369"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:28.868Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::alirocumab::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02959047","NCT04847752","NCT06083961","NCT05129241","NCT03507374"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:27.954Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::alprostadil::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"ALPROSTADIL","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04312555","NCT04197323","NCT01758874"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:29.309Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T145613-8c5b9a71::dexamethasone::atherosclerosis","analysisId":"20260318T145613-8c5b9a71","recordedAt":"2026-03-18T14:56:14.014Z","drug":"DEXAMETHASONE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01507558","NCT02807779","NCT01983449","NCT03942601"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:28.381Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01349920","NCT02073526","NCT03801928","NCT04196920","NCT00553176"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:21.078Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02073526","NCT04196920","NCT02065570","NCT04259138","NCT02087878"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:20.615Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01418131","NCT01570348","NCT00514982","NCT00643071"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:22.889Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::mifamurtide::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:38:22.426Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::inarigivir_soproxil::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"INARIGIVIR SOPROXIL","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:38:23.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::chembl:chembl1351908::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:38:24.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::chembl:chembl585502::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"CHEMBL:CHEMBL585502","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:38:24.708Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT03844932","NCT06126835","NCT05112263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:23.369Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::celecoxib::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01284504","NCT00175032","NCT00177866","NCT00473980","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:21.957Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143653-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260318T143653-91dbcf4e","recordedAt":"2026-03-18T14:36:53.693Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:40.703Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T143227-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:40.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T143227-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:39.611Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T143227-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:39.965Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T143227-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:34:46.065Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143227-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:46.503Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143227-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:46.934Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143227-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:19.277Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143227-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:38:19.723Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143227-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:44.761Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T143227-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260318T143227-5b7100d5","recordedAt":"2026-03-18T14:32:27.843Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:45.199Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T141817-e99833ac::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260318T141817-e99833ac","recordedAt":"2026-03-18T14:18:17.195Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Tofersen is an antisense oligonucleotide that causes degradation of SOD1 mRNA through binding to SOD1 mRNA, which results in a reduction of SOD1 protein synthesis.","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:39.258Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T135303-78e027ed::repotrectinib::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"REPOTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06140836","NCT04772235","NCT06315010","NCT03093116","NCT06552234"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2017-03-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:38.516Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T135303-78e027ed::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:40.326Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T135303-78e027ed::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:38.870Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T135303-78e027ed::regorafenib::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"REGORAFENIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03475953","NCT04701476","NCT03520842","NCT02795156","NCT06047379"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:43.421Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T135303-78e027ed::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:34:42.530Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T135303-78e027ed::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:41.653Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T135303-78e027ed::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:42.982Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T135303-78e027ed::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:34:42.088Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T135303-78e027ed::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:39.889Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T135303-78e027ed::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T135303-78e027ed","recordedAt":"2026-03-18T13:53:03.763Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:41.202Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T131258-3067acf1::nirogacestat::alzheimer's_disease","analysisId":"20260318T131258-3067acf1","recordedAt":"2026-03-18T13:12:58.682Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:34:38.046Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T131258-3067acf1::lecanemab::alzheimer's_disease","analysisId":"20260318T131258-3067acf1","recordedAt":"2026-03-18T13:12:58.682Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:38.162Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T131258-3067acf1::donepezil::alzheimer's_disease","analysisId":"20260318T131258-3067acf1","recordedAt":"2026-03-18T13:12:58.682Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:38.478Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T131258-3067acf1::galantamine::alzheimer's_disease","analysisId":"20260318T131258-3067acf1","recordedAt":"2026-03-18T13:12:58.682Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:38.921Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T131258-3067acf1::rivastigmine::alzheimer's_disease","analysisId":"20260318T131258-3067acf1","recordedAt":"2026-03-18T13:12:58.682Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:34:39.367Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T131258-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260318T131258-3067acf1","recordedAt":"2026-03-18T13:12:58.682Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:28.288Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::bortezomib::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"BORTEZOMIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00382954","NCT02208037","NCT01075425","NCT02352558","NCT00383474"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:26.433Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::sunitinib::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"SUNITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02779283","NCT01620216","NCT03878524","NCT00890747","NCT00783653"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:27.750Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::sorafenib::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"SORAFENIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01576185","NCT02474290","NCT02196857","NCT01159301","NCT02270788"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:27.303Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::pacritinib::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"PACRITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02532010","NCT01620216","NCT04282187","NCT02323607"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:26.872Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::azacitidine::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02071927","NCT06384261","NCT00398983","NCT06058741","NCT06429670"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:25.641Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::decitabine::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00398983","NCT01001143","NCT03226418","NCT06316960","NCT06536959"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:25.195Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::idarubicin::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"IDARUBICIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03226418","NCT06316960","NCT00382954","NCT04953780","NCT01698879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:24.711Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::midostaurin::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03226418","NCT01161550","NCT01477606","NCT02665065","NCT04496999"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:23.786Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T042706-ae6826c9::gilteritinib::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070093","NCT06734585","NCT05564390","NCT02927262","NCT04293562"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:37.416Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T042706-ae6826c9::ponatinib::acute_myeloid_leukemia","analysisId":"20260318T042706-ae6826c9","recordedAt":"2026-03-18T04:27:06.749Z","drug":"PONATINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02779283","NCT01424982","NCT03147612","NCT03934372","NCT01207440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:37.809Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T035116-ac05ef48::neratinib::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"NERATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01111825","NCT01042379","NCT06008275","NCT03812393"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:18.564Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T035116-ac05ef48::lapatinib::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02158507","NCT01272141","NCT01426880"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:19.060Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T035116-ac05ef48::cetuximab::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"CETUXIMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00600249","NCT00633464","NCT01097642","NCT00463788","NCT04485013"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:20.011Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T035116-ac05ef48::panitumumab::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"PANITUMUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02876107","NCT01009983","NCT00894504","NCT05177796","NCT02593175"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:20.582Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T035116-ac05ef48::vandetanib::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"VANDETANIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:22:22.414Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T035116-ac05ef48::erlotinib::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00998036","NCT00733408","NCT05827614","NCT00834678","NCT01650506"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:21.490Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T035116-ac05ef48::pertuzumab::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"PERTUZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05180006","NCT05582499","NCT05020860","NCT04193059"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:35.849Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T035116-ac05ef48::afatinib::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:36.231Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T035116-ac05ef48::paclitaxel::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:36.629Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T035116-ac05ef48::gefitinib::triple-negative_breast_cancer","analysisId":"20260318T035116-ac05ef48","recordedAt":"2026-03-18T03:51:16.612Z","drug":"GEFITINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01732276"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2012-11-22","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:37.018Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T031935-68ebe42d::neratinib::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:35.457Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T031935-68ebe42d::vandetanib::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00995007","NCT00441142","NCT00613223","NCT00821080","NCT00613054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:10.925Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T031935-68ebe42d::regorafenib::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06095375","NCT02926222","NCT06047379","NCT03970447","NCT04051606"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:08.541Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T031935-68ebe42d::sunitinib::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00535379","NCT01100177","NCT00499473","NCT00606008","NCT03275558"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:09.014Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T031935-68ebe42d::lapatinib::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00107003","NCT00099060","NCT02101905","NCT00095940","NCT04135807"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:11.379Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T031935-68ebe42d::erlotinib::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00086879","NCT00671970","NCT00112736","NCT00525525","NCT00445588"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:09.993Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T031935-68ebe42d::temozolomide::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"TEMOZOLOMIDE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04730869","NCT04968366","NCT00086879","NCT00662506","NCT05551013"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:22:18.073Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T031935-68ebe42d::afatinib::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00875433","NCT02423525","NCT00977431","NCT05432518","NCT00727506"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:09.513Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T031935-68ebe42d::gefitinib::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00042991","NCT01310855","NCT00025675","NCT00052208","NCT00027625"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:10.481Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T031935-68ebe42d::cetuximab::glioblastoma","analysisId":"20260318T031935-68ebe42d","recordedAt":"2026-03-18T03:19:35.686Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03603379","NCT00311857","NCT05929456","NCT01884740","NCT00463073"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:08.042Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:03:06.094Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:06.611Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:35.079Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T023526-e301c0b6::regorafenib::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"REGORAFENIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03475953","NCT04701476","NCT03520842","NCT02795156","NCT06047379"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:07.071Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:03:05.602Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:05.105Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:04.618Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:03.649Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:03.162Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T023526-e301c0b6::repotrectinib::non-small_cell_lung_cancer","analysisId":"20260318T023526-e301c0b6","recordedAt":"2026-03-18T02:35:26.331Z","drug":"REPOTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06140836","NCT04772235","NCT06315010","NCT03093116","NCT06552234"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2017-03-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:34.725Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T020455-260a7b06::lecanemab::alzheimer's_disease","analysisId":"20260318T020455-260a7b06","recordedAt":"2026-03-18T02:04:55.496Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:34.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T020455-260a7b06::galantamine::alzheimer's_disease","analysisId":"20260318T020455-260a7b06","recordedAt":"2026-03-18T02:04:55.496Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:02.208Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T020455-260a7b06::rivastigmine::alzheimer's_disease","analysisId":"20260318T020455-260a7b06","recordedAt":"2026-03-18T02:04:55.496Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:02.723Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T020455-260a7b06::aducanumab::alzheimer's_disease","analysisId":"20260318T020455-260a7b06","recordedAt":"2026-03-18T02:04:55.496Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:57.068Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T020455-260a7b06::nirogacestat::alzheimer's_disease","analysisId":"20260318T020455-260a7b06","recordedAt":"2026-03-18T02:04:55.496Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T05:03:01.255Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T020455-260a7b06::donepezil::alzheimer's_disease","analysisId":"20260318T020455-260a7b06","recordedAt":"2026-03-18T02:04:55.496Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T05:03:01.760Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:54.745Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::alectinib::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:53.092Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:52.560Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:52.118Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:54.292Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:56.138Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:33.947Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T015724-3210ab2a::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:55.675Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:37:55.191Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015724-3210ab2a::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T015724-3210ab2a","recordedAt":"2026-03-18T01:57:24.671Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:56.614Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015201-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:50.704Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015201-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:37:48.824Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015201-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:32.886Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T015201-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:33.593Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T015201-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:49.318Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015201-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:47.840Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015201-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:47.362Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015201-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:49.774Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015201-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:37:51.156Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T015201-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260318T015201-5b7100d5","recordedAt":"2026-03-18T01:52:01.152Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:33.239Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T014904-da593734::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:50.705Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::tretinoin::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"TRETINOIN","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:51.570Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::ruxolitinib::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"RUXOLITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:37:46.444Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::tofacitinib::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"TOFACITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:37:46.911Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::entrectinib::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:49.351Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::gentian_violet_cation::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:49.788Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::mycophenolate::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:50.258Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::palbociclib::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:48.459Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::vandetanib::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:48.899Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T014904-da593734::ketoconazole::parkinson's_disease","analysisId":"20260318T014904-da593734","recordedAt":"2026-03-18T01:49:07.034Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:51.135Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T010215-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260318T010215-33db16bd","recordedAt":"2026-03-18T01:02:16.003Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:32.533Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T010215-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260318T010215-33db16bd","recordedAt":"2026-03-18T01:02:16.003Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:19:45.811Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T010215-33db16bd::nirogacestat::alzheimers_disease","analysisId":"20260318T010215-33db16bd","recordedAt":"2026-03-18T01:02:16.003Z","drug":"NIROGACESTAT","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:46.683Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T010215-33db16bd::donepezil::alzheimers_disease","analysisId":"20260318T010215-33db16bd","recordedAt":"2026-03-18T01:02:16.003Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:19:47.122Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T010215-33db16bd::galantamine::alzheimers_disease","analysisId":"20260318T010215-33db16bd","recordedAt":"2026-03-18T01:02:16.003Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:19:47.576Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T010215-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260318T010215-33db16bd","recordedAt":"2026-03-18T01:02:16.003Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:19:48.014Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005943-99db93fe::temozolomide::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:31.787Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T005943-99db93fe::palbociclib::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:19:45.372Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005943-99db93fe::carboplatin::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:19:44.935Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005943-99db93fe::sirolimus::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:19:44.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005943-99db93fe::sapanisertib::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:42.715Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005943-99db93fe::vemurafenib::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:19:41.834Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005943-99db93fe::paclitaxel::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:24.888Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005943-99db93fe::cetuximab::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:19:42.281Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005943-99db93fe::panitumumab::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:31.394Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T005943-99db93fe::gemcitabine::pan-cancer","analysisId":"20260318T005943-99db93fe","recordedAt":"2026-03-18T00:59:43.095Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:32.180Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T005724-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:24.400Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005724-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:20.667Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005724-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:22.051Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005724-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:22.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005724-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:07:22.997Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005724-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:21.113Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005724-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:20.221Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005724-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:23.941Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005724-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:31.040Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T005724-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260318T005724-557c91d1","recordedAt":"2026-03-18T00:57:24.184Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:23.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005459-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:17.351Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005459-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:17.852Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005459-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:30.261Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T005459-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:18.808Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005459-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:29.873Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T005459-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:19.322Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005459-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:15.535Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005459-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:15.977Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005459-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T04:07:16.912Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005459-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260318T005459-5b7100d5","recordedAt":"2026-03-18T00:54:59.204Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:30.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T005232-c46e28d2::talazoparib::breast_cancer","analysisId":"20260318T005232-c46e28d2","recordedAt":"2026-03-18T00:52:33.284Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:29.091Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260318T005232-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260318T005232-c46e28d2","recordedAt":"2026-03-18T00:52:33.284Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T04:07:15.045Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005232-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260318T005232-c46e28d2","recordedAt":"2026-03-18T00:52:33.284Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:29.488Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260318T005232-c46e28d2::olaparib::breast_cancer","analysisId":"20260318T005232-c46e28d2","recordedAt":"2026-03-18T00:52:33.284Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:23.619Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005232-c46e28d2::niraparib::breast_cancer","analysisId":"20260318T005232-c46e28d2","recordedAt":"2026-03-18T00:52:33.284Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:24.292Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005232-c46e28d2::rucaparib::breast_cancer","analysisId":"20260318T005232-c46e28d2","recordedAt":"2026-03-18T00:52:33.284Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:24.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005232-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260318T005232-c46e28d2","recordedAt":"2026-03-18T00:52:33.284Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:25.680Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260318T005232-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260318T005232-c46e28d2","recordedAt":"2026-03-18T00:52:33.284Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:26.261Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234804-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260317T234804-33db16bd","recordedAt":"2026-03-17T23:48:04.770Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:23.050Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234804-33db16bd::galantamine::alzheimers_disease","analysisId":"20260317T234804-33db16bd","recordedAt":"2026-03-17T23:48:04.770Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:22.530Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234804-33db16bd::donepezil::alzheimers_disease","analysisId":"20260317T234804-33db16bd","recordedAt":"2026-03-17T23:48:04.770Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:21.969Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234804-33db16bd::nirogacestat::alzheimers_disease","analysisId":"20260317T234804-33db16bd","recordedAt":"2026-03-17T23:48:04.770Z","drug":"NIROGACESTAT","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T03:41:21.426Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234804-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260317T234804-33db16bd","recordedAt":"2026-03-17T23:48:04.770Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:20.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234804-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260317T234804-33db16bd","recordedAt":"2026-03-17T23:48:04.770Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T16:19:28.691Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T234553-99db93fe::panitumumab::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"PANITUMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05084859"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-20","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T16:19:28.301Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T234553-99db93fe::temozolomide::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:29.613Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T234553-99db93fe::carboplatin::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"CARBOPLATIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02476955","NCT03989336","NCT06333314","NCT06607185","NCT06297811"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:19.589Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234553-99db93fe::sirolimus::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"SIROLIMUS","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03065387","NCT01473095"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:19.137Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234553-99db93fe::sapanisertib::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"SAPANISERTIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T03:41:16.914Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234553-99db93fe::vemurafenib::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"VEMURAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T03:41:16.003Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234553-99db93fe::paclitaxel::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"PACLITAXEL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06991491","NCT02476955","NCT03989336","NCT04872985"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:15.519Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234553-99db93fe::cetuximab::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"CETUXIMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06585488","NCT06607185","NCT01816984"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:16.479Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234553-99db93fe::gemcitabine::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"GEMCITABINE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT05585320","NCT04004234","NCT06607185"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:29.257Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T234553-99db93fe::palbociclib::pan-cancer","analysisId":"20260317T234553-99db93fe","recordedAt":"2026-03-17T23:45:53.984Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:20.025Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::mobocertinib_succinate::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"MOBOCERTINIB SUCCINATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T02:09:31.175Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::mobocertinib::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"MOBOCERTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05863819","NCT05241873","NCT04051827","NCT04129502","NCT04576208"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:30.558Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::capmatinib::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:30.110Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::alectinib::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:29.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:28.698Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:28.251Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::amivantamab::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:28.867Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T234338-557c91d1::cetuximab::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"CETUXIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00985855","NCT00193453","NCT01059188","NCT05395052"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T03:41:15.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::afatinib::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:32.349Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234338-557c91d1::tepotinib::non-small_cell_lung_cancer","analysisId":"20260317T234338-557c91d1","recordedAt":"2026-03-17T23:43:38.617Z","drug":"TEPOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06106802","NCT06083857","NCT03531762","NCT06031688","NCT03492437"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:31.779Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234052-5b7100d5::selumetinib::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"SELUMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01287130","NCT02450656","NCT01134601","NCT02586987","NCT00600496"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:25.542Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234052-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:27.798Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T234052-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T02:09:25.098Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234052-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:24.187Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234052-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:23.750Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234052-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:28.510Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T234052-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06963502","NCT00101686","NCT05338866","NCT00075556","NCT03465202"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:27.356Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234052-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02577588","NCT00101686","NCT06225622","NCT00499369","NCT04595266"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:26.911Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234052-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00889343","NCT01466504","NCT00826540","NCT01290926","NCT00869570"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:25.997Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T234052-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260317T234052-5b7100d5","recordedAt":"2026-03-17T23:40:52.701Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:28.154Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T233826-c46e28d2::talazoparib::breast_cancer","analysisId":"20260317T233826-c46e28d2","recordedAt":"2026-03-17T23:38:27.651Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:27.441Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T233826-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260317T233826-c46e28d2","recordedAt":"2026-03-17T23:38:27.651Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06155331","NCT00129896","NCT06595758","NCT02810743","NCT06175390"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:21.965Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T233826-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260317T233826-c46e28d2","recordedAt":"2026-03-17T23:38:27.651Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:27.038Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260317T233826-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260317T233826-c46e28d2","recordedAt":"2026-03-17T23:38:27.651Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03254654","NCT04848454","NCT03423849","NCT00192062","NCT05131841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:23.305Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T233826-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260317T233826-c46e28d2","recordedAt":"2026-03-17T23:38:27.651Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02360059","NCT06474988","NCT00075270","NCT05068141","NCT00919880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T02:09:22.409Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T233826-c46e28d2::rucaparib::breast_cancer","analysisId":"20260317T233826-c46e28d2","recordedAt":"2026-03-17T23:38:27.651Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00664781","NCT01074970","NCT02711137","NCT02505048","NCT03840200"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:20.028Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T233826-c46e28d2::niraparib::breast_cancer","analysisId":"20260317T233826-c46e28d2","recordedAt":"2026-03-17T23:38:27.651Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04481113","NCT04508803","NCT04240106","NCT05461690","NCT05601440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:19.543Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T233826-c46e28d2::olaparib::breast_cancer","analysisId":"20260317T233826-c46e28d2","recordedAt":"2026-03-17T23:38:27.651Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03330847","NCT02810743","NCT06175390","NCT00679783","NCT05252390"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:19.078Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T223854-e99833ac::riluzole::amyotrophic_lateral_sclerosis","analysisId":"20260317T223854-e99833ac","recordedAt":"2026-03-17T22:38:54.667Z","drug":"RILUZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01378676","NCT03693781","NCT02166944","NCT00876772","NCT00560287"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:18.526Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T223854-e99833ac::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260317T223854-e99833ac","recordedAt":"2026-03-17T22:38:54.667Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:26.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T212048-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:13.895Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T212048-17ab599a::dabrafenib::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05963087","NCT02465060","NCT04439292","NCT06967155","NCT01750918"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:15.274Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T212048-17ab599a::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101270","NCT06963502","NCT00101686","NCT06225622","NCT01060423"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:15.709Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T212048-17ab599a::nivolumab::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03414983","NCT04503694","NCT06011330","NCT02842125","NCT04912765"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:16.292Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T212048-17ab599a::pembrolizumab::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03182894","NCT03396926","NCT02921256","NCT06011330","NCT06555003"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:17.172Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T212048-17ab599a::cobimetinib::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02291289","NCT04190628","NCT06229340","NCT03989115","NCT05768178"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:17.616Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T212048-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:26.276Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T212048-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:13.448Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T212048-17ab599a::adagrasib::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:25.921Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T212048-17ab599a::panitumumab::colorectal_cancer","analysisId":"20260317T212048-17ab599a","recordedAt":"2026-03-17T21:20:48.904Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00425204","NCT05863195","NCT02476045","NCT00655499"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:16.729Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T211256-8ac6221f::olanzapine::huntington's_disease","analysisId":"20260317T211256-8ac6221f","recordedAt":"2026-03-17T21:12:56.727Z","drug":"OLANZAPINE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00632645"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:47:13.000Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T211256-8ac6221f::haloperidol_decanoate::huntington's_disease","analysisId":"20260317T211256-8ac6221f","recordedAt":"2026-03-17T21:12:56.727Z","drug":"HALOPERIDOL DECANOATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04071639"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-08-28","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:25.564Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T202111-7bbe5c56::tofacitinib::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"TOFACITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:47:12.034Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:47:10.282Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::mycophenolate::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:26.546Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::palbociclib::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:24.505Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::gentian_violet_cation::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:25.924Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::entrectinib::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:25.488Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::ruxolitinib::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"RUXOLITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:47:11.576Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::vandetanib::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:24.976Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::ketoconazole::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:47:10.712Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T202111-7bbe5c56::tretinoin::parkinson's_disease","analysisId":"20260317T202111-7bbe5c56","recordedAt":"2026-03-17T20:21:11.948Z","drug":"TRETINOIN","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:47:11.148Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T195508-e99833ac::riluzole::amyotrophic_lateral_sclerosis","analysisId":"20260317T195508-e99833ac","recordedAt":"2026-03-17T19:55:08.436Z","drug":"RILUZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01378676","NCT03693781","NCT02166944","NCT00876772","NCT00560287"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:41:23.804Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T195508-e99833ac::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260317T195508-e99833ac","recordedAt":"2026-03-17T19:55:08.436Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:25.178Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T165343-e99833ac::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260317T165343-e99833ac","recordedAt":"2026-03-17T16:53:43.105Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:24.822Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T165343-e99833ac::riluzole::amyotrophic_lateral_sclerosis","analysisId":"20260317T165343-e99833ac","recordedAt":"2026-03-17T16:53:43.105Z","drug":"RILUZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01378676","NCT03693781","NCT02166944","NCT00876772","NCT00560287"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:41:22.903Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::interleukin-11::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"INTERLEUKIN-11","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:21.769Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::lithium::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"LITHIUM","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:18.582Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::sorbitol::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"SORBITOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:18.052Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:17.547Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:17.080Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::genistein::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"GENISTEIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:19.583Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::pioglitazone_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:20.738Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::melatonin::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"MELATONIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:21.232Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::procarbazine_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"PROCARBAZINE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:19.140Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T162026-5021da0e::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260317T162026-5021da0e","recordedAt":"2026-03-17T16:20:26.959Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T01:41:20.213Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03182894","NCT03396926","NCT02921256","NCT06011330","NCT06555003"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:41:16.098Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02291289","NCT04190628","NCT06229340","NCT03989115","NCT05768178"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:41:16.637Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03414983","NCT04503694","NCT06011330","NCT02842125","NCT04912765"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:41:15.171Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:24.429Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T152222-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00101270","NCT06963502","NCT00101686","NCT06225622","NCT01060423"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:52.753Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05963087","NCT02465060","NCT04439292","NCT06967155","NCT01750918"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:52.274Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06856590","NCT03475953","NCT03563157","NCT03890731","NCT04503694"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:50.765Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05725200","NCT02857270","NCT06578559","NCT01436656","NCT06207656"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:50.316Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00425204","NCT05863195","NCT02476045","NCT00655499"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:41:15.643Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T152222-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260317T152222-5b7100d5","recordedAt":"2026-03-17T15:22:22.889Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:24.039Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260317T151831-bf3608f6::vandetanib::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00995007","NCT00441142","NCT00613223","NCT00821080","NCT00613054"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:45.131Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::regorafenib::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06095375","NCT02926222","NCT06047379","NCT03970447","NCT04051606"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:45.640Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::bevacizumab::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02060955","NCT01526837","NCT02511405","NCT03914768","NCT02078648"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:46.108Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::afatinib::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00875433","NCT02423525","NCT00977431","NCT05432518","NCT00727506"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:46.633Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::cetuximab::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03603379","NCT00311857","NCT05929456","NCT01884740","NCT00463073"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:47.170Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::erlotinib::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00086879","NCT00671970","NCT00112736","NCT00525525","NCT00445588"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:47.598Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::lapatinib::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00107003","NCT00099060","NCT02101905","NCT00095940","NCT04135807"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:48.069Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::sunitinib::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00535379","NCT01100177","NCT00499473","NCT00606008","NCT03275558"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:49.158Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::gefitinib::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00042991","NCT01310855","NCT00025675","NCT00052208","NCT00027625"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:49.669Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260317T151831-bf3608f6::neratinib::glioblastoma","analysisId":"20260317T151831-bf3608f6","recordedAt":"2026-03-17T15:18:31.771Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:23.649Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T010319-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:23.292Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T010319-33db16bd::crenezumab::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03114657","NCT02670083","NCT01998841","NCT01397578","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:44.662Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010319-33db16bd::donanemab::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05108922","NCT04437511","NCT06996730","NCT03367403"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:37.144Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010319-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02782975","NCT05108922","NCT05469009","NCT02477800","NCT02434718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:36.269Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010319-33db16bd::donepezil::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00096473","NCT03432195","NCT00177671","NCT00104273","NCT01972204"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:41.460Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010319-33db16bd::galantamine::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01039194","NCT00216515","NCT01529619","NCT00253201","NCT00309725"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:42.018Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010319-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00428389","NCT00948766","NCT01529619","NCT01312363","NCT01399125"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:42.467Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010319-33db16bd::bapineuzumab::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01254773","NCT00397891","NCT00574132","NCT00663026","NCT00575055"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:42.944Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010319-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00531804","NCT03443973","NCT04592341","NCT01224106","NCT06424236"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:43.397Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010319-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260316T010319-33db16bd","recordedAt":"2026-03-16T01:03:19.310Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01127633","NCT02614131","NCT00904683","NCT01900665","NCT01760005"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T01:32:43.898Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010046-99db93fe::ipilimumab::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT02492815","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:31.845Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010046-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:22.902Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T010046-99db93fe::temozolomide::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:22.514Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T010046-99db93fe::abemaciclib::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:22.129Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T010046-99db93fe::dabrafenib::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:21.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T010046-99db93fe::olaparib::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT04532645"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:35.826Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010046-99db93fe::fluorouracil::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02575508","NCT05585320","NCT06068023","NCT06055166","NCT00004150"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:35.388Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010046-99db93fe::palbociclib::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06739395","NCT03238196","NCT03065387","NCT06126276"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:34.066Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010046-99db93fe::nivolumab::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03899155","NCT02702492","NCT04566380","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:32.303Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T010046-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260316T010046-99db93fe","recordedAt":"2026-03-16T01:00:46.306Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:21.357Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005829-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02355431","NCT03071705","NCT02037997","NCT00826449","NCT00855894"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:30.947Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005829-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04621188","NCT04541706","NCT06858410","NCT06682884"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:31.415Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005829-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:20.969Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005829-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03375242","NCT03596866","NCT02134912","NCT02194738","NCT04056572"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:27.165Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005829-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06620835","NCT03596866","NCT04887519","NCT01449461","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:28.081Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005829-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04139317","NCT01911507","NCT04816214","NCT02276027","NCT03693339"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:28.524Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005829-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03071705","NCT01999985","NCT01542437","NCT02747953","NCT01649284"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:28.963Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005829-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03596866","NCT04115410","NCT06624059","NCT02604342","NCT05834348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:29.399Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005829-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299505","NCT04115410","NCT02276027","NCT05834348","NCT01828099"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-03-21T00:57:29.833Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005829-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260316T005829-c6b7ce28","recordedAt":"2026-03-16T00:58:29.616Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T00:57:30.505Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005548-c46e28d2::carboplatin::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:21.248Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:20.459Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:22.426Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::olaparib::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:21.640Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:22.814Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04759248","NCT01161368","NCT00176488","NCT04605575","NCT02985658"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:23.198Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::talazoparib::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:23.598Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::rucaparib::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:22.034Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:20.850Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260316T005548-c46e28d2::niraparib::breast_cancer","analysisId":"20260316T005548-c46e28d2","recordedAt":"2026-03-16T00:55:48.238Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:20.067Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:16.911Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:17.692Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260316T005529-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:18.087Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:29.995Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:19.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:18.497Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:18.899Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:19.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:16.518Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005529-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260316T005529-5b7100d5","recordedAt":"2026-03-16T00:55:36.207Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:17.304Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:27.677Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:28.470Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-21T00:35:21.005Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260316T005526-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:08:26.491Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:26.883Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:28.080Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:28.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:29.640Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:27.285Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005526-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260316T005526-c6b7ce28","recordedAt":"2026-03-16T00:55:26.711Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:08:29.249Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:23.754Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260316T005241-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:22.592Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:26.098Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:25.717Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:24.928Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:23.369Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:25.323Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:24.541Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:24.133Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005241-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260316T005241-5b7100d5","recordedAt":"2026-03-16T00:52:41.235Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:22.981Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::vandetanib::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:19.491Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::lapatinib::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:21.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::gefitinib::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:21.038Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::erlotinib::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:20.264Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::sunitinib::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:19.877Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::afatinib::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:22.209Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::bevacizumab::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01413438","NCT00345163","NCT01433991","NCT03532295","NCT02386826"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-27","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:21.429Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::regorafenib::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:20.653Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005030-bf3608f6::cetuximab::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05956821","NCT01044225","NCT00463073","NCT01238237","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-04-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:19.098Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260316T005030-bf3608f6::neratinib::glioblastoma","analysisId":"20260316T005030-bf3608f6","recordedAt":"2026-03-16T00:50:30.406Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:08:18.715Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:16.384Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:17.174Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::olaparib::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:14.804Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::niraparib::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:18.336Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:17.949Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::rucaparib::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:16.784Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::carboplatin::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:15.990Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::talazoparib::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:15.594Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::vinorelbine::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"VINORELBINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04759248","NCT01161368","NCT00176488","NCT04605575","NCT02985658"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:08:15.197Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260316T005007-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260316T005007-c46e28d2","recordedAt":"2026-03-16T00:50:08.276Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:08:17.559Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:11.651Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:14.019Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:12.838Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::bapineuzumab::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:08:14.416Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:13.622Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T233819-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:13.230Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:12.042Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:10.846Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::crenezumab::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:11.247Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233819-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T233819-33db16bd","recordedAt":"2026-03-15T23:38:19.575Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:08:12.429Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:59:31.602Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:28.642Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:59:28.254Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:30.918Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T233602-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:59:30.535Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:59:30.157Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:27.866Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:59:29.772Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:59:29.385Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233602-99db93fe::olaparib::pan-cancer","analysisId":"20260315T233602-99db93fe","recordedAt":"2026-03-15T23:36:02.268Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:28.997Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260315T233333-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:59:25.903Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233333-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:27.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233333-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-20T23:53:06.237Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T233333-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T14:59:25.095Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233333-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:25.502Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233333-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:26.684Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233333-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:26.297Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233333-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:27.084Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233333-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:24.704Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233333-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T233333-c6b7ce28","recordedAt":"2026-03-15T23:33:33.069Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:24.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:26.593Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:28.014Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:27.658Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T233107-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:27.304Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:26.948Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:59:23.902Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:29.079Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:28.724Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:28.369Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T233107-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260315T233107-5b7100d5","recordedAt":"2026-03-15T23:31:07.458Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:26.238Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:22.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:25.882Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:25.494Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:25.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T232959-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:24.332Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:23.946Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:23.550Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:22.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:24.725Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232959-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260315T232959-5b7100d5","recordedAt":"2026-03-15T23:29:59.846Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:23.159Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:34.421Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:53:31.673Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:33.252Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T14:41:21.989Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:34.825Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:33.645Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:32.858Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:32.459Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:34.033Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T232813-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T232813-c46e28d2","recordedAt":"2026-03-15T23:28:15.538Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:32.062Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:27.736Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:30.498Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::crenezumab::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:31.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:28.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:30.887Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:28.134Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::bapineuzumab::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:53:28.530Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:29.316Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:29.711Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224416-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T224416-33db16bd","recordedAt":"2026-03-15T22:44:16.428Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:30.100Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T224201-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:48.386Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224201-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:51.079Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224201-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:49.539Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224201-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:49.927Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224201-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:50.316Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224201-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:50.701Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224201-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:48.773Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T224201-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:51.464Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T224201-99db93fe::olaparib::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:53:27.345Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260315T224201-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T224201-99db93fe","recordedAt":"2026-03-15T22:42:01.220Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:49.159Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:46.042Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:45.646Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:47.229Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:48.006Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:47.615Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:46.841Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:46.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:45.253Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:44.861Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223939-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T223939-c6b7ce28","recordedAt":"2026-03-15T22:39:39.095Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-20T23:37:51.936Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T223703-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:42.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223703-5b7100d5::adagrasib::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"ADAGRASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06039384","NCT05722327","NCT04330664","NCT04793958"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-04-01","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:44.080Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223703-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:44.473Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223703-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:41.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T223703-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:40.973Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223703-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:43.308Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223703-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:42.922Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223703-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:42.140Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223703-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:41.741Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223703-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T223703-5b7100d5","recordedAt":"2026-03-15T22:37:03.757Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:43.696Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223536-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260315T223536-91dbcf4e","recordedAt":"2026-03-15T22:35:36.318Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:39.782Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223536-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260315T223536-91dbcf4e","recordedAt":"2026-03-15T22:35:36.318Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:40.573Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260315T223536-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260315T223536-91dbcf4e","recordedAt":"2026-03-15T22:35:36.318Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:40.177Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T223444-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:39.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:38.623Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:37.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:36.269Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:35.878Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:37.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:36.659Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:39.398Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:38.236Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T223444-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T223444-c46e28d2","recordedAt":"2026-03-15T22:34:45.393Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:37.441Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:33.067Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:34.286Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::bapineuzumab::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T13:29:32.671Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:32.272Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:50.061Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:33.898Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:35.081Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::crenezumab::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:34.684Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:35.480Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222610-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T222610-33db16bd","recordedAt":"2026-03-15T22:26:10.022Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T13:29:33.509Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T222353-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:46.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222353-99db93fe::olaparib::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:49.661Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260315T222353-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:42:48.896Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222353-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:48.514Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T222353-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:48.129Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222353-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:42:47.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222353-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:42:47.358Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222353-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:42:46.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222353-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:42:46.202Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222353-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T222353-99db93fe","recordedAt":"2026-03-15T22:23:54.003Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:42:49.281Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:43.473Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:43.085Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:44.259Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-18T15:28:17.875Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T222113-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:42.689Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:42:44.654Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:42:45.423Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:43.859Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:45.814Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T222113-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T222113-c6b7ce28","recordedAt":"2026-03-15T22:21:13.612Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:42:45.039Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::everolimus::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:21.889Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:24.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:23.060Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T221850-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:23.447Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:23.834Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:24.608Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:25.007Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:25.421Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:22.673Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221850-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T221850-5b7100d5","recordedAt":"2026-03-15T22:18:50.928Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:22.286Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::regorafenib::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:20.309Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::erlotinib::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:18.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::lapatinib::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:21.494Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::cetuximab::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05956821","NCT01044225","NCT00463073","NCT01238237","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-04-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:21.098Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260315T221726-bf3608f6::gefitinib::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:20.708Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::neratinib::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:19.908Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::bevacizumab::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01413438","NCT00345163","NCT01433991","NCT03532295","NCT02386826"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-27","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:19.508Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::afatinib::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:19.105Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::sunitinib::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:18.710Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221726-bf3608f6::vandetanib::glioblastoma","analysisId":"20260315T221726-bf3608f6","recordedAt":"2026-03-15T22:17:26.351Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:17.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:17.542Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:14.404Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:14.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:14.801Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:17.153Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:16.770Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:16.372Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:15.577Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:15.974Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221633-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T221633-c46e28d2","recordedAt":"2026-03-15T22:16:34.375Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:15.187Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:13.622Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:13.232Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:10.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::crenezumab::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:12.842Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:12.447Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:11.669Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:11.286Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:10.887Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T221416-33db16bd::bapineuzumab::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:10.499Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221416-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T221416-33db16bd","recordedAt":"2026-03-15T22:14:16.572Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:12.056Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221204-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:08.156Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221204-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:07.776Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221204-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:07.001Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T221204-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:07.383Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221204-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:09.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221204-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:08.925Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221204-99db93fe::olaparib::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:40:08.541Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260315T221204-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:06.225Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221204-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:09.714Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T221204-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T221204-99db93fe","recordedAt":"2026-03-15T22:12:04.412Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:40:06.614Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:04.091Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:02.522Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-18T15:08:03.631Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T220955-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:03.312Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:03.697Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:14:02.133Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:04.477Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:04.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T12:14:05.255Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220955-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T220955-c6b7ce28","recordedAt":"2026-03-15T22:09:55.102Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:02.915Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:00.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:59.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:59.413Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:00.963Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T220726-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:59.793Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:01.741Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::everolimus::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:01.353Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:58.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:58.631Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220726-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T220726-5b7100d5","recordedAt":"2026-03-15T22:07:26.543Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:14:00.176Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:58.213Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:40:00.528Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T12:13:57.860Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:57.413Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:59.788Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:57.827Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:58.606Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:59.009Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:59.400Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T220515-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T220515-c46e28d2","recordedAt":"2026-03-15T22:05:16.372Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:40:00.173Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:55.092Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T212650-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:56.251Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:54.710Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:53.540Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:56.635Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:55.863Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:54.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::crenezumab::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:55.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::bapineuzumab::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:57.023Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212650-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260315T212650-33db16bd","recordedAt":"2026-03-15T21:26:50.405Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:53.935Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212420-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:51.631Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212420-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:51.243Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212420-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:49.710Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T212420-99db93fe::olaparib::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:50.089Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260315T212420-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:50.475Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212420-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:50.856Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212420-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:52.011Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212420-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:52.394Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212420-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:52.779Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212420-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T212420-99db93fe","recordedAt":"2026-03-15T21:24:20.320Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:53.158Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:48.531Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:47.756Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:48.929Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:49.322Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:47.363Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-18T15:02:04.616Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T212149-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:48.145Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:46.970Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:39:46.185Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T212149-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T212149-c6b7ce28","recordedAt":"2026-03-15T21:21:49.998Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:46.581Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:42.262Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:45.410Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::everolimus::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:43.055Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:44.633Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:45.020Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T211918-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:44.247Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:43.857Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:43.460Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:42.656Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211918-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T211918-5b7100d5","recordedAt":"2026-03-15T21:19:18.503Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:45.796Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:45.009Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:44.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:44.235Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:43.087Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:41.872Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:43.849Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:42.684Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:45.398Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:43.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T211641-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T211641-c46e28d2","recordedAt":"2026-03-15T21:16:43.100Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:39:41.482Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::lecanemab::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:39.571Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::gantenerumab::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:40.737Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::donanemab::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:40.346Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::aducanumab::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:42.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::crenezumab::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:41.906Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::bapineuzumab::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:41.518Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::solanezumab::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:41.127Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::rivastigmine::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:39.961Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T200446-28a2f925::galantamine::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:39.180Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200446-28a2f925::donepezil::alzheimers_disease","analysisId":"20260315T200446-28a2f925","recordedAt":"2026-03-15T20:04:46.627Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:38.791Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200222-65d64218::ipilimumab::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:36.844Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T200222-65d64218::temozolomide::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:36.069Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200222-65d64218::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:35.678Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200222-65d64218::pembrolizumab::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:37.227Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200222-65d64218::nivolumab::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:37.626Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200222-65d64218::palbociclib::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:38.018Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200222-65d64218::dabrafenib::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:38.404Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200222-65d64218::olaparib::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:36.451Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260315T200222-65d64218::abemaciclib::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:35.290Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200222-65d64218::fluorouracil::pan-cancer","analysisId":"20260315T200222-65d64218","recordedAt":"2026-03-15T20:02:22.205Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:34.909Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:31.316Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:32.506Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-18T14:37:11.576Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T200003-62102268::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:33.730Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:34.517Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:34.122Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:33.297Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T00:32:32.900Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:32.105Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T200003-62102268::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T200003-62102268","recordedAt":"2026-03-15T20:00:03.918Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:31.711Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::everolimus::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:28.161Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:30.926Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:30.519Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:30.111Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:29.726Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:29.338Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:28.944Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:28.551Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T195745-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:27.368Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195745-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T195745-5b7100d5","recordedAt":"2026-03-15T19:57:45.745Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:27.765Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::niraparib::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:57.739Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:56.972Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::talazoparib::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:56.586Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::veliparib::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:26.980Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:26.580Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::tamoxifen::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T00:32:26.187Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::carboplatin::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:58.905Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::rucaparib::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:58.520Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::olaparib::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:57.357Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T195504-b44315aa::paclitaxel::breast_cancer","analysisId":"20260315T195504-b44315aa","recordedAt":"2026-03-15T19:55:05.896Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:58.125Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"GENETIC","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:52.717Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::crenezumab::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:54.644Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:56.192Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::bapineuzumab::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:55.806Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:55.417Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T183338-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:55.036Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:54.259Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:53.876Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:53.106Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183338-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T183338-33db16bd","recordedAt":"2026-03-15T18:33:38.328Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:53.492Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:49.259Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:49.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:48.875Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:50.025Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:50.795Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:51.180Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T183054-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:51.567Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:51.950Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:50.405Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T183054-99db93fe::olaparib::pan-cancer","analysisId":"20260315T183054-99db93fe","recordedAt":"2026-03-15T18:30:54.934Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:52.330Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":null},{"id":"20260315T182820-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:46.944Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182820-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:48.495Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182820-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:48.107Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182820-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:47.718Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182820-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:47.335Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182820-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:49:46.158Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182820-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:45.772Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182820-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-18T14:29:38.322Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182820-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:45.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182820-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T182820-c6b7ce28","recordedAt":"2026-03-15T18:28:20.216Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:46.548Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::everolimus::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:43.449Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::cobimetinib::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:42.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::pembrolizumab::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:41.482Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::dabrafenib::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:42.669Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:41.873Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::encorafenib::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:44.996Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::cetuximab::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:44.603Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::regorafenib::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:44.219Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"BASIC_SCIENCE"},{"id":"20260315T182530-17ab599a::panitumumab::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:43.834Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182530-17ab599a::nivolumab::colorectal_cancer","analysisId":"20260315T182530-17ab599a","recordedAt":"2026-03-15T18:25:30.354Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:43.056Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T182319-da593734::pergolide::parkinson's_disease","analysisId":"20260315T182319-da593734","recordedAt":"2026-03-15T18:23:19.694Z","drug":"PERGOLIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.","trialNctIds":["NCT00605683","NCT00624741","NCT00234364","NCT00202657","NCT00311532"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:41.095Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"PROCEDURE","primaryPurpose":null},{"id":"20260315T182319-da593734::selegiline::parkinson's_disease","analysisId":"20260315T182319-da593734","recordedAt":"2026-03-15T18:23:19.694Z","drug":"SELEGILINE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.","trialNctIds":["NCT02225548","NCT00443872","NCT04968613","NCT00640159","NCT00282152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-01-25","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:40.715Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DEVICE","primaryPurpose":"OTHER"},{"id":"20260315T182256-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:11.369Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182256-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:10.597Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182256-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:19:10.207Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182256-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:40.322Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"TREATMENT"},{"id":"20260315T182256-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:11.755Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182256-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:10.983Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182256-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:09.821Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182256-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:09.423Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182256-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:09.024Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T182256-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T182256-c46e28d2","recordedAt":"2026-03-15T18:22:57.402Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:49:39.921Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260315T174550-33db16bd::crenezumab::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:05.092Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:07.051Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:08.625Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::solanezumab::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:08.237Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::gantenerumab::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:07.842Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:06.650Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::bapineuzumab::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:19:06.265Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:05.871Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:05.485Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174550-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T174550-33db16bd","recordedAt":"2026-03-15T17:45:50.809Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:07.438Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174440-d7b8eb67::riluzole::amyotrophic_lateral_sclerosis","analysisId":"20260315T174440-d7b8eb67","recordedAt":"2026-03-15T17:44:40.347Z","drug":"RILUZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04518540","NCT00231140","NCT00353665","NCT02166944","NCT03127267"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-10-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:04.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174440-d7b8eb67::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260315T174440-d7b8eb67","recordedAt":"2026-03-15T17:44:40.347Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:04.705Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:03.552Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:19:00.456Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:19:03.938Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::olaparib::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:03.165Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:19:02.780Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:02.400Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:02.014Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:19:01.614Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:19:01.236Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174339-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T174339-99db93fe","recordedAt":"2026-03-15T17:43:39.343Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:19:00.849Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:18:56.908Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:19:00.069Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:59.671Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:58.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-18T13:53:18.560Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:59.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:58.880Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:57.300Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T23:18:57.688Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T174125-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T174125-c6b7ce28","recordedAt":"2026-03-15T17:41:25.272Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:58.084Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:56.512Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:52.967Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:55.718Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:54.932Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:54.545Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:54.155Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:53.763Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::everolimus::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:53.363Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:55.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173915-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T173915-5b7100d5","recordedAt":"2026-03-15T17:39:15.271Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:56.110Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:52.391Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:53.889Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:53.534Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:53.179Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:52.781Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:51.617Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:51.263Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:50.907Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:52.004Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T173637-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T173637-c46e28d2","recordedAt":"2026-03-15T17:36:38.513Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T23:18:52.555Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172815-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T172815-33db16bd","recordedAt":"2026-03-15T17:28:15.207Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:50.514Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172815-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T172815-33db16bd","recordedAt":"2026-03-15T17:28:15.207Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:50.131Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172815-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T172815-33db16bd","recordedAt":"2026-03-15T17:28:15.207Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:49.355Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172815-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T172815-33db16bd","recordedAt":"2026-03-15T17:28:15.207Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:49.747Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172815-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T172815-33db16bd","recordedAt":"2026-03-15T17:28:15.207Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:48.969Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172815-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T172815-33db16bd","recordedAt":"2026-03-15T17:28:15.207Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:48.584Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:46.640Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::olaparib::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:46.257Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:45.878Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:45.499Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:45.123Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:44.738Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:47.414Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:47.801Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:48.190Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172552-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T172552-99db93fe","recordedAt":"2026-03-15T17:25:52.093Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:47.029Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:44.348Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:42.781Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:43.955Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:43.565Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:43.174Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:41.603Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:40.808Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:42.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:41.994Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172338-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T172338-c6b7ce28","recordedAt":"2026-03-15T17:23:38.096Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:41.213Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:09:39.248Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:38.858Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:38.471Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:38.085Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:37.694Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:36.915Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:37.305Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:40.419Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:40.021Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T172119-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260315T172119-5b7100d5","recordedAt":"2026-03-15T17:21:19.346Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:39.630Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:06.921Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:07.324Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:34.950Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:35.351Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:35.743Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:36.133Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:09:36.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:06:06.530Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:05.745Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T171827-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T171827-c46e28d2","recordedAt":"2026-03-15T17:18:28.288Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:06.140Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::gantenerumab::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"GANTENERUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:01.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::bapineuzumab::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"BAPINEUZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:06:05.357Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::rivastigmine::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:04.959Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::galantamine::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:04.575Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::crenezumab::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"CRENEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:03.810Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::solanezumab::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"SOLANEZUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:02.648Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::lecanemab::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP","APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:04.194Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::donanemab::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:03.038Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::aducanumab::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:02.252Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170242-3a29aab7::donepezil::alzheimers_disease","analysisId":"20260315T170242-3a29aab7","recordedAt":"2026-03-15T17:02:42.362Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:03.422Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:06:01.470Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:06:01.087Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:00.704Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::olaparib::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:06:00.317Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:05:59.933Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:05:59.164Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:05:58.783Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:58.395Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:58.010Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T170002-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T170002-99db93fe","recordedAt":"2026-03-15T17:00:02.198Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:05:59.551Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:05:56.827Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:54.874Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:57.231Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:56.050Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:55.264Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:57.623Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::erlotinib_hydrochloride::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"ERLOTINIB HYDROCHLORIDE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","ALK","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:55.662Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::dacomitinib_anhydrous::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"DACOMITINIB ANHYDROUS","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-18T02:05:30.631Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:56.442Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165801-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T165801-c6b7ce28","recordedAt":"2026-03-15T16:58:01.408Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:05:54.472Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::everolimus::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:50.539Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:51.731Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:52.135Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:52.519Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:52.906Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:53.292Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:54.076Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::cobimetinib::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:50.947Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:53.689Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165547-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260315T165547-5b7100d5","recordedAt":"2026-03-15T16:55:47.175Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:51.339Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::afatinib::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:37.655Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::vandetanib::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:38.009Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::regorafenib::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:38.364Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::cetuximab::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05956821","NCT01044225","NCT00463073","NCT01238237","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-04-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:38.717Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::atezolizumab::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"ATEZOLIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04729959","NCT06328036","NCT04808245","NCT03158389"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-05-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:48.194Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::lapatinib::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:48.588Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::gefitinib::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:48.977Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::neratinib::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T21:05:49.361Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::sunitinib::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:49.750Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165312-69fea679::erlotinib::glioblastoma","analysisId":"20260315T165312-69fea679","recordedAt":"2026-03-15T16:53:12.998Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T21:05:50.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:35.708Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:37.301Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:36.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:34.906Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:33.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:36.499Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:36.106Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:34.505Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:35.306Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T165234-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T165234-c46e28d2","recordedAt":"2026-03-15T16:52:36.034Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:34.115Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::gefitinib::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:32.167Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::neratinib::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:31.777Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::afatinib::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:31.394Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::cetuximab::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05956821","NCT01044225","NCT00463073","NCT01238237","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-04-20","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:31.000Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::atezolizumab::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"ATEZOLIZUMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["CD274"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04729959","NCT06328036","NCT04808245","NCT03158389"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-05-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:30.613Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::lapatinib::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:30.223Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::vandetanib::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:29.828Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::regorafenib::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:32.555Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::sunitinib::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:33.343Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T164625-bf3608f6::erlotinib::glioblastoma","analysisId":"20260315T164625-bf3608f6","recordedAt":"2026-03-15T16:46:25.932Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:32.947Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::lithium::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"LITHIUM","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:21.200Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::sorbitol::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"SORBITOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:20.728Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:20.306Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:19.880Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::procarbazine_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"PROCARBAZINE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:21.630Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::genistein::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"GENISTEIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:22.054Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::interleukin-11::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"INTERLEUKIN-11","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:23.822Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::melatonin::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"MELATONIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:23.340Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::pioglitazone_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:22.911Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T160800-5021da0e::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260315T160800-5021da0e","recordedAt":"2026-03-15T16:08:01.419Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T22:39:22.485Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155413-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T155413-33db16bd","recordedAt":"2026-03-15T15:54:13.226Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:27.439Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155413-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T155413-33db16bd","recordedAt":"2026-03-15T15:54:13.226Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:27.840Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155413-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T155413-33db16bd","recordedAt":"2026-03-15T15:54:13.226Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:28.242Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155413-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T155413-33db16bd","recordedAt":"2026-03-15T15:54:13.226Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:28.650Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155413-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T155413-33db16bd","recordedAt":"2026-03-15T15:54:13.226Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:29.035Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155413-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T155413-33db16bd","recordedAt":"2026-03-15T15:54:13.226Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:29.431Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:25.462Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:25.851Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::olaparib::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:23.888Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:25.060Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:23.504Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:26.243Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:26.649Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:24.673Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:27.041Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T155151-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T155151-99db93fe","recordedAt":"2026-03-15T15:51:51.311Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:24.283Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:21.488Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:19.882Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:20.289Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:20.698Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:21.096Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:21.911Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:22.309Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:58:22.712Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:23.119Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154931-cd023095::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T154931-cd023095","recordedAt":"2026-03-15T15:49:31.289Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:58:19.482Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::fruquintinib::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:09.381Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::ipilimumab::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:07.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::regorafenib::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:08.603Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::atezolizumab::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:46:08.993Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::fluorouracil::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:06.670Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:09.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::capecitabine::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:08.219Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::encorafenib::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:07.836Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::bevacizumab::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:07.054Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154636-28812772::cetuximab::colorectal_cancer","analysisId":"20260315T154636-28812772","recordedAt":"2026-03-15T15:46:36.541Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:06.283Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:03.953Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:05.898Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:05.509Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:04.728Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:04.339Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:03.565Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:02.406Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:03.183Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:02.792Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T154400-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T154400-c46e28d2","recordedAt":"2026-03-15T15:44:01.887Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:46:05.118Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::tramadol::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"TRAMADOL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:21:28.532Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::methylphenidate_hydrochloride::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"METHYLPHENIDATE HYDROCHLORIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:21:28.116Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::dactinomycin::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:21:27.702Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::nicotine_polacrilex::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"NICOTINE POLACRILEX","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:16.147Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::capsaicin::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"CAPSAICIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:21:29.784Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::zinc_sulfate_anhydrous::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"ZINC SULFATE ANHYDROUS","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:21:29.363Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::lithium::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"LITHIUM","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00095355"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:02.013Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::fluticasone::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:21:28.950Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::nortriptyline::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"NORTRIPTYLINE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:21:30.618Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T152129-8ac6221f::propranolol_hydrochloride::huntington's_disease","analysisId":"20260315T152129-8ac6221f","recordedAt":"2026-03-15T15:21:29.986Z","drug":"PROPRANOLOL HYDROCHLORIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:21:30.199Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::decitabine::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05426798","NCT02085408","NCT03358719","NCT06113289","NCT06802523"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-12","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:00.889Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::glasdegib::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"GLASDEGIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04230564","NCT02038777","NCT04655391","NCT02367456","NCT04093505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-17","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:58.940Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::enasidenib::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"ENASIDENIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05564390","NCT05441514","NCT03683433","NCT04822766","NCT03728335"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2018-09-25","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:45:58.551Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::midostaurin::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01846624","NCT00233454","NCT02624570","NCT00866281","NCT00093600"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:59.327Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::daunorubicin_liposomal::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3","NPM1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01236144","NCT02652871","NCT02085408","NCT02403310","NCT01587430"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-11-08","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:59.719Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::gilteritinib_fumarate::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"GILTERITINIB FUMARATE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070093","NCT06734585","NCT05564390","NCT02927262","NCT04293562"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:01.281Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::ponatinib::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"PONATINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02779283","NCT01424982","NCT03147612","NCT03934372","NCT01207440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:00.500Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::gilteritinib::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070093","NCT06734585","NCT05564390","NCT02927262","NCT04293562"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:01.637Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::azacitidine::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05426798","NCT02085408","NCT01835587"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-04-19","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:58.165Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145605-ae6826c9::cytarabine::acute_myeloid_leukemia","analysisId":"20260315T145605-ae6826c9","recordedAt":"2026-03-15T14:56:05.234Z","drug":"CYTARABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01127009","NCT00602225","NCT01236144"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-28","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:46:00.108Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::interleukin-11::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"INTERLEUKIN-11","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:11.153Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:07.447Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:07.865Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::sorbitol::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"SORBITOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:08.279Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::lithium::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"LITHIUM","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:08.687Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::procarbazine_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"PROCARBAZINE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:09.100Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::genistein::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"GENISTEIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:09.508Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:09.925Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::pioglitazone_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:10.336Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T145111-5021da0e::melatonin::neurodegeneration_biomarker_panel","analysisId":"20260315T145111-5021da0e","recordedAt":"2026-03-15T14:51:12.987Z","drug":"MELATONIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T20:18:10.744Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140421-3a29aab7::lecanemab::alzheimers_disease","analysisId":"20260315T140421-3a29aab7","recordedAt":"2026-03-15T14:04:21.597Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:55.850Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140421-3a29aab7::aducanumab::alzheimers_disease","analysisId":"20260315T140421-3a29aab7","recordedAt":"2026-03-15T14:04:21.597Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:57.778Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140421-3a29aab7::donepezil::alzheimers_disease","analysisId":"20260315T140421-3a29aab7","recordedAt":"2026-03-15T14:04:21.597Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:57.006Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140421-3a29aab7::rivastigmine::alzheimers_disease","analysisId":"20260315T140421-3a29aab7","recordedAt":"2026-03-15T14:04:21.597Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:56.233Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140421-3a29aab7::galantamine::alzheimers_disease","analysisId":"20260315T140421-3a29aab7","recordedAt":"2026-03-15T14:04:21.597Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:57.388Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140421-3a29aab7::donanemab::alzheimers_disease","analysisId":"20260315T140421-3a29aab7","recordedAt":"2026-03-15T14:04:21.597Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:56.620Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:45:53.153Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:45:53.540Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:45:53.928Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::olaparib::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:54.308Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:45:54.694Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:55.464Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:45:55.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:51.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:52.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T140144-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T140144-99db93fe","recordedAt":"2026-03-15T14:01:44.998Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:45:52.768Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:13.135Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:13.915Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:42:15.098Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:15.502Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:51.607Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T20:45:50.825Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T20:45:51.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:13.523Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:14.705Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135905-cd023095::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T135905-cd023095","recordedAt":"2026-03-15T13:59:05.382Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:14.313Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:10.405Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:12.741Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:12.351Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:11.963Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:11.574Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:42:11.187Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:10.798Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:09.630Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:09.242Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135621-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260315T135621-5b7100d5","recordedAt":"2026-03-15T13:56:21.344Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:10.019Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::mycophenolate::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:54:00.258Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::gentian_violet_cation::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:53:59.836Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::palbociclib::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:53:58.591Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::vandetanib::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:53:59.008Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::tofacitinib::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"TOFACITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:54:02.359Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::entrectinib::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:53:59.424Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::ruxolitinib::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"RUXOLITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:54:01.944Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::tretinoin::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"TRETINOIN","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:54:01.521Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::ketoconazole::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:54:01.105Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135557-0deaa442::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260315T135557-0deaa442","recordedAt":"2026-03-15T13:55:57.304Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T16:54:00.688Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::carboplatin::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:16.597Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::talazoparib::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:16.242Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:15.532Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::rucaparib::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:14.822Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::olaparib::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:15.887Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::niraparib::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:15.178Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::paclitaxel::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:14.468Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::veliparib::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:08.845Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::tamoxifen::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:08.457Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T135401-56260220::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T135401-56260220","recordedAt":"2026-03-15T13:54:02.890Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:42:08.060Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::atezolizumab::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:10.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::fluorouracil::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:12.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::fruquintinib::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:14.113Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::encorafenib::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:13.725Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:13.329Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::cetuximab::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:12.919Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::ipilimumab::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:12.134Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::bevacizumab::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:11.744Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::capecitabine::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:11.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134823-28812772::regorafenib::colorectal_cancer","analysisId":"20260315T134823-28812772","recordedAt":"2026-03-15T13:48:23.063Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:10.964Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:08.223Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::niraparib::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:09.803Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::talazoparib::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:09.022Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::rucaparib::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:08.625Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::carboplatin::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:07.830Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:07.425Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::tamoxifen::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:07.033Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::veliparib::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:06.639Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::paclitaxel::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:09.413Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134535-56260220::olaparib::breast_cancer","analysisId":"20260315T134535-56260220","recordedAt":"2026-03-15T13:45:36.859Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:10.191Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134233-3a29aab7::donepezil::alzheimers_disease","analysisId":"20260315T134233-3a29aab7","recordedAt":"2026-03-15T13:42:33.402Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:04.286Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134233-3a29aab7::lecanemab::alzheimers_disease","analysisId":"20260315T134233-3a29aab7","recordedAt":"2026-03-15T13:42:33.402Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:04.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134233-3a29aab7::galantamine::alzheimers_disease","analysisId":"20260315T134233-3a29aab7","recordedAt":"2026-03-15T13:42:33.402Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:05.459Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134233-3a29aab7::rivastigmine::alzheimers_disease","analysisId":"20260315T134233-3a29aab7","recordedAt":"2026-03-15T13:42:33.402Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:06.248Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134233-3a29aab7::aducanumab::alzheimers_disease","analysisId":"20260315T134233-3a29aab7","recordedAt":"2026-03-15T13:42:33.402Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:05.860Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T134233-3a29aab7::donanemab::alzheimers_disease","analysisId":"20260315T134233-3a29aab7","recordedAt":"2026-03-15T13:42:33.402Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:05.070Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::pembrolizumab::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:03.895Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::fluorouracil::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:03.113Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::olaparib::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:01.169Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::nivolumab::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:03.509Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::ipilimumab::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:02.347Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::abemaciclib::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:01.553Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:00.782Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::palbociclib::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:39:01.948Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::dabrafenib::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:02.727Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133942-65fa096d::temozolomide::pan-cancer","analysisId":"20260315T133942-65fa096d","recordedAt":"2026-03-15T13:39:43.019Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:39:00.391Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:38:58.786Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:38:59.202Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:38:59.601Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:38:59.999Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:25.289Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:25.676Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:24:26.074Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:38:57.588Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:38:57.992Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133653-cd023095::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T133653-cd023095","recordedAt":"2026-03-15T13:36:54.016Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:38:58.389Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::fruquintinib::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:21.423Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::ipilimumab::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:21.811Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:24.934Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::fluorouracil::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:22.586Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::capecitabine::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:22.199Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::encorafenib::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:22.987Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::regorafenib::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:23.374Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::bevacizumab::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:23.762Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::atezolizumab::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:24:24.154Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133404-28812772::cetuximab::colorectal_cancer","analysisId":"20260315T133404-28812772","recordedAt":"2026-03-15T13:34:04.284Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:24.544Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:18:49.628Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::tretinoin::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"TRETINOIN","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:20:42.931Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::ruxolitinib::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"RUXOLITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:20:43.347Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::tofacitinib::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"TOFACITINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:20:43.761Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::palbociclib::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:18:47.547Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::vandetanib::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:18:47.963Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::entrectinib::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:18:48.373Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::gentian_violet_cation::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:18:48.787Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::mycophenolate::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:18:49.206Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133320-0deaa442::ketoconazole::parkinson's_disease","analysisId":"20260315T133320-0deaa442","recordedAt":"2026-03-15T13:33:20.716Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-17T15:20:42.516Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::tamoxifen::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:19.080Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:23.358Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::paclitaxel::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:23.713Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::veliparib::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:20.259Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::carboplatin::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:21.042Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:20.647Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::rucaparib::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:19.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::niraparib::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:19.469Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::talazoparib::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:24:18.686Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T133114-56260220::olaparib::breast_cancer","analysisId":"20260315T133114-56260220","recordedAt":"2026-03-15T13:31:15.745Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:24.069Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132346-3a29aab7::donanemab::alzheimers_disease","analysisId":"20260315T132346-3a29aab7","recordedAt":"2026-03-15T13:23:46.179Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:22.230Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132346-3a29aab7::donepezil::alzheimers_disease","analysisId":"20260315T132346-3a29aab7","recordedAt":"2026-03-15T13:23:46.179Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:22.617Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132346-3a29aab7::galantamine::alzheimers_disease","analysisId":"20260315T132346-3a29aab7","recordedAt":"2026-03-15T13:23:46.179Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:21.455Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132346-3a29aab7::aducanumab::alzheimers_disease","analysisId":"20260315T132346-3a29aab7","recordedAt":"2026-03-15T13:23:46.179Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:21.073Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132346-3a29aab7::lecanemab::alzheimers_disease","analysisId":"20260315T132346-3a29aab7","recordedAt":"2026-03-15T13:23:46.179Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:21.844Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132346-3a29aab7::rivastigmine::alzheimers_disease","analysisId":"20260315T132346-3a29aab7","recordedAt":"2026-03-15T13:23:46.179Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:23.002Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:18.789Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::temozolomide::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:18.396Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::nivolumab::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:18.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::dabrafenib::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:17.620Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::ipilimumab::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:17.240Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::palbociclib::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:19.942Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::abemaciclib::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:19.170Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::olaparib::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:20.682Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::fluorouracil::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:19.554Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T132059-65fa096d::pembrolizumab::pan-cancer","analysisId":"20260315T132059-65fa096d","recordedAt":"2026-03-15T13:20:59.371Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:20.327Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:16.854Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:13.727Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:14.119Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:14.506Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:15.677Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:16.073Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:14.899Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:15.289Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:16.460Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131816-cd023095::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T131816-cd023095","recordedAt":"2026-03-15T13:18:16.375Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:13.335Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::bevacizumab::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:11.379Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::regorafenib::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:11.766Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::capecitabine::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:12.156Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::fruquintinib::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:10.611Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:10.226Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::encorafenib::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:09.840Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::fluorouracil::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:09.438Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::ipilimumab::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:12.931Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::atezolizumab::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:12.544Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131510-28812772::cetuximab::colorectal_cancer","analysisId":"20260315T131510-28812772","recordedAt":"2026-03-15T13:15:10.137Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:10.995Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::carboplatin::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:08.658Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::talazoparib::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:07.864Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::paclitaxel::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:06.676Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::olaparib::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:05.488Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::niraparib::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:06.281Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:20:08.257Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:09.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::rucaparib::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:07.074Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::veliparib::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:07.464Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T131223-56260220::tamoxifen::breast_cancer","analysisId":"20260315T131223-56260220","recordedAt":"2026-03-15T13:12:25.108Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:05.887Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::ipilimumab::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:47.629Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::olaparib::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:20:05.097Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::fluorouracil::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:49.549Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::abemaciclib::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:49.166Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::dabrafenib::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:48.783Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::pembrolizumab::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:48.400Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::nivolumab::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:48.018Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:47.238Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::temozolomide::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:46.853Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130917-65fa096d::palbociclib::pan-cancer","analysisId":"20260315T130917-65fa096d","recordedAt":"2026-03-15T13:09:17.642Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:46.469Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:44.547Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:46.079Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:45.687Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:43.448Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:45.332Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:43.803Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:44.192Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:43.054Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:42.668Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130543-cd023095::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T130543-cd023095","recordedAt":"2026-03-15T13:05:43.539Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:44.940Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:42.313Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:41.158Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:40.765Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:41.927Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:40.377Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:39.990Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:39.606Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:39.221Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:38.832Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130247-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T130247-5b7100d5","recordedAt":"2026-03-15T13:02:47.996Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:41.541Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:36.070Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:35.677Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:38.429Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:38.037Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:37.637Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:37.249Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:36.854Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:36.462Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:35.287Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T130019-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T130019-c46e28d2","recordedAt":"2026-03-15T13:00:20.507Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:34.902Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::ramucirumab::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"RAMUCIRUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT04310007","NCT01703091","NCT03909334","NCT05800418"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-10-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:33.716Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::pemetrexed_disodium::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"PEMETREXED DISODIUM","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00698815","NCT03366064","NCT05014464","NCT05940532","NCT02041533"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:30.954Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:34.516Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:33.313Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::pembrolizumab::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"PEMBROLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05609578","NCT04585750","NCT04964479","NCT05627960"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-10-14","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T19:14:32.912Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:34.125Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:32.521Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::gefitinib::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"GEFITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00478049","NCT00268255","NCT01933347","NCT01000740","NCT00020709"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:32.132Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::erlotinib::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"ERLOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:31.746Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T125326-aad286c6::nivolumab::non-small_cell_lung_cancer","analysisId":"20260315T125326-aad286c6","recordedAt":"2026-03-15T12:53:27.162Z","drug":"NIVOLUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04500535","NCT02041533","NCT03326752","NCT05022394","NCT04310007"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-22","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:31.354Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123652-3a29aab7::lecanemab::alzheimers_disease","analysisId":"20260315T123652-3a29aab7","recordedAt":"2026-03-15T12:36:52.072Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:21.912Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123652-3a29aab7::donepezil::alzheimers_disease","analysisId":"20260315T123652-3a29aab7","recordedAt":"2026-03-15T12:36:52.072Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T19:14:30.553Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123652-3a29aab7::donanemab::alzheimers_disease","analysisId":"20260315T123652-3a29aab7","recordedAt":"2026-03-15T12:36:52.072Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:21.527Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123652-3a29aab7::galantamine::alzheimers_disease","analysisId":"20260315T123652-3a29aab7","recordedAt":"2026-03-15T12:36:52.072Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:21.140Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123652-3a29aab7::rivastigmine::alzheimers_disease","analysisId":"20260315T123652-3a29aab7","recordedAt":"2026-03-15T12:36:52.072Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:20.754Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123652-3a29aab7::aducanumab::alzheimers_disease","analysisId":"20260315T123652-3a29aab7","recordedAt":"2026-03-15T12:36:52.072Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:20.369Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:59:16.507Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:59:19.978Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:59:19.212Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:18.833Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:18.444Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:18.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:59:17.662Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:59:17.286Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::olaparib::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:19.594Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123405-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T123405-99db93fe","recordedAt":"2026-03-15T12:34:05.920Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:59:16.895Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:15.338Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:13.762Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:15.729Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:12.977Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:13.377Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:14.158Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:36.473Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:59:16.123Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:14.551Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123143-cd023095::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T123143-cd023095","recordedAt":"2026-03-15T12:31:43.683Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:59:14.942Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123130-16889da3::troglitazone::type_2_diabetes_mellitus","analysisId":"20260315T123130-16889da3","recordedAt":"2026-03-15T12:31:30.710Z","drug":"TROGLITAZONE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02475499","NCT02476760","NCT01068860","NCT01055223","NCT02456428"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-01-25","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:34.176Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123130-16889da3::pioglitazone_hydrochloride::type_2_diabetes_mellitus","analysisId":"20260315T123130-16889da3","recordedAt":"2026-03-15T12:31:30.710Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00770835","NCT06399835","NCT00722631","NCT00240370","NCT05305287"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-18","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:33.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123130-16889da3::insulin,_regular,_human::type_2_diabetes_mellitus","analysisId":"20260315T123130-16889da3","recordedAt":"2026-03-15T12:31:30.710Z","drug":"INSULIN, REGULAR, HUMAN","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["SLC2A4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00916357","NCT03102801","NCT02205996","NCT01865279","NCT00228878"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-29","trialPhase":"Phase 2/PHASE3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:35.732Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123130-16889da3::glyburide::type_2_diabetes_mellitus","analysisId":"20260315T123130-16889da3","recordedAt":"2026-03-15T12:31:30.710Z","drug":"GLYBURIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00770835","NCT00313313","NCT00388986","NCT01456650","NCT03089333"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-04-12","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:34.950Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123130-16889da3::glipizide::type_2_diabetes_mellitus","analysisId":"20260315T123130-16889da3","recordedAt":"2026-03-15T12:31:30.710Z","drug":"GLIPIZIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["SLC2A4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00350779","NCT00707993","NCT00946504","NCT01698775","NCT02475499"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-11","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:34.567Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123130-16889da3::metformin::type_2_diabetes_mellitus","analysisId":"20260315T123130-16889da3","recordedAt":"2026-03-15T12:31:30.710Z","drug":"METFORMIN","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","TCF7L2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01349387","NCT00473525","NCT00817271","NCT00970593","NCT00770835"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-05-15","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:35.338Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T123130-16889da3::rosiglitazone_maleate::type_2_diabetes_mellitus","analysisId":"20260315T123130-16889da3","recordedAt":"2026-03-15T12:31:30.710Z","drug":"ROSIGLITAZONE MALEATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00615212","NCT00150410","NCT00350779","NCT01332370","NCT00571506"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-08","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:36.118Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::capecitabine::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:33.011Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::cetuximab::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:30.283Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::bevacizumab::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:31.053Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::atezolizumab::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:29.905Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:31.838Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::encorafenib::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:31.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::fruquintinib::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:30.668Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::fluorouracil::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:33.400Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::ipilimumab::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:32.235Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122850-28812772::nivolumab::colorectal_cancer","analysisId":"20260315T122850-28812772","recordedAt":"2026-03-15T12:28:50.043Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:32.626Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T22:17:37.558Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::genistein::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"GENISTEIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T22:17:37.181Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::procarbazine_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"PROCARBAZINE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T22:17:36.805Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::pioglitazone_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T22:17:37.934Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::interleukin-11::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"INTERLEUKIN-11","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T22:17:38.682Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::melatonin::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"MELATONIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T22:17:38.311Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::lithium::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"LITHIUM","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T18:23:42.516Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::sorbitol::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"SORBITOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T18:23:42.140Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T18:23:41.757Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122638-0a88fbce::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260315T122638-0a88fbce","recordedAt":"2026-03-15T12:26:38.483Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T18:23:41.382Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:29.137Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:28.749Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:26.391Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:28.359Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:27.585Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:27.174Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:27.974Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:29.520Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:26.778Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T122606-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T122606-c46e28d2","recordedAt":"2026-03-15T12:26:07.851Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:26.125Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121739-3a29aab7::donanemab::alzheimers_disease","analysisId":"20260315T121739-3a29aab7","recordedAt":"2026-03-15T12:17:39.586Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:24.255Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121739-3a29aab7::donepezil::alzheimers_disease","analysisId":"20260315T121739-3a29aab7","recordedAt":"2026-03-15T12:17:39.586Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:25.033Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121739-3a29aab7::aducanumab::alzheimers_disease","analysisId":"20260315T121739-3a29aab7","recordedAt":"2026-03-15T12:17:39.586Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:25.615Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121739-3a29aab7::galantamine::alzheimers_disease","analysisId":"20260315T121739-3a29aab7","recordedAt":"2026-03-15T12:17:39.586Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:25.220Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121739-3a29aab7::rivastigmine::alzheimers_disease","analysisId":"20260315T121739-3a29aab7","recordedAt":"2026-03-15T12:17:39.586Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:25.416Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121739-3a29aab7::lecanemab::alzheimers_disease","analysisId":"20260315T121739-3a29aab7","recordedAt":"2026-03-15T12:17:39.586Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:24.643Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:22.891Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:22.700Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:22.505Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:21.580Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:20.463Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:23.283Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:23.083Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::olaparib::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:22.321Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:21.202Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121500-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T121500-99db93fe","recordedAt":"2026-03-15T12:15:00.316Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:21.935Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:16.541Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:18.498Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:17.410Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:16.934Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:16.145Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:15.747Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:18.885Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:18.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:19.007Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T121231-cd023095::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T121231-cd023095","recordedAt":"2026-03-15T12:12:31.980Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:19.410Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:13.003Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:14.181Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:11.823Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:12.209Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:12.601Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:15.353Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:13.782Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:13.392Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:14.963Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120948-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T120948-5b7100d5","recordedAt":"2026-03-15T12:09:48.653Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:14.571Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::veliparib::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:08.675Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:07.864Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::paclitaxel::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:10.665Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::carboplatin::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:08.269Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:11.440Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::niraparib::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:11.053Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::olaparib::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:10.274Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::rucaparib::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:09.882Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::tamoxifen::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:09.487Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T120733-56260220::talazoparib::breast_cancer","analysisId":"20260315T120733-56260220","recordedAt":"2026-03-15T12:07:34.376Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:55:09.079Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:07.476Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:37.162Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:36.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::olaparib::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:36.388Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:37.539Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:37.923Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:38.308Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:38.695Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:39.102Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101810-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T101810-99db93fe","recordedAt":"2026-03-15T10:18:10.202Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:55:07.081Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:35.225Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:36.008Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:34.832Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:34.434Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:34.031Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:33.633Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:35.616Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:33.236Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:32.455Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101548-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T101548-c6b7ce28","recordedAt":"2026-03-15T10:15:48.391Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:32.846Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::trametinib_dimethyl_sulfoxide::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"TRAMETINIB DIMETHYL SULFOXIDE","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04439292"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-06-19","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:32.061Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::regorafenib::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:30.462Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::cetuximab::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:30.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:30.080Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::vemurafenib::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"VEMURAFENIB","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05540951","NCT01791309","NCT02164916","NCT01787500","NCT02291289"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-02-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:28.572Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::encorafenib::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:28.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::gemcitabine::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"GEMCITABINE","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00007943","NCT06333314","NCT01909830","NCT02711137"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-04-13","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:28.961Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::panitumumab::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:31.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::pembrolizumab::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:29.720Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101447-9dd83c0b::nivolumab::colorectal_cancer","analysisId":"20260315T101447-9dd83c0b","recordedAt":"2026-03-15T10:14:47.139Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:29.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:24.726Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:25.895Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:25.504Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:25.117Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:24.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:27.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:26.666Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:26.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:27.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101316-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T101316-5b7100d5","recordedAt":"2026-03-15T10:13:16.855Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:27.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:21.170Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:52:20.368Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:22.731Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:23.547Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:23.129Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:22.342Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:21.954Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:23.939Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:21.560Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T101052-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T101052-c46e28d2","recordedAt":"2026-03-15T10:10:54.011Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:20.764Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T052154-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T052154-33db16bd","recordedAt":"2026-03-15T05:21:54.126Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:52.298Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T052154-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T052154-33db16bd","recordedAt":"2026-03-15T05:21:54.126Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:53.010Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T052154-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T052154-33db16bd","recordedAt":"2026-03-15T05:21:54.126Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:52.654Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T052154-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T052154-33db16bd","recordedAt":"2026-03-15T05:21:54.126Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:19.970Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T052154-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T052154-33db16bd","recordedAt":"2026-03-15T05:21:54.126Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:52:19.573Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T052154-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T052154-33db16bd","recordedAt":"2026-03-15T05:21:54.126Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:51.942Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:49.588Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:49.987Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:50.391Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:48.031Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:50.789Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::olaparib::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:51.585Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:51.190Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:48.414Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:48.810Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051733-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T051733-99db93fe","recordedAt":"2026-03-15T05:17:33.812Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:49.192Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:47.641Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:45.276Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:44.101Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:44.886Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:47.246Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:44.493Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:45.666Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:46.052Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:46.441Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051520-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T051520-c6b7ce28","recordedAt":"2026-03-15T05:15:20.193Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:46.841Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:41.768Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::ipilimumab::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:42.156Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::encorafenib::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:43.709Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::cetuximab::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:42.926Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::bevacizumab::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:40.213Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::capecitabine::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:39.829Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::atezolizumab::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:43.318Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::nivolumab::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:40.990Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::fruquintinib::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:41.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051304-28812772::fluorouracil::colorectal_cancer","analysisId":"20260315T051304-28812772","recordedAt":"2026-03-15T05:13:04.841Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:42.541Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:37.874Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:39.446Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:38.667Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:38.263Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:37.484Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:36.694Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:36.307Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:35.902Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:39.052Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T051029-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T051029-c46e28d2","recordedAt":"2026-03-15T05:10:30.315Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:50:37.082Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033341-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T033341-33db16bd","recordedAt":"2026-03-15T03:33:41.814Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:35.095Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033341-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T033341-33db16bd","recordedAt":"2026-03-15T03:33:41.814Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:34.294Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033341-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T033341-33db16bd","recordedAt":"2026-03-15T03:33:41.814Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:34.694Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033341-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T033341-33db16bd","recordedAt":"2026-03-15T03:33:41.814Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:35.503Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033341-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T033341-33db16bd","recordedAt":"2026-03-15T03:33:41.814Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:33.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033341-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T033341-33db16bd","recordedAt":"2026-03-15T03:33:41.814Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:50:33.497Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::abemaciclib::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:23.757Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::palbociclib::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:21.042Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:21.826Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::fluorouracil::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:20.655Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::olaparib::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:24.138Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::dabrafenib::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:22.210Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::temozolomide::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:22.599Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:22.989Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::nivolumab::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:21.438Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T033122-99db93fe::ipilimumab::pan-cancer","analysisId":"20260315T033122-99db93fe","recordedAt":"2026-03-15T03:31:23.014Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:23.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:20.268Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:19.069Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:17.883Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:16.706Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:17.495Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:19.466Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:41:17.101Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:18.671Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:18.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032905-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T032905-c6b7ce28","recordedAt":"2026-03-15T03:29:05.806Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:41:19.873Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:03.989Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:03.597Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:03.211Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:02.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:02.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:02.417Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:01.636Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:01.248Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:38:00.852Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032641-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T032641-5b7100d5","recordedAt":"2026-03-15T03:26:41.546Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:04.376Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:56.900Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:57.690Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:58.483Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:58.871Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:59.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:59.676Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:38:00.463Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:38:00.065Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:58.080Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T032422-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T032422-c46e28d2","recordedAt":"2026-03-15T03:24:23.420Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:37:57.291Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012531-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260315T012531-33db16bd","recordedAt":"2026-03-15T01:25:31.133Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:07.124Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012531-33db16bd::donanemab::alzheimers_disease","analysisId":"20260315T012531-33db16bd","recordedAt":"2026-03-15T01:25:31.133Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:07.833Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012531-33db16bd::donepezil::alzheimers_disease","analysisId":"20260315T012531-33db16bd","recordedAt":"2026-03-15T01:25:31.133Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:08.219Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012531-33db16bd::galantamine::alzheimers_disease","analysisId":"20260315T012531-33db16bd","recordedAt":"2026-03-15T01:25:31.133Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:08.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012531-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260315T012531-33db16bd","recordedAt":"2026-03-15T01:25:31.133Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:08.979Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012531-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260315T012531-33db16bd","recordedAt":"2026-03-15T01:25:31.133Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:07.479Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::fluorouracil::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:36:03.300Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::abemaciclib::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:36:06.771Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:36:05.996Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::pembrolizumab::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:36:06.385Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::dabrafenib::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:36:05.228Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::palbociclib::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:04.839Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::temozolomide::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:36:04.459Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::nivolumab::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:04.075Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::ipilimumab::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:03.686Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T012236-65d64218::olaparib::pan-cancer","analysisId":"20260315T012236-65d64218","recordedAt":"2026-03-15T01:22:36.998Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:05.609Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:59.378Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:36:00.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:36:02.911Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:00.557Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:59.772Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:02.518Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:02.127Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:01.726Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:01.336Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011954-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260315T011954-c6b7ce28","recordedAt":"2026-03-15T01:19:54.705Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:36:00.948Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:55.496Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:56.663Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:56.273Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:55.891Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:58.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:58.606Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:58.222Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:57.444Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:57.835Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011706-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260315T011706-5b7100d5","recordedAt":"2026-03-15T01:17:06.114Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:35:57.055Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:52.740Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:52.349Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T17:35:54.715Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::olaparib::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:51.956Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::rucaparib::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:51.562Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::niraparib::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:53.536Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:53.932Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::talazoparib::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:54.328Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::veliparib::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:55.105Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260315T011428-c46e28d2::carboplatin::breast_cancer","analysisId":"20260315T011428-c46e28d2","recordedAt":"2026-03-15T01:14:29.407Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:53.142Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215251-3a29aab7::rivastigmine::alzheimers_disease","analysisId":"20260314T215251-3a29aab7","recordedAt":"2026-03-14T21:52:51.804Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:50.379Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215251-3a29aab7::galantamine::alzheimers_disease","analysisId":"20260314T215251-3a29aab7","recordedAt":"2026-03-14T21:52:51.804Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:32.823Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215251-3a29aab7::donepezil::alzheimers_disease","analysisId":"20260314T215251-3a29aab7","recordedAt":"2026-03-14T21:52:51.804Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:32.439Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215251-3a29aab7::lecanemab::alzheimers_disease","analysisId":"20260314T215251-3a29aab7","recordedAt":"2026-03-14T21:52:51.804Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:49.990Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215251-3a29aab7::donanemab::alzheimers_disease","analysisId":"20260314T215251-3a29aab7","recordedAt":"2026-03-14T21:52:51.804Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:51.163Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215251-3a29aab7::aducanumab::alzheimers_disease","analysisId":"20260314T215251-3a29aab7","recordedAt":"2026-03-14T21:52:51.804Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T17:35:50.772Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::abemaciclib::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:01:29.948Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::dabrafenib::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:01:32.053Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::nivolumab::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:31.677Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::olaparib::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:31.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::fluorouracil::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:01:30.729Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::palbociclib::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:30.340Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:01:29.570Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::temozolomide::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:01:29.181Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::ipilimumab::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:28.797Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T215011-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260314T215011-99db93fe","recordedAt":"2026-03-14T21:50:11.309Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:01:28.418Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:25.663Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:25.276Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:00:07.994Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:28.036Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:27.650Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:27.264Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:26.436Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:26.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:01:26.869Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214800-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260314T214800-c6b7ce28","recordedAt":"2026-03-14T21:48:00.304Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:00:07.641Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:06.229Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:04.464Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:04.817Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:05.170Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:05.523Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:05.876Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:06.582Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:07.288Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T16:00:06.935Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214558-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260314T214558-5b7100d5","recordedAt":"2026-03-14T21:45:58.541Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:04.112Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214412-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260314T214412-91dbcf4e","recordedAt":"2026-03-14T21:44:12.928Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:03.759Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214412-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260314T214412-91dbcf4e","recordedAt":"2026-03-14T21:44:12.928Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:03.369Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214412-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260314T214412-91dbcf4e","recordedAt":"2026-03-14T21:44:12.928Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:02.974Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::carboplatin::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:02.592Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:59.623Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::talazoparib::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:59.980Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::olaparib::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:00.367Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::rucaparib::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:01.144Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::niraparib::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:01.533Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::veliparib::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:01.886Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:02.239Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:59:59.270Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214332-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260314T214332-c46e28d2","recordedAt":"2026-03-14T21:43:33.280Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T16:00:00.751Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:56.158Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:58.112Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:57.719Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:59:58.500Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:59:55.382Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:55.767Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:58.890Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:56.546Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:56.935Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T214012-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260314T214012-c6b7ce28","recordedAt":"2026-03-14T21:40:12.525Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:57.325Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:54.991Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:59:54.214Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:53.447Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:54.595Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:53.832Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:52.683Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:53.067Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:51.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:52.302Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213808-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260314T213808-5b7100d5","recordedAt":"2026-03-14T21:38:08.865Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:51.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::rucaparib::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:12.989Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:43:12.634Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::veliparib::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:51.145Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::niraparib::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:14.052Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::carboplatin::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:49.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:13.698Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:50.753Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:50.372Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::talazoparib::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:59:49.975Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213541-c46e28d2::olaparib::breast_cancer","analysisId":"20260314T213541-c46e28d2","recordedAt":"2026-03-14T21:35:42.908Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:13.344Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:09.555Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:09.935Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::rucaparib::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:10.329Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::olaparib::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:09.170Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:08.778Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:43:11.108Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::veliparib::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:11.892Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::niraparib::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:12.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::carboplatin::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:11.502Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T213238-c46e28d2::talazoparib::breast_cancer","analysisId":"20260314T213238-c46e28d2","recordedAt":"2026-03-14T21:32:39.111Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:10.724Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::abemaciclib::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"ABEMACICLIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06630325","NCT06561022"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2024-08-19","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:43:08.004Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::niraparib::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"NIRAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T12:53:38.923Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::talazoparib::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"TALAZOPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T12:31:50.965Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::veliparib::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"VELIPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T12:53:41.569Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::anastrozole::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"ANASTROZOLE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T12:53:40.809Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::olaparib::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"OLAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299999","NCT06630325","NCT02624973"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:43:08.388Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::sacituzumab_govitecan::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-26","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:43:07.233Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::ado-trastuzumab_emtansine::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"ADO-TRASTUZUMAB EMTANSINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T12:53:40.438Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::rucaparib::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"RUCAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T12:53:39.303Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T211816-68e7fb0c::capecitabine::breast_cancer_precision_medicine","analysisId":"20260314T211816-68e7fb0c","recordedAt":"2026-03-14T21:18:16.780Z","drug":"CAPECITABINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102824","NCT02299999"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T15:43:07.619Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194817-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260314T194817-91dbcf4e","recordedAt":"2026-03-14T19:48:17.122Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T15:43:06.851Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194817-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260314T194817-91dbcf4e","recordedAt":"2026-03-14T19:48:17.122Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:47.702Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194817-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260314T194817-91dbcf4e","recordedAt":"2026-03-14T19:48:17.122Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:47.307Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194802-33db16bd::galantamine::alzheimers_disease","analysisId":"20260314T194802-33db16bd","recordedAt":"2026-03-14T19:48:04.375Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:45.740Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194802-33db16bd::donepezil::alzheimers_disease","analysisId":"20260314T194802-33db16bd","recordedAt":"2026-03-14T19:48:04.375Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:45.356Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194802-33db16bd::donanemab::alzheimers_disease","analysisId":"20260314T194802-33db16bd","recordedAt":"2026-03-14T19:48:04.375Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:44.970Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194802-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260314T194802-33db16bd","recordedAt":"2026-03-14T19:48:04.375Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:46.913Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194802-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260314T194802-33db16bd","recordedAt":"2026-03-14T19:48:04.375Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:46.518Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194802-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260314T194802-33db16bd","recordedAt":"2026-03-14T19:48:04.375Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:46.136Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194357-677edf52::hydroxychloroquine::rheumatoid_arthritis","analysisId":"20260314T194357-677edf52","recordedAt":"2026-03-14T19:43:57.567Z","drug":"HYDROXYCHLOROQUINE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT05016297","NCT00908089","NCT05670535","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2009-05-25","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:43.409Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194357-677edf52::etanercept::rheumatoid_arthritis","analysisId":"20260314T194357-677edf52","recordedAt":"2026-03-14T19:43:57.567Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT03781375","NCT00920478","NCT00913458","NCT01137838"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-04","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:42.646Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194357-677edf52::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260314T194357-677edf52","recordedAt":"2026-03-14T19:43:57.567Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00160602","NCT00993668","NCT02319642","NCT01147341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-12","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:42.256Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194357-677edf52::adalimumab::rheumatoid_arthritis","analysisId":"20260314T194357-677edf52","recordedAt":"2026-03-14T19:43:57.567Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01162421","NCT00497614","NCT03223012","NCT01197144","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-06","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:44.579Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194357-677edf52::lenalidomide::rheumatoid_arthritis","analysisId":"20260314T194357-677edf52","recordedAt":"2026-03-14T19:43:57.567Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q) myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-alpha and IL-6) by monocytes. In multiple myeloma cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-15T12:31:46.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194357-677edf52::infliximab::rheumatoid_arthritis","analysisId":"20260314T194357-677edf52","recordedAt":"2026-03-14T19:43:57.567Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02925338","NCT00394589","NCT00908089","NCT00095147","NCT01927263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-02","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:43.807Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194357-677edf52::rituximab::rheumatoid_arthritis","analysisId":"20260314T194357-677edf52","recordedAt":"2026-03-14T19:43:57.567Z","drug":"RITUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01534884","NCT01075477","NCT00468546","NCT06003283","NCT01196780"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-05-02","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:44.191Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194357-677edf52::golimumab::rheumatoid_arthritis","analysisId":"20260314T194357-677edf52","recordedAt":"2026-03-14T19:43:57.567Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05842213","NCT04188249","NCT01217814","NCT01698515"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:43.026Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::abemaciclib::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:39.812Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:39.043Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::nivolumab::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:41.873Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:39.434Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::ipilimumab::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:38.274Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::temozolomide::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:38.657Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::olaparib::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:41.477Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::fluorouracil::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:41.095Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::dabrafenib::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:40.706Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T194344-99db93fe::palbociclib::pan-cancer","analysisId":"20260314T194344-99db93fe","recordedAt":"2026-03-14T19:43:45.754Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:40.206Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:36.823Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:35.048Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:34.694Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:36.469Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:37.888Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:37.178Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:37.533Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:36.114Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:35.758Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193916-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260314T193916-c6b7ce28","recordedAt":"2026-03-14T19:39:18.277Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:35.403Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:30.788Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:31.193Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:31.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:32.377Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:32.768Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:33.946Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:33.163Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-25T14:02:31.593Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:33.556Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193649-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260314T193649-c6b7ce28","recordedAt":"2026-03-14T19:36:49.205Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:34.339Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:29.805Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:28.823Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:29.213Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:29.603Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:29.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-25T14:02:30.396Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:31.274Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:30.919Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:30.565Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193356-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260314T193356-5b7100d5","recordedAt":"2026-03-14T19:33:56.247Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:30.207Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::rucaparib::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:27.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::niraparib::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:27.441Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::carboplatin::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:28.255Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::talazoparib::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:28.657Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:29.053Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:29.450Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:25.837Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:27.826Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::olaparib::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:26.226Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T193155-c46e28d2::veliparib::breast_cancer","analysisId":"20260314T193155-c46e28d2","recordedAt":"2026-03-14T19:31:56.689Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:26.628Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175632-33db16bd::donepezil::alzheimers_disease","analysisId":"20260314T175632-33db16bd","recordedAt":"2026-03-14T17:56:32.650Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:24.256Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175632-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260314T175632-33db16bd","recordedAt":"2026-03-14T17:56:32.650Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:23.856Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175632-33db16bd::donanemab::alzheimers_disease","analysisId":"20260314T175632-33db16bd","recordedAt":"2026-03-14T17:56:32.650Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:24.647Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175632-33db16bd::galantamine::alzheimers_disease","analysisId":"20260314T175632-33db16bd","recordedAt":"2026-03-14T17:56:32.650Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:25.048Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175632-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260314T175632-33db16bd","recordedAt":"2026-03-14T17:56:32.650Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:25.433Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175632-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260314T175632-33db16bd","recordedAt":"2026-03-14T17:56:32.650Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:23.461Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::doxorubicin_hydrochloride::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06333314","NCT04872985","NCT00933985"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2009-07-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:19.953Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:22.678Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::palbociclib::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:22.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::abemaciclib::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:21.897Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::temozolomide::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:21.519Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::nivolumab::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:21.126Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::olaparib::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"OLAPARIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04532645","NCT06739395"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-08-31","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:20.733Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::dabrafenib::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:19.563Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::fluorouracil::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"FLUOROURACIL","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06279130","NCT05585320","NCT06068023","NCT06607185","NCT06055166"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:20.352Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":5,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175318-99db93fe::ipilimumab::pan-cancer","analysisId":"20260314T175318-99db93fe","recordedAt":"2026-03-14T17:53:18.657Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:23.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:17.568Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:15.498Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:16.717Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:17.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:18.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:19.177Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:15.899Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:17.135Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:16.314Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T175053-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260314T175053-c6b7ce28","recordedAt":"2026-03-14T17:50:53.601Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:45:18.773Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:11.784Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:15.096Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:14.696Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:14.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::ipilimumab::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"IPILIMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05176483","NCT04500548","NCT03752398","NCT05456165","NCT03442569"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-02-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:13.889Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:13.470Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::fruquintinib::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"FRUQUINTINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05025631","NCT06979908","NCT06010888","NCT05571644","NCT04733963"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2021-02-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:12.604Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:13.026Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:45:12.198Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174750-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260314T174750-5b7100d5","recordedAt":"2026-03-14T17:47:50.088Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:38:39.805Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::propranolol_hydrochloride::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"PROPRANOLOL HYDROCHLORIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:36.904Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::fluticasone::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:35.594Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::nicotine_polacrilex::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"NICOTINE POLACRILEX","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:33.884Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::dactinomycin::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:34.312Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::methylphenidate_hydrochloride::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"METHYLPHENIDATE HYDROCHLORIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:34.741Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::tramadol::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"TRAMADOL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:35.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::lithium::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"LITHIUM","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00095355"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:39.416Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::zinc_sulfate_anhydrous::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"ZINC SULFATE ANHYDROUS","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:36.027Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::capsaicin::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"CAPSAICIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:36.449Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174509-8ac6221f::nortriptyline::huntington's_disease","analysisId":"20260314T174509-8ac6221f","recordedAt":"2026-03-14T17:45:09.405Z","drug":"NORTRIPTYLINE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T21:18:37.335Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::veliparib::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:37.973Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::olaparib::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:37.618Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::carboplatin::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:36.125Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::tamoxifen::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:36.835Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:36.480Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::niraparib::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:39.037Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::sacituzumab_govitecan::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:38:37.219Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::paclitaxel::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:35.770Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::talazoparib::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:38.682Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T174449-b44315aa::rucaparib::breast_cancer","analysisId":"20260314T174449-b44315aa","recordedAt":"2026-03-14T17:45:00.799Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:38.328Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::procarbazine_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"PROCARBAZINE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:38.375Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::genistein::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"GENISTEIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:38.833Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:39.311Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::pioglitazone_hydrochloride::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:39.735Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::melatonin::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"MELATONIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:40.172Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::interleukin-11::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"INTERLEUKIN-11","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:40.592Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:36.623Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:37.045Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::sorbitol::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"SORBITOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:37.520Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T164918-288f873c::lithium::neurodegeneration_biomarker_panel","analysisId":"20260314T164918-288f873c","recordedAt":"2026-03-14T16:49:20.644Z","drug":"LITHIUM","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T19:48:37.955Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163449-33db16bd::rivastigmine::alzheimers_disease","analysisId":"20260314T163449-33db16bd","recordedAt":"2026-03-14T16:34:49.928Z","drug":"RIVASTIGMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:34.605Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163449-33db16bd::donepezil::alzheimers_disease","analysisId":"20260314T163449-33db16bd","recordedAt":"2026-03-14T16:34:49.928Z","drug":"DONEPEZIL","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:33.840Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163449-33db16bd::galantamine::alzheimers_disease","analysisId":"20260314T163449-33db16bd","recordedAt":"2026-03-14T16:34:49.928Z","drug":"GALANTAMINE","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:34.224Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163449-33db16bd::lecanemab::alzheimers_disease","analysisId":"20260314T163449-33db16bd","recordedAt":"2026-03-14T16:34:49.928Z","drug":"LECANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:33.457Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163449-33db16bd::donanemab::alzheimers_disease","analysisId":"20260314T163449-33db16bd","recordedAt":"2026-03-14T16:34:49.928Z","drug":"DONANEMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:35.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163449-33db16bd::aducanumab::alzheimers_disease","analysisId":"20260314T163449-33db16bd","recordedAt":"2026-03-14T16:34:49.928Z","drug":"ADUCANUMAB","disease":"alzheimers disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:34.998Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::palbociclib::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"PALBOCICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06126276","NCT03065387","NCT06739395","NCT03238196"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-02-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:33.071Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::navtemadlin::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"NAVTEMADLIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["MDM2","TP53"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T16:49:48.573Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::ipilimumab::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"IPILIMUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02492815","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-07-09","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:30.771Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::dabrafenib::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"DABRAFENIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-10-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:38:31.922Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::temozolomide::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"TEMOZOLOMIDE","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04566380","NCT03899155","NCT06739395"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:38:32.307Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::abemaciclib::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"ABEMACICLIB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05774899"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-03-20","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:38:32.685Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::nivolumab::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"NIVOLUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02702492","NCT04566380","NCT03899155","NCT03668119"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2016-03-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:31.542Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::pembrolizumab::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"PEMBROLIZUMAB","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05585320","NCT06607185","NCT03899155"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-04-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:38:31.153Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::granisetron::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"GRANISETRON","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T16:49:47.700Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163251-99db93fe::idasanutlin::pan-cancer","analysisId":"20260314T163251-99db93fe","recordedAt":"2026-03-14T16:32:51.512Z","drug":"IDASANUTLIN","disease":"pan-cancer","genes":["CDKN2A","MDM2","TP53"],"targets":["MDM2","TP53"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T16:49:48.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::alectinib::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:29.207Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::afatinib_dimaleate::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"AFATINIB DIMALEATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:29.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::capmatinib::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"CAPMATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["MET"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.","trialNctIds":["NCT04323436","NCT04741789","NCT04816214","NCT05110196","NCT02323126"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:28.815Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::ceritinib::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:30.383Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::crizotinib::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:26.856Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::cemiplimab::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"CEMIPLIMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06616584","NCT06052852","NCT06918132","NCT05429866","NCT03515629"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2018-05-03","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:38:29.604Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::amivantamab::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:38:28.030Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::brigatinib::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:27.637Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::atezolizumab::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"ATEZOLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03976518","NCT05102214","NCT05395052","NCT04214262"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-06-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:28.423Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T163054-c6b7ce28::afatinib::non-small_cell_lung_cancer","analysisId":"20260314T163054-c6b7ce28","recordedAt":"2026-03-14T16:30:54.596Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","MET"],"targets":["ALK","EGFR","MET"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:27.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00160602","NCT00993668","NCT02319642","NCT01147341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-12","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:26.074Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::hydroxychloroquine::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"HYDROXYCHLOROQUINE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT05016297","NCT00908089","NCT05670535","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2009-05-25","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:23.736Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::rilonacept::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"RILONACEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00534495","NCT00094900"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:26.454Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::lenalidomide::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T16:29:10.180Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::siltuximab::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"SILTUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T16:29:10.601Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::golimumab::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05842213","NCT04188249","NCT01217814","NCT01698515"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:24.125Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::infliximab::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02925338","NCT00394589","NCT00908089","NCT00095147","NCT01927263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-02","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:24.525Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::adalimumab::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01162421","NCT00497614","NCT03223012","NCT01197144","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-06","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:25.686Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::rituximab::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"RITUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01534884","NCT01075477","NCT00468546","NCT06003283","NCT01196780"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-05-02","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:24.910Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162839-677edf52::etanercept::rheumatoid_arthritis","analysisId":"20260314T162839-677edf52","recordedAt":"2026-03-14T16:28:39.193Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT03781375","NCT00920478","NCT00913458","NCT01137838"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-04","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:25.298Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00003038","NCT01640847","NCT00027885","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:22.956Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::tamoxifen::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"TAMOXIFEN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03280563","NCT04129216","NCT00003042","NCT00482391","NCT02344550"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:23.351Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":2,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::paclitaxel::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:50.884Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:51.275Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::olaparib::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:51.671Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::niraparib::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:20.944Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::carboplatin::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:21.346Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::veliparib::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"VELIPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02985658","NCT02163694","NCT01042379","NCT01366144","NCT01281150"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:21.770Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::rucaparib::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:22.173Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T162759-c46e28d2::talazoparib::breast_cancer","analysisId":"20260314T162759-c46e28d2","recordedAt":"2026-03-14T16:28:04.606Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:38:22.567Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:49.061Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:49.774Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:50.130Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:49.418Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:48.705Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:47.636Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T16:08:01.314Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:48.348Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:47.992Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T160735-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260314T160735-5b7100d5","recordedAt":"2026-03-14T16:07:35.229Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:50.486Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::rivaroxaban::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"RIVAROXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04925219","NCT03718429","NCT05009862","NCT04824729","NCT04853719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-10-24","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:44.505Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::apixaban::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"APIXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04229264"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-01-18","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:45.307Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::alirocumab::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03507374","NCT03273972","NCT03559309","NCT06080256"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-06","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:44.109Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::atorvastatin_calcium_trihydrate::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T13:51:49.628Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::dabigatran::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"DABIGATRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02544932","NCT01352702","NCT06058130","NCT04847752"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-05-12","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:44.915Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::edoxaban::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"EDOXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04010955","NCT01802775"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-03-01","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:45.698Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::evolocumab::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"EVOLOCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04416425","NCT04306081","NCT05585151","NCT03829046"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-04","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:46.091Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::inclisiran::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04929249","NCT06249165","NCT05362903","NCT04873934","NCT06126367"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2021-05-05","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:46.486Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::lovastatin::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02548936","NCT00125593","NCT04638400","NCT01105975","NCT00127218"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-08-01","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:46.885Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T135136-8cdebcc8::pravastatin_sodium::atherosclerosis","analysisId":"20260314T135136-8cdebcc8","recordedAt":"2026-03-14T13:51:36.241Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00127218","NCT00000461","NCT00054938","NCT01872845","NCT00147797"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-28","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:47.281Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132457-da593734::cinpanemab::parkinson's_disease","analysisId":"20260314T132457-da593734","recordedAt":"2026-03-14T13:24:57.924Z","drug":"CINPANEMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T13:25:21.682Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:43.714Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:43.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:42.879Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:42.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:41.663Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:41.265Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:40.868Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:40.474Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T13:21:41.942Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T132128-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260314T132128-5b7100d5","recordedAt":"2026-03-14T13:21:28.759Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:42.076Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::donanemab::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:38.440Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::lecanemab::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:39.260Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:37.995Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::avagacestat::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"AVAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01002079","NCT00890890","NCT00901498","NCT00726726","NCT01057030"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:39.653Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::rivastigmine::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:38.843Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::semagacestat::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"SEMAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00762411","NCT01035138","NCT00594568"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:37.575Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::crenezumab::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"CRENEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:37.158Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::galantamine::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:36.738Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::az7188::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"AZ7188","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T13:17:02.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T131650-3067acf1::donepezil::alzheimer's_disease","analysisId":"20260314T131650-3067acf1","recordedAt":"2026-03-14T13:16:50.031Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:40.065Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::capecitabine::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"CAPECITABINE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT06787339","NCT06134375","NCT04443348","NCT04333706"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-04-03","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:32.958Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::carboplatin::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:33.835Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::abemaciclib::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"ABEMACICLIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT06365788","NCT03130439","NCT05867251"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:35.520Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::cyclophosphamide_anhydrous::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"CYCLOPHOSPHAMIDE ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T13:03:04.648Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::cemiplimab::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"CEMIPLIMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06052852","NCT01042379","NCT06022029","NCT04916002","NCT04954599"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:34.261Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::talazoparib::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"TALAZOPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT05035745","NCT03911973"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:34.681Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::niraparib::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"NIRAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT04762901","NCT03945721","NCT05461690","NCT04178460"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:35.090Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::rucaparib::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"RUCAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01074970","NCT03101280","NCT03992131","NCT03911453","NCT03542175"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:35.924Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::olaparib::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"OLAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02789332","NCT01042379","NCT05209529","NCT03594396","NCT02681562"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:36.336Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T130252-ac05ef48::atezolizumab::triple-negative_breast_cancer","analysisId":"20260314T130252-ac05ef48","recordedAt":"2026-03-14T13:02:52.171Z","drug":"ATEZOLIZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02322814","NCT03197935","NCT05742269","NCT04770272","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T23:32:33.411Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::levonorgestrel::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:13.164Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::onapristone::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:11.427Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::budesonide::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:11.874Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::dydrogesterone::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:12.307Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::fluticasone::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:12.736Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:13.590Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::norethindrone::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:14.015Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::progesterone::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:14.457Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::zileuton::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:14.886Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124555-8ac6221f::apr19::huntington's_disease","analysisId":"20260314T124555-8ac6221f","recordedAt":"2026-03-14T12:45:55.244Z","drug":"APR19","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:46:15.309Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T124105-357e5474::rovelizumab::systemic_lupus_erythematosus","analysisId":"20260314T124105-357e5474","recordedAt":"2026-03-14T12:41:05.565Z","drug":"ROVELIZUMAB","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:41:13.073Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::olaparib::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"OLAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299999","NCT06630325","NCT02624973"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:39.471Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::carboplatin::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"CARBOPLATIN","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102824","NCT02299999","NCT06630325"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:39.080Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::capecitabine::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"CAPECITABINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102824","NCT02299999"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:32.145Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::rucaparib::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"RUCAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:35:52.366Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::ado-trastuzumab_emtansine::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"ADO-TRASTUZUMAB EMTANSINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:35:53.324Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::niraparib::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"NIRAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:35:51.935Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::abemaciclib::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"ABEMACICLIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06630325","NCT06561022"],"trialFound":true,"trialCompleted":false,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2024-08-19","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:39.861Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::talazoparib::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"TALAZOPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:35:51.467Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::anastrozole::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"ANASTROZOLE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:35:53.749Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T123541-bfd42066::docetaxel_anhydrous::breast_cancer_precision_medicine","analysisId":"20260314T123541-bfd42066","recordedAt":"2026-03-14T12:35:41.497Z","drug":"DOCETAXEL ANHYDROUS","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299999","NCT02624973"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T23:32:32.551Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:36.203Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:36.913Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:37.267Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:37.621Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:37.975Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:38.329Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:38.684Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:35.847Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:20:29.643Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T120150-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260314T120150-5b7100d5","recordedAt":"2026-03-14T12:01:50.784Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:36.558Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T011637-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260314T011637-91dbcf4e","recordedAt":"2026-03-14T01:16:37.819Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:34.688Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T011637-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260314T011637-91dbcf4e","recordedAt":"2026-03-14T01:16:37.819Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:35.102Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T011637-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260314T011637-91dbcf4e","recordedAt":"2026-03-14T01:16:37.819Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:35.493Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::bevacizumab::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"BEVACIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06060704","NCT04247984","NCT01399684","NCT02162563"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-22","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:32.777Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:02:06.517Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::fluorouracil::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"FLUOROURACIL","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT06275958","NCT01399684"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:31.268Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:31.623Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:31.977Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:32.386Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::atezolizumab::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"ATEZOLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06555133","NCT05395052","NCT06603818","NCT06557278","NCT04017455"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-07-12","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:33.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::capecitabine::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"CAPECITABINE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04247984","NCT06275958","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-01-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:33.572Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:34.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004843-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260314T004843-5b7100d5","recordedAt":"2026-03-14T00:48:43.668Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:33.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::nivolumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"NIVOLUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:02:02.132Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::dabrafenib::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"DABRAFENIB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":[],"confidence":"0.800","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:01:59.964Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::trametinib::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"TRAMETINIB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":[],"confidence":"0.800","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:02:00.388Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::avelumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"AVELUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:02:00.822Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::dostarlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:02:01.260Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::cemiplimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:49:03.724Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::durvalumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"DURVALUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:02:01.705Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::pembrolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T12:02:02.561Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::ipilimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"IPILIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:49:02.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260314T004157-f8f8fa3f::atezolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260314T004157-f8f8fa3f","recordedAt":"2026-03-14T00:42:00.018Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:49:03.274Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:59.882Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:58.440Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["B2M","BRAF","CD274","JAK1","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:58.013Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::avelumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"AVELUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:49:02.346Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::tremelimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:49:01.909Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:49:01.477Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:49:01.019Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:49:00.586Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:59.337Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T010145-cdd27892::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T010145-cdd27892","recordedAt":"2026-03-13T01:01:45.287Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","PDCD1","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:58.869Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::copanlisib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"COPANLISIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Pan-class I PI3K inhibitor; targets PTEN-loss-driven AKT/mTOR hyperactivation in IO-resistant tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:55.808Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:54.951Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["CTLA4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:54.438Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::ruxolitinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"RUXOLITINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["JAK1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"JAK1/JAK2 inhibitor; reduces IFN-gamma signaling and PD-L1 upregulation in immunosuppressive TME","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:57.586Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:53.587Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["LAG3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:55.382Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::cobolimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"COBOLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["HAVCR2"],"confidence":"0.300","phase":"Phase 2","mechanism":"Anti-TIM-3 monoclonal antibody; targets terminal T-cell exhaustion marker; in Phase 2/3 trials for NSCLC and melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:57.135Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::trametinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"TRAMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["BRAF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:56.709Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:54.014Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260313T005810-04c91828::dabrafenib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260313T005810-04c91828","recordedAt":"2026-03-13T00:58:10.692Z","drug":"DABRAFENIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["BRAF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-14T00:48:56.250Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::lapatinib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02158507","NCT01272141","NCT01426880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-01-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:28.805Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::pertuzumab::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"PERTUZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05180006","NCT05582499","NCT05020860","NCT04193059"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:29.620Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::erlotinib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:29.203Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::olaparib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"OLAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02789332","NCT01042379","NCT05209529","NCT03594396","NCT02681562"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:30.057Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::rucaparib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"RUCAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01074970","NCT03101280","NCT03992131","NCT03911453","NCT03542175"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:30.457Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::brigatinib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T16:56:17.287Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::niraparib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"NIRAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT04762901","NCT03945721","NCT05461690","NCT04178460"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:28.413Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::tucatinib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"TUCATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05868226","NCT06157892"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:28.005Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::neratinib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"NERATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT01111825","NCT06008275","NCT03812393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:27.607Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T165546-ac05ef48::talazoparib::triple-negative_breast_cancer","analysisId":"20260312T165546-ac05ef48","recordedAt":"2026-03-12T16:55:46.369Z","drug":"TALAZOPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT05035745","NCT03911973"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:30.865Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::gefitinib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:23.613Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::afatinib_dimaleate::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:24.835Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::neratinib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:27.181Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::vandetanib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:26.412Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::osimertinib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:26.797Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::sunitinib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:25.625Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::lapatinib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:25.231Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::afatinib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:24.033Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::regorafenib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:26.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T150140-68ebe42d::erlotinib::glioblastoma","analysisId":"20260312T150140-68ebe42d","recordedAt":"2026-03-12T15:01:40.067Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN","PDGFRA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:24.427Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:05.988Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["B2M","BRAF","CD274","JAK1","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:04.150Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:04.625Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","PDCD1","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:05.065Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:05.555Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:06.406Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:06.897Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:07.405Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::tremelimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:07.895Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T142935-b0d06aca::avelumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T142935-b0d06aca","recordedAt":"2026-03-12T14:29:35.583Z","drug":"AVELUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T14:30:08.325Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:46:00.545Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:46:01.021Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:46:01.470Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:46:01.896Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:46:02.368Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::tremelimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:46:03.053Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::avelumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"AVELUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:46:03.528Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["B2M","BRAF","CD274","JAK1","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:45:59.253Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:45:59.683Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T044538-01dd6ef0::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T044538-01dd6ef0","recordedAt":"2026-03-12T04:45:38.140Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","PDCD1","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:46:00.113Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:24.756Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::sotorasib::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:24.400Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:21.180Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:45:20.731Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:22.400Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:22.809Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::temsirolimus::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:23.224Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:22.002Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:24:04.634Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T042335-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260312T042335-5b7100d5","recordedAt":"2026-03-12T04:23:35.232Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:45:21.597Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::avelumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"AVELUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:24:02.483Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::tremelimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:24:02.033Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:24:01.580Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:24:01.144Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:24:00.715Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:24:00.275Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:23:59.811Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","PDCD1","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:23:59.385Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:23:58.952Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T021233-479cd4a9::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260312T021233-479cd4a9","recordedAt":"2026-03-12T02:12:33.875Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["B2M","BRAF","CD274","JAK1","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T04:23:58.530Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:21.687Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:21.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::temsirolimus::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:20.908Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:22.876Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T02:13:20.089Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:22.489Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::sotorasib::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:22.082Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:24.044Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:23.655Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260312T005512-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260312T005512-5b7100d5","recordedAt":"2026-03-12T00:55:12.820Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:23.269Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::adalimumab::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF","IL6"],"confidence":"0.800","phase":"FDA Approved","mechanism":"A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.","trialNctIds":["NCT01162421","NCT00497614","NCT03223012","NCT01197144","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-06","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:20.114Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::infliximab::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02925338","NCT00394589","NCT00908089","NCT00095147","NCT01927263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-02","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:19.707Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::golimumab::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05842213","NCT04188249","NCT01217814","NCT01698515"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:19.291Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00160602","NCT00993668","NCT02319642","NCT01147341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-12","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:17.737Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::lenalidomide::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T02:13:15.658Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::siltuximab::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"SILTUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T02:13:16.100Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::etanercept::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT03781375","NCT00920478","NCT00913458","NCT01137838"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-04","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:20.510Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::rituximab::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"RITUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01534884","NCT01075477","NCT00468546","NCT06003283","NCT01196780"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-05-02","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:18.908Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::rilonacept::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"RILONACEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00534495","NCT00094900"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-28","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:18.126Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T235911-677edf52::hydroxychloroquine::rheumatoid_arthritis","analysisId":"20260311T235911-677edf52","recordedAt":"2026-03-11T23:59:11.525Z","drug":"HYDROXYCHLOROQUINE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT05016297","NCT00908089","NCT05670535","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2009-05-25","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:18.518Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T234237-da593734::prasinezumab::parkinson's_disease","analysisId":"20260311T234237-da593734","recordedAt":"2026-03-11T23:42:37.608Z","drug":"PRASINEZUMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03100149","NCT04777331"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-04-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:16.958Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T234237-da593734::pergolide::parkinson's_disease","analysisId":"20260311T234237-da593734","recordedAt":"2026-03-11T23:42:37.608Z","drug":"PERGOLIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.","trialNctIds":["NCT00605683","NCT00624741","NCT00234364","NCT00202657","NCT00311532"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:17.342Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T234237-da593734::cinpanemab::parkinson's_disease","analysisId":"20260311T234237-da593734","recordedAt":"2026-03-11T23:42:37.608Z","drug":"CINPANEMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T02:13:09.087Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T234237-da593734::selegiline::parkinson's_disease","analysisId":"20260311T234237-da593734","recordedAt":"2026-03-11T23:42:37.608Z","drug":"SELEGILINE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.","trialNctIds":["NCT02225548","NCT00443872","NCT04968613","NCT00640159","NCT00282152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-01-25","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:16.570Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::tucatinib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"TUCATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05868226","NCT06157892"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:14.758Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::neratinib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"NERATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT01111825","NCT06008275","NCT03812393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:13.687Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::lapatinib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02158507","NCT01272141","NCT01426880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-01-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:13.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::niraparib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"NIRAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT04762901","NCT03945721","NCT05461690","NCT04178460"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:16.181Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::erlotinib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:15.470Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::olaparib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"OLAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02789332","NCT01042379","NCT05209529","NCT03594396","NCT02681562"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:14.401Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::talazoparib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"TALAZOPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT05035745","NCT03911973"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:14.045Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::brigatinib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T02:13:08.579Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::rucaparib::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"RUCAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01074970","NCT03101280","NCT03992131","NCT03911453","NCT03542175"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:15.114Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T230905-1d871595::pertuzumab::triple-negative_breast_cancer","analysisId":"20260311T230905-1d871595","recordedAt":"2026-03-11T23:09:05.089Z","drug":"PERTUZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05180006","NCT05582499","NCT05020860","NCT04193059"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:15.826Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::tremelimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:46.268Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:45.801Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:45.381Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:44.947Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:44.521Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:44.096Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","PDCD1","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:43.623Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::avelumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"AVELUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:46.692Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:43.198Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T225649-a025770c::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T225649-a025770c","recordedAt":"2026-03-11T22:56:49.590Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["B2M","BRAF","CD274","JAK1","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:42.660Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:37.541Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::ruxolitinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"RUXOLITINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["JAK1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"JAK1/JAK2 inhibitor; reduces IFN-gamma signaling and PD-L1 upregulation in immunosuppressive TME","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:42.225Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::cobolimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"COBOLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["HAVCR2"],"confidence":"0.300","phase":"Phase 2","mechanism":"Anti-TIM-3 monoclonal antibody; targets terminal T-cell exhaustion marker; in Phase 2/3 trials for NSCLC and melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:41.765Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::trametinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"TRAMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["BRAF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:41.320Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::dabrafenib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"DABRAFENIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["BRAF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:40.819Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::copanlisib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"COPANLISIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Pan-class I PI3K inhibitor; targets PTEN-loss-driven AKT/mTOR hyperactivation in IO-resistant tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:40.279Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["LAG3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-12T00:55:39.842Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:38.811Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["CTLA4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:38.388Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T224727-4c79f9b4::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T224727-4c79f9b4","recordedAt":"2026-03-11T22:47:27.774Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:37.963Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::relatlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"RELATLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:37.115Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::tremelimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:36.686Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::ipilimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"IPILIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:36.263Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::dostarlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:35.840Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::avelumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"AVELUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:35.397Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::atezolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:34.955Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::pembrolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:34.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::nivolumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"NIVOLUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:34.103Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::durvalumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"DURVALUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:33.678Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T222702-f8f8fa3f::cemiplimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T222702-f8f8fa3f","recordedAt":"2026-03-11T22:27:02.252Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:33.251Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T202912-d1bec9c9::bepranemab::neurodegeneration_biomarker_panel","analysisId":"20260311T202912-d1bec9c9","recordedAt":"2026-03-11T20:29:12.791Z","drug":"BEPRANEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:30.655Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T202912-d1bec9c9::tilavonemab::neurodegeneration_biomarker_panel","analysisId":"20260311T202912-d1bec9c9","recordedAt":"2026-03-11T20:29:12.791Z","drug":"TILAVONEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:32.362Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T202912-d1bec9c9::posdinemab::neurodegeneration_biomarker_panel","analysisId":"20260311T202912-d1bec9c9","recordedAt":"2026-03-11T20:29:12.791Z","drug":"POSDINEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:31.511Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T202912-d1bec9c9::zagotenemab::neurodegeneration_biomarker_panel","analysisId":"20260311T202912-d1bec9c9","recordedAt":"2026-03-11T20:29:12.791Z","drug":"ZAGOTENEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:32.832Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T202912-d1bec9c9::semorinemab::neurodegeneration_biomarker_panel","analysisId":"20260311T202912-d1bec9c9","recordedAt":"2026-03-11T20:29:12.791Z","drug":"SEMORINEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:31.938Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T202912-d1bec9c9::gosuranemab::neurodegeneration_biomarker_panel","analysisId":"20260311T202912-d1bec9c9","recordedAt":"2026-03-11T20:29:12.791Z","drug":"GOSURANEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:31.086Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T201849-357e5474::rovelizumab::systemic_lupus_erythematosus","analysisId":"20260311T201849-357e5474","recordedAt":"2026-03-11T20:18:49.661Z","drug":"ROVELIZUMAB","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:30.232Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::neratinib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"NERATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT01111825","NCT06008275","NCT03812393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:12.975Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::pertuzumab::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"PERTUZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05180006","NCT05582499","NCT05020860","NCT04193059"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:10.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::brigatinib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:59:29.803Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::erlotinib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:09.846Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::talazoparib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"TALAZOPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT05035745","NCT03911973"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:10.642Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::rucaparib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"RUCAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01074970","NCT03101280","NCT03992131","NCT03911453","NCT03542175"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:11.032Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::olaparib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"OLAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02789332","NCT01042379","NCT05209529","NCT03594396","NCT02681562"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:11.422Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::lapatinib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02158507","NCT01272141","NCT01426880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-01-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:11.809Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::niraparib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"NIRAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT04762901","NCT03945721","NCT05461690","NCT04178460"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:12.197Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T200658-ac05ef48::tucatinib::triple-negative_breast_cancer","analysisId":"20260311T200658-ac05ef48","recordedAt":"2026-03-11T20:06:58.624Z","drug":"TUCATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05868226","NCT06157892"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:12.586Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::afatinib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:05.936Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::erlotinib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN","PDGFRA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:06.333Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::neratinib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:32:09.455Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::lapatinib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:07.116Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::gefitinib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:07.896Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::osimertinib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:08.282Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::sunitinib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:08.678Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::afatinib_dimaleate::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:09.072Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::regorafenib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:07.504Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T195027-bf3608f6::vandetanib::glioblastoma","analysisId":"20260311T195027-bf3608f6","recordedAt":"2026-03-11T19:50:27.070Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:32:06.722Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:09:36.394Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["B2M","BRAF","CD274","JAK1","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:09:35.964Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","PDCD1","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:09:36.832Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::avelumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"AVELUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:43:08.461Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::tremelimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:43:08.034Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:43:07.591Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:43:07.161Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:43:06.614Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:09:37.682Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T194044-cdd27892::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T194044-cdd27892","recordedAt":"2026-03-11T19:40:44.892Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:09:37.258Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00160602","NCT00993668","NCT02319642","NCT01147341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-12","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:26.587Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::hydroxychloroquine::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"HYDROXYCHLOROQUINE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT05016297","NCT00908089","NCT05670535","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2009-05-25","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:26.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::rituximab::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"RITUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01534884","NCT01075477","NCT00468546","NCT06003283","NCT01196780"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-05-02","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:27.756Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::adalimumab::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF","IL6"],"confidence":"0.800","phase":"FDA Approved","mechanism":"A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.","trialNctIds":["NCT01162421","NCT00497614","NCT03223012","NCT01197144","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-06","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:27.366Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::lenalidomide::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:09:34.667Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::rilonacept::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"RILONACEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00534495","NCT00094900"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-28","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:28.139Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::siltuximab::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"SILTUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:09:35.090Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::golimumab::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05842213","NCT04188249","NCT01217814","NCT01698515"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:25.403Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::infliximab::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02925338","NCT00394589","NCT00908089","NCT00095147","NCT01927263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-02","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:25.804Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T190555-677edf52::etanercept::rheumatoid_arthritis","analysisId":"20260311T190555-677edf52","recordedAt":"2026-03-11T19:05:55.919Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT03781375","NCT00920478","NCT00913458","NCT01137838"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-04","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:26.197Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::osimertinib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:24.305Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::afatinib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:24.661Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::neratinib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:27:23.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::sunitinib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:22.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::lapatinib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:22.173Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::vandetanib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:21.817Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::erlotinib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN","PDGFRA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:25.016Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::gefitinib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:23.595Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::afatinib_dimaleate::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:23.950Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T184628-bf3608f6::regorafenib::glioblastoma","analysisId":"20260311T184628-bf3608f6","recordedAt":"2026-03-11T18:46:28.203Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:22.884Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::afatinib_dimaleate::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:17.967Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::sunitinib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:21.461Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::vandetanib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:18.744Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::gefitinib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:18.355Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::neratinib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:27:21.072Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::lapatinib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:20.689Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::afatinib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:20.302Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::osimertinib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:19.913Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::regorafenib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:19.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T170211-bf3608f6::erlotinib::glioblastoma","analysisId":"20260311T170211-bf3608f6","recordedAt":"2026-03-11T17:02:11.477Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN","PDGFRA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:19.141Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::atorvastatin_calcium_trihydrate::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:04:09.133Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::rosuvastatin::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"ROSUVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02532309","NCT05585151","NCT01105975","NCT06604117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-04-19","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:17.197Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::apixaban::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"APIXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04229264"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-01-18","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:27:15.251Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::pravastatin_sodium::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00127218","NCT00000461","NCT00054938","NCT01872845","NCT00147797"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-28","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:14.482Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::evolocumab::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"EVOLOCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9","LDLR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04416425","NCT04306081","NCT05585151","NCT03829046"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-04","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:14.866Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::dabigatran::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"DABIGATRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02544932","NCT01352702","NCT06058130","NCT04847752"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-05-12","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:27:15.636Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::lovastatin::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02548936","NCT00125593","NCT04638400","NCT01105975","NCT00127218"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-08-01","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:16.026Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::inclisiran::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04929249","NCT06249165","NCT05362903","NCT04873934","NCT06126367"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2021-05-05","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:16.416Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::alirocumab::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03507374","NCT03273972","NCT03559309","NCT06080256"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-06","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:16.807Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T165749-8c5b9a71::edoxaban::atherosclerosis","analysisId":"20260311T165749-8c5b9a71","recordedAt":"2026-03-11T16:57:49.791Z","drug":"EDOXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04010955","NCT01802775"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-03-01","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:17.578Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:10.953Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::temsirolimus::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:14.098Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:27:12.506Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:12.119Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::sotorasib::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:27:11.344Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:13.306Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:13.700Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:47.937Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:12.909Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T164858-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260311T164858-5b7100d5","recordedAt":"2026-03-11T16:48:58.455Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:11.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::durvalumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"DURVALUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:41.580Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::avelumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"AVELUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:43.332Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::relatlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"RELATLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:45.606Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::cemiplimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:41.089Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::atezolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:42.878Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::pembrolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:42.453Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::nivolumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"NIVOLUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:42.006Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::tremelimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:45.170Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::ipilimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"IPILIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:44.419Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T163323-3708f5c0::dostarlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T163323-3708f5c0","recordedAt":"2026-03-11T16:33:23.723Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:43.943Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::decitabine::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05426798","NCT02085408","NCT03358719","NCT06113289","NCT06802523"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-12","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:10.564Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::sunitinib::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"SUNITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02779283","NCT00783653","NCT00387426","NCT03878524","NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2006-10-13","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:10.167Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::pacritinib::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"PACRITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04282187","NCT02532010","NCT01620216","NCT02323607"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2012-06-15","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:09.769Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::midostaurin::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01846624","NCT00233454","NCT02624570","NCT00866281","NCT00093600"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-08","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:27:09.366Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::daunorubicin_liposomal::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3","NPM1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01236144","NCT02652871","NCT02085408","NCT02403310","NCT01587430"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-11-08","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:22.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::ponatinib::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"PONATINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02779283","NCT01424982","NCT03147612","NCT03934372","NCT01207440"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-23","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:21.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::gilteritinib_fumarate::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"GILTERITINIB FUMARATE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070093","NCT06734585","NCT05564390","NCT02927262","NCT04293562"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:21.239Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::azacitidine::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05426798","NCT02085408","NCT01835587"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-04-19","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:20.833Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::gilteritinib::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03070093","NCT06734585","NCT05564390","NCT02927262","NCT04293562"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:22.382Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T161627-ae6826c9::sorafenib::acute_myeloid_leukemia","analysisId":"20260311T161627-ae6826c9","recordedAt":"2026-03-11T16:16:27.673Z","drug":"SORAFENIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05596981","NCT01254890","NCT01253070","NCT02779283","NCT03622541"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-12-03","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:22.771Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["B2M","BRAF","CD274","JAK1","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:13.739Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::tremelimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:18.042Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::avelumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"AVELUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:18.766Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:17.457Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:17.012Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:16.452Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:15.738Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:15.295Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","PDCD1","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:14.823Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T153653-b0d06aca::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T153653-b0d06aca","recordedAt":"2026-03-11T15:36:53.428Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:14.384Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::tucatinib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"TUCATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05868226","NCT06157892"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:19.338Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::rucaparib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"RUCAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01074970","NCT03101280","NCT03992131","NCT03911453","NCT03542175"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:18.598Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::niraparib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"NIRAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT04762901","NCT03945721","NCT05461690","NCT04178460"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:18.207Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::pertuzumab::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"PERTUZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05180006","NCT05582499","NCT05020860","NCT04193059"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:20.084Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::brigatinib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:03:13.312Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::talazoparib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"TALAZOPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT05035745","NCT03911973"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:17.818Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::olaparib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"OLAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02789332","NCT01042379","NCT05209529","NCT03594396","NCT02681562"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:17.426Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::lapatinib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02158507","NCT01272141","NCT01426880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-01-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:20.440Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::neratinib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"NERATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT01111825","NCT06008275","NCT03812393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:19.692Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T152342-ac05ef48::erlotinib::triple-negative_breast_cancer","analysisId":"20260311T152342-ac05ef48","recordedAt":"2026-03-11T15:23:42.690Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:18.953Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::semagacestat::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"SEMAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00762411","NCT01035138","NCT00594568"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-15","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:14.320Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::lecanemab::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:16.266Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::donepezil::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:17.039Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::avagacestat::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"AVAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01002079","NCT00890890","NCT00901498","NCT00726726","NCT01057030"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:16.652Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::crenezumab::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"CRENEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:15.878Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::rivastigmine::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"RIVASTIGMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01183806","NCT04731311","NCT00627848","NCT05564169"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-03","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:15.484Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:15.101Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::galantamine::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"GALANTAMINE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01872598","NCT01029132","NCT05564169","NCT03565809","NCT01054976"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-09","trialPhase":"NA","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:13.923Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::donanemab::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:14.711Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T150431-3067acf1::az7188::alzheimer's_disease","analysisId":"20260311T150431-3067acf1","recordedAt":"2026-03-11T15:04:32.691Z","drug":"AZ7188","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:02:30.280Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143858-da593734::pergolide::parkinson's_disease","analysisId":"20260311T143858-da593734","recordedAt":"2026-03-11T14:38:59.415Z","drug":"PERGOLIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.","trialNctIds":["NCT00605683","NCT00624741","NCT00234364","NCT00202657","NCT00311532"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:12.760Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143858-da593734::cinpanemab::parkinson's_disease","analysisId":"20260311T143858-da593734","recordedAt":"2026-03-11T14:38:59.415Z","drug":"CINPANEMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:02:24.068Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143858-da593734::prasinezumab::parkinson's_disease","analysisId":"20260311T143858-da593734","recordedAt":"2026-03-11T14:38:59.415Z","drug":"PRASINEZUMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03100149","NCT04777331"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-04-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:13.538Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143858-da593734::selegiline::parkinson's_disease","analysisId":"20260311T143858-da593734","recordedAt":"2026-03-11T14:38:59.415Z","drug":"SELEGILINE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.","trialNctIds":["NCT02225548","NCT00443872","NCT04968613","NCT00640159","NCT00282152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-01-25","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:13.149Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::lapatinib::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"LAPATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:02:21.101Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::tucatinib::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"TUCATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:02:23.418Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::margetuximab::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"MARGETUXIMAB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:02:22.983Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::fam-trastuzumab_deruxtecan-nxki::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"FAM-TRASTUZUMAB DERUXTECAN-NXKI","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:02:22.556Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::ado-trastuzumab_emtansine::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"ADO-TRASTUZUMAB EMTANSINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:02:22.126Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::neratinib::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"NERATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T23:02:21.542Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::rucaparib::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"RUCAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:24.897Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::talazoparib::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"TALAZOPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:24.040Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::olaparib::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"OLAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299999","NCT06630325","NCT02624973"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:12.375Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T143049-68e7fb0c::niraparib::breast_cancer_precision_medicine","analysisId":"20260311T143049-68e7fb0c","recordedAt":"2026-03-11T14:30:49.845Z","drug":"NIRAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:24.469Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::relatlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"RELATLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["LAG3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:20.766Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::nivolumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"NIVOLUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:20.245Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::trametinib::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"TRAMETINIB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:22.700Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::dostarlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:19.651Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::ruxolitinib::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"RUXOLITINIB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"JAK1/JAK2 inhibitor; reduces IFN-gamma signaling and PD-L1 upregulation in immunosuppressive TME","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:23.125Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::ipilimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"IPILIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:22.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::pembrolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:19.184Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::dabrafenib::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"DABRAFENIB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:21.837Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T142021-72b5e056::cobolimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T142021-72b5e056","recordedAt":"2026-03-11T14:20:21.776Z","drug":"COBOLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["HAVCR2"],"confidence":"0.300","phase":"Phase 2","mechanism":"Anti-TIM-3 monoclonal antibody; targets terminal T-cell exhaustion marker; in Phase 2/3 trials for NSCLC and melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:21.374Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::relatlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"RELATLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:18.747Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::ipilimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"IPILIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:17.735Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::tremelimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:18.301Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::cemiplimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:14.460Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::durvalumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"DURVALUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:15.123Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::nivolumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"NIVOLUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:15.585Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::pembrolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:16.009Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::atezolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:16.457Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::avelumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"AVELUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:16.882Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T141801-3708f5c0::dostarlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T141801-3708f5c0","recordedAt":"2026-03-11T14:18:02.461Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:57:17.302Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::ceritinib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:10.015Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::erlotinib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"ERLOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:09.622Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::gefitinib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"GEFITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00478049","NCT00268255","NCT01933347","NCT01000740","NCT00020709"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:08.843Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::adagrasib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"ADAGRASIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05609578","NCT06039384","NCT06875310","NCT05853575","NCT05673187"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-11-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:10.803Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:11.595Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::crizotinib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:11.209Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::afatinib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:10.410Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::brigatinib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:09.233Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::alectinib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:08.453Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134627-78e027ed::sotorasib::non-small_cell_lung_cancer","analysisId":"20260311T134627-78e027ed","recordedAt":"2026-03-11T13:46:27.402Z","drug":"SOTORASIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05631249","NCT06333678","NCT04959981","NCT05273047","NCT05311709"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2021-07-13","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:11.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:04.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::sotorasib::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:05.306Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:06.098Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:05.708Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:47:55.802Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:06.883Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::temsirolimus::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:06.488Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:08.055Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::tovorafenib::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:14:07.266Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T134350-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260311T134350-5b7100d5","recordedAt":"2026-03-11T13:43:51.450Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:07.655Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::olaparib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"OLAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02789332","NCT01042379","NCT05209529","NCT03594396","NCT02681562"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:06.775Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::talazoparib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"TALAZOPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT05035745","NCT03911973"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:01:07.190Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::pertuzumab::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"PERTUZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05180006","NCT05582499","NCT05020860","NCT04193059"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:01:08.292Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::lapatinib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02158507","NCT01272141","NCT01426880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-01-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:04.510Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::brigatinib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:47:53.650Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::neratinib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"NERATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT01111825","NCT06008275","NCT03812393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:03.725Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::tucatinib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"TUCATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05868226","NCT06157892"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:01:07.937Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::rucaparib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"RUCAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01074970","NCT03101280","NCT03992131","NCT03911453","NCT03542175"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:08.685Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::niraparib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"NIRAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT04762901","NCT03945721","NCT05461690","NCT04178460"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:01:07.583Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T133713-ac05ef48::erlotinib::triple-negative_breast_cancer","analysisId":"20260311T133713-ac05ef48","recordedAt":"2026-03-11T13:37:14.967Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:14:04.116Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:05.710Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::avelumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"AVELUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:07.024Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::tremelimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:06.591Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:06.148Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:05.285Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:04.850Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:04.415Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","PDCD1","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:03.960Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:03.533Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T132156-cdd27892::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T132156-cdd27892","recordedAt":"2026-03-11T13:21:56.485Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["B2M","BRAF","CD274","JAK1","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:03.063Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::pembrolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:39.829Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::ruxolitinib::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"RUXOLITINIB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"JAK1/JAK2 inhibitor; reduces IFN-gamma signaling and PD-L1 upregulation in immunosuppressive TME","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:02.625Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::trametinib::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"TRAMETINIB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:02.184Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::ipilimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"IPILIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:01.746Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::dabrafenib::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"DABRAFENIB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":[],"confidence":"0.300","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:01.295Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::cobolimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"COBOLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["HAVCR2"],"confidence":"0.300","phase":"Phase 2","mechanism":"Anti-TIM-3 monoclonal antibody; targets terminal T-cell exhaustion marker; in Phase 2/3 trials for NSCLC and melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:00.855Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::relatlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"RELATLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["LAG3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:45:00.427Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::nivolumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"NIVOLUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:40.691Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T131443-72b5e056::dostarlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T131443-72b5e056","recordedAt":"2026-03-11T13:14:43.974Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD8A","CXCL9","CXCL10","PDCD1","CD274","LAG3","TIGIT","HAVCR2"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:40.256Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::durvalumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"DURVALUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:35.807Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::nivolumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"NIVOLUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:36.236Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::cemiplimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:35.360Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::relatlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"RELATLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:39.378Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::tremelimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:38.878Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::ipilimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"IPILIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:38.453Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::dostarlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:38.027Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::avelumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"AVELUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:37.543Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::atezolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:37.104Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T125327-3708f5c0::pembrolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T125327-3708f5c0","recordedAt":"2026-03-11T12:53:27.294Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:36.668Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::pembrolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1","CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:31.063Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::avelumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"AVELUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:34.932Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::cemiplimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:34.508Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::relatlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"RELATLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["LAG3"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:34.083Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::tremelimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"TREMELIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:33.650Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::ipilimumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"IPILIMUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:33.213Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::durvalumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"DURVALUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274","PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:32.791Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::dostarlimab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:32.360Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::atezolizumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["CD274"],"confidence":"0.800","phase":"Phase 2","mechanism":"A monoclonal antibody that targets programmed death-ligand 1 (CD274 ANTIGEN) and is used to treat urothelial carcinoma, the most common type of bladder cancer.","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:31.933Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T042013-3708f5c0::nivolumab::metastatic_melanoma_inflamed_tme_checkpoint_immunotherapy_candidate","analysisId":"20260311T042013-3708f5c0","recordedAt":"2026-03-11T04:20:13.616Z","drug":"NIVOLUMAB","disease":"metastatic melanoma inflamed TME checkpoint immunotherapy candidate","genes":["CD274","CD8A","CXCL10","CXCL9","HAVCR2","LAG3","PDCD1","TIGIT"],"targets":["PDCD1","CD274"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T22:27:31.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1","B2M","BRAF","CD274","JAK1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:26.467Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::trametinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"TRAMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:30.304Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:27.308Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::dabrafenib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"DABRAFENIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:29.886Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:29.466Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:29.049Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:28.582Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:28.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CTLA4","BRAF","CD274","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:27.723Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T041344-597ad629::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T041344-597ad629","recordedAt":"2026-03-11T04:13:44.999Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1","BRAF","CD274","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:26.890Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1","BRAF","CD274","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:22.554Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CTLA4","BRAF","CD274","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:23.461Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::trametinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"TRAMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:26.042Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:24.734Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:24.310Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:23.885Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::durvalumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"DURVALUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:25.202Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::dabrafenib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"DABRAFENIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:25.623Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1","B2M","BRAF","CD274","JAK1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:22.066Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260311T030648-4b147bde::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260311T030648-4b147bde","recordedAt":"2026-03-11T03:06:48.316Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:29:23.030Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::tucatinib::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"TUCATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05091528","NCT04579380","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:03.938Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::crizotinib::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:03.231Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::brigatinib::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:05.358Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::pembrolizumab::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"PEMBROLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05609578","NCT04585750","NCT04964479","NCT05627960"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-10-14","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:01:05.711Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::pemetrexed_disodium::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"PEMETREXED DISODIUM","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00698815","NCT03366064","NCT05014464","NCT05940532","NCT02041533"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:06.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::bevacizumab::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"BEVACIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02596958","NCT01995188","NCT06313268","NCT00578149","NCT00666692"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-21","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:06.420Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::lapatinib::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"LAPATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02230553","NCT00073008","NCT04591431","NCT01306045","NCT00313599"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:03.585Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::cisplatin::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"CISPLATIN","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00005825","NCT02041533","NCT05609578","NCT01066234","NCT03413358"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:04.292Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::carboplatin::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"CARBOPLATIN","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00004011","NCT05014464","NCT05940532","NCT02041533","NCT05609578"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:04.648Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T140945-9b9a01fa::osimertinib_mesylate::non-small_cell_lung_cancer","analysisId":"20260310T140945-9b9a01fa","recordedAt":"2026-03-10T14:09:45.432Z","drug":"OSIMERTINIB MESYLATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02197234","NCT02503722","NCT06970639","NCT06067776"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-22","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:05.002Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T133107-85a0b316::bikeap1::oxidative_stress_cancer_biomarker","analysisId":"20260310T133107-85a0b316","recordedAt":"2026-03-10T13:31:08.403Z","drug":"BIKEAP1","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1"],"targets":["KEAP1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:45.368Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T133107-85a0b316::ml385::oxidative_stress_cancer_biomarker","analysisId":"20260310T133107-85a0b316","recordedAt":"2026-03-10T13:31:08.403Z","drug":"ML385","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1"],"targets":["NFE2L2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:44.953Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T133107-85a0b316::monomethyl_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260310T133107-85a0b316","recordedAt":"2026-03-10T13:31:08.403Z","drug":"MONOMETHYL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1"],"targets":["KEAP1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:44.541Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T133107-85a0b316::diroximel_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260310T133107-85a0b316","recordedAt":"2026-03-10T13:31:08.403Z","drug":"DIROXIMEL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1"],"targets":["KEAP1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:44.127Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T133107-85a0b316::bardoxolone_methyl::oxidative_stress_cancer_biomarker","analysisId":"20260310T133107-85a0b316","recordedAt":"2026-03-10T13:31:08.403Z","drug":"BARDOXOLONE METHYL","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1"],"targets":["KEAP1","NFE2L2"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:43.711Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T133107-85a0b316::omaveloxolone::oxidative_stress_cancer_biomarker","analysisId":"20260310T133107-85a0b316","recordedAt":"2026-03-10T13:31:08.403Z","drug":"OMAVELOXOLONE","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1"],"targets":["NFE2L2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:43.294Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T133107-85a0b316::dimethyl_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260310T133107-85a0b316","recordedAt":"2026-03-10T13:31:08.403Z","drug":"DIMETHYL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1"],"targets":["KEAP1","NFE2L2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:42.879Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260310T133107-85a0b316::nrf2_peptide_[pmid:_23647822]::oxidative_stress_cancer_biomarker","analysisId":"20260310T133107-85a0b316","recordedAt":"2026-03-10T13:31:08.403Z","drug":"NRF2 PEPTIDE [PMID: 23647822]","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1"],"targets":["KEAP1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:42:55.964Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::capivasertib::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"CAPIVASERTIB","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03742102","NCT03801369","NCT04556773","NCT03997123","NCT04712396"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-11-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:59.811Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::granisetron::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"GRANISETRON","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:42.049Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::cisplatin::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:02.065Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::carboplatin::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:01.711Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::olaparib::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"OLAPARIB","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02789332","NCT01042379","NCT05209529","NCT03594396","NCT02681562"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:01.356Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::capecitabine::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"CAPECITABINE","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04849364","NCT06787339","NCT06134375","NCT04443348","NCT04333706"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-04-03","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:01:00.963Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::epirubicin::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"EPIRUBICIN","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT03154749","NCT02789332","NCT03799679"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:00.565Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::paclitaxel::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:00.164Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::siremadlin::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"SIREMADLIN","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02890069"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-07","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:02.878Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T231739-fab108e9::ipilimumab::triple-negative_breast_cancer","analysisId":"20260309T231739-fab108e9","recordedAt":"2026-03-09T23:17:41.077Z","drug":"IPILIMUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03752398","NCT06342037","NCT03326258","NCT03126110","NCT03815890"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-04-24","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:01:02.476Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::afatinib_dimaleate::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:56.223Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::sunitinib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:59.407Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::lapatinib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:59.053Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::neratinib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:58.698Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::gefitinib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:57.638Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::vandetanib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:57.284Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::erlotinib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:56.930Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::osimertinib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:56.576Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::afatinib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:58.345Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T203416-bf3608f6::regorafenib::glioblastoma","analysisId":"20260309T203416-bf3608f6","recordedAt":"2026-03-09T20:34:16.895Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:57.992Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175819-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260309T175819-91dbcf4e","recordedAt":"2026-03-09T17:58:19.887Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:55.869Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175819-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260309T175819-91dbcf4e","recordedAt":"2026-03-09T17:58:19.887Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:55.160Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175819-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260309T175819-91dbcf4e","recordedAt":"2026-03-09T17:58:19.887Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:55.515Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::atorvastatin_calcium_trihydrate::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:20.409Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::apixaban::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"APIXABAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04229264"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-01-18","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:54.400Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::rosuvastatin::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"ROSUVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02532309","NCT05585151","NCT01105975","NCT06604117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-04-19","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:54.805Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::inclisiran::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"INCLISIRAN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR","PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04929249","NCT06249165","NCT05362903","NCT04873934","NCT06126367"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2021-05-05","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:52.918Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::alirocumab::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"ALIROCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["LDLR","PCSK9"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03507374","NCT03273972","NCT03559309","NCT06080256"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-06","trialPhase":"NA","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:52.122Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::evolocumab::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"EVOLOCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04416425","NCT04306081","NCT05585151","NCT03829046"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-04","trialPhase":"Phase 4","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:53.664Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::lovastatin::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"LOVASTATIN","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02548936","NCT00125593","NCT04638400","NCT01105975","NCT00127218"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-08-01","trialPhase":"Phase 4","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:52.520Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::alprostadil::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"ALPROSTADIL","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04312555","NCT01758874","NCT04197323"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-01","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:54.018Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::bococizumab::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"BOCOCIZUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:24:20.820Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T175429-8c5b9a71::pravastatin_sodium::atherosclerosis","analysisId":"20260309T175429-8c5b9a71","recordedAt":"2026-03-09T17:54:31.312Z","drug":"PRAVASTATIN SODIUM","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB","LDLR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00127218","NCT00000461","NCT00054938","NCT01872845","NCT00147797"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"1999-10-28","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:53.310Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::carboplatin::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:51.728Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::paclitaxel::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:51.375Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::osimertinib::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:49.836Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::erlotinib::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:49.481Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::cisplatin::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:49.128Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::brigatinib::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:19:12.438Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::tucatinib::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"TUCATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05868226","NCT06157892"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:51.020Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::neratinib::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"NERATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT01111825","NCT06008275","NCT03812393"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:50.628Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::lapatinib::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"LAPATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02158507","NCT01272141","NCT01426880"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-01-07","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:50.234Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T174923-ac05ef48::pertuzumab::triple-negative_breast_cancer","analysisId":"20260309T174923-ac05ef48","recordedAt":"2026-03-09T17:49:23.237Z","drug":"PERTUZUMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01042379","NCT05180006","NCT05582499","NCT05020860","NCT04193059"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:48.770Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::ceritinib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1","EGFR"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:47.271Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::alectinib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:46.918Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::crizotinib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:46.564Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::brigatinib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:46.205Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::erlotinib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"ERLOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:45.051Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::gefitinib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"GEFITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00478049","NCT00268255","NCT01933347","NCT01000740","NCT00020709"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:48.015Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::afatinib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:48.368Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::adagrasib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"ADAGRASIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05609578","NCT06039384","NCT06875310","NCT05853575","NCT05673187"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-11-08","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:45.849Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::sotorasib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"SOTORASIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05631249","NCT06333678","NCT04959981","NCT05273047","NCT05311709"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2021-07-13","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:45.450Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T173616-78e027ed::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260309T173616-78e027ed","recordedAt":"2026-03-09T17:36:16.064Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:47.626Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:42.571Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:42.214Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:18.316Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:43.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:44.343Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:44.697Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:41.854Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:43.989Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:43.635Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T172445-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260309T172445-5b7100d5","recordedAt":"2026-03-09T17:24:45.423Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:42.926Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T171450-da593734::selegiline::parkinson's_disease","analysisId":"20260309T171450-da593734","recordedAt":"2026-03-09T17:14:52.178Z","drug":"SELEGILINE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.","trialNctIds":["NCT02225548","NCT00443872","NCT04968613","NCT00640159","NCT00282152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-01-25","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:41.499Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T171450-da593734::prasinezumab::parkinson's_disease","analysisId":"20260309T171450-da593734","recordedAt":"2026-03-09T17:14:52.178Z","drug":"PRASINEZUMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03100149","NCT04777331"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-04-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:40.790Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T171450-da593734::pergolide::parkinson's_disease","analysisId":"20260309T171450-da593734","recordedAt":"2026-03-09T17:14:52.178Z","drug":"PERGOLIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.","trialNctIds":["NCT00605683","NCT00624741","NCT00234364","NCT00202657","NCT00311532"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:41.145Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T171450-da593734::dopamine::parkinson's_disease","analysisId":"20260309T171450-da593734","recordedAt":"2026-03-09T17:14:52.178Z","drug":"DOPAMINE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.","trialNctIds":["NCT01550484","NCT06785298","NCT00105508","NCT00985517","NCT06978920"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-03-16","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:40.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T171450-da593734::cinpanemab::parkinson's_disease","analysisId":"20260309T171450-da593734","recordedAt":"2026-03-09T17:14:52.178Z","drug":"CINPANEMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:14.981Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::tucatinib::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"TUCATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:12.904Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::talazoparib::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"TALAZOPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:14.575Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::neratinib::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"NERATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:11.242Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::lapatinib::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"LAPATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:10.827Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::carboplatin::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"CARBOPLATIN","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102824","NCT02299999","NCT06630325"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:39.305Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::ado-trastuzumab_emtansine::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"ADO-TRASTUZUMAB EMTANSINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:11.655Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::fam-trastuzumab_deruxtecan-nxki::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"FAM-TRASTUZUMAB DERUXTECAN-NXKI","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:12.080Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::olaparib::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"OLAPARIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02299999","NCT06630325","NCT02624973"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:39.694Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::sacituzumab_govitecan::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-26","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:40.081Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T165026-68e7fb0c::margetuximab::breast_cancer_precision_medicine","analysisId":"20260309T165026-68e7fb0c","recordedAt":"2026-03-09T16:50:27.717Z","drug":"MARGETUXIMAB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:14:12.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T161325-91dbcf4e::azathioprine::inflammatory_bowel_disease","analysisId":"20260309T161325-91dbcf4e","recordedAt":"2026-03-09T16:13:25.785Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:38.560Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T161325-91dbcf4e::adalimumab::inflammatory_bowel_disease","analysisId":"20260309T161325-91dbcf4e","recordedAt":"2026-03-09T16:13:25.785Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:38.914Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T161325-91dbcf4e::infliximab::inflammatory_bowel_disease","analysisId":"20260309T161325-91dbcf4e","recordedAt":"2026-03-09T16:13:25.785Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:38.206Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:45.648Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::levonorgestrel::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:45.235Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::apr19::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"APR19","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:46.889Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::progesterone::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:46.476Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::dydrogesterone::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:44.408Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::zileuton::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:43.582Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::norethindrone::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:46.061Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::fluticasone::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:44.825Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::budesonide::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:43.994Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T160640-8ac6221f::onapristone::huntington's_disease","analysisId":"20260309T160640-8ac6221f","recordedAt":"2026-03-09T16:06:51.777Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:43.165Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::encorafenib::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:36.402Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:40.239Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::cetuximab::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:35.297Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::pembrolizumab::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"PEMBROLIZUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT04585750","NCT02318901","NCT04432857"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2014-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:34.943Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:37.852Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::dabrafenib::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:37.143Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::regorafenib::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:37.497Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::panitumumab::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"PANITUMUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02162563","NCT00346099","NCT03803436","NCT05468892"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2006-06-29","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:36.789Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::nivolumab::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"NIVOLUMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02848443","NCT05942768","NCT05395052","NCT05176483"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-07-28","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:36.048Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T155620-5b7100d5::sorafenib::colorectal_cancer","analysisId":"20260309T155620-5b7100d5","recordedAt":"2026-03-09T15:56:32.421Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:35.652Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::bapineuzumab::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"BAPINEUZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:33.133Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::crenezumab::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"CRENEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:33.487Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::semagacestat::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"SEMAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00762411","NCT01035138","NCT00594568"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-15","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:33.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:34.195Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::avagacestat::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"AVAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01002079","NCT00890890","NCT00901498","NCT00726726","NCT01057030"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:34.550Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::az8838::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"AZ8838","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:37.324Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::c391::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"C391","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:13:38.571Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::lecanemab::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:32.779Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::az7188::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"AZ7188","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:19.535Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T153959-3067acf1::begacestat::alzheimer's_disease","analysisId":"20260309T153959-3067acf1","recordedAt":"2026-03-09T15:39:59.831Z","drug":"BEGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00959881","NCT00547560"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-22","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:32.426Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::fam-trastuzumab_deruxtecan-nxki::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"FAM-TRASTUZUMAB DERUXTECAN-NXKI","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:17.023Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::dacomitinib_anhydrous::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"DACOMITINIB ANHYDROUS","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:16.607Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::afatinib_dimaleate::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"AFATINIB DIMALEATE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:16.194Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::afatinib::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"AFATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:15.776Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::gemcitabine::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"GEMCITABINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","BRCA2","ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06102824","NCT02299999","NCT06630325"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-11-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:32.071Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::ado-trastuzumab_emtansine::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"ADO-TRASTUZUMAB EMTANSINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:15.360Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::tamoxifen::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"TAMOXIFEN","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA1","ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06630325","NCT02624973"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-12-09","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:31.679Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::lapatinib::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"LAPATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:14.108Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::neratinib::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"NERATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:14.943Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T151938-68e7fb0c::masoprocol::breast_cancer_precision_medicine","analysisId":"20260309T151938-68e7fb0c","recordedAt":"2026-03-09T15:19:39.830Z","drug":"MASOPROCOL","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:14.526Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T140521-28b9a562::bikeap1::oxidative_stress_cancer_biomarker","analysisId":"20260309T140521-28b9a562","recordedAt":"2026-03-09T14:05:22.622Z","drug":"BIKEAP1","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:12.796Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T140521-28b9a562::ml385::oxidative_stress_cancer_biomarker","analysisId":"20260309T140521-28b9a562","recordedAt":"2026-03-09T14:05:22.622Z","drug":"ML385","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["NFE2L2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:12.386Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T140521-28b9a562::monomethyl_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260309T140521-28b9a562","recordedAt":"2026-03-09T14:05:22.622Z","drug":"MONOMETHYL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:11.972Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T140521-28b9a562::diroximel_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260309T140521-28b9a562","recordedAt":"2026-03-09T14:05:22.622Z","drug":"DIROXIMEL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:11.553Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T140521-28b9a562::nrf2_peptide_[pmid:_23647822]::oxidative_stress_cancer_biomarker","analysisId":"20260309T140521-28b9a562","recordedAt":"2026-03-09T14:05:22.622Z","drug":"NRF2 PEPTIDE [PMID: 23647822]","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:42:55.542Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T140521-28b9a562::bardoxolone_methyl::oxidative_stress_cancer_biomarker","analysisId":"20260309T140521-28b9a562","recordedAt":"2026-03-09T14:05:22.622Z","drug":"BARDOXOLONE METHYL","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1","NFE2L2"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:11.135Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T140521-28b9a562::omaveloxolone::oxidative_stress_cancer_biomarker","analysisId":"20260309T140521-28b9a562","recordedAt":"2026-03-09T14:05:22.622Z","drug":"OMAVELOXOLONE","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["NFE2L2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:10.721Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T140521-28b9a562::dimethyl_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260309T140521-28b9a562","recordedAt":"2026-03-09T14:05:22.622Z","drug":"DIMETHYL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["CAT","GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1","NFE2L2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:10.308Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134825-b390e206::nrf2_peptide_[pmid:_23647822]::oxidative_stress_cancer_biomarker","analysisId":"20260309T134825-b390e206","recordedAt":"2026-03-09T13:48:25.395Z","drug":"NRF2 PEPTIDE [PMID: 23647822]","disease":"oxidative stress cancer biomarker","genes":["GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:42:55.126Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134825-b390e206::bikeap1::oxidative_stress_cancer_biomarker","analysisId":"20260309T134825-b390e206","recordedAt":"2026-03-09T13:48:25.395Z","drug":"BIKEAP1","disease":"oxidative stress cancer biomarker","genes":["GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:07:09.841Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134825-b390e206::ml385::oxidative_stress_cancer_biomarker","analysisId":"20260309T134825-b390e206","recordedAt":"2026-03-09T13:48:25.395Z","drug":"ML385","disease":"oxidative stress cancer biomarker","genes":["GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["NFE2L2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:49.852Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134825-b390e206::monomethyl_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260309T134825-b390e206","recordedAt":"2026-03-09T13:48:25.395Z","drug":"MONOMETHYL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:49.439Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134825-b390e206::diroximel_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260309T134825-b390e206","recordedAt":"2026-03-09T13:48:25.395Z","drug":"DIROXIMEL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:49.022Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134825-b390e206::bardoxolone_methyl::oxidative_stress_cancer_biomarker","analysisId":"20260309T134825-b390e206","recordedAt":"2026-03-09T13:48:25.395Z","drug":"BARDOXOLONE METHYL","disease":"oxidative stress cancer biomarker","genes":["GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1","NFE2L2"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:48.589Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134825-b390e206::omaveloxolone::oxidative_stress_cancer_biomarker","analysisId":"20260309T134825-b390e206","recordedAt":"2026-03-09T13:48:25.395Z","drug":"OMAVELOXOLONE","disease":"oxidative stress cancer biomarker","genes":["GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["NFE2L2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:48.176Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134825-b390e206::dimethyl_fumarate::oxidative_stress_cancer_biomarker","analysisId":"20260309T134825-b390e206","recordedAt":"2026-03-09T13:48:25.395Z","drug":"DIMETHYL FUMARATE","disease":"oxidative stress cancer biomarker","genes":["GPX1","KEAP1","NFE2L2","SOD1","SOD2"],"targets":["KEAP1","NFE2L2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:47.768Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::vandetanib::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:31.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::afatinib_dimaleate::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:29.862Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::lapatinib::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:30.924Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::gefitinib::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:30.570Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::erlotinib::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:30.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::afatinib::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:29.508Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::neratinib::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:29.154Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::osimertinib::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:28.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::bevacizumab::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01413438","NCT00345163","NCT01433991","NCT03532295","NCT02386826"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-27","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:28.445Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T134024-1c57c438::cetuximab::glioblastoma","analysisId":"20260309T134024-1c57c438","recordedAt":"2026-03-09T13:40:24.167Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05956821","NCT01044225","NCT00463073","NCT01238237","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-04-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:28.091Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T133122-d1bec9c9::semorinemab::neurodegeneration_biomarker_panel","analysisId":"20260309T133122-d1bec9c9","recordedAt":"2026-03-09T13:31:23.722Z","drug":"SEMORINEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:42.389Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T133122-d1bec9c9::posdinemab::neurodegeneration_biomarker_panel","analysisId":"20260309T133122-d1bec9c9","recordedAt":"2026-03-09T13:31:23.722Z","drug":"POSDINEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:41.981Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T133122-d1bec9c9::gosuranemab::neurodegeneration_biomarker_panel","analysisId":"20260309T133122-d1bec9c9","recordedAt":"2026-03-09T13:31:23.722Z","drug":"GOSURANEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:41.565Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T133122-d1bec9c9::bepranemab::neurodegeneration_biomarker_panel","analysisId":"20260309T133122-d1bec9c9","recordedAt":"2026-03-09T13:31:23.722Z","drug":"BEPRANEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:41.152Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T133122-d1bec9c9::zagotenemab::neurodegeneration_biomarker_panel","analysisId":"20260309T133122-d1bec9c9","recordedAt":"2026-03-09T13:31:23.722Z","drug":"ZAGOTENEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:43.216Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T133122-d1bec9c9::tilavonemab::neurodegeneration_biomarker_panel","analysisId":"20260309T133122-d1bec9c9","recordedAt":"2026-03-09T13:31:23.722Z","drug":"TILAVONEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:42.803Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:27.027Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::carboplatin::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:26.673Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::cisplatin::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:26.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::osimertinib::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:25.611Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:40.741Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::amivantamab::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T20:04:40.329Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::brigatinib::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:33.349Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::paclitaxel::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:25.965Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::afatinib::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:27.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T125759-ac05ef48::erlotinib::triple-negative_breast_cancer","analysisId":"20260309T125759-ac05ef48","recordedAt":"2026-03-09T12:58:00.465Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:27.382Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::iloprost::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"ILOPROST","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01718288","NCT01458041"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-10-24","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:24.873Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::lerodalcibep::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"LERODALCIBEP","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:30.444Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::treprostinil::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"TREPROSTINIL","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00651885","NCT00067041","NCT00445159","NCT00060996"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-05-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:24.462Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::evolocumab::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"EVOLOCUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04416425","NCT04306081","NCT05585151","NCT03829046"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-04","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:24.080Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::frovocimab::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"FROVOCIMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:30.030Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::ongericimab::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"ONGERICIMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:30.852Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::dinoprostone::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"DINOPROSTONE","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:28.786Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::bococizumab::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"BOCOCIZUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:27.945Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::ralpancizumab::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"RALPANCIZUMAB","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["PCSK9"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:31.261Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T124619-81a35823::alprostadil::atherosclerosis","analysisId":"20260309T124619-81a35823","recordedAt":"2026-03-09T12:46:19.455Z","drug":"ALPROSTADIL","disease":"atherosclerosis","genes":["APOB","LDLR","PCSK9"],"targets":["APOB"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04312555","NCT01758874","NCT04197323"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-01","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:25.257Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T115702-168b2255::prasinezumab::parkinson's_disease","analysisId":"20260309T115702-168b2255","recordedAt":"2026-03-09T11:57:02.923Z","drug":"PRASINEZUMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03100149","NCT04777331"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-04-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:23.674Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T115702-168b2255::cinpanemab::parkinson's_disease","analysisId":"20260309T115702-168b2255","recordedAt":"2026-03-09T11:57:02.923Z","drug":"CINPANEMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:26.701Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::osimertinib::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:22.254Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::carboplatin::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:21.900Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::cisplatin::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:21.191Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:26.298Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::paclitaxel::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:21.546Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::afatinib::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:23.318Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::amivantamab::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:25.886Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:22.964Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::erlotinib::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:22.608Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T041814-a84ea1e7::brigatinib::triple-negative_breast_cancer","analysisId":"20260309T041814-a84ea1e7","recordedAt":"2026-03-09T04:18:14.294Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:54:24.201Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::binimetinib::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02510001","NCT00959127","NCT03374254","NCT02041481","NCT05355701"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-08-14","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:19.065Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::cobimetinib::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:20.129Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::sorafenib::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:19.774Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::cetuximab::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:19.419Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::dabrafenib::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:20.836Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::irinotecan_hydrochloride::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"IRINOTECAN HYDROCHLORIDE","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT01205711","NCT04247984","NCT02162563","NCT06065371"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-09-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:18.711Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::everolimus::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:18.311Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::encorafenib::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:17.956Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:50:47.308Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T035718-1bd532ed::regorafenib::colorectal_cancer","analysisId":"20260309T035718-1bd532ed","recordedAt":"2026-03-09T03:57:19.603Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:20.482Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T032948-7bbe5c56::cinpanemab::parkinson's_disease","analysisId":"20260309T032948-7bbe5c56","recordedAt":"2026-03-09T03:29:48.413Z","drug":"CINPANEMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:50:44.410Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T032948-7bbe5c56::dopamine::parkinson's_disease","analysisId":"20260309T032948-7bbe5c56","recordedAt":"2026-03-09T03:29:48.413Z","drug":"DOPAMINE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.","trialNctIds":["NCT01550484","NCT06785298","NCT00105508","NCT00985517","NCT06978920"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-03-16","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:17.249Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T032948-7bbe5c56::prasinezumab::parkinson's_disease","analysisId":"20260309T032948-7bbe5c56","recordedAt":"2026-03-09T03:29:48.413Z","drug":"PRASINEZUMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03100149","NCT04777331"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-04-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:17.603Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T032948-7bbe5c56::selegiline::parkinson's_disease","analysisId":"20260309T032948-7bbe5c56","recordedAt":"2026-03-09T03:29:48.413Z","drug":"SELEGILINE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.","trialNctIds":["NCT02225548","NCT00443872","NCT04968613","NCT00640159","NCT00282152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-01-25","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:16.471Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T032948-7bbe5c56::pergolide::parkinson's_disease","analysisId":"20260309T032948-7bbe5c56","recordedAt":"2026-03-09T03:29:48.413Z","drug":"PERGOLIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Unknown","mechanism":"A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.","trialNctIds":["NCT00605683","NCT00624741","NCT00234364","NCT00202657","NCT00311532"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:16.857Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T032213-9db99067::tofersen::als","analysisId":"20260309T032213-9db99067","recordedAt":"2026-03-09T03:22:13.933Z","drug":"TOFERSEN","disease":"ALS","genes":["SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:16.073Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::palbociclib::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"PALBOCICLIB","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03158389","NCT02255461","NCT05432518","NCT01227434"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-25","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:14.077Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::olaparib::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"OLAPARIB","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05463848","NCT01390571","NCT04614909","NCT05432518","NCT02974621"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-11","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:14.892Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::eprenetapopt::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"EPRENETAPOPT","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:50:43.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::apg115::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"APG115","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["MDM2","TP53"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:50:42.750Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::granisetron::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"GRANISETRON","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:50:42.331Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::siremadlin::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"SIREMADLIN","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["MDM2","TP53"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:50:41.496Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::idasanutlin::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"IDASANUTLIN","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["MDM2","TP53"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03158389"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-05-18","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:15.679Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::everolimus::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"EVEROLIMUS","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["CDKN2A"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00613132","NCT01434602","NCT03355794","NCT00085566","NCT03834740"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-06-11","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:15.298Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031558-ebdc600e::navtemadlin::glioblastoma_multiforme","analysisId":"20260309T031558-ebdc600e","recordedAt":"2026-03-09T03:15:58.585Z","drug":"NAVTEMADLIN","disease":"glioblastoma multiforme","genes":["CDKN2A","MDM2","TP53"],"targets":["MDM2","TP53"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03107780"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2017-04-11","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:14.462Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::az8838::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"AZ8838","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:41:06.180Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::az7188::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"AZ7188","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:41:05.768Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::semagacestat::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"SEMAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00762411","NCT01035138","NCT00594568"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-15","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:13.667Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:11.861Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::bapineuzumab::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"BAPINEUZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:11.507Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::lecanemab::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:13.311Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::crenezumab::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"CRENEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:12.571Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::begacestat::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"BEGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00959881","NCT00547560"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-22","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:12.955Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::avagacestat::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"AVAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01002079","NCT00890890","NCT00901498","NCT00726726","NCT01057030"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-01","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:12.216Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T031531-3067acf1::c391::alzheimer's_disease","analysisId":"20260309T031531-3067acf1","recordedAt":"2026-03-09T03:15:32.575Z","drug":"C391","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:41:07.437Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T025855-e99833ac::sphingomyelin_synthase_2_inhibitor_15w::amyotrophic_lateral_sclerosis","analysisId":"20260309T025855-e99833ac","recordedAt":"2026-03-09T02:58:55.374Z","drug":"SPHINGOMYELIN SYNTHASE 2 INHIBITOR 15W","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["FUS"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:41:03.256Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T025855-e99833ac::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260309T025855-e99833ac","recordedAt":"2026-03-09T02:58:55.374Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Tofersen is an antisense oligonucleotide that causes degradation of SOD1 mRNA through binding to SOD1 mRNA, which results in a reduction of SOD1 protein synthesis.","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:11.152Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T025855-e99833ac::compound_d24_[pmid:_24374347]::amyotrophic_lateral_sclerosis","analysisId":"20260309T025855-e99833ac","recordedAt":"2026-03-09T02:58:55.374Z","drug":"COMPOUND D24 [PMID: 24374347]","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["FUS"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:42:54.701Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::pembrolizumab::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"PEMBROLIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05609578","NCT04585750","NCT04964479","NCT05627960"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-10-14","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:07.812Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::pemetrexed_disodium::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"PEMETREXED DISODIUM","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00698815","NCT03366064","NCT05014464","NCT05940532","NCT02041533"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:07.403Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::carboplatin::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"CARBOPLATIN","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00004011","NCT05014464","NCT05940532","NCT02041533","NCT05609578"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:08.564Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::afatinib::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:09.668Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::amivantamab::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:08.168Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::crizotinib::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:10.798Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::cisplatin::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"CISPLATIN","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00005825","NCT02041533","NCT05609578","NCT01066234","NCT03413358"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:10.444Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::bevacizumab::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"BEVACIZUMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02596958","NCT01995188","NCT06313268","NCT00578149","NCT00666692"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-21","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:08.956Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::brigatinib::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:09.311Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T024439-9b9a01fa::osimertinib_mesylate::non-small_cell_lung_cancer","analysisId":"20260309T024439-9b9a01fa","recordedAt":"2026-03-09T02:44:39.944Z","drug":"OSIMERTINIB MESYLATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02197234","NCT02503722","NCT06970639","NCT06067776"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-22","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:10.022Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:06.694Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::pemetrexed_disodium::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"PEMETREXED DISODIUM","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00698815","NCT03366064","NCT05014464","NCT05940532","NCT02041533"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:05.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::ceritinib::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["ALK","ROS1","EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:04.137Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::alectinib::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:04.850Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::entrectinib::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"ENTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03178552","NCT04302025","NCT02568267","NCT06694129"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:05.208Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::osimertinib_mesylate::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"OSIMERTINIB MESYLATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["EGFR","ALK","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02197234","NCT02503722","NCT06970639","NCT06067776"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-22","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:04.493Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::amivantamab::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T21:00:07.048Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::brigatinib::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:05.563Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::afatinib::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["EGFR","ALK","ROS1"],"confidence":"0.550","phase":"Phase 3","mechanism":"A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER.","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:03.780Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023743-267128b5::crizotinib::non-small_cell_lung_cancer","analysisId":"20260309T023743-267128b5","recordedAt":"2026-03-09T02:37:43.991Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:06.339Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::axitinib::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"AXITINIB","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04258956"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2020-02-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:01.411Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::sorafenib::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"SORAFENIB","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01091207","NCT00265798"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2005-12-15","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:03.005Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::imatinib::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"IMATINIB","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.","trialNctIds":["NCT01114087","NCT00461929","NCT01991379","NCT06087263","NCT02924714"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2007-04-18","trialPhase":"Phase 4","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:02.605Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::avapritinib::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"AVAPRITINIB","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04254939","NCT04825574","NCT04714086","NCT03862885","NCT05461664"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2019-03-05","trialPhase":"N/A","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:02.212Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::sunitinib::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"SUNITINIB","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.800","phase":"Phase 3","mechanism":"An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.","trialNctIds":["NCT05366816","NCT05160168","NCT01743300","NCT00877045","NCT01468688"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-04-07","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:01.810Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::ripretinib::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"RIPRETINIB","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05697107","NCT05160168","NCT06507683","NCT05489237","NCT04148092"],"trialFound":true,"trialCompleted":true,"trialStatus":"APPROVED_FOR_MARKETING","trialFirstPostedDate":"2019-11-01","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:01.017Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::midostaurin::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"MIDOSTAURIN","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:09:29.533Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::dasatinib_anhydrous::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"DASATINIB ANHYDROUS","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:09:28.699Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::regorafenib::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"REGORAFENIB","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06087263","NCT01933958","NCT05366816","NCT05160168","NCT02365441"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-09-02","trialPhase":"N/A","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:03.418Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T023041-ce5f2bce::masitinib::gastrointestinal_stromal_tumor","analysisId":"20260309T023041-ce5f2bce","recordedAt":"2026-03-09T02:30:42.443Z","drug":"MASITINIB","disease":"gastrointestinal stromal tumor","genes":["KIT","PDGFRA"],"targets":["KIT","PDGFRA"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00998751","NCT01506336","NCT02009423","NCT00812240","NCT01694277"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2008-12-22","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:00.604Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::olutasidenib::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"OLUTASIDENIB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["IDH1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03684811","NCT06161974"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-09-26","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:58.206Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::nivolumab::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"NIVOLUMAB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["BRAF","IDH1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02550249","NCT02648633","NCT04047706","NCT03233152","NCT03718767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-15","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:57.815Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::bevacizumab::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"BEVACIZUMAB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["BRAF","IDH1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01413438","NCT00345163","NCT05512351","NCT03532295","NCT06801730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-27","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:57.415Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::regorafenib::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"REGORAFENIB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["BRAF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:57.016Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::vorasidenib::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"VORASIDENIB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["IDH1","IDH2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06478212","NCT06780930","NCT05484622"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-08-02","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:58.592Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::dabrafenib::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"DABRAFENIB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["BRAF","IDH1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03919071","NCT03340506","NCT03975829","NCT05099068","NCT02684058"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-02-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T21:00:00.211Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::sorafenib::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"SORAFENIB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["BRAF","IDH2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00884416","NCT00335764","NCT01434602","NCT01441388","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-12","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:59.810Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::dasatinib_anhydrous::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"DASATINIB ANHYDROUS","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["BRAF","IDH1","IDH2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T19:09:21.990Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::encorafenib::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"ENCORAFENIB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["BRAF"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03973918"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-06-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:59.384Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T022358-681836a4::ivosidenib::glioma","analysisId":"20260309T022358-681836a4","recordedAt":"2026-03-09T02:24:00.188Z","drug":"IVOSIDENIB","disease":"glioma","genes":["BRAF","IDH1","IDH2"],"targets":["IDH1","IDH2"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04056910","NCT02073994","NCT04195555","NCT03343197","NCT06648473"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-02-28","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:58.979Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::cetuximab::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"CETUXIMAB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05956821","NCT01044225","NCT00463073","NCT01238237","NCT03603379"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-04-20","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:52.900Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::erlotinib::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:56.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::bevacizumab::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"BEVACIZUMAB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01413438","NCT00345163","NCT01433991","NCT03532295","NCT02386826"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-27","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:55.570Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::neratinib::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:53.253Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::vandetanib::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:56.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::afatinib_dimaleate::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:55.174Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::lapatinib::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:53.962Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::osimertinib::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:54.316Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::gefitinib::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:53.608Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260309T021502-e680e906::afatinib::glioblastoma","analysisId":"20260309T021502-e680e906","recordedAt":"2026-03-09T02:15:04.213Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:55.924Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::siremadlin::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"SIREMADLIN","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02890069"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-07","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:51.406Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::epirubicin::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"EPIRUBICIN","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00559845","NCT00176488","NCT06107673","NCT00516425","NCT02838225"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:52.161Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::abemaciclib::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"ABEMACICLIB","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04305236","NCT03280563","NCT04351230","NCT04964934"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-12","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:49.252Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::paclitaxel::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:49.607Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::cisplatin::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003042","NCT01216111","NCT02985658","NCT01606748","NCT02124148"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:49.961Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::olaparib::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:50.669Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::carboplatin::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:51.764Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::capecitabine::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"CAPECITABINE","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05334147","NCT01077726","NCT04487236","NCT04849364","NCT06787339"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-03-01","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:50.314Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::granisetron::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"GRANISETRON","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01298193","NCT05408676","NCT00293384","NCT01649258","NCT00475085"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-17","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:51.024Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T210855-b667a1d7::nivolumab::breast_cancer","analysisId":"20260308T210855-b667a1d7","recordedAt":"2026-03-08T21:08:55.661Z","drug":"NIVOLUMAB","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04075604","NCT05888831","NCT04331067","NCT05429866"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-09-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:52.514Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::carboplatin::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"CARBOPLATIN","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00004011","NCT05014464","NCT05940532","NCT02041533","NCT02264678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:48.140Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::lapatinib::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"LAPATINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02230553","NCT00073008","NCT01218529","NCT01184482","NCT04591431"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:48.848Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::erlotinib::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"ERLOTINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:48.494Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::afatinib::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"AFATINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT04201756"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:47.786Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::amivantamab::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"AMIVANTAMAB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:47.431Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::osimertinib::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"OSIMERTINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02197234","NCT02503722","NCT06970639","NCT06067776"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-22","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:47.075Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::gefitinib::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"GEFITINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01697163","NCT00478049","NCT00268255","NCT01933347","NCT01000740"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2005-12-22","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:46.716Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::bevacizumab::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"BEVACIZUMAB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02596958","NCT04107168","NCT01995188","NCT06313268","NCT00578149"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-21","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:46.359Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::tucatinib::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"TUCATINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05091528","NCT04579380","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:46.005Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205654-cd7bf56f::vandetanib::lung_cancer","analysisId":"20260308T205654-cd7bf56f","recordedAt":"2026-03-08T20:56:54.039Z","drug":"VANDETANIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02117167","NCT01004419","NCT00404924","NCT00047840","NCT00459121"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-10-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:45.651Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::carboplatin::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"CARBOPLATIN","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00004011","NCT05014464","NCT05940532","NCT02041533","NCT02264678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:45.295Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::osimertinib::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"OSIMERTINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02197234","NCT02503722","NCT06970639","NCT06067776"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-22","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:41.719Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::amivantamab::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"AMIVANTAMAB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:42.137Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::afatinib::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"AFATINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT04201756"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:42.535Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::gefitinib::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"GEFITINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01697163","NCT00478049","NCT00268255","NCT01933347","NCT01000740"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2005-12-22","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:43.310Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::tucatinib::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"TUCATINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05091528","NCT04579380","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-08","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:43.707Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::lapatinib::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"LAPATINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02230553","NCT00073008","NCT01218529","NCT01184482","NCT04591431"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:44.111Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::vandetanib::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"VANDETANIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02117167","NCT01004419","NCT00404924","NCT00047840","NCT00459121"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-10-24","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:44.506Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::bevacizumab::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"BEVACIZUMAB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02596958","NCT04107168","NCT01995188","NCT06313268","NCT00578149"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-21","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:44.897Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T205320-cd7bf56f::erlotinib::lung_cancer","analysisId":"20260308T205320-cd7bf56f","recordedAt":"2026-03-08T20:53:20.066Z","drug":"ERLOTINIB","disease":"lung cancer","genes":["EGFR","KRAS"],"targets":["EGFR","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:42.927Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::capecitabine::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"CAPECITABINE","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05334147","NCT01077726","NCT04487236","NCT04849364","NCT06787339"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-03-01","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:38.457Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::palbociclib::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"PALBOCICLIB","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04711252","NCT04025541","NCT04654208","NCT03573648"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:40.231Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::carboplatin::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["BRCA1","PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:38.103Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::cisplatin::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["BRCA1","PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003042","NCT01216111","NCT02985658","NCT01606748","NCT02124148"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:38.812Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::olaparib::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["BRCA1","PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:39.167Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::paclitaxel::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["BRCA1","PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:39.521Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::pembrolizumab::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"PEMBROLIZUMAB","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04585750","NCT04849364","NCT03989089","NCT06353997","NCT05627960"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:40.592Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::nivolumab::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"NIVOLUMAB","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04075604","NCT05888831","NCT04331067","NCT05429866"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-09-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:39.875Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::granisetron::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"GRANISETRON","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01298193","NCT05408676","NCT00293384","NCT01649258","NCT00475085"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-17","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:40.945Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204823-6a2e0d96::gsk2636771::breast_cancer","analysisId":"20260308T204823-6a2e0d96","recordedAt":"2026-03-08T20:48:23.780Z","drug":"GSK2636771","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02465060"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:41.300Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:57:47.589Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::osimertinib::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:37.395Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::erlotinib::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:35.625Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::paclitaxel::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:36.333Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::afatinib::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:35.979Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::brigatinib::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:52:06.698Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:37.749Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::carboplatin::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:37.041Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::cisplatin::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:36.687Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204729-a84ea1e7::amivantamab::triple-negative_breast_cancer","analysisId":"20260308T204729-a84ea1e7","recordedAt":"2026-03-08T20:47:29.317Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:57:47.170Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::gsk2636771::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"GSK2636771","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02465060"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:34.090Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::palbociclib::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"PALBOCICLIB","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04711252","NCT04025541","NCT04654208","NCT03573648"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2018-06-29","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:35.271Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::capecitabine::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"CAPECITABINE","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05334147","NCT01077726","NCT04487236","NCT04849364","NCT06787339"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-03-01","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:34.873Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::granisetron::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"GRANISETRON","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01298193","NCT05408676","NCT00293384","NCT01649258","NCT00475085"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-17","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:34.484Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::nivolumab::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"NIVOLUMAB","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT04075604","NCT05888831","NCT04331067","NCT05429866"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-09-03","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:33.301Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::olaparib::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["BRCA1","PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:32.903Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::paclitaxel::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["BRCA1","PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00001493","NCT00499525","NCT02436993","NCT00093145","NCT00559845"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2002-12-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:32.549Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::carboplatin::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["BRCA1","PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:32.142Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::pembrolizumab::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"PEMBROLIZUMAB","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04585750","NCT04849364","NCT03989089","NCT06353997","NCT05627960"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2019-06-18","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:33.696Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T204626-6a2e0d96::cisplatin::breast_cancer","analysisId":"20260308T204626-6a2e0d96","recordedAt":"2026-03-08T20:46:26.493Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","PTEN","TP53"],"targets":["BRCA1","PTEN","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00003042","NCT01216111","NCT02985658","NCT01606748","NCT02124148"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:31.788Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::crenezumab::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"CRENEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:29.665Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::lecanemab::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer disease.","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:31.434Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::semagacestat::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"SEMAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00762411","NCT01035138","NCT00594568"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:30.373Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::avagacestat::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"AVAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01002079","NCT00890890","NCT00901498","NCT00726726","NCT01057030"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:30.726Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::ponezumab::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"PONEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00733642","NCT01125631","NCT00607308","NCT00722046","NCT00945672"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:29.311Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::tramiprosate::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"TRAMIPROSATE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT04585347","NCT03382353","NCT04770220","NCT00314912"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2006-04-17","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:31.080Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::bapineuzumab::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"BAPINEUZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:30.019Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::gantenerumab::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"GANTENERUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:28.957Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::solanezumab::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"SOLANEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT02614131","NCT00749216","NCT01900665","NCT04623242","NCT00904683"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-09-09","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:28.603Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T202511-3067acf1::aducanumab::alzheimer's_disease","analysisId":"20260308T202511-3067acf1","recordedAt":"2026-03-08T20:25:11.148Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:28.203Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T194919-e99833ac::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260308T194919-e99833ac","recordedAt":"2026-03-08T19:49:19.744Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Tofersen is an antisense oligonucleotide that causes degradation of SOD1 mRNA through binding to SOD1 mRNA, which results in a reduction of SOD1 protein synthesis.","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:27.850Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T194919-e99833ac::sphingomyelin_synthase_2_inhibitor_15w::amyotrophic_lateral_sclerosis","analysisId":"20260308T194919-e99833ac","recordedAt":"2026-03-08T19:49:19.744Z","drug":"SPHINGOMYELIN SYNTHASE 2 INHIBITOR 15W","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["FUS"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:51:56.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T194919-e99833ac::compound_d24_[pmid:_24374347]::amyotrophic_lateral_sclerosis","analysisId":"20260308T194919-e99833ac","recordedAt":"2026-03-08T19:49:19.744Z","drug":"COMPOUND D24 [PMID: 24374347]","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["FUS"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:42:54.277Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::binimetinib::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02510001","NCT00959127","NCT03374254","NCT02041481","NCT05355701"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-08-14","trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:25.616Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::cetuximab::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"CETUXIMAB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT02029326","NCT00286130","NCT01243372"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-02-03","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:26.009Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::encorafenib::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:26.785Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::everolimus::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"EVEROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02599324","NCT01637194","NCT01139138","NCT00337545","NCT01149434"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-16","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:25.261Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::dabrafenib::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:24.843Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::regorafenib::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:27.496Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::b-raf/vegfr-2_inhibitor_raf265::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"B-RAF/VEGFR-2 INHIBITOR RAF265","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:47.561Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::sorafenib::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:27.139Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:44.658Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T192529-1bd532ed::cobimetinib::colorectal_cancer","analysisId":"20260308T192529-1bd532ed","recordedAt":"2026-03-08T19:25:29.308Z","drug":"COBIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.550","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04190628","NCT03989115","NCT02457793","NCT02291289","NCT02788279"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-11-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:26.429Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:42.165Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::fluticasone::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:41.339Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::dydrogesterone::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:40.927Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::onapristone::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:39.687Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::zileuton::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:40.102Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::budesonide::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:40.516Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::dactinomycin::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:43.411Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::progesterone::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:42.995Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::norethindrone::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:42.578Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T190944-0678785a::levonorgestrel::huntington's_disease","analysisId":"20260308T190944-0678785a","recordedAt":"2026-03-08T19:09:44.960Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:41.750Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::zagotenemab::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"ZAGOTENEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:38.451Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:35.597Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::2-mercaptoethanesulfonic_acid::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"2-MERCAPTOETHANESULFONIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:38.862Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::tilavonemab::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"TILAVONEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:38.040Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::5-hydroxytryptophan::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"5-HYDROXYTRYPTOPHAN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:39.275Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::semorinemab::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"SEMORINEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:37.627Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::posdinemab::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"POSDINEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T18:46:37.216Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::gosuranemab::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"GOSURANEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:36.832Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::bepranemab::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"BEPRANEMAB","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:36.419Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T183601-b4e502dc::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260308T183601-b4e502dc","recordedAt":"2026-03-08T18:36:01.376Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:36.013Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:24.488Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:32.703Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::compound_d24_[pmid:_24374347]::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"COMPOUND D24 [PMID: 24374347]","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["FUS"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:42:53.852Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:35.187Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:34.774Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:33.947Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:33.119Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:34.362Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:33.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T180607-828e8541::sphingomyelin_synthase_2_inhibitor_15w::amyotrophic_lateral_sclerosis","analysisId":"20260308T180607-828e8541","recordedAt":"2026-03-08T18:06:07.060Z","drug":"SPHINGOMYELIN SYNTHASE 2 INHIBITOR 15W","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["FUS"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:32.291Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::adalimumab::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:23.074Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::infliximab::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:22.720Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::celecoxib::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:23.428Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::mifamurtide::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:30.164Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::chembl:chembl1351908::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:30.578Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::chembl:chembl1456848::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"CHEMBL:CHEMBL1456848","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:30.988Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::chembl:chembl577660::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"CHEMBL:CHEMBL577660","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:31.403Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:22.366Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:24.134Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T174138-405a407e::azathioprine::inflammatory_bowel_disease","analysisId":"20260308T174138-405a407e","recordedAt":"2026-03-08T17:41:40.694Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:23.780Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::progesterone::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:26.804Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::dydrogesterone::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:14.261Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::fluticasone::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:14.675Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::levonorgestrel::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:25.551Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:25.966Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::norethindrone::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:26.383Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::budesonide::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:13.845Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::onapristone::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:13.015Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::dactinomycin::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T17:02:27.229Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T165042-0678785a::zileuton::huntington's_disease","analysisId":"20260308T165042-0678785a","recordedAt":"2026-03-08T16:50:42.216Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:13.433Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::siltuximab::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"SILTUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:10.535Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::lenalidomide::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:09.710Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::rilonacept::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"RILONACEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00534495","NCT00094900"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:20.948Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::golimumab::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05842213","NCT04188249","NCT01217814","NCT01698515"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:20.592Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::olokizumab::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"OLOKIZUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT01533714","NCT03120949","NCT04246762","NCT01463059","NCT02760407"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-01","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:19.886Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00160602","NCT00993668","NCT02319642","NCT01147341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:20.239Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::pf-04236921::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"PF-04236921","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT00838565","NCT01166555"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-02-06","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:21.303Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::lutikizumab::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"LUTIKIZUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":["NCT06972446"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-05-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:19.532Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::adalimumab::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01162421","NCT00497614","NCT03223012","NCT01197144","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-06","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:22.012Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T163312-fa0c8486::infliximab::rheumatoid_arthritis","analysisId":"20260308T163312-fa0c8486","recordedAt":"2026-03-08T16:33:14.333Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02925338","NCT00394589","NCT00908089","NCT00095147","NCT01927263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-02","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:21.658Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::alectinib::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:15.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::osimertinib_mesylate::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"OSIMERTINIB MESYLATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02197234","NCT02503722","NCT06970639","NCT06067776"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-22","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:17.056Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::ceritinib::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:16.348Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:18.117Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::amivantamab::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:18.471Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::crizotinib::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:17.410Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::tucatinib::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"TUCATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06067776","NCT05091528","NCT04579380","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:18.825Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::brigatinib::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:19.178Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::entrectinib::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"ENTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03178552","NCT04302025","NCT02568267","NCT06694129"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:17.763Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T162719-4ec4453e::lapatinib::non-small_cell_lung_cancer","analysisId":"20260308T162719-4ec4453e","recordedAt":"2026-03-08T16:27:20.691Z","drug":"LAPATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02230553","NCT00073008","NCT04591431","NCT01306045","NCT00313599"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:16.702Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::afatinib_dimaleate::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"AFATINIB DIMALEATE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:26.541Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::afatinib::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"AFATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:26.127Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::masoprocol::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"MASOPROCOL","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:03.843Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::neratinib::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"NERATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:04.255Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::gefitinib::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"GEFITINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06630325"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2024-10-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:15.640Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::genistein::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"GENISTEIN","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["BRCA2","ESR1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:25.288Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::ado-trastuzumab_emtansine::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"ADO-TRASTUZUMAB EMTANSINE","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:25.706Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::lapatinib::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"LAPATINIB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2","ESR1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:03.425Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::margetuximab::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"MARGETUXIMAB","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:58:03.009Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T152734-3725df05::dacomitinib_anhydrous::breast_cancer_precision_medicine","analysisId":"20260308T152734-3725df05","recordedAt":"2026-03-08T15:27:34.519Z","drug":"DACOMITINIB ANHYDROUS","disease":"breast cancer precision medicine","genes":["BRCA1","BRCA2","ERBB2","ESR1"],"targets":["ERBB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:26.956Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::neratinib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:14.533Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::regorafenib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:12.404Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::sunitinib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:12.050Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::afatinib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:13.471Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::vandetanib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:14.887Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::afatinib_dimaleate::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:15.241Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::lapatinib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:14.179Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::erlotinib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:13.825Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::osimertinib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:12.761Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T151309-03d2cbf2::gefitinib::glioblastoma","analysisId":"20260308T151309-03d2cbf2","recordedAt":"2026-03-08T15:13:14.116Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:13.116Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::chembl:chembl1351908::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:19.868Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::mifamurtide::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Other/unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:19.458Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::celecoxib::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:11.696Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::infliximab::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:10.989Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::adalimumab::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:09.925Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::chembl:chembl577660::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"CHEMBL:CHEMBL577660","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:20.695Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::chembl:chembl1456848::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"CHEMBL:CHEMBL1456848","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:49:20.281Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:11.343Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:10.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T150818-405a407e::azathioprine::inflammatory_bowel_disease","analysisId":"20260308T150818-405a407e","recordedAt":"2026-03-08T15:08:18.355Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:10.634Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::tovorafenib::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:09.570Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::sorafenib::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:08.860Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::temsirolimus::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:07.444Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::b-raf/vegfr-2_inhibitor_raf265::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"B-RAF/VEGFR-2 INHIBITOR RAF265","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:51.905Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:51.491Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::dabrafenib::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:08.506Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::sotorasib::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:07.089Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::binimetinib::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02510001","NCT00959127","NCT03374254","NCT02041481","NCT05355701"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-08-14","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:08.152Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::encorafenib::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:07.798Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T025803-8a6e2b5d::regorafenib::colorectal_cancer","analysisId":"20260308T025803-8a6e2b5d","recordedAt":"2026-03-08T02:58:03.250Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:09.214Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::dabrafenib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"DABRAFENIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:48.552Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::cobimetinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"COBIMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:48.136Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::trametinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"TRAMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:48.968Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::binimetinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"BINIMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:47.727Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:47.313Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CTLA4","BRAF","CD274","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:46.901Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:46.484Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1","B2M","BRAF","CD274","JAK1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:45.230Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:45.644Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T023501-3b3a2d04::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260308T023501-3b3a2d04","recordedAt":"2026-03-08T02:35:03.511Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1","BRAF","CD274","PTEN","STK11"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:46.062Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::theophylline::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"THEOPHYLLINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:44.809Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::aldesleukin::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"ALDESLEUKIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04397107","NCT05631717","NCT02084238","NCT01988506","NCT03312335"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-11-20","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:06.735Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::dimethyl_sulfoxide::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"DIMETHYL SULFOXIDE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05747651","NCT05458622"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-07-14","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:06.348Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::phenylephrine::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"PHENYLEPHRINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:44.401Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::paregoric::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"PAREGORIC","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:43.986Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::hydrocortisone_butyrate::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"HYDROCORTISONE BUTYRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:43.575Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::fentanyl_citrate::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"FENTANYL CITRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:43.159Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::clarithromycin::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"CLARITHROMYCIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:42.339Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::atorvastatin_calcium_trihydrate::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:41.928Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T022257-357e5474::rovelizumab::systemic_lupus_erythematosus","analysisId":"20260308T022257-357e5474","recordedAt":"2026-03-08T02:22:57.679Z","drug":"ROVELIZUMAB","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:33:41.098Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::crizotinib::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:04.895Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::entrectinib::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"ENTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT03178552","NCT04302025","NCT02568267","NCT06694129"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:04.140Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::tucatinib::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"TUCATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06067776","NCT05091528","NCT04579380","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:03.038Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::brigatinib::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:02.683Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::ceritinib::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:03.786Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::osimertinib_mesylate::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"OSIMERTINIB MESYLATE","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02197234","NCT02503722","NCT06970639","NCT06067776"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-07-22","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:03.432Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::amivantamab::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"AMIVANTAMAB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05395052","NCT05908734","NCT05241873","NCT04538664","NCT05388669"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-09-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:04.541Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::alectinib::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:05.603Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::lapatinib::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"LAPATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02230553","NCT00073008","NCT04591431","NCT01306045","NCT00313599"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:05.248Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T020846-72b50631::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260308T020846-72b50631","recordedAt":"2026-03-08T02:08:46.382Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:05.962Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::siltuximab::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"SILTUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:23.715Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::lenalidomide::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:22.888Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::adalimumab::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01162421","NCT00497614","NCT03223012","NCT01197144","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-06","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:02.329Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00160602","NCT00993668","NCT02319642","NCT01147341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:00.530Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::olokizumab::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"OLOKIZUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":["NCT01533714","NCT03120949","NCT04246762","NCT01463059","NCT02760407"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-01","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:01.975Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::infliximab::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02925338","NCT00394589","NCT00908089","NCT00095147","NCT01927263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-02","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:01.621Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::lutikizumab::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"LUTIKIZUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":["NCT06972446"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-05-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:59:01.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::pf-04236921::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"PF-04236921","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":["NCT00838565","NCT01166555"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-02-06","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:00.175Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::rilonacept::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"RILONACEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00534495","NCT00094900"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:59.821Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015923-fa0c8486::golimumab::rheumatoid_arthritis","analysisId":"20260308T015923-fa0c8486","recordedAt":"2026-03-08T01:59:23.841Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05842213","NCT04188249","NCT01217814","NCT01698515"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:59:00.884Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::tramiprosate::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"TRAMIPROSATE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"Modulator of target","trialNctIds":["NCT04585347","NCT03382353","NCT04770220","NCT00314912"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2006-04-17","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:56.338Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::aducanumab::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Binder of target","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:56.691Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::avagacestat::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"AVAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":["NCT01002079","NCT00890890","NCT00901498","NCT00726726","NCT01057030"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-01","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:59.060Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::semagacestat::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"SEMAGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["PSEN1"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":["NCT00762411","NCT01035138","NCT00594568"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:59.467Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::lecanemab::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:58.674Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::nirogacestat::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:18.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::crenezumab::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"CRENEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":["NCT03491150","NCT03114657","NCT01723826","NCT02353598","NCT01343966"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-04-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:58.319Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::ponezumab::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"PONEZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"Binder of target","trialNctIds":["NCT00733642","NCT01125631","NCT00607308","NCT00722046","NCT00945672"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-05","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:57.905Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::bapineuzumab::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"BAPINEUZUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"Binder of target","trialNctIds":["NCT00998764","NCT00667810","NCT00606476","NCT00996918","NCT00174525"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:58:57.494Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T015115-e9c3046b::gantenerumab::alzheimer's_disease","analysisId":"20260308T015115-e9c3046b","recordedAt":"2026-03-08T01:51:15.858Z","drug":"GANTENERUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"Phase 1","mechanism":"Binder of target","trialNctIds":["NCT01656525","NCT06424236","NCT04374253","NCT04592341","NCT04339413"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-08-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:57.095Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:12.515Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::tofersen::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"TOFERSEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04972487","NCT05725759","NCT03070119"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-03-03","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:55.935Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::sphingomyelin_synthase_2_inhibitor_15w::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"SPHINGOMYELIN SYNTHASE 2 INHIBITOR 15W","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["FUS"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:17.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::compound_d24_[pmid:_24374347]::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"COMPOUND D24 [PMID: 24374347]","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["FUS"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-27T23:42:53.435Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:15.003Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:14.584Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:14.172Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:13.757Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:13.344Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260308T010846-828e8541::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260308T010846-828e8541","recordedAt":"2026-03-08T01:08:48.271Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:12.927Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:10.437Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::amivantamab::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:10.019Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::cisplatin::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:55.531Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::paclitaxel::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:55.178Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::osimertinib::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:58:54.824Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::carboplatin::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:54.470Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:58:54.116Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::erlotinib::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:53.762Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::afatinib::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:58:53.407Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T190418-df66ea06::brigatinib::triple-negative_breast_cancer","analysisId":"20260307T190418-df66ea06","recordedAt":"2026-03-07T19:04:20.297Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:11.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::progesterone::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:06.280Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::fluticasone::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:04.627Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::dydrogesterone::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:04.212Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::budesonide::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:03.798Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::onapristone::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:07.100Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::zileuton::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:07.511Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::levonorgestrel::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:05.042Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::dactinomycin::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:06.691Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:05.458Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T163440-0678785a::norethindrone::huntington's_disease","analysisId":"20260307T163440-0678785a","recordedAt":"2026-03-07T16:34:40.277Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:05.867Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::dabrafenib::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:50.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::encorafenib::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:52.699Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::b-raf/vegfr-2_inhibitor_raf265::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"B-RAF/VEGFR-2 INHIBITOR RAF265","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:52.399Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::sorafenib::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:52.344Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::temsirolimus::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:51.279Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:52.813Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::tovorafenib::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:58:53.053Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::regorafenib::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:51.989Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::sotorasib::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:58:51.634Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T162705-8a6e2b5d::belvarafenib::colorectal_cancer","analysisId":"20260307T162705-8a6e2b5d","recordedAt":"2026-03-07T16:27:05.395Z","drug":"BELVARAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:30:03.382Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:46.553Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:50.290Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:49.876Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:49.463Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:49.049Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:48.633Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:48.213Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:47.799Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:47.383Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T091949-828e8541::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260307T091949-828e8541","recordedAt":"2026-03-07T09:19:49.507Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:46.967Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::midostaurin::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01846624","NCT00233454","NCT02624570","NCT00866281","NCT00093600"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:50.174Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::bortezomib::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"BORTEZOMIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01127009","NCT01465386","NCT00742625","NCT00703300","NCT00789256"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-23","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:47.809Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::cabozantinib_s-malate::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"CABOZANTINIB S-MALATE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:43.609Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::decitabine::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05426798","NCT02085408","NCT03358719","NCT06113289","NCT06802523"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:50.571Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::azacitidine::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05426798","NCT02085408","NCT01835587"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-04-19","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:49.781Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::ceritinib::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"CERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-16","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:48.604Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::fedratinib_hydrochloride::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"FEDRATINIB HYDROCHLORIDE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:45.290Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::crizotinib::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"CRIZOTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-16","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:49.383Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::gilteritinib::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"GILTERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT03070093","NCT06734585","NCT05564390","NCT02927262","NCT04293562"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:48.223Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T080931-bd825805::clofarabine::acute_myeloid_leukemia","analysisId":"20260307T080931-bd825805","recordedAt":"2026-03-07T08:09:31.814Z","drug":"CLOFARABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00602225","NCT01236144","NCT02085408","NCT04994808","NCT00334074"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-06-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:49.002Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:45.872Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:47.934Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:46.282Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:48.764Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:48.351Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T16:16:41.922Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:46.693Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:47.111Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:47.521Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T075808-828e8541::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260307T075808-828e8541","recordedAt":"2026-03-07T07:58:08.588Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:45.453Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:44.950Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::bithionol::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"BITHIONOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:45.358Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:41.657Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:42.070Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::2-mercaptoethanesulfonic_acid::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"2-MERCAPTOETHANESULFONIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:42.479Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::5-hydroxytryptophan::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"5-HYDROXYTRYPTOPHAN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:42.893Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::acitretin::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"ACITRETIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:43.305Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::apigenin::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"APIGENIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:43.710Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::apomorphine::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"APOMORPHINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:44.121Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T074855-c9f5ab3b::ascorbic_acid::neurodegeneration_biomarker_panel","analysisId":"20260307T074855-c9f5ab3b","recordedAt":"2026-03-07T07:48:55.436Z","drug":"ASCORBIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:44.537Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::neratinib::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:58:46.005Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::afatinib::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:46.359Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::osimertinib::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:46.712Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::vandetanib::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:47.419Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::erlotinib::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:44.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::gefitinib::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:47.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::amivantamab::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"AMIVANTAMAB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06632236"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-09","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:58:45.651Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::afatinib_dimaleate::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:45.273Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::sunitinib::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:44.881Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T072230-03d2cbf2::lapatinib::glioblastoma","analysisId":"20260307T072230-03d2cbf2","recordedAt":"2026-03-07T07:22:30.554Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:44.527Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::celecoxib::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:43.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::infliximab::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:42.048Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:42.403Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::chembl:chembl1351908::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:36.282Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::chembl:chembl1456848::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"CHEMBL:CHEMBL1456848","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:36.692Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::chembl:chembl577660::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"CHEMBL:CHEMBL577660","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:37.103Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::adalimumab::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:42.756Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::azathioprine::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:43.110Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:43.818Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T071435-405a407e::mifamurtide::inflammatory_bowel_disease","analysisId":"20260307T071435-405a407e","recordedAt":"2026-03-07T07:14:35.397Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Other/unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:42:35.874Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00160602","NCT00993668","NCT02319642","NCT01147341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:50.019Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::adalimumab::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01162421","NCT00497614","NCT03223012","NCT01197144","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-06","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:51.514Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::golimumab::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05842213","NCT04188249","NCT01217814","NCT01698515"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:50.374Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::rilonacept::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"RILONACEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00534495","NCT00094900"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:51.869Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::pf-04236921::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"PF-04236921","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":["NCT00838565","NCT01166555"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-02-06","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:58:41.694Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::siltuximab::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"SILTUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:19.080Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::alteplase::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"ALTEPLASE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:21.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::infliximab::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02925338","NCT00394589","NCT00908089","NCT00095147","NCT01927263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-02","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:50.728Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::lenalidomide::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:18.260Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T020231-fa0c8486::olokizumab::rheumatoid_arthritis","analysisId":"20260307T020231-fa0c8486","recordedAt":"2026-03-07T02:02:31.740Z","drug":"OLOKIZUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":["NCT01533714","NCT03120949","NCT04246762","NCT01463059","NCT02760407"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-11-01","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:51.157Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:15.034Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:15.868Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:14.623Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:14.209Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:13.795Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:13.384Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:12.972Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:16.601Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:17.014Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T014719-828e8541::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260307T014719-828e8541","recordedAt":"2026-03-07T01:47:19.956Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:15.453Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::dabrafenib::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:49.309Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:37:11.297Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::abemaciclib::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"ABEMACICLIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02784795","NCT02857270","NCT04616183","NCT02745769"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-04-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:47.183Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::sorafenib::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:47.537Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::tovorafenib::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:46.828Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::binimetinib::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02510001","NCT00959127","NCT03374254","NCT02041481","NCT05355701"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-08-14","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:47.891Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::temsirolimus::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:48.954Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::sotorasib::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:48.600Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::encorafenib::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:49.664Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T004947-8a6e2b5d::regorafenib::colorectal_cancer","analysisId":"20260307T004947-8a6e2b5d","recordedAt":"2026-03-07T00:49:47.169Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:48.246Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:46.119Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::mifamurtide::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Other/unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:24:06.316Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::chembl:chembl1351908::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:24:06.728Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::celecoxib::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:44.702Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::infliximab::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:45.411Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:46.474Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::chembl:chembl1456848::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"CHEMBL:CHEMBL1456848","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:24:07.134Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::chembl:chembl577660::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"CHEMBL:CHEMBL577660","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:24:07.546Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::adalimumab::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:45.056Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260307T003157-405a407e::azathioprine::inflammatory_bowel_disease","analysisId":"20260307T003157-405a407e","recordedAt":"2026-03-07T00:31:57.163Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:45.765Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::curcumin::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"CURCUMIN","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04606420","NCT06470061","NCT01716637","NCT01811381","NCT03431896"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-10-30","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:42.575Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::donanemab::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Negative modulator of target","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:42.930Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::donepezil::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:43.284Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::bupropion_hydrochloride::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"BUPROPION HYDROCHLORIDE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553173","NCT06736509","NCT01047254","NCT05557409","NCT04797715"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-01-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:43.994Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::nirogacestat::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:24:00.480Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::amphotericin_b_liposomal::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"AMPHOTERICIN B LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:24:00.894Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::aducanumab::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Binder of target","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:43.639Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::lecanemab::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:44.348Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::clioquinol::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"CLIOQUINOL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:24:01.729Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T205423-e9c3046b::daunorubicin_liposomal::alzheimer's_disease","analysisId":"20260306T205423-e9c3046b","recordedAt":"2026-03-06T20:54:23.518Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:24:02.567Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::granisetron::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"GRANISETRON","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Activator of target","trialNctIds":["NCT03325816"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-10-30","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:40.630Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::acalabrutinib::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"ACALABRUTINIB","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04716075","NCT02448303","NCT04564040"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-05-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:41.020Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::abiraterone_acetate::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"ABIRATERONE ACETATE","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02711137","NCT03170960","NCT05084859","NCT02740985","NCT01884285"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-06-24","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:41.430Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::abemaciclib::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"ABEMACICLIB","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06810544","NCT03654833","NCT02308020","NCT02152631","NCT02857270"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-06-02","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:41.830Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::alectinib::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"ALECTINIB","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:39.642Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::alemtuzumab::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"ALEMTUZUMAB","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00800943","NCT00328198","NCT02061800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:42.221Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::apomorphine::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"APOMORPHINE","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:23:59.234Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::anisindione::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"ANISINDIONE","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:23:58.817Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::amoxapine::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"AMOXAPINE","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T15:23:58.406Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T204501-27e91a6b::alpelisib::lung_cancer","analysisId":"20260306T204501-27e91a6b","recordedAt":"2026-03-06T20:45:01.804Z","drug":"ALPELISIB","disease":"lung cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05627960","NCT04591431","NCT02276027"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-10-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:39.245Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::alteplase::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"ALTEPLASE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:25.622Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::adalimumab::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01162421","NCT00497614","NCT03223012","NCT01197144","NCT05626348"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-06","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:37.273Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::rilonacept::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"RILONACEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00534495","NCT00094900"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-28","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:36.877Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::lenalidomide::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:23.544Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::siltuximab::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"SILTUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:24.377Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::echinacea_preparation::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"ECHINACEA PREPARATION","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:26.033Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::golimumab::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05842213","NCT04188249","NCT01217814","NCT01698515"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2010-10-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:37.663Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::infliximab::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02925338","NCT00394589","NCT00908089","NCT00095147","NCT01927263"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-02","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:38.461Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::etanercept::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03813771","NCT03781375","NCT00920478","NCT00913458","NCT01137838"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-04","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:38.853Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203739-fa0c8486::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260306T203739-fa0c8486","recordedAt":"2026-03-06T20:37:39.700Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00160602","NCT00993668","NCT02319642","NCT01147341"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:38.047Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::erlotinib::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:35.762Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::cisplatin::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:34.342Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::paclitaxel::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:36.471Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:35.407Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::afatinib::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:35.051Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::carboplatin::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:34.697Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:21.035Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::amivantamab::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:20.620Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::brigatinib::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:21.455Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T203439-df66ea06::osimertinib::triple-negative_breast_cancer","analysisId":"20260306T203439-df66ea06","recordedAt":"2026-03-06T20:34:39.329Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:36.116Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::pioglitazone_hydrochloride::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00770835","NCT06399835","NCT00722631","NCT00240370","NCT05305287"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-18","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:32.568Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::bezafibrate::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"BEZAFIBRATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00506298"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-25","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:32.214Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::troglitazone::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"TROGLITAZONE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT02475499","NCT02476760","NCT01068860","NCT01055223","NCT02456428"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-01-25","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:31.860Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::balsalazide_disodium::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"BALSALAZIDE DISODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:14.759Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::mesalamine::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"MESALAMINE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:15.588Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::olsalazine_sodium::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"OLSALAZINE SODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:39:16.006Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::estradiol_valerate::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"ESTRADIOL VALERATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06513104","NCT00254800","NCT01508858","NCT01686828","NCT05153564"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-11-17","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:33.986Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::metformin::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"METFORMIN","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","TCF7L2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01349387","NCT00473525","NCT00817271","NCT00970593","NCT00770835"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-05-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:33.632Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::glyburide::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"GLYBURIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00770835","NCT00313313","NCT00388986","NCT01456650","NCT03089333"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-04-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:33.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200906-caaed5f5::rosiglitazone_maleate::type_2_diabetes_mellitus","analysisId":"20260306T200906-caaed5f5","recordedAt":"2026-03-06T20:09:06.827Z","drug":"ROSIGLITAZONE MALEATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00615212","NCT00150410","NCT00350779","NCT01332370","NCT00571506"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-08","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:32.922Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:16.060Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:16.479Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:16.892Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:17.300Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:15.232Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:13.990Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:14.404Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:14.816Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:15.648Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T200606-828e8541::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260306T200606-828e8541","recordedAt":"2026-03-06T20:06:06.078Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:17.712Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::brigatinib::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:12.741Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::paclitaxel::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:29.731Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::afatinib::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:30.796Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::amivantamab::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:11.912Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::cisplatin::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:30.442Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:30.086Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::osimertinib::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:29.370Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::carboplatin::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:31.151Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:12.330Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195831-df66ea06::erlotinib::triple-negative_breast_cancer","analysisId":"20260306T195831-df66ea06","recordedAt":"2026-03-06T19:58:31.983Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:31.505Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::clioquinol::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"CLIOQUINOL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:07.754Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::curcumin::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"CURCUMIN","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04606420","NCT06470061","NCT01716637","NCT01811381","NCT03431896"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-10-30","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:28.224Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::lecanemab::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:28.622Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::bupropion_hydrochloride::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"BUPROPION HYDROCHLORIDE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553173","NCT06736509","NCT01047254","NCT05557409","NCT04797715"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-01-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:29.013Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::amphotericin_b_liposomal::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"AMPHOTERICIN B LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:06.915Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::nirogacestat::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:06.499Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::donanemab::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Negative modulator of target","trialNctIds":["NCT03367403","NCT06957418","NCT05108922","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-12-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:27.429Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::donepezil::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05804279","NCT06840054","NCT01872598","NCT05811000","NCT00177671"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:27.028Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::daunorubicin_liposomal::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:31:08.587Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T195228-e9c3046b::aducanumab::alzheimer's_disease","analysisId":"20260306T195228-e9c3046b","recordedAt":"2026-03-06T19:52:28.240Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Binder of target","trialNctIds":["NCT02484547","NCT01677572","NCT01397539","NCT05097131","NCT02477800"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-07-19","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:27.834Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::rosiglitazone_maleate::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"ROSIGLITAZONE MALEATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00615212","NCT00150410","NCT00350779","NCT01332370","NCT00571506"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-08","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:25.916Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::bezafibrate::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"BEZAFIBRATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00506298"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-25","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:25.207Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::pioglitazone_hydrochloride::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00770835","NCT06399835","NCT00722631","NCT00240370","NCT05305287"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-18","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:24.853Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::troglitazone::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"TROGLITAZONE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT02475499","NCT02476760","NCT01068860","NCT01055223","NCT02456428"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-01-25","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:24.498Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::metformin::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"METFORMIN","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","TCF7L2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01349387","NCT00473525","NCT00817271","NCT00970593","NCT00770835"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-05-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:26.626Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::glyburide::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"GLYBURIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00770835","NCT00313313","NCT00388986","NCT01456650","NCT03089333"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-04-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:26.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::olsalazine_sodium::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"OLSALAZINE SODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:57.394Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::mesalamine::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"MESALAMINE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:56.982Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::balsalazide_disodium::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"BALSALAZIDE DISODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:56.146Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T153422-caaed5f5::estradiol_valerate::type_2_diabetes_mellitus","analysisId":"20260306T153422-caaed5f5","recordedAt":"2026-03-06T15:34:22.271Z","drug":"ESTRADIOL VALERATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06513104","NCT00254800","NCT01508858","NCT01686828","NCT05153564"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-11-17","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:25.561Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::mifamurtide::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Other/unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:54.078Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:24.142Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::azathioprine::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:23.788Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::celecoxib::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:23.433Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:23.078Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::adalimumab::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:22.369Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::chembl:chembl577660::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"CHEMBL:CHEMBL577660","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:55.317Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::chembl:chembl1456848::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"CHEMBL:CHEMBL1456848","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:54.904Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::chembl:chembl1351908::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:54.489Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T140759-405a407e::infliximab::inflammatory_bowel_disease","analysisId":"20260306T140759-405a407e","recordedAt":"2026-03-06T14:07:59.980Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:22.724Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::abemaciclib::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"ABEMACICLIB","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT04305236","NCT03280563","NCT03938337","NCT04351230"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-09-12","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:21.620Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::abiraterone_acetate::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"ABIRATERONE ACETATE","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT01913015","NCT06204302","NCT06592924","NCT06527690","NCT04495179"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-07-31","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:21.223Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::anisindione::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"ANISINDIONE","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:50.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::amoxapine::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"AMOXAPINE","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:27:50.322Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::alpelisib::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"ALPELISIB","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05154487","NCT03439046","NCT05627960","NCT02038010","NCT02077933"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-16","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:19.262Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::alemtuzumab::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"ALEMTUZUMAB","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00336206","NCT00077961","NCT00086580","NCT00416884","NCT00436904"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2004-02-18","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:19.670Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::granisetron::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"GRANISETRON","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Activator of target","trialNctIds":["NCT02858310","NCT01536392","NCT01843868","NCT01909856","NCT02563951"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-02-22","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:22.015Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::acalabrutinib::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"ACALABRUTINIB","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06548152","NCT04961801","NCT04484012","NCT04155710"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-11-07","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:20.061Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::alectinib::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"ALECTINIB","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT05014464","NCT03178552","NCT03498521","NCT02521051","NCT06862869"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:20.453Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T015110-f7094e57::apomorphine::cancer","analysisId":"20260306T015110-f7094e57","recordedAt":"2026-03-06T01:51:10.091Z","drug":"APOMORPHINE","disease":"cancer","genes":["TP53"],"targets":["TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT06240390"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2024-02-05","trialPhase":"NA","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:20.832Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::dabrafenib::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:18.154Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::sorafenib::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:18.509Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::binimetinib::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02510001","NCT00959127","NCT03374254","NCT02041481","NCT05355701"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-08-14","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:17.446Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::encorafenib::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:17.092Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::regorafenib::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:16.738Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::temsirolimus::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:17.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:24:43.021Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::sotorasib::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:16.383Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::tovorafenib::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:16.029Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013814-8a6e2b5d::abemaciclib::colorectal_cancer","analysisId":"20260306T013814-8a6e2b5d","recordedAt":"2026-03-06T01:38:14.357Z","drug":"ABEMACICLIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02784795","NCT02857270","NCT04616183","NCT02745769"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-04-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:18.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::lapatinib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:14.967Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::afatinib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:12.486Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::imatinib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT00613132","NCT00401024","NCT00387933","NCT00354068","NCT00171938"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:13.195Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::osimertinib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:14.258Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::erlotinib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:15.321Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::gefitinib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:14.613Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::regorafenib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:15.675Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::sunitinib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:12.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::neratinib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:13.904Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260306T013035-03d2cbf2::vandetanib::glioblastoma","analysisId":"20260306T013035-03d2cbf2","recordedAt":"2026-03-06T01:30:35.330Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:13.549Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::osimertinib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:11.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::imatinib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00613132","NCT00401024","NCT00387933","NCT00354068","NCT00171938"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:10.712Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::regorafenib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:08.937Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::vandetanib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:11.774Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::afatinib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:09.290Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::gefitinib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:10.004Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::lapatinib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:12.129Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::sunitinib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:09.645Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::erlotinib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:11.420Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T165722-03d2cbf2::neratinib::glioblastoma","analysisId":"20260305T165722-03d2cbf2","recordedAt":"2026-03-05T16:57:22.960Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:10.357Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::celecoxib::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00175032","NCT00808743","NCT00473980","NCT00177866","NCT05960864"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:07.403Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::cyclosporine::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT04564638","NCT05112263","NCT01536535","NCT00542152"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-10-10","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:06.629Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::adalimumab::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT03464136","NCT00408629","NCT03223012","NCT05407350","NCT05313620"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-12-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:07.797Z","completedOutcomeClass":"mixed","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00347048","NCT01536535","NCT06867042","NCT03204136"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-07-04","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:08.189Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::chembl:chembl1351908::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:18:29.767Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::mifamurtide::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Other/unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:18:29.356Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::infliximab::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00583232","NCT02925338","NCT03553472","NCT03884439","NCT02799615"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-31","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:08.583Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::azathioprine::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT03553472","NCT03189888","NCT02177071","NCT02929706"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-06-27","trialPhase":"Phase 4","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:07.015Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::chembl:chembl1456848::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"CHEMBL:CHEMBL1456848","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:18:30.177Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T160414-405a407e::chembl:chembl577660::inflammatory_bowel_disease","analysisId":"20260305T160414-405a407e","recordedAt":"2026-03-05T16:04:14.993Z","drug":"CHEMBL:CHEMBL577660","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:18:30.587Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::amivantamab::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:18:24.785Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::paclitaxel::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05670925","NCT04443348","NCT02322814","NCT01216111","NCT06637306"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:04.634Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::osimertinib::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:06.203Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::erlotinib::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01650506","NCT00733408","NCT00998036","NCT05827614","NCT00491816"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2007-06-26","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:05.820Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::brigatinib::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:18:25.610Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:05.424Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::afatinib::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:03.836Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T14:18:25.197Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::carboplatin::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT04443348","NCT01216111","NCT03154749","NCT06637306","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:04.233Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154731-df66ea06::cisplatin::triple-negative_breast_cancer","analysisId":"20260305T154731-df66ea06","recordedAt":"2026-03-05T15:47:31.094Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01216111","NCT02985658","NCT04750382","NCT01674842","NCT03170960"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-10-07","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:05.037Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::erlotinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"ERLOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:59.947Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::afatinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:00.301Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::alectinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT03178552","NCT02521051","NCT06862869","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-08-13","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:01.470Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::ceritinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01685138","NCT01772797","NCT04647110","NCT02040870","NCT02299505"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-09-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:01.881Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:02.632Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::crizotinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT01685138","NCT00585195","NCT06254599","NCT03647111"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-01-03","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:03.451Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::lapatinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"LAPATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02230553","NCT00073008","NCT04591431","NCT01306045","NCT00313599"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:00.718Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::tucatinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"TUCATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06067776","NCT05091528","NCT04579380","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:01.072Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::brigatinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT05735327","NCT04647110","NCT04223596","NCT04887519"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2020-01-10","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:57:02.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T154340-72b50631::entrectinib::non-small_cell_lung_cancer","analysisId":"20260305T154340-72b50631","recordedAt":"2026-03-05T15:43:40.881Z","drug":"ENTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT03178552","NCT04302025","NCT02568267","NCT06694129"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:57:03.032Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::sorafenib::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:58.171Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:39.948Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::dabrafenib::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:59.593Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::regorafenib::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:57.108Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::abemaciclib::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"ABEMACICLIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02784795","NCT02857270","NCT04616183","NCT02745769"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-04-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:56.753Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::tovorafenib::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:58.882Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::sotorasib::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:59.237Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::temsirolimus::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:57.817Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::encorafenib::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:57.462Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T153703-8a6e2b5d::binimetinib::colorectal_cancer","analysisId":"20260305T153703-8a6e2b5d","recordedAt":"2026-03-05T15:37:03.908Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02510001","NCT00959127","NCT03374254","NCT02041481","NCT05355701"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-08-14","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:58.526Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::sunitinib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:53.553Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::osimertinib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:56.399Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::imatinib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00613132","NCT00401024","NCT00387933","NCT00354068","NCT00171938"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:56.045Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::lapatinib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:54.981Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::erlotinib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:54.626Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::afatinib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:54.268Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::regorafenib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:53.908Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::gefitinib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:53.199Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::neratinib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:55.335Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T151535-03d2cbf2::vandetanib::glioblastoma","analysisId":"20260305T151535-03d2cbf2","recordedAt":"2026-03-05T15:15:35.461Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:55.690Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::mitomycin::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"MITOMYCIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01196455","NCT01091168","NCT00003893","NCT02299999"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:52.454Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::carboplatin::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02561832","NCT02264678","NCT02436993","NCT00093145","NCT05415215"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:50.863Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::olaparib::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:52.843Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::cisplatin::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00003042","NCT01216111","NCT02985658","NCT01606748","NCT02124148"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:52.066Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::niraparib::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"NIRAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01905592","NCT01042379","NCT02826512","NCT05601440","NCT04481113"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:51.672Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::rucaparib::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"RUCAPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02711137","NCT03840200","NCT01074970","NCT03101280","NCT03992131"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:51.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::talazoparib::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"TALAZOPARIB","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2","PALB2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT04849364","NCT03901469","NCT01042379","NCT04987931","NCT01286987"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2010-01-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:50.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::genistein::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"GENISTEIN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00290758","NCT00769990","NCT00099008","NCT05306002","NCT00244933"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-12-09","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:49.676Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::gemcitabine::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00618826","NCT00006459","NCT05945732","NCT01606748","NCT00431106"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-02-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:49.286Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144802-c46e28d2::sacituzumab_govitecan::breast_cancer","analysisId":"20260305T144802-c46e28d2","recordedAt":"2026-03-05T14:48:03.008Z","drug":"SACITUZUMAB GOVITECAN","disease":"breast cancer","genes":["BRCA1","BRCA2","PALB2"],"targets":["BRCA1","BRCA2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05627960","NCT06462092","NCT02161679","NCT03424005","NCT06102824"],"trialFound":true,"trialCompleted":false,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2014-06-12","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:50.068Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::dactinomycin::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:28.092Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::progesterone::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:27.677Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::norethindrone::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:27.268Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:26.860Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::fluticasone::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:26.027Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::levonorgestrel::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:26.448Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::budesonide::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:25.203Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::dydrogesterone::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:25.614Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::zileuton::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:28.907Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T144538-0678785a::onapristone::huntington's_disease","analysisId":"20260305T144538-0678785a","recordedAt":"2026-03-05T14:45:38.199Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:28.499Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::cinpanemab::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"CINPANEMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:23.964Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::palbociclib::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"PALBOCICLIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:23.146Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::mycophenolate::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"MYCOPHENOLATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:22.735Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::prasinezumab::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"PRASINEZUMAB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"Binder of target","trialNctIds":["NCT03100149","NCT04777331"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2017-04-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:48.892Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::2-chloroadenosine-5-triphosphate::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"2-CHLOROADENOSINE-5-TRIPHOSPHATE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"Phase 1","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:24.793Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::ketoconazole::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"KETOCONAZOLE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:22.322Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::entrectinib::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"ENTRECTINIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:21.499Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::vandetanib::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"VANDETANIB","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["LRRK2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:23.554Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::gentian_violet_cation::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"GENTIAN VIOLET CATION","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:21.911Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142913-168b2255::doxorubicin_hydrochloride::parkinson's_disease","analysisId":"20260305T142913-168b2255","recordedAt":"2026-03-05T14:29:13.210Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"Parkinson's disease","genes":["LRRK2","PARK7","SNCA"],"targets":["SNCA"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:48:21.087Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::pioglitazone_hydrochloride::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00770835","NCT06399835","NCT00722631","NCT00240370","NCT05305287"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-18","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:46.937Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::bezafibrate::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"BEZAFIBRATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00506298"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-25","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:47.716Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::olsalazine_sodium::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"OLSALAZINE SODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:45.742Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::mesalamine::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"MESALAMINE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:45.328Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::balsalazide_disodium::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"BALSALAZIDE DISODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:44.428Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::troglitazone::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"TROGLITAZONE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT02475499","NCT02476760","NCT01068860","NCT01055223","NCT02456428"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-01-25","trialPhase":"N/A","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:46.153Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::metformin::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"METFORMIN","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","TCF7L2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01349387","NCT00473525","NCT00817271","NCT00970593","NCT00770835"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-05-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:48.501Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::rosiglitazone_maleate::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"ROSIGLITAZONE MALEATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00615212","NCT00150410","NCT00350779","NCT01332370","NCT00571506"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-08","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:48.105Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::estradiol_valerate::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"ESTRADIOL VALERATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06513104","NCT00254800","NCT01508858","NCT01686828","NCT05153564"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-11-17","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:47.336Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260305T142430-caaed5f5::glyburide::type_2_diabetes_mellitus","analysisId":"20260305T142430-caaed5f5","recordedAt":"2026-03-05T14:24:30.086Z","drug":"GLYBURIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00770835","NCT00313313","NCT00388986","NCT01456650","NCT03089333"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-04-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:46.544Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::osimertinib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:44.973Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::regorafenib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02926222","NCT04051606","NCT05759195","NCT03970447","NCT04810182"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-06","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:43.804Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::gefitinib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00132158","NCT00027625","NCT00085566","NCT00250887","NCT00014170"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:42.628Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::afatinib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00727506","NCT00977431","NCT05432518","NCT00875433","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-04","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:43.416Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::vandetanib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00821080","NCT00995007","NCT00613054","NCT00613223","NCT00441142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-02-28","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:44.589Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::neratinib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:45.359Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::imatinib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00613132","NCT00401024","NCT00387933","NCT00354068","NCT00171938"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-15","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:45.758Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::sunitinib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01441388","NCT00499473","NCT00611728","NCT03025893","NCT00923117"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-11","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:43.021Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::lapatinib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00099060","NCT00350727","NCT00095940","NCT01591577","NCT02101905"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-11-09","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:44.194Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T222343-852dee6d::erlotinib::glioblastoma","analysisId":"20260304T222343-852dee6d","recordedAt":"2026-03-04T22:23:43.736Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01103375","NCT00335764","NCT00671970","NCT00274833","NCT00227032"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2005-09-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:42.241Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:38.475Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:38.891Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:38.064Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:37.651Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:37.236Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:36.826Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:36.412Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:35.998Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:35.589Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T215759-828e8541::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260304T215759-828e8541","recordedAt":"2026-03-04T21:57:59.362Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:46:35.175Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::sorafenib::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00703638","NCT01376453","NCT00326495","NCT01507740","NCT01183663"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2006-05-17","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:39.881Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::sotorasib::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:38.530Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::dabrafenib::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:41.068Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-03-11T13:44:20.053Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::abemaciclib::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"ABEMACICLIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02784795","NCT02857270","NCT04616183","NCT02745769"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-04-20","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:41.463Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::tovorafenib::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:41.852Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::encorafenib::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04607421","NCT04800822","NCT05308446","NCT05039177","NCT02928224"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-10-10","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:39.477Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::binimetinib::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02510001","NCT00959127","NCT03374254","NCT02041481","NCT05355701"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-08-14","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:39.058Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::regorafenib::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05189171","NCT06089330","NCT05942768","NCT02402036","NCT04996355"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2015-03-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:40.667Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T211528-acf90865::temsirolimus::colorectal_cancer","analysisId":"20260304T211528-acf90865","recordedAt":"2026-03-04T21:15:28.587Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01637194","NCT01183663","NCT06950385","NCT01149434","NCT00522665"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-08-30","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:40.276Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::lapatinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"LAPATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00073008","NCT02230553","NCT04591431","NCT01306045","NCT00313599"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:45:03.200Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::crizotinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:45:01.423Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::brigatinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:45:01.776Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::alectinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:45:02.128Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::ceritinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:45:02.481Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05014464","NCT02927340","NCT06410040"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2016-10-07","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-24T20:56:37.332Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::afatinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02047903","NCT04814056","NCT00993499","NCT02450656","NCT06486142"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-12","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:36.936Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::erlotinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"ERLOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:38.134Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::tucatinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"TUCATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06067776","NCT05091528","NCT04579380","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2016-09-08","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-24T20:56:37.734Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T210400-72b50631::entrectinib::non-small_cell_lung_cancer","analysisId":"20260304T210400-72b50631","recordedAt":"2026-03-04T21:04:00.847Z","drug":"ENTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT03178552","NCT04302025","NCT02568267","NCT06694129"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:20.570Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260304T205914-a3146e87::amphotericin_b_liposomal::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"AMPHOTERICIN B LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:58.915Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::curcumin::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"CURCUMIN","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00099710","NCT01001637","NCT03431896","NCT00164749","NCT01716637"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-12-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:59.983Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::clioquinol::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"CLIOQUINOL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:59.627Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::aducanumab::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Binder of target","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:57.828Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::nirogacestat::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:58.552Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::daunorubicin_liposomal::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:45:00.340Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::donanemab::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Negative modulator of target","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:45:00.693Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::donepezil::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:45:01.064Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::bupropion_hydrochloride::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"BUPROPION HYDROCHLORIDE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00692510","NCT05557409","NCT03226522","NCT04797715","NCT01047254"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:59.272Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205914-a3146e87::lecanemab::alzheimer's_disease","analysisId":"20260304T205914-a3146e87","recordedAt":"2026-03-04T20:59:14.142Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:20.172Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260304T205223-1d8ffc07::neratinib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:19.779Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260304T205223-1d8ffc07::gefitinib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:55.316Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205223-1d8ffc07::lapatinib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02101905","NCT00095940","NCT00107003","NCT04135807","NCT01591577"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-04-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:55.675Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205223-1d8ffc07::erlotinib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:54.961Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205223-1d8ffc07::afatinib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:54.602Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205223-1d8ffc07::vandetanib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:54.237Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205223-1d8ffc07::regorafenib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:57.474Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205223-1d8ffc07::imatinib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00615927","NCT00290771","NCT00613132","NCT00021229","NCT00387933"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-13","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:57.120Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205223-1d8ffc07::sunitinib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:56.763Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T205223-1d8ffc07::osimertinib::glioblastoma","analysisId":"20260304T205223-1d8ffc07","recordedAt":"2026-03-04T20:52:23.494Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:56.403Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T195523-df66ea06::afatinib::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:19.423Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260304T195523-df66ea06::brigatinib::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:50.660Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T195523-df66ea06::erlotinib::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:51.017Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T195523-df66ea06::carboplatin::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:51.739Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T195523-df66ea06::cisplatin::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01920061","NCT04491942","NCT01091454","NCT02658214","NCT01167192"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:52.089Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T195523-df66ea06::paclitaxel::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06845319","NCT05266937","NCT03057600","NCT03997123","NCT05763992"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:52.443Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T195523-df66ea06::amivantamab::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:53.520Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T195523-df66ea06::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01920061"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:53.884Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260304T195523-df66ea06::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:18.711Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260304T195523-df66ea06::osimertinib::triple-negative_breast_cancer","analysisId":"20260304T195523-df66ea06","recordedAt":"2026-03-04T19:55:23.130Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:19.067Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260301T144938-49a7193b::erlotinib::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:46.951Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T144938-49a7193b::gefitinib::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:47.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T144938-49a7193b::neratinib::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:18.355Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260301T144938-49a7193b::lapatinib::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02101905","NCT00095940","NCT00107003","NCT04135807","NCT01591577"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-04-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:47.670Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T144938-49a7193b::osimertinib::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:48.378Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T144938-49a7193b::vandetanib::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:48.744Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T144938-49a7193b::afatinib_dimaleate::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"AFATINIB DIMALEATE","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:49.398Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T144938-49a7193b::brigatinib::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"BRIGATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:50.308Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T144938-49a7193b::afatinib::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:46.596Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T144938-49a7193b::amivantamab::glioblastoma","analysisId":"20260301T144938-49a7193b","recordedAt":"2026-03-01T14:49:38.518Z","drug":"AMIVANTAMAB","disease":"glioblastoma","genes":["EGFR","PTEN"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06632236"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-09","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:17.999Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"HEALTH_SERVICES_RESEARCH"},{"id":"20260301T140559-bbc4646c::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:17.224Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260301T140559-bbc4646c::osimertinib::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:16.836Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260301T140559-bbc4646c::amivantamab::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:45.881Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T140559-bbc4646c::paclitaxel::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06845319","NCT05266937","NCT03057600","NCT03997123","NCT05763992"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:44.814Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T140559-bbc4646c::cisplatin::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01920061","NCT04491942","NCT01091454","NCT02658214","NCT01167192"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:44.464Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T140559-bbc4646c::carboplatin::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:44.108Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T140559-bbc4646c::erlotinib::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:43.380Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T140559-bbc4646c::brigatinib::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:43.023Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T140559-bbc4646c::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01920061"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:46.233Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260301T140559-bbc4646c::afatinib::triple-negative_breast_cancer","analysisId":"20260301T140559-bbc4646c","recordedAt":"2026-03-01T14:05:59.861Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:17.614Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260228T232209-538f772f::lapatinib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02101905","NCT00095940","NCT00107003","NCT04135807","NCT01591577"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-04-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:40.865Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::vandetanib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:39.438Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::afatinib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:39.796Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::osimertinib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:41.573Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::sunitinib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:41.936Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::imatinib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00615927","NCT00290771","NCT00613132","NCT00021229","NCT00387933"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-13","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:42.297Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::regorafenib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:42.666Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::erlotinib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:40.147Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::gefitinib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:40.505Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T232209-538f772f::neratinib::glioblastoma","analysisId":"20260228T232209-538f772f","recordedAt":"2026-02-28T23:22:09.623Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:16.447Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260228T163232-e991391c::dabrafenib::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:15.735Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260228T163232-e991391c::sorafenib::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:36.915Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T163232-e991391c::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00920868","NCT01703910","NCT00504153","NCT00501410","NCT04164069"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:37.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T163232-e991391c::temsirolimus::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:37.997Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T163232-e991391c::abemaciclib::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"ABEMACICLIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06654037","NCT02745769","NCT02857270","NCT04165031","NCT02784795"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:38.714Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T163232-e991391c::binimetinib::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02041481","NCT06229340","NCT03981614","NCT04044430","NCT03475004"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:39.072Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T163232-e991391c::tovorafenib::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:16.091Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260228T163232-e991391c::sotorasib::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:15.378Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260228T163232-e991391c::regorafenib::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:36.556Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260228T163232-e991391c::encorafenib::colorectal_cancer","analysisId":"20260228T163232-e991391c","recordedAt":"2026-02-28T16:32:32.631Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:36.205Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["LAG3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:33.111Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::cemiplimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"CEMIPLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CD274","PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:35.491Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::atezolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"ATEZOLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","CD274","CTLA4","PTEN","STK11"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:35.057Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::cobolimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"COBOLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["HAVCR2"],"confidence":"0.300","phase":"Phase 2","mechanism":"Anti-TIM-3 monoclonal antibody; targets terminal T-cell exhaustion marker; in Phase 2/3 trials for NSCLC and melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:34.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:34.172Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::trametinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"TRAMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:33.822Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::dabrafenib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"DABRAFENIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["BRAF","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:33.472Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["CTLA4","BRAF","CD274","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:32.757Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1","BRAF","CD274","PTEN","STK11"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:32.405Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T221425-ae6c5039::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260227T221425-ae6c5039","recordedAt":"2026-02-27T22:14:25.640Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["B2M","BRAF","CD274","CTLA4","HAVCR2","JAK1","LAG3","PDCD1","PTEN","STK11"],"targets":["PDCD1","B2M","BRAF","CD274","JAK1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:32.054Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::ustekinumab::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"USTEKINUMAB","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02349061","NCT03517722","NCT04060888"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-01-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:31.703Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::clarithromycin::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"CLARITHROMYCIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:29.192Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::atorvastatin_calcium_trihydrate::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00120887","NCT00065806","NCT00432354","NCT00519363","NCT00412841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:28.831Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::fentanyl_citrate::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"FENTANYL CITRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:29.909Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::dimethyl_sulfoxide::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"DIMETHYL SULFOXIDE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05747651","NCT05458622"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-07-14","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:15.021Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"SUPPORTIVE_CARE"},{"id":"20260227T220301-2c14b9b0::hydrocortisone_butyrate::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"HYDROCORTISONE BUTYRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05748899","NCT02756546","NCT06842316","NCT02558517","NCT00849745"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-02-28","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:30.271Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::paregoric::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"PAREGORIC","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:30.624Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::aldesleukin::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"ALDESLEUKIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01988506","NCT04397107","NCT05631717","NCT02932137","NCT03312335"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-11-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:28.473Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::phenylephrine::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"PHENYLEPHRINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:30.987Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T220301-2c14b9b0::theophylline::systemic_lupus_erythematosus","analysisId":"20260227T220301-2c14b9b0","recordedAt":"2026-02-27T22:03:01.429Z","drug":"THEOPHYLLINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:31.350Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::apomorphine::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"APOMORPHINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:27.039Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::apigenin::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"APIGENIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:26.680Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::bithionol::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"BITHIONOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:28.114Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:27.752Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::ascorbic_acid::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"ASCORBIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:27.399Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:24.903Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:25.256Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::2-mercaptoethanesulfonic_acid::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"2-MERCAPTOETHANESULFONIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:25.607Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::5-hydroxytryptophan::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"5-HYDROXYTRYPTOPHAN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:25.965Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T213913-69b9444d::acitretin::neurodegeneration_biomarker_panel","analysisId":"20260227T213913-69b9444d","recordedAt":"2026-02-27T21:39:13.710Z","drug":"ACITRETIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:26.329Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T204201-c25502d0::midostaurin::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01174888","NCT00866281","NCT03280030","NCT01830361","NCT02078609"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:22.040Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T204201-c25502d0::crizotinib::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"CRIZOTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:24.190Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T204201-c25502d0::clofarabine::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"CLOFARABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00932412","NCT01193400","NCT01534702","NCT01160354","NCT00042354"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:23.829Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T204201-c25502d0::ceritinib::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"CERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:23.478Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T204201-c25502d0::cabozantinib_s-malate::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"CABOZANTINIB S-MALATE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:23.114Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T204201-c25502d0::bortezomib::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"BORTEZOMIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01174888","NCT00382954","NCT01371981","NCT00005064","NCT00742625"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:22.757Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T204201-c25502d0::daunorubicin_liposomal::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3","NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT04817241","NCT02642965","NCT00276601","NCT00878722","NCT00382954"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-03-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:22.396Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T204201-c25502d0::decitabine::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05426798","NCT02085408","NCT03358719","NCT06113289","NCT06802523"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:14.636Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260227T204201-c25502d0::azacitidine::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05426798","NCT02085408","NCT01835587"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-04-19","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:14.280Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260227T204201-c25502d0::fedratinib_hydrochloride::acute_myeloid_leukemia","analysisId":"20260227T204201-c25502d0","recordedAt":"2026-02-27T20:42:01.224Z","drug":"FEDRATINIB HYDROCHLORIDE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04282187"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:13.922Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260227T201604-d0f51bb0::sotorasib::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:12.783Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260227T201604-d0f51bb0::dabrafenib::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:13.566Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260227T201604-d0f51bb0::binimetinib::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02041481","NCT06229340","NCT03981614","NCT04044430","NCT03475004"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:20.982Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T201604-d0f51bb0::abemaciclib::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"ABEMACICLIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06654037","NCT02745769","NCT02857270","NCT04165031","NCT02784795"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:20.629Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T201604-d0f51bb0::temsirolimus::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:19.910Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T201604-d0f51bb0::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00920868","NCT01703910","NCT00504153","NCT00501410","NCT04164069"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-14","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:19.180Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T201604-d0f51bb0::sorafenib::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:18.822Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T201604-d0f51bb0::regorafenib::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:18.465Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T201604-d0f51bb0::tovorafenib::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:13.169Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260227T201604-d0f51bb0::encorafenib::colorectal_cancer","analysisId":"20260227T201604-d0f51bb0","recordedAt":"2026-02-27T20:16:04.139Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:18.112Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:16.324Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:16.682Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:15.611Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:15.257Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:14.905Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:14.554Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:14.191Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:17.044Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:17.402Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T144241-0ce994a2::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260227T144241-0ce994a2","recordedAt":"2026-02-27T14:42:41.617Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:15.966Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::infliximab::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05906576","NCT00791557","NCT03221166","NCT01787786","NCT05584228"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-06-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:12.023Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::mifamurtide::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Other/unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:12.374Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::chembl:chembl1351908::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"CHEMBL:CHEMBL1351908","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:12.861Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::chembl:chembl577660::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"CHEMBL:CHEMBL577660","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:13.835Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::adalimumab::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT03938701","NCT01144156","NCT05394805","NCT01629628"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-05-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:10.225Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::chembl:chembl1456848::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"CHEMBL:CHEMBL1456848","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"Phase 1","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:13.328Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01418131","NCT00643071","NCT03204136","NCT01536535","NCT02954159"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-08-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:10.583Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::azathioprine::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT03760003","NCT05584228","NCT05040464","NCT04304950","NCT01957423"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-29","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:10.941Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::cyclosporine::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT03844932","NCT05112263","NCT01536535","NCT06126835"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-02-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:11.666Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260227T143901-5718568b::celecoxib::inflammatory_bowel_disease","analysisId":"20260227T143901-5718568b","recordedAt":"2026-02-27T14:39:02.022Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00640809","NCT01284504","NCT00808743","NCT00177866","NCT00473980"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-20","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:11.301Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::lapatinib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02101905","NCT00095940","NCT00107003","NCT04135807","NCT01591577"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-04-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:08.091Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::erlotinib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:07.384Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::afatinib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:07.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::vandetanib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:06.667Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::osimertinib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:08.800Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::sunitinib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:09.157Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::regorafenib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:09.870Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::imatinib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00615927","NCT00290771","NCT00613132","NCT00021229","NCT00387933"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-13","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:09.515Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::gefitinib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:44:07.735Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T215155-538f772f::neratinib::glioblastoma","analysisId":"20260226T215155-538f772f","recordedAt":"2026-02-26T21:51:55.842Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:12.387Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T213846-c286302b::fluticasone::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:04.509Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::dactinomycin::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:06.315Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::progesterone::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:05.941Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::norethindrone::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:05.582Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:05.230Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::levonorgestrel::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:04.874Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::dydrogesterone::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:04.143Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::budesonide::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:03.789Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::zileuton::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:03.433Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T213846-c286302b::onapristone::huntington's_disease","analysisId":"20260226T213846-c286302b","recordedAt":"2026-02-26T21:38:46.674Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:03.066Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::5-hydroxytryptophan::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"5-HYDROXYTRYPTOPHAN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:00.559Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:02.365Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::ascorbic_acid::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"ASCORBIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:02.006Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::apigenin::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"APIGENIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:01.283Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::apomorphine::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"APOMORPHINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:01.641Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:59.475Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:59.843Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::2-mercaptoethanesulfonic_acid::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"2-MERCAPTOETHANESULFONIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:00.197Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::bithionol::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"BITHIONOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:02.716Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T210055-c81377ea::acitretin::neurodegeneration_biomarker_panel","analysisId":"20260226T210055-c81377ea","recordedAt":"2026-02-26T21:00:55.410Z","drug":"ACITRETIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:44:00.925Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205912-8067cfe1::crizotinib::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"CRIZOTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:58.764Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205912-8067cfe1::ceritinib::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"CERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:58.049Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205912-8067cfe1::daunorubicin_liposomal::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3","NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT04817241","NCT02642965","NCT00276601","NCT00878722","NCT00382954"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-03-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:56.982Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205912-8067cfe1::cabozantinib_s-malate::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"CABOZANTINIB S-MALATE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:57.688Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205912-8067cfe1::bortezomib::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"BORTEZOMIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01174888","NCT00382954","NCT01371981","NCT00005064","NCT00742625"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:57.335Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205912-8067cfe1::fedratinib_hydrochloride::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"FEDRATINIB HYDROCHLORIDE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04282187"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-02-24","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:58:11.603Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T205912-8067cfe1::clofarabine::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"CLOFARABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00932412","NCT01193400","NCT01534702","NCT01160354","NCT00042354"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:58.407Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205912-8067cfe1::azacitidine::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05426798","NCT02085408","NCT01835587"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-04-19","trialPhase":"Phase 1/PHASE2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:11.219Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T205912-8067cfe1::midostaurin::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01174888","NCT00866281","NCT03280030","NCT01830361","NCT02078609"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:56.624Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205912-8067cfe1::decitabine::acute_myeloid_leukemia","analysisId":"20260226T205912-8067cfe1","recordedAt":"2026-02-26T20:59:12.835Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05426798","NCT02085408","NCT03358719","NCT06113289","NCT06802523"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-12","trialPhase":"Phase 3","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:58:12.003Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T205701-3a66a593::osimertinib::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"OSIMERTINIB","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06618287","NCT06630325","NCT05785741","NCT02465060"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-06-08","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:35.195Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"SCREENING"},{"id":"20260226T205701-3a66a593::dacomitinib_anhydrous::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"DACOMITINIB ANHYDROUS","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01920061","NCT03878524"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:55.550Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205701-3a66a593::afatinib::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"AFATINIB","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01325428","NCT00708214","NCT00425854","NCT01531764","NCT00431067"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-03-28","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:54.199Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205701-3a66a593::paclitaxel::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"PACLITAXEL","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01891123","NCT03839823","NCT03493854","NCT06845319","NCT05266937"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2013-07-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:53.713Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205701-3a66a593::cisplatin::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:53.225Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205701-3a66a593::carboplatin::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:52.858Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205701-3a66a593::erlotinib::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"ERLOTINIB","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00574366","NCT00109265","NCT01594398","NCT00733408","NCT00732810"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-12-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:51.996Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205701-3a66a593::afatinib_dimaleate::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"AFATINIB DIMALEATE","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01325428","NCT00708214","NCT00425854","NCT01531764","NCT00431067"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-03-28","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:54.651Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T205701-3a66a593::amivantamab::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"AMIVANTAMAB","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05395052"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2022-05-27","trialPhase":"Phase 1","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:34.790Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T205701-3a66a593::brigatinib::breast_cancer","analysisId":"20260226T205701-3a66a593","recordedAt":"2026-02-26T20:57:01.425Z","drug":"BRIGATINIB","disease":"breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04591431"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-10-19","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:34.409Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T204935-0ce994a2::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:50.552Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:49.492Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:49.142Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:48.782Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:48.415Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:48.052Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:47.700Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:50.909Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:49.842Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T204935-0ce994a2::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260226T204935-0ce994a2","recordedAt":"2026-02-26T20:49:35.832Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:50.192Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:45.200Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:44.117Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:44.482Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:44.847Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:45.559Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:45.915Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:46.266Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:46.623Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:46.979Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T185353-2912fcbc::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260226T185353-2912fcbc","recordedAt":"2026-02-26T18:53:53.458Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:47.342Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::daunorubicin_liposomal::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:43.058Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::curcumin::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"CURCUMIN","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00099710","NCT01001637","NCT03431896","NCT00164749","NCT01716637"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-12-19","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:42.694Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::clioquinol::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"CLIOQUINOL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:42.342Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::bupropion_hydrochloride::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"BUPROPION HYDROCHLORIDE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00692510","NCT05557409","NCT03226522","NCT04797715","NCT01047254"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-05","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:41.983Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::amphotericin_b_liposomal::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"AMPHOTERICIN B LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:41.626Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::donepezil::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:43.765Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::nirogacestat::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:41.267Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::aducanumab::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Binder of target","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:40.559Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T182159-2b1727d8::lecanemab::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:34.025Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T182159-2b1727d8::donanemab::alzheimer's_disease","analysisId":"20260226T182159-2b1727d8","recordedAt":"2026-02-26T18:21:59.208Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Negative modulator of target","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:43.411Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::lenalidomide::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"LENALIDOMIDE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:36.623Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::etanercept::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"ETANERCEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00244556","NCT00346294","NCT00445770","NCT00706797","NCT02353780"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-10-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:40.206Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::echinacea_preparation::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"ECHINACEA PREPARATION","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:39.738Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::alteplase::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"ALTEPLASE","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:39.257Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::adalimumab::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"ADALIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02565810","NCT03938701","NCT01078402","NCT02353780","NCT00650026"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-30","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:38.816Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::infliximab::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"INFLIXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B","IL6","TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01299545","NCT02353780","NCT00705289","NCT02925338","NCT05379049"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2011-02-17","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:38.362Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::rilonacept::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"RILONACEPT","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL1B"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00534495","NCT00094900"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-09-25","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:37.121Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::golimumab::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"GOLIMUMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01962974","NCT03414502","NCT02778789","NCT01081717","NCT04188249"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2013-10-15","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:36.071Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::certolizumab_pegol::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"CERTOLIZUMAB PEGOL","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["TNF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01147341","NCT02353780","NCT02319642","NCT05651373","NCT02466581"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-06-21","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:35.524Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T174619-2a5df430::siltuximab::rheumatoid_arthritis","analysisId":"20260226T174619-2a5df430","recordedAt":"2026-02-26T17:46:19.307Z","drug":"SILTUXIMAB","disease":"rheumatoid arthritis","genes":["IL1B","IL6","PTPN22","TNF"],"targets":["IL6"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:37.549Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::bithionol::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"BITHIONOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:34.969Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::ascorbic_acid::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"ASCORBIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:34.244Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::apomorphine::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"APOMORPHINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:33.891Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::apigenin::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"APIGENIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:33.529Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::acitretin::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"ACITRETIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:33.176Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::5-hydroxytryptophan::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"5-HYDROXYTRYPTOPHAN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:32.825Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::2-mercaptoethanesulfonic_acid::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"2-MERCAPTOETHANESULFONIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:32.461Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:31.760Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:32.111Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171742-e7bdf9eb::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260226T171742-e7bdf9eb","recordedAt":"2026-02-26T17:17:42.996Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:34.609Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::paregoric::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"PAREGORIC","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:30.332Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::aldesleukin::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"ALDESLEUKIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01988506","NCT04397107","NCT05631717","NCT02932137","NCT03312335"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-11-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:28.201Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::atorvastatin_calcium_trihydrate::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00120887","NCT00065806","NCT00432354","NCT00519363","NCT00412841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-18","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:28.555Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::clarithromycin::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"CLARITHROMYCIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:28.910Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::fentanyl_citrate::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"FENTANYL CITRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:29.625Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::hydrocortisone_butyrate::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"HYDROCORTISONE BUTYRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05748899","NCT02756546","NCT06842316","NCT02558517","NCT00849745"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-02-28","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:29.976Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::dimethyl_sulfoxide::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"DIMETHYL SULFOXIDE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT05747651","NCT05458622"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-07-14","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:33.670Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"SUPPORTIVE_CARE"},{"id":"20260226T171656-8cde2a54::theophylline::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"THEOPHYLLINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:31.043Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::ustekinumab::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"USTEKINUMAB","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02349061","NCT03517722","NCT04060888"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-01-27","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:31.408Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T171656-8cde2a54::phenylephrine::systemic_lupus_erythematosus","analysisId":"20260226T171656-8cde2a54","recordedAt":"2026-02-26T17:16:56.627Z","drug":"PHENYLEPHRINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:30.692Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T170321-30ec27eb::amivantamab::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"AMIVANTAMAB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:27.320Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T170321-30ec27eb::paclitaxel::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"PACLITAXEL","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06845319","NCT05266937","NCT03057600","NCT03997123","NCT05763992"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:25.669Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T170321-30ec27eb::cisplatin::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"CISPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01920061","NCT04491942","NCT01091454","NCT02658214","NCT01167192"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:24.980Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T170321-30ec27eb::carboplatin::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"CARBOPLATIN","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1","EGFR","TP53"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT06845319","NCT05266937","NCT05763992","NCT04907344","NCT00618657"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:24.471Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T170321-30ec27eb::erlotinib::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"ERLOTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00733408","NCT00491816","NCT01650506","NCT00998036","NCT00834678"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-08-12","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:23.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T170321-30ec27eb::brigatinib::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"BRIGATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:22.904Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T170321-30ec27eb::osimertinib::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"OSIMERTINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR","TP53"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06618287"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-01","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:32.929Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T170321-30ec27eb::dacomitinib_anhydrous::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"DACOMITINIB ANHYDROUS","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT01920061"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-08-08","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:27.837Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T170321-30ec27eb::afatinib::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"AFATINIB","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:32.542Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T170321-30ec27eb::afatinib_dimaleate::triple-negative_breast_cancer","analysisId":"20260226T170321-30ec27eb","recordedAt":"2026-02-26T17:03:22.001Z","drug":"AFATINIB DIMALEATE","disease":"triple-negative breast cancer","genes":["BRCA1","EGFR","TP53"],"targets":["EGFR"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT02511847"],"trialFound":true,"trialCompleted":false,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2015-07-30","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:33.315Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T163856-95076a7d::dostarlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"DOSTARLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:20.691Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::trametinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"TRAMETINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["BRAF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:20.251Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::ruxolitinib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"RUXOLITINIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["JAK1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"JAK1/JAK2 inhibitor; reduces IFN-gamma signaling and PD-L1 upregulation in immunosuppressive TME","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:22.453Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::nivolumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"NIVOLUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:18.281Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::ipilimumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"IPILIMUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["CTLA4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:18.794Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::dabrafenib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"DABRAFENIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["BRAF"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:19.740Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::relatlimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"RELATLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["LAG3"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:19.291Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::copanlisib::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"COPANLISIB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PTEN"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Pan-class I PI3K inhibitor; targets PTEN-loss-driven AKT/mTOR hyperactivation in IO-resistant tumors","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:21.939Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::pembrolizumab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"PEMBROLIZUMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["PDCD1"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:17.499Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163856-95076a7d::cobolimab::metastatic_melanoma_anti-pd-1_immunotherapy_resistance","analysisId":"20260226T163856-95076a7d","recordedAt":"2026-02-26T16:38:56.637Z","drug":"COBOLIMAB","disease":"metastatic melanoma anti-PD-1 immunotherapy resistance","genes":["PDCD1","CD274","CTLA4","LAG3","HAVCR2","PTEN","B2M","JAK1","BRAF","STK11"],"targets":["HAVCR2"],"confidence":"0.300","phase":"Phase 2","mechanism":"Anti-TIM-3 monoclonal antibody; targets terminal T-cell exhaustion marker; in Phase 2/3 trials for NSCLC and melanoma","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"Phase 2","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:21.429Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:15.812Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::alectinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:14.397Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::afatinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:16.542Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::crizotinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:13.677Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::brigatinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:14.032Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::lapatinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"LAPATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT00073008","NCT02230553","NCT04591431","NCT01306045","NCT00313599"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-16","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:15.460Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::tucatinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"TUCATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT06067776","NCT04579380","NCT05091528","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2023-10-04","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:16.178Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::ceritinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:14.747Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T163023-5d32903a::erlotinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"ERLOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:32.152Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T163023-5d32903a::entrectinib::non-small_cell_lung_cancer","analysisId":"20260226T163023-5d32903a","recordedAt":"2026-02-26T16:30:23.714Z","drug":"ENTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Inhibitor of target","trialNctIds":["NCT03178552","NCT04302025","NCT02568267","NCT06694129"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:31.796Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T155955-2b1727d8::donepezil::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:13.315Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155955-2b1727d8::amphotericin_b_liposomal::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"AMPHOTERICIN B LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:11.176Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155955-2b1727d8::nirogacestat::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:10.817Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155955-2b1727d8::aducanumab::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Binder of target","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:10.107Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155955-2b1727d8::lecanemab::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:31.441Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T155955-2b1727d8::bupropion_hydrochloride::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"BUPROPION HYDROCHLORIDE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00692510","NCT05557409","NCT03226522","NCT04797715","NCT01047254"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:11.528Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155955-2b1727d8::clioquinol::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"CLIOQUINOL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:11.890Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155955-2b1727d8::curcumin::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"CURCUMIN","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00099710","NCT01001637","NCT03431896","NCT00164749","NCT01716637"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-12-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:12.240Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155955-2b1727d8::daunorubicin_liposomal::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:12.592Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155955-2b1727d8::donanemab::alzheimer's_disease","analysisId":"20260226T155955-2b1727d8","recordedAt":"2026-02-26T15:59:55.568Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Negative modulator of target","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:12.952Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::clioquinol::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"CLIOQUINOL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:08.311Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::lecanemab::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:31.086Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T155953-65a4ba91::bupropion_hydrochloride::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"BUPROPION HYDROCHLORIDE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00692510","NCT05557409","NCT03226522","NCT04797715","NCT01047254"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:07.960Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::amphotericin_b_liposomal::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"AMPHOTERICIN B LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:07.608Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::nirogacestat::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:07.254Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::aducanumab::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Binder of target","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:06.543Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::donepezil::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:09.744Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::donanemab::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Negative modulator of target","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:09.391Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::daunorubicin_liposomal::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:09.033Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T155953-65a4ba91::curcumin::alzheimer's_disease","analysisId":"20260226T155953-65a4ba91","recordedAt":"2026-02-26T15:59:53.930Z","drug":"CURCUMIN","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00099710","NCT01001637","NCT03431896","NCT00164749","NCT01716637"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-12-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:08.676Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::donepezil::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:06.185Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::lecanemab::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:30.730Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260226T154230-2b1727d8::donanemab::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Negative modulator of target","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:05.824Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::daunorubicin_liposomal::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:05.466Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::curcumin::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"CURCUMIN","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00099710","NCT01001637","NCT03431896","NCT00164749","NCT01716637"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-12-19","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:05.116Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::clioquinol::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"CLIOQUINOL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:04.759Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::bupropion_hydrochloride::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"BUPROPION HYDROCHLORIDE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00692510","NCT05557409","NCT03226522","NCT04797715","NCT01047254"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-05","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:04.397Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::amphotericin_b_liposomal::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"AMPHOTERICIN B LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:04.034Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::nirogacestat::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:03.668Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T154230-2b1727d8::aducanumab::alzheimer's_disease","analysisId":"20260226T154230-2b1727d8","recordedAt":"2026-02-26T15:42:30.783Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Binder of target","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:43:02.952Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::apomorphine::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"APOMORPHINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:01.172Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::ascorbic_acid::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"ASCORBIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:01.610Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::masoprocol::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"MASOPROCOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:58.402Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::aspirin::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"ASPIRIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:02.097Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::nifedipine::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"NIFEDIPINE","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["GFAP","MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:58.879Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::bithionol::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"BITHIONOL","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:02.591Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::2-mercaptoethanesulfonic_acid::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"2-MERCAPTOETHANESULFONIC ACID","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:59.351Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::5-hydroxytryptophan::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"5-HYDROXYTRYPTOPHAN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:59.821Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::acitretin::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"ACITRETIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:00.278Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260226T153302-e7bdf9eb::apigenin::neurodegeneration_biomarker_panel","analysisId":"20260226T153302-e7bdf9eb","recordedAt":"2026-02-26T15:33:02.732Z","drug":"APIGENIN","disease":"neurodegeneration biomarker panel","genes":["GFAP","MAPT","NEFL","NEFL","S100B"],"targets":["MAPT"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:43:00.736Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:57.522Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:57.170Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:56.811Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:56.454Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:54.654Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:55.012Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:55.379Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:55.737Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:56.096Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T171811-2912fcbc::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260224T171811-2912fcbc","recordedAt":"2026-02-24T17:18:11.423Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"0.550","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:57.873Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::pioglitazone_hydrochloride::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT04027023","NCT01135394","NCT05760677","NCT02426294","NCT00541450"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:52.869Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::balsalazide_disodium::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"BALSALAZIDE DISODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:51.444Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::bezafibrate::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"BEZAFIBRATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00506298"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:51.795Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::mesalamine::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"MESALAMINE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:52.159Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::olsalazine_sodium::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"OLSALAZINE SODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:52.512Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::glyburide::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"GLYBURIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00194896","NCT01698931","NCT00300105","NCT00549874","NCT01045590"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:53.930Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::metformin::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"METFORMIN","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","TCF7L2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT04027023","NCT01871558","NCT02040246","NCT02627027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:54.296Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::estradiol_valerate::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"ESTRADIOL VALERATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00254800","NCT01686828","NCT01458210","NCT05153564","NCT02845219"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:53.577Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::rosiglitazone_maleate::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"ROSIGLITAZONE MALEATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00194896","NCT00549874","NCT01045590","NCT01706211","NCT00402909"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:53.227Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T165040-f74482c6::troglitazone::type_2_diabetes_mellitus","analysisId":"20260224T165040-f74482c6","recordedAt":"2026-02-24T16:50:40.955Z","drug":"TROGLITAZONE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT02456428","NCT03492580","NCT02476760","NCT02475499","NCT01068860"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:51.080Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::glyburide::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"GLYBURIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00194896","NCT01698931","NCT00300105","NCT00549874","NCT01045590"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:50.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::metformin::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"METFORMIN","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","TCF7L2"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT04027023","NCT01871558","NCT02040246","NCT02627027"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:50.715Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::estradiol_valerate::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"ESTRADIOL VALERATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Unknown of target","trialNctIds":["NCT00254800","NCT01686828","NCT01458210","NCT05153564","NCT02845219"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-11-16","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:49.817Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::rosiglitazone_maleate::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"ROSIGLITAZONE MALEATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00194896","NCT00549874","NCT01045590","NCT01706211","NCT00402909"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:49.368Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::pioglitazone_hydrochloride::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"PIOGLITAZONE HYDROCHLORIDE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT04027023","NCT01135394","NCT05760677","NCT02426294","NCT00541450"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2019-07-18","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:48.841Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::olsalazine_sodium::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"OLSALAZINE SODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:48.363Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::mesalamine::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"MESALAMINE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:47.929Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::bezafibrate::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"BEZAFIBRATE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT00506298"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2007-07-24","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:47.493Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::balsalazide_disodium::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"BALSALAZIDE DISODIUM","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:47.060Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T163649-f74482c6::troglitazone::type_2_diabetes_mellitus","analysisId":"20260224T163649-f74482c6","recordedAt":"2026-02-24T16:36:49.252Z","drug":"TROGLITAZONE","disease":"type 2 diabetes mellitus","genes":["PPARG","SLC2A4","TCF7L2"],"targets":["PPARG","SLC2A4"],"confidence":"0.300","phase":"FDA Approved","mechanism":"Agonist of target","trialNctIds":["NCT02456428","NCT03492580","NCT02476760","NCT02475499","NCT01068860"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-05-27","trialPhase":"FDA Approved","repurposingScore":32,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:46.626Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T162843-95427aa0::dabrafenib::melanoma","analysisId":"20260224T162843-95427aa0","recordedAt":"2026-02-24T16:28:43.189Z","drug":"DABRAFENIB","disease":"melanoma","genes":["CTLA4","EGFR","PDCD1"],"targets":[],"confidence":"0.550","phase":"FDA Approved","mechanism":"Selective BRAF V600E/V600K kinase inhibitor; combined with trametinib for BRAF-mutant melanoma","trialNctIds":["NCT01153763","NCT01227889","NCT02110355","NCT02967692","NCT05848219"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-06-29","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:45.634Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T162843-95427aa0::trametinib::melanoma","analysisId":"20260224T162843-95427aa0","recordedAt":"2026-02-24T16:28:43.189Z","drug":"TRAMETINIB","disease":"melanoma","genes":["CTLA4","EGFR","PDCD1"],"targets":[],"confidence":"0.550","phase":"FDA Approved","mechanism":"MEK1/MEK2 inhibitor; combined with dabrafenib as standard of care for BRAF V600 melanoma","trialNctIds":["NCT05677373","NCT02110355","NCT02967692","NCT04417621","NCT05275374"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2023-01-09","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:46.118Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T162843-95427aa0::pembrolizumab::melanoma","analysisId":"20260224T162843-95427aa0","recordedAt":"2026-02-24T16:28:43.189Z","drug":"PEMBROLIZUMAB","disease":"melanoma","genes":["CTLA4","EGFR","PDCD1"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; blocks PD-1/PD-L1 interaction to restore T-cell anti-tumor activity","trialNctIds":["NCT02089685","NCT04483778","NCT05308901","NCT04187872","NCT01993719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-17","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:43.326Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T162843-95427aa0::relatlimab::melanoma","analysisId":"20260224T162843-95427aa0","recordedAt":"2026-02-24T16:28:43.189Z","drug":"RELATLIMAB","disease":"melanoma","genes":["CTLA4","EGFR","PDCD1"],"targets":[],"confidence":"0.550","phase":"FDA Approved","mechanism":"Anti-LAG-3 monoclonal antibody; combined with nivolumab (Opdualag) for melanoma, blocks LAG-3 exhaustion pathway","trialNctIds":["NCT06712927","NCT05625399","NCT03978611"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-12-02","trialPhase":"FDA Approved","repurposingScore":52,"tier":"II","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:45.158Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T162843-95427aa0::nivolumab::melanoma","analysisId":"20260224T162843-95427aa0","recordedAt":"2026-02-24T16:28:43.189Z","drug":"NIVOLUMAB","disease":"melanoma","genes":["CTLA4","EGFR","PDCD1"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 IgG4 monoclonal antibody; restores effector T-cell function by blocking PD-1","trialNctIds":["NCT03326258","NCT04146324","NCT04165967","NCT06712927","NCT02637531"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2017-10-30","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:43.775Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T162843-95427aa0::ipilimumab::melanoma","analysisId":"20260224T162843-95427aa0","recordedAt":"2026-02-24T16:28:43.189Z","drug":"IPILIMUMAB","disease":"melanoma","genes":["CTLA4","EGFR","PDCD1"],"targets":["CTLA4"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-CTLA-4 monoclonal antibody; enhances T-cell activation by blocking CTLA-4 co-inhibitory signaling","trialNctIds":["NCT03326258","NCT02089685","NCT02385669","NCT06712927","NCT02905266"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2017-10-30","trialPhase":"FDA Approved","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:44.236Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T162843-95427aa0::dostarlimab::melanoma","analysisId":"20260224T162843-95427aa0","recordedAt":"2026-02-24T16:28:43.189Z","drug":"DOSTARLIMAB","disease":"melanoma","genes":["CTLA4","EGFR","PDCD1"],"targets":["PDCD1"],"confidence":"0.800","phase":"FDA Approved","mechanism":"Anti-PD-1 monoclonal antibody; approved for dMMR/MSI-H cancers including solid tumors","trialNctIds":["NCT02817633","NCT04139902","NCT06521567","NCT05060432"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2016-06-29","trialPhase":"Phase 1","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:30.376Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260224T021911-8cec341a::esflurbiprofen::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"ESFLURBIPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:42.367Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::artemisinin::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"ARTEMISININ","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:38.638Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::estrone::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"ESTRONE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:42.816Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::doxycycline_anhydrous::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"DOXYCYCLINE ANHYDROUS","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["SOD1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:41.920Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::diclofenac_sodium::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"DICLOFENAC SODIUM","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:41.477Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::dexibuprofen::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"DEXIBUPROFEN","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:41.037Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::chlorhexidine_gluconate::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"CHLORHEXIDINE GLUCONATE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:40.599Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::chenodeoxycholic_acid::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"CHENODEOXYCHOLIC ACID","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:40.152Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::bifonazole::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"BIFONAZOLE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:39.521Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T021911-8cec341a::benzethonium_chloride::amyotrophic_lateral_sclerosis","analysisId":"20260224T021911-8cec341a","recordedAt":"2026-02-24T02:19:11.460Z","drug":"BENZETHONIUM CHLORIDE","disease":"amyotrophic lateral sclerosis","genes":["C9ORF72","FUS","SOD1","TARDBP"],"targets":["TARDBP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:39.097Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::fluticasone::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:36.311Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:37.025Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::zileuton::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:35.242Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::progesterone::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:37.743Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::dactinomycin::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:38.114Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::norethindrone::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:37.387Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::levonorgestrel::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:36.676Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::budesonide::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:35.593Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::onapristone::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:34.876Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020635-9336a7de::dydrogesterone::huntington's_disease","analysisId":"20260224T020635-9336a7de","recordedAt":"2026-02-24T02:06:35.057Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:35.951Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::lapatinib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02101905","NCT00095940","NCT00107003","NCT04135807","NCT01591577"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-04-01","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:32.692Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::gefitinib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:32.337Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::imatinib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00615927","NCT00290771","NCT00613132","NCT00021229","NCT00387933"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-13","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:34.150Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::regorafenib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:34.516Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::afatinib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:31.630Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::erlotinib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:31.984Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::sunitinib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:33.784Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::vandetanib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:31.278Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::osimertinib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-02-24","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:33.422Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T020305-be314a25::neratinib::glioblastoma","analysisId":"20260224T020305-be314a25","recordedAt":"2026-02-24T02:03:05.443Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:29.991Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260224T010449-d85fb695::curcumin::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"CURCUMIN","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00099710","NCT01001637","NCT03431896","NCT00164749","NCT01716637"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-12-19","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:29.522Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T010449-d85fb695::lecanemab::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"LECANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE","APP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01767311","NCT02094729"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-01-14","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:29.636Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260224T010449-d85fb695::nirogacestat::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"NIROGACESTAT","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP","PSEN1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:27.574Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T010449-d85fb695::aducanumab::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"ADUCANUMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05097131","NCT05310071","NCT02782975","NCT02434718","NCT01677572"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-10-26","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:26.636Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T010449-d85fb695::clioquinol::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"CLIOQUINOL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:29.008Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T010449-d85fb695::daunorubicin_liposomal::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:29.969Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T010449-d85fb695::donanemab::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"DONANEMAB","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06566170","NCT03367403","NCT04437511","NCT05026866","NCT06996730"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-08-21","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:30.454Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T010449-d85fb695::donepezil::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"DONEPEZIL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01023867","NCT00548145","NCT01860625","NCT02787746","NCT02968719"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-12-01","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:30.927Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T010449-d85fb695::amphotericin_b_liposomal::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"AMPHOTERICIN B LIPOSOMAL","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APP"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:28.049Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260224T010449-d85fb695::bupropion_hydrochloride::alzheimer's_disease","analysisId":"20260224T010449-d85fb695","recordedAt":"2026-02-24T01:04:49.955Z","drug":"BUPROPION HYDROCHLORIDE","disease":"Alzheimer's disease","genes":["APOE","APP","PSEN1"],"targets":["APOE"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00692510","NCT05557409","NCT03226522","NCT04797715","NCT01047254"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-05","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:28.557Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::sunitinib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:25.435Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::osimertinib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-02-24","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:25.076Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::vandetanib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:22.925Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::afatinib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:23.277Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::neratinib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:29.236Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T234839-be314a25::erlotinib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:23.634Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::gefitinib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:23.992Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::lapatinib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02101905","NCT00095940","NCT00107003","NCT04135807","NCT01591577"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-04-01","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:24.353Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::regorafenib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:26.151Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234839-be314a25::imatinib::glioblastoma","analysisId":"20260223T234839-be314a25","recordedAt":"2026-02-23T23:48:39.414Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00615927","NCT00290771","NCT00613132","NCT00021229","NCT00387933"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-13","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:25.794Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::paregoric::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"PAREGORIC","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:21.112Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::hydrocortisone_butyrate::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"HYDROCORTISONE BUTYRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05748899","NCT02756546","NCT06842316","NCT02558517","NCT00849745"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2023-02-28","trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:20.645Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::fentanyl_citrate::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"FENTANYL CITRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:20.185Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::phenylephrine::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"PHENYLEPHRINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:21.561Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::theophylline::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"THEOPHYLLINE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:22.061Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::aldesleukin::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"ALDESLEUKIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01988506","NCT04397107","NCT05631717","NCT02932137","NCT03312335"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-11-19","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:18.307Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::ustekinumab::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"USTEKINUMAB","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["STAT4"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02349061","NCT03517722","NCT04060888"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-01-27","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:22.567Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::atorvastatin_calcium_trihydrate::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"ATORVASTATIN CALCIUM TRIHYDRATE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00120887","NCT00065806","NCT00432354","NCT00519363","NCT00412841"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-07-18","trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:18.781Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::clarithromycin::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"CLARITHROMYCIN","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:19.221Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T234358-75b76d5d::dimethyl_sulfoxide::systemic_lupus_erythematosus","analysisId":"20260223T234358-75b76d5d","recordedAt":"2026-02-23T23:43:58.709Z","drug":"DIMETHYL SULFOXIDE","disease":"systemic lupus erythematosus","genes":["IRF5","ITGAM","STAT4"],"targets":["ITGAM"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05747651","NCT05458622"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-07-14","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:28.881Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"BIOLOGICAL","primaryPurpose":"SUPPORTIVE_CARE"},{"id":"20260223T233020-7a36e084::cyclosporine::inflammatory_bowel_disease","analysisId":"20260223T233020-7a36e084","recordedAt":"2026-02-23T23:30:20.566Z","drug":"CYCLOSPORINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT03844932","NCT05112263","NCT01536535","NCT06126835"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2019-02-18","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:16.789Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T233020-7a36e084::adalimumab::inflammatory_bowel_disease","analysisId":"20260223T233020-7a36e084","recordedAt":"2026-02-23T23:30:20.566Z","drug":"ADALIMUMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["ATG16L1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT03938701","NCT01144156","NCT05394805","NCT01629628"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2019-05-05","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:14.969Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T233020-7a36e084::infliximab::inflammatory_bowel_disease","analysisId":"20260223T233020-7a36e084","recordedAt":"2026-02-23T23:30:20.566Z","drug":"INFLIXIMAB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05906576","NCT00791557","NCT03221166","NCT01787786","NCT05584228"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-06-17","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:17.331Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T233020-7a36e084::celecoxib::inflammatory_bowel_disease","analysisId":"20260223T233020-7a36e084","recordedAt":"2026-02-23T23:30:20.566Z","drug":"CELECOXIB","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00640809","NCT01284504","NCT00808743","NCT00177866","NCT00473980"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-03-20","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:16.329Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T233020-7a36e084::azathioprine::inflammatory_bowel_disease","analysisId":"20260223T233020-7a36e084","recordedAt":"2026-02-23T23:30:20.566Z","drug":"AZATHIOPRINE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["IL23R"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT03760003","NCT05584228","NCT05040464","NCT04304950","NCT01957423"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2018-11-29","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:15.878Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T233020-7a36e084::anhydrous_tacrolimus::inflammatory_bowel_disease","analysisId":"20260223T233020-7a36e084","recordedAt":"2026-02-23T23:30:20.566Z","drug":"ANHYDROUS TACROLIMUS","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01418131","NCT00643071","NCT03204136","NCT01536535","NCT02954159"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-08-15","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:15.423Z","completedOutcomeClass":"negative","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":1,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T233020-7a36e084::mifamurtide::inflammatory_bowel_disease","analysisId":"20260223T233020-7a36e084","recordedAt":"2026-02-23T23:30:20.566Z","drug":"MIFAMURTIDE","disease":"inflammatory bowel disease","genes":["ATG16L1","IL23R","NOD2"],"targets":["NOD2"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:17.833Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230837-59907ad1::afatinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"AFATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02438722","NCT03623750","NCT04356118","NCT03370770","NCT02183883"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-05-07","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:14.054Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230837-59907ad1::lorlatinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"LORLATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06893354","NCT06876675","NCT04362072","NCT03612154","NCT04541407"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2025-03-24","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:13.041Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230837-59907ad1::lapatinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"LAPATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00073008","NCT02230553","NCT04591431","NCT01306045","NCT00313599"],"trialFound":true,"trialCompleted":true,"trialStatus":"TERMINATED","trialFirstPostedDate":"2003-11-16","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:12.580Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230837-59907ad1::ceritinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"CERITINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT04356118","NCT01772797","NCT02450903","NCT01828099","NCT04647110"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:11.595Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230837-59907ad1::alectinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"ALECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT04356118","NCT05713006","NCT02604342","NCT02450903","NCT04351334"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2020-04-21","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:11.118Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230837-59907ad1::brigatinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"BRIGATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","ROS1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05200481","NCT02737501","NCT04074993","NCT04647110","NCT03707938"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-19","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:10.619Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230837-59907ad1::crizotinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"CRIZOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00932451","NCT01637597","NCT04193007","NCT06082635","NCT02228421"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:10.116Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230837-59907ad1::entrectinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"ENTRECTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","ROS1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT03178552","NCT04302025","NCT02568267","NCT06694129"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2015-10-05","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:28.497Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":4,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T230837-59907ad1::erlotinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"ERLOTINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["ALK","EGFR","KRAS","ROS1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00091663","NCT00606502","NCT00871923","NCT02037997","NCT00287989"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2004-09-16","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:28.103Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T230837-59907ad1::tucatinib::non-small_cell_lung_cancer","analysisId":"20260223T230837-59907ad1","recordedAt":"2026-02-23T23:08:37.699Z","drug":"TUCATINIB","disease":"non-small cell lung cancer","genes":["ALK","EGFR","KRAS","ROS1"],"targets":["EGFR","KRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06067776","NCT04579380","NCT05091528","NCT02892123"],"trialFound":true,"trialCompleted":true,"trialStatus":"NOT_YET_RECRUITING","trialFirstPostedDate":"2023-10-04","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:13.549Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230212-dccb03da::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00920868","NCT01703910","NCT00504153","NCT00501410","NCT04164069"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-14","trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:07.845Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230212-dccb03da::binimetinib::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02041481","NCT06229340","NCT03981614","NCT04044430","NCT03475004"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-21","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:09.623Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230212-dccb03da::abemaciclib::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"ABEMACICLIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06654037","NCT02745769","NCT02857270","NCT04165031","NCT02784795"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-22","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:09.262Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230212-dccb03da::temsirolimus::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:08.555Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230212-dccb03da::dabrafenib::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:27.351Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T230212-dccb03da::sorafenib::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:07.487Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230212-dccb03da::regorafenib::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:07.129Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230212-dccb03da::encorafenib::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:06.776Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T230212-dccb03da::tovorafenib::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:27.706Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T230212-dccb03da::sotorasib::colorectal_cancer","analysisId":"20260223T230212-dccb03da","recordedAt":"2026-02-23T23:02:12.094Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:26.996Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T222747-e3a132d0::fedratinib_hydrochloride::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"FEDRATINIB HYDROCHLORIDE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT04282187"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2020-02-24","trialPhase":"Phase 2","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:26.641Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T222747-e3a132d0::midostaurin::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"MIDOSTAURIN","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3","NPM1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01174888","NCT00866281","NCT03280030","NCT01830361","NCT02078609"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:02.821Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T222747-e3a132d0::clofarabine::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"CLOFARABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00932412","NCT01193400","NCT01534702","NCT01160354","NCT00042354"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-07-02","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:05.123Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T222747-e3a132d0::daunorubicin_liposomal::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"DAUNORUBICIN LIPOSOMAL","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3","NPM1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT04817241","NCT02642965","NCT00276601","NCT00878722","NCT00382954"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2021-03-25","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:03.299Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T222747-e3a132d0::bortezomib::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"BORTEZOMIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01174888","NCT00382954","NCT01371981","NCT00005064","NCT00742625"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-08-03","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:03.780Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T222747-e3a132d0::ceritinib::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"CERITINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["NPM1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-15","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:04.667Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T222747-e3a132d0::crizotinib::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"CRIZOTINIB","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["NPM1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02551718"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2015-09-15","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:42:05.595Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T222747-e3a132d0::decitabine::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"DECITABINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05426798","NCT02085408","NCT03358719","NCT06113289","NCT06802523"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-03-12","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:26.262Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T222747-e3a132d0::cabozantinib_s-malate::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"CABOZANTINIB S-MALATE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["FLT3"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:04.218Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T222747-e3a132d0::azacitidine::acute_myeloid_leukemia","analysisId":"20260223T222747-e3a132d0","recordedAt":"2026-02-23T22:27:47.738Z","drug":"AZACITIDINE","disease":"acute myeloid leukemia","genes":["DNMT3A","FLT3","NPM1"],"targets":["DNMT3A","FLT3"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05426798","NCT02085408","NCT01835587"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2013-04-19","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:25.868Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T202100-9336a7de::norethindrone::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"NORETHINDRONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:00.288Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::zileuton::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"ZILEUTON","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["CREB1"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:41:57.530Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::progesterone::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"PROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:00.800Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::levonorgestrel::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"LEVONORGESTREL","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:41:59.395Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::fluticasone::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"FLUTICASONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:41:58.931Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::dydrogesterone::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"DYDROGESTERONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:41:58.485Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::dactinomycin::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"DACTINOMYCIN","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF","HTT"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:42:01.260Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::onapristone::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"ONAPRISTONE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:41:57.072Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::medroxyprogesterone_acetate::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"MEDROXYPROGESTERONE ACETATE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:41:59.842Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T202100-9336a7de::budesonide::huntington's_disease","analysisId":"20260223T202100-9336a7de","recordedAt":"2026-02-23T20:21:00.074Z","drug":"BUDESONIDE","disease":"Huntington's disease","genes":["BDNF","CREB1","HTT"],"targets":["BDNF"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":[],"trialFound":false,"trialCompleted":false,"trialStatus":null,"trialFirstPostedDate":null,"trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"insufficient_data","outcomeAt":"2026-04-23T01:41:58.034Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T201602-f08e5cc6::sotorasib::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"SOTORASIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06645236","NCT06252649","NCT05198934"],"trialFound":true,"trialCompleted":false,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-01-20","trialPhase":"Phase 3","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:25.118Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T201602-f08e5cc6::encorafenib::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"ENCORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06102902","NCT01719380","NCT02675946","NCT05308446"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2023-10-25","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:52.860Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T201602-f08e5cc6::dabrafenib::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"DABRAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT04294160","NCT06978400","NCT01750918","NCT05963087","NCT06967155"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2012-12-17","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:25.473Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":3,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T201602-f08e5cc6::binimetinib::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"BINIMETINIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02041481","NCT06229340","NCT03981614","NCT04044430","NCT03475004"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-01-21","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:56.642Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T201602-f08e5cc6::abemaciclib::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"ABEMACICLIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06654037","NCT02745769","NCT02857270","NCT04165031","NCT02784795"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2024-10-22","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:56.148Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T201602-f08e5cc6::temsirolimus::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"TEMSIROLIMUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT03190174","NCT01364844","NCT03203525","NCT04230499","NCT02423954"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2017-06-15","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:55.184Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T201602-f08e5cc6::dasatinib_anhydrous::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"DASATINIB ANHYDROUS","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00920868","NCT01703910","NCT00504153","NCT00501410","NCT04164069"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-06-14","trialPhase":"unknown","repurposingScore":28,"tier":"III","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:54.284Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T201602-f08e5cc6::sorafenib::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"SORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00703638","NCT00134069","NCT00865709","NCT00989469","NCT00326495"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-06-22","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:53.783Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T201602-f08e5cc6::regorafenib::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"REGORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","KRAS","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05582031","NCT06456515","NCT04660812","NCT02316340","NCT06930118"],"trialFound":true,"trialCompleted":true,"trialStatus":"WITHDRAWN","trialFirstPostedDate":"2022-10-16","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:53.306Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T201602-f08e5cc6::tovorafenib::colorectal_cancer","analysisId":"20260223T201602-f08e5cc6","recordedAt":"2026-02-23T20:16:02.435Z","drug":"TOVORAFENIB","disease":"colorectal cancer","genes":["BRAF","KRAS","NRAS"],"targets":["BRAF","NRAS"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT04985604"],"trialFound":true,"trialCompleted":false,"trialStatus":"TERMINATED","trialFirstPostedDate":"2021-08-02","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:24.721Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T194135-bbdcbc2e::granisetron::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"GRANISETRON","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01298193","NCT00293384","NCT00475085","NCT05408676","NCT01649258"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2011-02-16","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:47.394Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::cisplatin::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"CISPLATIN","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00006260","NCT01920061","NCT04491942","NCT01091454","NCT03423849"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:48.584Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::daunorubicin_hydrochloride::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"DAUNORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:49.056Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::doxorubicin_hydrochloride::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"DOXORUBICIN HYDROCHLORIDE","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00212082","NCT03493854","NCT00544167","NCT01498588","NCT02078388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2005-09-20","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:49.548Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::gemcitabine::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"GEMCITABINE","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT03839823","NCT02263495","NCT04491942","NCT03423849","NCT06383767"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2019-02-14","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:50.006Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::oxaliplatin::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"OXALIPLATIN","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01351597","NCT01937507","NCT03065478","NCT02658214","NCT00274859"],"trialFound":true,"trialCompleted":true,"trialStatus":"UNKNOWN","trialFirstPostedDate":"2011-05-10","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:51.891Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"weak","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::mitomycin::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"MITOMYCIN","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT01091168","NCT02299999","NCT00003893","NCT01196455"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2010-03-22","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:50.474Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::mitoxantrone::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"MITOXANTRONE","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05582499","NCT04927481","NCT00003893","NCT00002544","NCT00002498"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-10-16","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:50.966Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::carboplatin::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"CARBOPLATIN","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT06845319","NCT05266937","NCT06884254","NCT01625429","NCT00256243"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2025-02-24","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:47.851Z","completedOutcomeClass":"positive","bestCompletedEndpointStrength":"strong","positiveCompletedTrialCount":1,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T194135-bbdcbc2e::olaparib::breast_cancer","analysisId":"20260223T194135-bbdcbc2e","recordedAt":"2026-02-23T19:41:35.491Z","drug":"OLAPARIB","disease":"breast cancer","genes":["BRCA1","TP53"],"targets":["BRCA1","TP53"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02561832","NCT02264678","NCT03641755","NCT05258747","NCT02789332"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2014-10-15","trialPhase":"Phase 1/PHASE2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-26T15:26:24.334Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T193520-e49b1b62::neratinib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"NERATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02977780"],"trialFound":true,"trialCompleted":false,"trialStatus":"RECRUITING","trialFirstPostedDate":"2016-11-30","trialPhase":"Phase 2","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"trial_active","outcomeAt":"2026-04-26T15:26:23.979Z","completedOutcomeClass":null,"bestCompletedEndpointStrength":"unknown","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":0,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":"DRUG","primaryPurpose":"TREATMENT"},{"id":"20260223T193520-e49b1b62::vandetanib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"VANDETANIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00995007","NCT00613054","NCT00441142","NCT00613223","NCT00821080"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2009-10-13","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:42.519Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T193520-e49b1b62::regorafenib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"REGORAFENIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05759195","NCT06095375","NCT02926222","NCT06047379","NCT04704154"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2023-03-07","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:46.915Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T193520-e49b1b62::imatinib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"IMATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00615927","NCT00290771","NCT00613132","NCT00021229","NCT00387933"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-13","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:46.448Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":3,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T193520-e49b1b62::sunitinib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"SUNITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["PDGFRA","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00611728","NCT00923117","NCT00864864","NCT03275558","NCT01441388"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-02-10","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:45.993Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":2,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T193520-e49b1b62::osimertinib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"OSIMERTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05256290","NCT04135807","NCT03732352"],"trialFound":true,"trialCompleted":true,"trialStatus":"ACTIVE_NOT_RECRUITING","trialFirstPostedDate":"2022-02-24","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:45.543Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":1,"activeTrialCount":2,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T193520-e49b1b62::lapatinib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"LAPATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT02101905","NCT00095940","NCT00107003","NCT04135807","NCT01591577"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2014-04-01","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:44.563Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T193520-e49b1b62::gefitinib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"GEFITINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00042991","NCT00027625","NCT00250887","NCT00238797","NCT01310855"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2003-01-26","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:44.078Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T193520-e49b1b62::erlotinib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"ERLOTINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT00672243","NCT01257594","NCT00045110","NCT00720356","NCT00086879"],"trialFound":true,"trialCompleted":true,"trialStatus":"COMPLETED","trialFirstPostedDate":"2008-05-05","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:43.610Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":5,"activeTrialCount":0,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null},{"id":"20260223T193520-e49b1b62::afatinib::glioblastoma","analysisId":"20260223T193520-e49b1b62","recordedAt":"2026-02-23T19:35:20.976Z","drug":"AFATINIB","disease":"glioblastoma","genes":["EGFR","PDGFRA","PTEN"],"targets":["EGFR","PTEN"],"confidence":"NaN","phase":"unknown","mechanism":"Not specified","trialNctIds":["NCT05432518","NCT00727506","NCT00875433","NCT00977431","NCT02423525"],"trialFound":true,"trialCompleted":true,"trialStatus":"RECRUITING","trialFirstPostedDate":"2022-06-26","trialPhase":"unknown","repurposingScore":72,"tier":"I","isProspective":false,"outcomeVerdict":"validated","outcomeAt":"2026-04-23T01:41:43.119Z","completedOutcomeClass":"neutral","bestCompletedEndpointStrength":"moderate","positiveCompletedTrialCount":0,"negativeCompletedTrialCount":0,"mixedCompletedTrialCount":0,"neutralCompletedTrialCount":4,"activeTrialCount":1,"diseaseSubtype":null,"interventionType":null,"primaryPurpose":null}],"calibration":{"curve":[{"confidenceBucket":0.3,"total":4121,"confirmed":3016,"active":542,"positiveCompleted":395,"negativeCompleted":15,"mixedCompleted":6,"neutralCompleted":2600,"trialMatchRate":0.732,"researchDirectionRate":0.863,"positiveCompletedRate":0.096,"weightedCompletedOutcomeRate":0.408,"observedRate":0.11,"avgConfInBin":0.3,"nWithOutcome":3579},{"confidenceBucket":0.5,"total":3697,"confirmed":2633,"active":666,"positiveCompleted":284,"negativeCompleted":7,"mixedCompleted":5,"neutralCompleted":2337,"trialMatchRate":0.712,"researchDirectionRate":0.892,"positiveCompletedRate":0.077,"weightedCompletedOutcomeRate":0.394,"observedRate":0.094,"avgConfInBin":0.544,"nWithOutcome":3031},{"confidenceBucket":0.8,"total":1629,"confirmed":1150,"active":216,"positiveCompleted":131,"negativeCompleted":6,"mixedCompleted":4,"neutralCompleted":1009,"trialMatchRate":0.706,"researchDirectionRate":0.839,"positiveCompletedRate":0.08,"weightedCompletedOutcomeRate":0.318,"observedRate":0.093,"avgConfInBin":0.8,"nWithOutcome":1413}],"brierScore":0.2715,"ece":0.3793,"totalWithOutcome":8023,"trialMatchRate":0.72,"researchDirectionRate":0.87,"positiveCompletedRate":0.086,"weightedCompletedOutcomeRate":0.387,"overallAccuracy":null,"totalPredictions":9447,"totalWithAnyTrial":8223,"totalValidated":6799,"totalValidatedPositive":810,"totalValidatedNegative":28,"totalValidatedMixed":15,"totalValidatedNeutral":5946,"totalActive":1424,"totalResolved":6799,"totalConfirmed":6799,"computedAt":"2026-05-01T18:30:35.127Z"},"lastChecked":"2026-05-01T15:03:52.647Z","summary":{"total":9447,"validated":6799,"trial_active":1424,"insufficient_data":1224,"unchecked":0,"confirmed":6799,"negative":28,"pending":1424,"trialsFound":8223,"trialsCompleted":6799,"positiveCompleted":810,"negativeCompleted":28,"mixedCompleted":15,"neutralCompleted":5946,"avgConfidence":0.462}}